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Abstract 
This thesis aims to deepen our understanding of the impact and cost-effectiveness of 
new HIV prevention products in South Africa. It explores how stated preferences for 
products vary across groups, and uses these data to estimate their cost-effectiveness in 
different populations. Also, it seeks to predict how products themselves may change the 
economics of sex work and lead to risk compensation among female sex workers (FSWs). 
The validity of predicting behaviours through the use of stated preference methods is 
explored through a systematic review and meta-analysis. 
By integrating methods from the fields of health economics and infectious disease 
modelling, this thesis aims to give better predictions of the potential impact and cost-
effectiveness of HIV prevention products. This is a paper-style thesis which incorporates 
seven papers and a short correspondence publication, linked by short pieces of 
supporting material.  
The thesis finds that products offering effective multipurpose protection would be cost-
effective among younger female groups and FSWs. However, it predicts that products 
could change the economics of sex work, potentially leading to risk compensation among 
FSWs. A dynamic transmission model is used to show how this risk compensation could 
meaningfully reduce product impact. This thesis demonstrates the value of combining 
economic and epidemiological modelling methods to explore preventative behaviours in 
HIV. Further work is needed to assess the external validity of these methods. 
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Chapter 1: Introduction 
Scope of thesis 
This thesis presents work which deepens our understanding of the impact and cost-
effectiveness of new antiretroviral (ARV)-based HIV prevention products in South 
Africa. It seeks to estimate how demand for different products will vary, and models the 
impact of this variation on the epidemic. Also, it explores how products themselves may 
change risk behaviours among female sex workers (FSWs). By integrating methods from 
the fields of health economics and infectious disease modelling, this thesis aims to give 
better predictions of the potential impact and cost-effectiveness of prevention products.  
This thesis details the development and application of two discrete choice experiments 
(DCEs) which are used to estimate the impact of new antiretroviral (ARV)-based HIV 
prevention products in South Africa. The first hereafter referred to as the “products 
DCE”, seeks to predict the uptake of new multipurpose prevention technologies (MPTs) 
among four populations of potential users in South Africa. The second hereafter referred 
to as the “FSW DCE”, aims to predict risk compensation in the form of increased 
provision of unprotected sex, attributable to use of an effective prevention product by 
HIV negative FSWs. Results from both DCEs are presented as standalone results papers 
(indicated by “R”): R1 is used to parameterise product uptake and condom substitution 
in paper R2, and R3 to inform a broader microeconomic framework of FSW risk 
compensation in paper R4.  
This is a paper-style thesis which, over 10 chapters with appendices, presents seven 
papers and one correspondence publication, linked by short pieces of supporting 
material and sections of additional information. This means that some material is 
repeated, particularly background information and citations in research papers. I have 
endeavoured to keep this to a minimum, for example by presenting methodological 
detail once in the results papers themselves. For this reason, the thesis does not use 
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typical Introduction-Methods-Results-Conclusions headings, though this is its broad 
structure. For consistency throughout, references are listed at the end of each chapter or 
research paper. 
Outline of thesis 
This introduction chapter (chapter 1) briefly describes how the human 
immunodeficiency virus (HIV) epidemic has developed in South Africa. It then outlines 
recent advances in treatment and prevention that offer promise in tackling the South 
African and other HIV epidemics. In particular, it details the development of 
antiretroviral (ARV)-based prevention products – implemented as pre-exposure 
prophylaxis (PrEP) – which are the focus of this thesis. The remainder of chapter 1 
outlines the overall objectives of the thesis, and lists its aims organised by research 
paper, before detailing the intellectual ownership of the research in the thesis and the 
involvement of the candidate in each activity. 
The background section in Chapter 2 begins with a summary of mathematical modelling 
of infectious diseases, before focusing on key applications to impact and cost-
effectiveness work within HIV. The chapter then highlights gaps in the literature where 
economic methods – specifically different applications of discrete choice experiments 
(DCEs) – could be gainfully employed. The theoretical underpinnings of DCEs are then 
described, followed by some relevant examples of their use. chapter 3 presents a 
research paper, a systematic review of the literature exploring economic influences on 
the choices and behaviours of FSWs. The final section of this chapter summarises 
important gaps identified in the literature and describes how this thesis intends to 
contribute to them.  
Chapter 4 presents a paper detailing a systematic review and meta-analysis of the 
predictive ability of DCEs, which is currently under revision. DCEs are used in this thesis 
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to predict health-related behaviours; this paper describes and synthesises published 
evidence on the validity of DCEs for this application. 
Chapter 7 presents the protocol for the products DCE, published in 2016 in BMJ Open. 
This paper details the primary data collection process and gives information on the 
formative development of the products DCE. Chapter 8 reports on the formative 
research to develop the products  DCE, and describes the development and testing 
process of the FSW DCE. Additional information on the design and implementation of 
fieldwork is provided in the protocol paper of appendix IX, a 2016 publication from BMJ 
Open. 
Chapters 6 to 9 present four results papers. Chapter 6, paper R1, describes the results of 
a DCE eliciting preferences for potential MPT products. Chapter 7, paper R2, uses uptake 
predictions from paper R1 to parameterise a cost-effectiveness model for MPTs among 
different population groups in South Africa. Chapter 8, paper R3, describes the results of 
a second DCE, which estimates how the introduction of a fully effective HIV prevention 
product might affect condom use and pricing in commercial sex work. Chapter 9, paper 
R4, combines these results with microeconomic theory in a dynamic transmission 
impact model to assess how changes in the economics of commercial sex – specifically 
on the supply-side – might affect the total impact of new HIV prevention products. 
Finally, Chapter 10 presents a discussion summarising and synthesising the key 
empirical and methodological contributions of the thesis. I reflect on the strengths and 
limitations of the approaches taken in the thesis, before discussing the implications of 
findings for further research and policy. The thesis ends with a brief conclusion. Figure 
1 shows the thesis structure, and Table 1 outlines the submission stages of each paper. 
  
14 
 
Figure 1: Outline of thesis 
 
Table 1: Outline of Chapter submission and publication status 
Chapter Title Submission status 
1 Introduction, aims and objectives  Unpublished, for thesis only 
2 Background on economic and modelling methods Unpublished, for thesis only 
3 Economic influences on female sex worker choices: A 
literature review 
Not yet submitted 
4 How well do discrete choice experiments predict 
health choices? A systematic review and meta-
analysis of external validity 
Accepted – European 
Journal of Health 
Economics 
5 Additional information on the formative phase of DCE 
development 
Unpublished, for thesis only 
6 Paper R1: Divergent preferences for HIV prevention: 
A discrete choice experiment for multipurpose HIV 
prevention products in South Africa 
Accepted – Medical 
Decision Making 2017 
7 Paper R2: The cost-effectiveness of multipurpose HIV 
and pregnancy prevention technologies in South 
Africa 
Accepted – Journal of the 
International AIDS Society 
8 Paper R3: The effect of HIV prevention products on 
the supply of condomless commercial sex amongst 
female sex workers in South Africa 
Revise and resubmit 
received – Health 
Economics 
9 Paper R4: Modelling the epidemiological impact of 
changing incentives in sex work due to HIV pre-
exposure prophylaxis 
Not yet submitted 
10 Discussion Unpublished, for thesis only 
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The HIV epidemic in South Africa 
South Africa has the world’s largest and highest profile HIV epidemic. It is estimated that 
7 million South Africans live with HIV, a prevalence of 19.2%[1]. Although 180,000 
people died from HIV-related conditions in 2015[2], this is a marked reduction from the 
320,000 deaths that occurred in 2010[2]. Progress in addressing the epidemic has been 
rapid since 2008, and South Africa now has the world’s largest ARV treatment 
programme in the world: 4 million people received treatment in 2014, 47% of all people 
living with HIV in the country[3].  
Notably, this HIV response has been largely funded from domestic resources, and the 
country invests more than $1.5 billion annually to run its HIV and AIDS programmes[2]. 
This progress has led to a “turning tide” of HIV incidence, which has reduced among most 
age categories[4]. Also, a largely evidence-based policy response has resulted in policies 
which are comparatively progressive for the region, such as removing CD4 cell counts 
on treatment initiation, and making oral PrEP available to FSWs and other high-risk 
groups through public facilities[5, 6]. 
Epidemiological variation and structural influences on HIV risk 
Today, the health and economic burden of HIV in South Africa is not borne equally[6]. 
Women are 40% more likely to be living with HIV than men, with a national prevalence 
of 14% compared to 10%. Adolescent girls (aged 15-19 years) face an 80% cumulative 
lifetime risk of HIV acquisition[4, 7]. In 2012, HIV incidence among women aged 15-24 
was around four times greater than among men the same age; this age group accounted 
for 25% of new infections in South Africa[4]. Among women, HIV prevalence is highest 
among those aged 30-34 (36%), and slightly alter among men (29% at 35-39 years old). 
Differences in HIV prevalence by age between genders has been partly attributed to age 
disparate relationships (with an older male partner).[11-13] 
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In response to this disproportionate burden of risk, the South African National Strategic 
Plan on HIV, TB and STIs 2017-2022 (NSP) notes: 
“Given the degree to which transmission among adolescent girls and young women 
is driving HIV across the country, every province, district and ward must take steps 
to intensify efforts to reduce new HIV infections and increase service access for 
adolescent girls and young women, including addressing the social and structural 
factors that increase vulnerability.”[3]  
The NSP also speaks of “prioritising” the South African response to meet the needs of 
other key populations, including sex workers[3]. FSWs are around four times more likely 
to be living with HIV than other South African women of reproductive age[14]. They face 
an extremely high risk of HIV acquisition as they report a large number of sexual 
partners, can face barriers to negotiating condom use and are often unable to engage 
with health systems due to criminalisation and stigma[15, 16]. The extent to which FSWs 
engage with treatment and prevention services may have a substantial impact on 
transmission from FSWs to the general population[17].  
Poverty, the relatively low status of women, and intimate partner violence (IPV) have 
been attributed as causes of the disparity in HIV prevalence between genders, with IPV 
attributable to around 20% of new HIV infections in young women[9, 10]. Vetten and 
Bhana [18] postulate four possible causal links between intimate partner violence and 
HIV risk: 1) violence leading to female genital injury, associated with increased 
transmission risk; 2) physical and non-physical abuse resulting in diminished 
negotiating power for condom use; 3) sexual abuse of a minor, which is associated with 
a greater likelihood of riskier sexual behaviour later in life; and 4) women who reveal a 
positive HIV status to a partner being subjected to abuse.  
Finally, although contested as a theory [11, 12], age-disparate relationships between 
adolescent girls and young women (AGYW) and older men are also thought to contribute 
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substantively to the increased prevalence among young women compared to men of the 
same age[19].  
Historical context 
South Africa has not always been a leader in the HIV response. Between 1999 and 2008, 
Thabo Mbeki’s presidency criticised evidence showing that HIV caused AIDS[20]. In 
1999 Mbeki announced that the government would not provide the ARV zidovudine, 
used for the prevention of mother-to-child transmission (PMTCT), on unsubstantiated 
grounds that it was toxic and dangerous[21]. Later, Mbeki’s government restricted the 
provision of the ARV nevirapine, although it was made available to South Africa free of 
charge by funders[22], and obstructed South African applications for global fund grants 
([23], cited in [24]). Chigwedere et al. estimate that this restriction of ARVs between 
2000 and 2005 caused the loss of 330,000 lives, and led to 25,000 babies acquiring HIV 
at birth[24].  
The history of HIV/AIDS in South Africa cannot be separated from the socio-political 
upheaval of its transition from a racialist white-minority government to a one-person 
one-vote democracy. 
“The heart stopping euphoria of the 1994 elections, when South Africans cast their 
votes in a democratic, non-racial election for the first time, could not alter the 
profound economic, social and cultural dislocations of apartheid society, given 
their scale and historical entrenchment.”[25] p.44  
The scars of apartheid are still very apparent in today’s South Africa, where affluent 
white suburbs sit alongside poor, mostly-formalised townships which almost exclusively 
house black South Africans. The neoliberal economic policies pursued first by the 
apartheid government of the 1980s, and then by the post-apartheid Mandela 
government in the late-1990s, have reinforced the migrant labour system that has 
supported the South African economy since the discovery of minerals in Kimberley and 
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the Rand in the late nineteenth century. In the late 1990s, Mark Lurie, then of the South 
African Medical Research Council described the situation: 
“If you wanted to spread a sexually transmitted disease, you’d take thousands of 
young men away from their families, isolate them in single-sex hostels, and give 
them easy access to alcohol and commercial sex. Then, to spread the disease around 
the country, you’d send them home every once in a while to their wives and 
girlfriends. And that’s basically the system we have.”[26] 
Despite facing enormous epidemiological, economic, and social challenges, South 
Africa’s recent HIV-related policies have led to a substantial increase in the proportion 
of HIV positive persons who know their status, are on treatment, and who have an 
undetectable viral load[3]. This has been associated with a reduction in HIV incidence 
and a decreasing AIDS-related death rate. The 2017-2022 NSP aims to make further 
progress in reducing HIV-related mortality and morbidity by achieving the UNAIDS 90-
90-90 targets by 2020(ibid.). 
HIV prevention 
In recent years, clinical trials have shown that antiretroviral (ARV)-based pre-exposure 
prophylaxis (PrEP) can be efficacious in preventing the transmission of human 
immunodeficiency virus (HIV)[27-31]. However, protection has been variable across 
trials, and different PrEP delivery systems have conferred less protection to younger 
women[30, 32]. In particular, topical PrEP delivered though microbicide gels was 
thought to be a promising, female-initiated HIV prevention option, but performed poorly 
in clinical trials[33]. Both oral and topical PrEP products have been more effective in 
men-who-have-sex-with-men (MSM) populations than females[27, 34, 35], with this 
difference thought to be partly explained by adherence, and partly by pharmacokinetic 
data, showing higher colorectal drug concentrations compared to those in the female 
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lower genital tract[32, 36], i.e. providing higher protection against anal than vaginal 
transmission.  
Trial data have shown that oral PrEP has high efficacy among many groups[27], and in 
May 2017 there were 55 ongoing or planned PrEP demonstration or implementation 
studies worldwide[37]. In South Africa, oral PrEP has been available to FSW and other 
high-risk groups since 2016, following the publication of national guidelines for 
implementation[5], and a number of projects are working to evaluate the impact of 
targeting oral PrEP distribution among AGYW groups[38].  
A promising field of HIV prevention is the development of multipurpose technologies 
(MPTs), products which simultaneously provide protection from two or more of HIV, 
other STIs, and unintended pregnancy[39, 40]. Current MPTs in development include: 1) 
long-acting drug delivery systems such as intravaginal rings designed to protect from 
HIV infection and pregnancy (currently in a phase-I trial, ClinicalTrials.gov Identifier: 
NCT02235662); 2) pericoital drug delivery systems such as vaginal gel, tablets, and films 
designed to protect from HIV; and 3) a combination of products such as a contraceptive 
diaphragm used with microbicide gel designed to protect from HIV, STIs, and 
pregnancy[39, 41]. A short correspondence paper, provided as Appendix I, gives further 
details of the promise of MPTs in aiding the HIV response. 
Aims and Objectives 
The overall aim of this thesis is to assess the potential impact and cost-effectiveness of 
new HIV prevention products in South Africa by eliciting the stated preferences of men, 
women, adolescent girls, and FSWs. The objectives of this thesis are: 
1) To quantify the determinants of demand for new HIV prevention technologies 
among adult men, women, and adolescent girls in the general population, and 
female sex workers 
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2) To estimate the impact and cost-effectiveness of new HIV prevention products 
among South African men, women, adolescent girls and female sex workers 
3) To assess whether HIV prevention products will change female sex worker 
preferences for the supply of condomless commercial sex  
4) To explore if changing incentives in sex work could substantially affect the 
impact of HIV prevention products through risk compensation 
5) To identify key findings from this thesis and discuss the implications for the 
introduction of HIV prevention products 
An additional methodological objective is: 
6) To assess the reliability of discrete choice experiments to predict health-related 
choices 
Four research papers make up the results section of this thesis, each answering one of 
these questions, while the fifth is tackled in the discussion. The research questions 
addressed in each paper are as follows: 
Paper R1: Divergent preferences for HIV prevention: A discrete choice experiment for 
multipurpose HIV prevention products in South Africa 
1. To explore which products are most attractive to potential users 
2. To estimate the importance of other product characteristics, relative to HIV 
prevention 
3. To identify key similarities and differences in preferences across populations 
Paper R2: The cost-effectiveness of multipurpose HIV and pregnancy prevention 
technologies in South Africa 
1. To use DCE data to predict uptake of candidate single- and multi-purpose HIV 
prevention products among female population groups in South Africa 
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2. To estimate the impact and costs associated with different scenarios of product 
introduction and rollout 
3. To highlight where introducing products is likely to be most cost-effective  
Paper R3: The effect of HIV prevention products on the supply of condomless commercial 
sex amongst female sex workers in South Africa 
1. To explore the key factors driving client and act-type choice among FSWs  
2. Assess how the use of an effective HIV prevention product will affect act price 
and levels of condom use 
3. To explore heterogeneity in preferences for act and client characteristics  
Paper R4: How could risk compensation change the impact of new HIV prevention 
products? Modelling stated preference evidence from female sex workers 
1. To explore how a new HIV prevention product could affect the economic 
environment of sex work and lead to risk compensatory behaviours among FSWs 
2. To estimate the effect of potential risk compensation on product impact by 
integrating epidemiological and economic modelling in a single methodological 
framework 
3. To explore the sensitivity of model estimates to key behavioural parameters 
An additional methodological paper is included in the methods Chapter. This paper 
assesses the suitability of using DCEs to predict health-related behaviours: 
Paper: How well do discrete choice experiments predict health choices? A systematic 
review and meta-analysis of external validity 
1) To systematically review and synthesise literature assessing the predictive 
ability of DCEs in health contexts 
2) To critically appraise the potential for DCEs to inform predictions of future 
health-related behaviours 
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Intellectual Ownership 
This research was undertaken as part of work supported by the Bill and Melinda Gates 
foundation, which covered fieldwork costs, and USAID, which covered data analysis 
alongside impact and cost-effectiveness analysis. The DCE exploring preferences for new 
HIV prevention products (Paper R1) was conceptualised by Fern Terris-Prestholt as an 
extension to previous research.[42] I led all stages of this DCE, from design to analysis, 
except the shortlisting of potential attributes for the DCE which was started before I 
joined the project. 
I led all other elements of the research contained in this thesis, with support and advice 
from my supervisors, advisory committee and upgrading examiners. Although the cost-
effectiveness paper (paper R2) was designed to meet project deliverables for USAID, the 
analysis plan, modelling methods, and paper writing were my work. A summary of my 
contribution to each of the research activities in this thesis is provided in Table 2. 
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Table 2: Summary of the role of candidate in research activities 
Component Activity Responsibility 
Additional 
input 
Preparatory 
work 
Development of project objectives and work 
plan MQ, FTP   
Site selection MQ, FTP WRHI, PRD 
Ethics submission and amendments MQ, FTP, FC   
Local authority permissions MQ WRHI, PRD 
DCE 
development 
(both DCEs) 
 
Attribute shortlisting  
Products DCE: 
MQ, FTP, FC 
FSW DCE: MQ WRHI 
DCE statistical designs MQ FTP 
Development of survey tools MQ FTP, WRHI 
Pre-piloting and pilot planning MQ, PRD FTP, WRHI 
Data collection 
  
  
  
  
  
  
Focus group guide development MQ, WRHI PRD 
Focus group conduct and survey data collection PRD MQ, WRHI 
Selection of survey sites MQ, FTP, PRD   
Training of interviewers  MQ, PRD   
Analysis of pilot data, redesign of survey and 
DCEs MQ FTP 
Survey enumeration PRD MQ, WRHI 
Data analysis MQ, FTP, PV WRHI 
Research 
papers 
  
  
  
Paper R1: Divergent preferences for HIV 
prevention: A discrete choice experiment for 
multipurpose HIV prevention products in South 
Africa MQ 
FTP, PV, 
WRHI 
Paper R2: The cost-effectiveness of 
multipurpose HIV and pregnancy prevention 
technologies in South Africa MQ 
PV, FTP, 
WRHI 
Paper R3: The effect of HIV prevention products 
on the supply of condomless commercial sex 
amongst female sex workers in South Africa MQ 
FTP, PV, 
WRHI 
Paper R4: How could risk compensation change 
the impact of new HIV prevention products? 
Modelling stated preference evidence from 
female sex workers MQ 
PV, FTP, 
WRHI 
Supervision 
  
Overall project (BMGF/USAID Deliverables) 
FTP, PV WRHI 
Overall PhD/Thesis FTP, PV   
MQ: Matthew Quaife; FTP: Fern Terris-Prestholt (Primary supervisor); PV: Peter Vickerman 
(Secondary supervisor); FC: Fiona Cianci; WRHI: Wits RHI (Robyn Eakle, Maria Cabrera, Sinead 
Delany-Moretlwe); PRD: Progressus Research and Development (Motlalepule Tsepe, Cornelius 
Monkwe, Lindokuhle Xulu and Reathe Rain-Taljaard) 
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Chapter 2: Background on economic and 
modelling methods 
This chapter presents background information on the economic and modelling methods 
used in this thesis. In particular, it seeks to identify gaps in these modelling methods and 
notes how they could be improved through integration with economic approaches. 
First, I present an overview of why impact and cost-effectiveness modelling is useful in 
HIV prevention by summarising key methodological advantages alongside notable 
examples of its use in HIV prevention. Second, I give an overview of the background of, 
and rationale for, using DCEs to inform modelling work. Third, I summarise key gaps in 
the literature and their implications for this thesis. 
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Background and the role of modelling in HIV 
prevention 
This section provides background information on the development and use of 
mathematical modelling in the HIV field. 
Mathematical models of infectious disease 
Infectious disease epidemics dominated public health in the nineteenth and twentieth 
centuries. However, advances in the treatment of disease and a greater understanding 
of pathogens and their transmission has seen morbidity and mortality from infectious 
disease reduce markedly[1]. A large number of infectious diseases are now curable or 
preventable in middle- and lower-income contexts, yet many – including HIV – are not, 
and still have a substantial and persistent impact on population health.[2] Mathematical 
models are used to describe and analyse the characteristics of infectious diseases to 
evaluate potential interventions to reduce ill health.[3, 4]  
A mathematical model is “a representation of the essential aspects of an existing 
system[…] which presents knowledge of that system in usable form” (Ekyhoff (1974), 
cited in Young 1981[5]). Mathematical models of natural systems have been used for 
centuries in the natural and social sciences, and use sets of equations to describe the 
physical behaviour or state of the system being modelled (ibid.). In health, models are 
useful to 1) plan or evaluate interventions, especially when a controlled trial is not 
possible, 2) explore the underlying causes of health phenomena and drivers of 
epidemics, and 3) predict the occurrence of rare or future events from recorded 
intermediate points, perhaps embedded within a trial to inform interim analyses (e.g. 
[6]) [7].  
An influential early model was developed by Bernoulli in 1760 to estimate the 
effectiveness of smallpox vaccination[8]. Bernoulli is considered the first author to study 
the benefits of vaccination through the use of mathematics[4], making a series of 
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simplifying assumptions to compare the long-term benefit of vaccination with the short-
term risk of dying.  Bernoulli made a number of simplifying assumptions to 
mathematically describe the spread of the pathogen in the population. Specifically, he 
split the population into those susceptible, infected, and immune to smallpox, and used 
(recently developed) calculus methods to describe the rates at which people became 
infected with smallpox. Per unit of time, people infected with smallpox die with a 
probability p, survive with the probability (1 – p), and become infected at a rate of λ, a 
parameter which was later termed the force of infection[9].  
Derivations of Bernoulli’s methods, including the susceptible-infected-immune 
structure and description of time-invariant rates of change, are still applied in static 
models today, including in paper R2 in this thesis. Dynamic, nonlinear modelling was 
developed by Kermack and McKendrick to represent the spread of cholera in a three-
compartment, susceptible-infectious-recovered, or SIR, model[10]. Nonlinearity was an 
important innovation to allow the rate of infection to be dependent on the number of 
those infected, how long they are infectious for, and the infectivity of a pathogen. This 
dynamic framework is useful for representing epidemics of pathogens with long 
incubation periods and changing populations of susceptible and infected persons, such 
as HIV, and can give a more accurate representation of the force of infection than static 
models[3]. A dynamic model is presented in results paper R4. 
A range of model forms can be used to describe the processes associated with infectious 
diseases. There are advantages and disadvantages of each, and decisions around model 
structure and the level of complexity modelled should be made based on the decision 
question being modelled and the availability of data[4]. For example, simple static 
models are relatively easy to develop, can be transparent, need comparatively few data, 
and can give robust approximations that allow the identification of key factors that 
impact disease transmission[7, 11, 12]. These simple models may miss key features of 
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epidemics or nuances that are epidemiologically important. For example, static models 
assume a constant force of infection (or incidence), independent of the number of 
infectious individuals in the model or the coverage of preventative interventions. In 
reality, the greater the number of infectious persons, the greater the probability that an 
effective contact will be with an infectious person, meaning that a static model would 
underestimate incidence. By contrast, static models may overestimate incidence when 
preventative interventions are present as they will not account for reduced likelihood 
that a given individual is infectious [4, 13]. Where these aspects of disease spread are 
considered important to the spread of a pathogen, or the effectiveness of 
prevention/treatment interventions, dynamic models should be used to more accurately 
reflect these dynamics in the model. 
Mathematical models can be characterised on four dimensions, as 1) individual or 
population based 2) deterministic or stochastic, 3) linear or nonlinear, and 4) static or 
dynamic[4, 7]: 
1) Population-based models (e.g.[14, 15]) track average changes across groups by 
characterising compartments of the population without specifying the 
individuals involved and are largely used to examine population-level processes 
and trends. Yet infectious disease systems are fundamentally individual-based 
stochastic processes[16], and although population-based models can capture the 
average dynamics of the epidemic over time, they may miss important variation 
in individual-level risks, behaviours, and stochastic variation. 
2) By contrast, individual-based models explicitly simulate the path of individuals 
over time through a model (e.g.[17]). Individual-based models offer more insight 
into individual-level behaviours and interactions and can include network 
structures, such as sexual mixing [7].  
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3) Deterministic models describe systems that are approximated for large 
populations and are fully described by a given set of parameter values with one 
solution. They are nearly always population-based models, and therefore share 
the weaknesses mentioned above in approximating individual-level dynamics. 
Stochastic models model individuals and are commonly used in small-scale 
epidemics or contexts where an outbreak may be largely due to chance[4]. They 
represent events with a certain probability and explicitly incorporate 
randomness into models(ibid.).  
Not all processes are accurately described by stochastic models; for example 
representing the chance of small outbreaks beginning on hospital wards fit the 
framework well, whilst representing complex social mixing processes across 
larger populations do not. For larger epidemic (such as HIV), stochastic 
representations of system elements are often incorporated into  population-
based dynamic models through sensitivity analyses or, in some cases, Bayesian 
methods for choosing relevant parameter sets[4]. 
4) Linear models are static and represent parameters as constant, linear functions 
of environmental factors. Nonlinear models have parameters that vary according 
to a functional form of some of the variables in the model. 
5) Dynamic models are used to describe changes in transmission risk over time 
because this risk depends on the number of infectious persons in the model. In 
static models, this risk is predetermined and exogenous to the model’s state[4]. 
Dynamic models are, by nature, non-linear. 
Mathematical models can give us perspectives on epidemics that we cannot obtain from 
statistical models of correlations or trends in data. In fact, mathematical models attempt 
to describe the underlying processes that cause these. In many cases, models are 
parameterised to fit the epidemiological indicators of a current epidemic before the 
impact of different control measures is simulated[4, 7]. Here, models are used to 
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estimate the potential impact of new or ongoing interventions, particularly when 
controlled trials are not possible, or population level impact is not measured. These 
models estimate the impact of alternative control approaches on distal outcomes of 
interest and help understand the impact observed, alongside assessing consistency with 
intermediate outcomes. Finally, modelling can help determine drivers of epidemics (e.g. 
commercial sex, pimps, sexual concurrency, acute phase of HIV[15, 18, 19]) to help 
design new interventions, and can evaluate unintended outcomes of interventions that 
may not be apparent from trial data. 
When combined with data on the cost of interventions and averted health costs, and 
parameterised in common measures of benefit such as disability-adjusted life years 
(DALYs) averted, the cost-effectiveness of interventions can be compared to a 
willingness-to-pay (WTP) threshold[20], or to other candidate interventions[21]. 
Models can also be used to guide resource allocation within budget constraints. 
Key considerations in the mathematical modelling of 
HIV  
Mathematical models of HIV have been widely applied to understand how different 
epidemics have developed in different contexts. Models have been used since the early 
days of the HIV/AIDS epidemic to understand the spread of the virus among a certain 
population, in particular, its development into a generalised epidemic, with key 
contributions by Anderson and May, LePont and Blower, Lin et al., Busenberg et al., and 
Jacquez et al.[22-26]. 
More recently, models have been used to explore more detailed dynamics in the spread 
and control of HIV, estimate the cost-effectiveness of innovations in treatment and 
prevention, and to get a deeper understanding of how the epidemic can be 
controlled[27]. For example, models have been used to evaluate HIV prevention 
programmes by generating a counterfactual epidemic for the large-scale Avahan 
33 
 
intervention in India[14], to make a case for a universal test and treat approach for HIV 
elimination[28] and to show that new HIV prevention products may be a cost-effective 
way of spending finite health resources if targeted to specific geographical areas or 
structurally vulnerable groups[29].  
R0 in HIV models 
Kermack and McKendrick’s SIR model structure is still used, with minor adaptation, to 
describe the spread of many pathogens[3, 4]. HIV takes a susceptible-infected (SI) 
structure, because an infected person can only suppress the virus, naturally or through 
treatment, and does not fully recover. In an example of how the characteristics of the 
epidemic in question shape modelling methods, compartmental HIV models take this 
simple SI structure but incorporate a) complexity among infected individuals such as 
treatment status and viral load, and b) variations in risk-taking behaviours and cross-
population mixing. This section details how these dynamics are formalised in an HIV 
model. 
An important factor in these models is the value of the basic reproduction number, R0, 
which represents the transmissibility of a pathogen by the number of secondary cases 
produced by a single infection in a susceptible population[4]. For an epidemic to be 
sustained, R0 must be greater than or equal to one. For the simplest model describing 
HIV transmission, R0 can be characterised as: 
𝑅0 = 𝛽𝑐𝑑 (1) 
Where:  
𝛽 represents the per-exposure transmission probability of HIV transmission; 
c represents the rate at which new partnerships are formed in the population; 
and 
d represents the duration of infectivity for infectious persons. 
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R0 is a simplistic characterisation of the complex factors that underlie these three 
parameters. Each of these has important implications for understanding the existence 
and persistence of HIV epidemics, and I discuss them in turn. 
𝛽, the per-exposure transmission probability of infection, varies according to the type of 
exposure. Table 1 presents estimates of 𝛽 as summarised by the US Centers for Disease 
Control and Prevention (CDC) [30]. This table shows the HIV risk per 10,000 exposures, 
for a range of HIV transmission modalities. For example, in every 10,000 blood 
transfusions with HIV infected blood we would anticipate 9,250 HIV infections, whilst in 
every 10,000 unprotected sex acts between a HIV negative male and HIV positive female, 
we would expect four infections to occur. Three things are particularly notable from 
these numbers: 1) that risk may vary by gender, with heterosexual male-to-female 
transmission risk roughly double that of female-to-male transmission; 2) receptive anal 
intercourse is by far the riskiest activity relative to other sexual activity; and 3) that 
needle-sharing during injecting drug use has a relatively high transmission risk 
compared to sexual activity, except receptive anal sex.  
Table 1: CDC summaries of estimated per exposure probability of acquiring HIV 
from an infected source, by exposure act 
Type of exposure  Risk per 10,000 exposures 
Blood transfusion  9,250 
Mother-to-child transmission (untreated) 4,500 
Receptive anal intercourse 138 
Needle-sharing during injecting drug use 63 
Insertive anal intercourse 11 
Receptive penile-vaginal intercourse 8 
Insertive penile-vaginal intercourse 4 
Oral intercourse (receptive or insertive), 
biting, spitting, and throwing body fluids 
Low or negligible  
Table adapted from CDC data[30] 
In most models estimating the preventative impact of interventions, the value of 𝛽 is 
reduced by the effectiveness of a method in reducing HIV transmission. For example, 
male condom use has been shown to reduce HIV risk by 80%[31, 32]. For example, when 
a condom is used by an HIV positive male in a heterosexual vaginal sex act with an HIV 
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negative female, we model the probability of HIV transmission to be reduced from 
0.0008 to 0.0008*(1-0.8) =0.00016. Conversely, male circumcision is estimated to 
reduce HIV female-to-male HIV transmission by around 50-60%[33-35]. The scale up of 
voluntary medical male circumcision has become an important part of HIV prevention 
programmes among men[36]. As described previously, PrEP is a promising new tool for 
HIV prevention despite concerns about variations in efficacy across populations and 
geographies. A recent systematic review[37] estimated that PrEP products have a 51% 
(95% CI: 27–67%) efficacy across all populations, though among women under the age 
of 25 PrEP was not found to be effective (point estimate 29% efficacy, 95% CI: -4 – 53%). 
The parameter c represents the rate at which individuals form new sexual partnerships. 
The rate at which partnerships change, or are concurrent, is particularly important in 
HIV because infectivity rates are at their highest during the early stage of HIV infection 
when viral loads are extremely high – termed the acute or high viremia phase[38, 39]. 
The extent to which this drives incidence is debated, with Pilcher et al. suggesting that 
transmission in the acute stage leads to a high incidence rate among concentrated 
populations of people with many sexual partners before disease progression slows the 
spread into the general population or to lower-risk individuals [40]. However, a 
reanalysis of the limited data on infectivity during the acute stage of HIV infection by 
Bellan et al. indicates that this stage may be less important to epidemic development 
than first thought[41]. The most recent contribution to the debate, Volz et al. in 2013 
[42], estimates that HIV positive persons are eight times more infectious during the first 
year of infection compared with chronic infection. 
Assumptions around the acute stage of HIV infection are also important when 
considering d, the duration of infection for HIV. More recently, the discovery that 
consistent use of HIV treatment reduced the probability of onward transmission by 
around 96%[43] led to optimism that treatment as prevention could be an effective and 
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efficient mechanism to tackle the epidemic in populations that can use treatment 
effectively. A provocative modelling analysis by Granich et al.[28] showed that annual 
HIV testing of most adults, with immediate linkage to treatment for all positive persons, 
would dramatically reduce HIV incidence and potentially lead to elimination. Garnett 
and Baggaley[44] suggest that this strategy “would reflect public health at its best and 
its worst”, potentially reducing HIV-related morbidity and mortality at the cost of over-
testing, over-treating and reducing the autonomy of individuals to choose care. Granich 
et al.’s model was one of twelve included in a systematic comparison by Eaton et al.[45], 
which showed that mathematical models were too optimistic in their estimation of the 
benefits of test and treat, particularly in the longer term. Although test and treat remains 
a fundamental part of the HIV response in many countries, it is now generally seen as 
part of a broader package of treatment and prevention services[46]. 
This scope of this thesis is to model the potential impact and cost-effectiveness of PrEP 
and other ARV-based HIV prevention products. In particular, it focuses on how different 
interventions may reduce the per-act probability of HIV transmission, 𝛽 and, in paper 
R4, the rate at which new partnerships are formed, c. This thesis does not focus on 
factors affecting d. 
In the next section, I describe the force of infection, with a particular focus on how 
protection is modelled in this framework. 
Estimating prevention coverage 
When combined, mathematical models and economics can give comprehensive insight 
into effective and cost-effective ways to tackle the HIV epidemic. Economic methods are 
used in all four results papers of this thesis and can be separated into two broad 
categories: microeconomic modelling and economic evaluation methods. Here I describe 
how, in this thesis, economic models can be integrated with mathematical models to 
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explore how the per-act transmission risk will be modified by the introduction of 
effective HIV prevention products. 
𝜆 = 𝛽𝐼 (2) 
Equation X.2 shows a simple representation of how to calculate the force of infection 𝜆. 
The force of infection represents the risk that a susceptible person becomes infected 
during a given time period, and depends on 𝛽 , as defined above, and I, a parameter 
representing the number of infectious persons in a given population.  
Parameterising uptake 
Where a preventative intervention is available, 𝜆 can be calculated by: 
𝜆 = 𝛽𝐼(1 − 𝜋𝜀) (3) 
Where 𝜀  represents the efficacy of the intervention and 𝜋  the proportion of the 
population using the intervention, such that 𝜆 is reduced by a factor representing the 
efficacy and use of the intervention. When implemented in HIV models, I represents a 
weighted average of infectivity, the proportion of the HIV positive population at each 
stage of disease, and treatment status. 
𝜋 represents the coverage of HIV prevention products and is the product of uptake and 
adherence. Whilst efficacy data is relatively easy to obtain from published trials and 
meta-analyses of interventions (e.g.[37]), predicting the uptake of and adherence to new 
products is much more difficult. Terris-Prestholt et al.[47] noted that early modelling 
studies for ARV-based HIV prevention assumed very high levels of coverage, whereas 
more recent analyses make less optimistic assumptions. Yet, in the absence of data from 
the rollout of similar products or demonstration projects of new products, uptake 
parameters for models are generally obtained through expert opinion, trials, uptake of 
similar products, or by assumptions with minimal grounding in data (e.g.[48-51]).  
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This thesis builds on earlier work[52] by the author and supervisors to predict product 
uptake using the stated preferences of potential users, included in Appendix III. This 
methodological approach, alongside its strengths and limitations, is discussed in results 
paper R2 and the discussion in chapter 10.  
Modelling risk compensation 
Parameterising 𝜋 is complicated further when there is more than one HIV prevention 
option available. Prior to the introduction of ARV-based products, the only effective 
methods of HIV prevention were male or female condoms, male circumcision, and 
abstinence or partner reduction. Although knowledge and use of female condoms is very 
low in South Africa[53], use of male condoms is relatively widespread and in 2012, self-
reported condom use at last sex was 85% and 66% among general population men and 
women aged 15-24 years, respectively[54].  
One approach to modelling the uptake of new prevention products is to assume that 1) 
the uptake of new products would be the same among condom users and non-users, or 
2) that condoms would be used to the same extent after the initiation of prevention 
product use as they were before (i.e. no substitution).[55-57] However, it is possible that 
the introduction of PrEP could result in condom substitution, where PrEP users cease 
condom use when using PrEP. Some data from oral PrEP trials, largely among MSM 
populations, indicate that self-reported condom use did not change among PrEP 
users[58-61]. In contrast, a number of studies have detected increased STI rates among 
PrEP users than non-users, an objective indication of increased levels of condomless 
sex[62-65].  
Prevention product coverage, in particular the extent of condom substitution, is critical 
in parameterising reliable transmission models. Despite this, only some models 
explicitly accounted for condom substitution or other forms of risk compensation. In 
2003, Foss et al.’s model of condom substitution with microbicide use found substantive 
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benefits of reasonable (50%) uptake of microbicides among low condom users (25% of 
sex acts or less), but raised concerns if consistent condom users (75% of sex acts or 
more) substituted condoms for microbicide use[12]. An extension of this model for PrEP 
in 2017 by Grant et al. (currently under review) predicted that condom substitution 
could be tolerated among FSWs with lower levels of condom use before PrEP (<50% of 
acts) or where PrEP effectiveness is high (>75%). The authors also found that exposure 
to STIs, with subsequent increased susceptibility to HIV infection, would have very little 
impact on PrEP effectiveness (<1% change in results). Mitchell et al.[21] found that a 
50% reduction in condom use by PrEP users was needed to negate the beneficial impact 
of PrEP. Punyacharoensin et al.[66] modelled scenarios of risk compensation among 
MSM PrEP users in the UK and found that PrEP effectiveness would be negated if the 
amount of condomless sex or sexual partners increased by around 50%, while projected 
decreases in HIV testing had little impact. Among MSM in the USA, Jenness et al.[67] 
estimated that full substitution away from condoms would lead to an 8% relative 
infection risk among PrEP users.  
The literature shows that assumptions around risk compensation could be important in 
PrEP models. Despite this, the integration of parameters for the existence and magnitude 
of behavioural changes due to PrEP has not been driven by data or a strong theoretical 
justification. Instead, assumptions have been made within models as sensitivity 
analyses, for example exploring a 50% or 100% condom reduction after PrEP use[66], 
or the extent of condom substitution required to fully negate the impact of an 
intervention.  
This thesis describes how a new methodological approach could be used to model 
prevention coverage. Paper R2 uses a DCE to predict prevention product uptake 
differentially among condom users and non-users. Paper R4 applies economic theory to 
the results of paper R3, which directly estimates changes in commercial sex act price and 
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condom use among PrEP users, to provide a more nuanced estimate of PrEP 
effectiveness. 
  
41 
 
Integrating economics and infectious disease modelling  
Overview of economic methods used in this thesis 
This thesis employs two economic methods: stated preference choice modelling using 
DCEs, and economic evaluation.  
Economic evaluation is used in paper R2 which combines a simple impact model with a 
cost model to estimate the cost-effectiveness of MPTs. The approach taken in this thesis 
is outlined fully in the methods sections of the results papers. This section gives more 
extensive background to each without duplicating information. 
Microeconomic methods 
This section outlines the key theories underlying the microeconomic methods used in 
this thesis. I first outline some approaches used to research consumer preferences and 
demand, before justifying the use of the stated preferences in this research. Second, I 
briefly outline the theoretical foundations of the DCE approach to obtain stated 
preference data. Third, I present a brief discussion of the benefits and challenges in using 
DCEs to inform models of HIV prevention.  
Consumer theory 
Kelvin Lancaster’s 1966 seminal paper “A New Approach to Consumer Theory” 
challenged the pervasive neoclassical theory of consumer demand, which was grounded 
in the assumption that consumers derive utility from the consumption of goods 
themselves. Lancaster’s key contribution was to suggest that goods, per se, do not 
provide consumers with utility, but that the characteristics of goods in aggregate give 
rise to utility.  
This may seem self-evident, but is an extension to the assumption of neoclassical theory 
that goods are non-divisible and intrinsically valuable. By describing the value of goods 
as the aggregation of their characteristics, Lancaster’s theory allows the consideration 
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of goods’ complementarity and substitutability. Complementary goods are those which 
are likely to be used together, for example, shoes and shoelaces – if the price of shoes 
goes up, we expect the demand for shoes to fall and subsequently the demand for 
shoelaces to fall as well. Sandals may be a substitute for shoes, where if the price of shoes 
goes up leading to a fall in quantity supplied, all else equal, the quantity of sandals 
purchased will go up. 
The key contribution of Lancaster's theory in this thesis is to explore tradeoffs in greater 
depth. More than one good may share characteristics. For example, two different cars 
may be the same colour, which implies that a consumer’s choice between cars of their 
preferred colour is strictly based on remaining differences such as speed or comfort. 
Furthermore, if we know how much consumers value certain characteristics of goods 
(their shadow price), we can predict the demand for new goods with similar attributes 
before they enter the market.  
Demand for health and health services 
Like any other good or service that provides utility, consumers demand good health. 
However, there are important limitations to using economic theory to describe choices 
in health contexts. Building on key limitations set out by Kenneth Arrow[68], Grossman’s 
1972 model of demand for health services[69] describes the demand for health care as 
a derived demand, whereby consumers do not gain utility from consumption of a health 
service itself but from the subsequent benefits to their stock of good health. Grossman’s 
description of health as a stock, allocated at birth, allows the use of an economic 
framework to describe behaviours that increase or diminish that stock according to the 
relative utility that actions give us. For example, a smoker can be said to gain more utility 
through the immediate consumption of a cigarette than from the subsequent reduction 
in long-term health stock.  
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Preference elicitation methods 
Where possible, economists observe behaviour and use statistical methods to 
understand why market participants behave in particular ways. Information gathered 
from observing real-life behaviour is referred to as revealed preference (RP) data, as 
preferences are revealed through a person's actions[70, 71].  
RP data can be limited or non-existent for consumers who act to maximise their health 
through consuming products that can improve (or maintain) their health, such as 
surgery[72, 73] or preventative products[74]. Such consumers rarely face market prices 
for their consumption due to public or private insurance and are subject to agency 
relationships between patients and providers where decisions are unlikely to solely 
reflect patient preferences[70, 71, 75]. There are often little or no revealed preference 
data available on consumer demand for new technologies or interventions[74-77].  
Stated preference methods 
Where revealed preference data are not available, economists have turned to stated 
preference (SP) methods where potential consumers (or those impacted by a policy or 
intervention) are asked what they would choose, as opposed to what they chose. The 
hypothetical nature of this method allows researchers to explore new or proposed 
products or situations where a convenient real-world experiment does not exist[70, 75, 
78]. Health practitioners have been enthusiastic adopters of SP techniques, which were 
first used in transport[79] and environmental[80] economics. 
An important limitation of stated preference methods is the potential for hypothetical 
bias, where the choices that participants make in stated preference exercises are 
different to the choices that they would make in reality. This is particularly important 
for this thesis where DCEs are used to predict uptake in impact and cost-effectiveness 
models. To acknowledge the potential for hypothetical bias, this thesis 1) conducts a 
systematic review to assess the external validity of DCEs to predict health choices, 
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presented as chapter 4, which concludes that DCEs have reasonable predictive validity 
to predict health choices; and 2) where DCE predictions are used in models, the large 
degree of uncertainty in their predictions is incorporated into sensitivity analysis with 
wide parameter ranges. 
Potential stated preference approaches 
This section describes two stated preference approaches that were considered for use 
in this thesis but were not chosen: contingent valuation and best-worst scaling.  
Contingent valuation (CV) involves asking respondents for their willingness to pay, or 
willingness to accept, certain conditions. It commonly uses open-ended questions (how 
much would you be willing to pay for $X?) or categorical questions (would you be willing 
to pay $X?), although other bidding games or dichotomous choice tasks have been 
used[81]. Although widely applied in transport, environmental and some health 
contexts, a large body of evidence suggests that hypothetical bias in CV studies can lead 
to a substantial overstatement of willingness to pay values[82-85]. Importantly for the 
objectives of this thesis, while CV could be used to value the importance of different 
attributes of prevention products, predicted probability analysis could not be carried out 
to predict product uptake.  
Best-worst scaling (BWS) is a relatively innovation for eliciting stated preferences. The 
approach is attractive for researchers as experiments gather more data per task than 
traditional DCEs, and is argued to be less cognitively burdensome as participants do not 
have to consider between sets of alternatives[86-91]. There are two common 
applications of BWS, the profile case 2 is most commonly applied, while the best-worst 
DCE case 3 is more similar to the traditional DCE. Figure 1 shows stylised examples of 
these compared to a traditional DCE.  
Recent literature has indicated that using the BWS profile case 2 in health can obtain 
similar results to other preference elicitation methods, including DCEs [92], and studies 
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require a smaller sample size due to the greater quantity of information obtained per 
response, alongside the reduced complexity of tasks[87, 93]. However, like CV, BWS 
profile case 2 exercises do not allow for the prediction of behaviours via predicted 
probability analysis, and only allow estimation of conditional demand, i.e. preferences 
based on wanting to use a given service or product. 
Figure 1: Types of best-worst scaling in comparison to DCE 
 
Act A Act B
Price 500 Rand 200 Rand
Protection No Condom Condom
Type of sex Vaginal Vaginal
Other HIV prevention 
products used?
HIV risk reduced by 
87%
HIV risk 
reduced 
by 0%
Act A Act B
✔
Best Worst
Price 500 Rand
Protection No Condom ✔
Type of sex Vaginal
Other HIV prevention 
products used?
HIV risk reduced by 
87% ✔
Act A Act B Act C
Price 500 Rand 200 Rand 500 Rand
Protection No Condom Condom No Condom
Type of sex Vaginal Vaginal Vaginal
Other HIV prevention 
products used?
HIV risk reduced by 
87%
HIV risk 
reduced 
by 0%
HIV risk 
reduced by 
0%
Best Worst
Please pick the transaction you would prefer
Best-Worst Scale - Profile Case 2
Please tick the best and worst characteristics of the following 
transaction:
Consider each of the three acts described above. Which would you 
describe as the best? Which would you describe as the worst?
Best-Worst Discrete Choice Experiment - Case 3
"Traditional" Discrete Choice Experiment
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Discrete choice experiments (DCEs) 
The most popular method of stated preference elicitation in recent health literature has 
been the DCE[94, 95]. DCEs require participants to pick one of two or more options, with 
each being described by a set of characteristics. Respondents are presented with a 
sequence of choice tasks (normally around 10), and their choices analysed to estimate a 
set of preferences as implied by a particular indirect utility function[74]. Estimates are 
then used to measure which attributes are important to people, or (when the DCE 
includes an opt-out alternative) predict future behaviour, a method commonly used to 
predict product market shares[87].  
DCEs are analysed using a discrete choice modelling framework as proposed by 
McFadden[96, 97]. Importantly, when opt-out (or status-quo) alternatives are included 
in DCE designs, the demand for new alternatives can be predicted relative to that of 
existing products – the estimation of this unconditional demand makes DCEs useful tools 
for predicting health behaviours, and provides insight that BWS methods do not, and 
that CV does only with substantial complexity. Further considerations in the design of 
the DCEs used in this thesis are described in the method Chapter. 
Four discrete choice models are used in this thesis: multinomial logit, mixed multinomial 
logit, nested logit, and latent class. These models and their estimation are described fully 
in each results paper, alongside their comparative advantages and disadvantages, and 
are not duplicated here. 
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Economic evaluation  
Drummond et al.[98] define an economic evaluation as “the comparative analysis of 
alternative courses of action regarding both their costs and consequences”. Where 
resources are finite and not allocated by a market, as in the case of health services, 
provision is left to governments who require information on the expected benefit from 
investments alongside their value for money. Studies which compare the costs and 
benefits of different health interventions are referred to as economic evaluations.  
Morris et al.[73] argue that the development of economic evaluation techniques to 
measure efficiency in non-market health settings is “perhaps the main contribution 
economics has made to decision making in health services”. Modern economic 
evaluation methods are largely based on cost-utility analyses and a) capture a range of 
health benefits regarding quantity and quality of life, b) use standardised measures to 
allow comparison of costs and consequences across health areas, and c) have become 
mainstream methods of service commissioning in the UK and elsewhere.[73, 98]  
The economic evaluation methods used in this thesis are described fully in results paper 
R2 and its supplementary material and are not duplicated here. Instead, I give a brief 
overview of the literature that assesses the cost-effectiveness of ARV-based HIV 
prevention products. 
Where economic evaluations are based on cost-utility analyses, because costs and 
benefits are estimated with different units, results are presented as incremental cost-
effectiveness ratios (ICERs): 
𝐼𝐶𝐸𝑅 =
𝑐𝑜𝑠𝑡𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 − 𝑐𝑜𝑠𝑡𝑐𝑜𝑚𝑝𝑎𝑟𝑎𝑡𝑜𝑟
𝑏𝑒𝑛𝑒𝑓𝑖𝑡𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 − 𝑏𝑒𝑛𝑒𝑓𝑖𝑡𝑐𝑜𝑚𝑝𝑎𝑟𝑎𝑡𝑜𝑟
 
(4) 
Observed cost data are often included in economic evaluation models through a separate 
cost modelling process where assumptions are made around the scale of an intervention, 
and its impact on the costs of labour and commodities[99].  
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In low and middle-income contexts, best-practice economic evaluations quantify benefit 
as the number of DALYs averted by an intervention over that of a defined 
comparator[100, 101]. DALYs are a composite measure of quality and quantity of life. 
Because they are not specific to disease outcomes, they allow comparison of cost-
effectiveness within and across disease areas. For example, DALYs allow direct 
comparison between interventions a) to improve HIV treatment or prevention services 
and b) seeking to avert HIV or malaria infections[73]. To assess cost-effectiveness, the 
ICER of an intervention is compared to a governmental WTP threshold which, in theory, 
represents the opportunity cost of disinvesting from existing health services to re-direct 
resources to the new intervention[73, 98]. In low- and middle-income countries, World 
Health Organization (WHO) thresholds of averting one DALY for one to three times per 
capita income have been widely used. However, this method has received criticism for 
not reflecting real-world funding decisions or the opportunity costs of healthcare 
spending[20, 102]. Therefore, in paper R2 we use the lower-bound of the South African 
WTP threshold of $1,175 estimated by Woods et al.[20], which is markedly lower, and 
hence more conservative, than the WHO thresholds. This threshold aims to reflect better 
the opportunity cost to the South African health system of investing in new health 
technologies by considering the health forgone because other interventions cannot be 
provided. 
Cost-effectiveness analyses for ARV-based HIV prevention 
Since the development of microbicides for HIV prevention, impact and cost-effectiveness 
modelling has sought to estimate the potential epidemiological and economic value of 
ARV-based prevention methods. Terris-Prestholt et al.[103] showed that a microbicide 
gel would be cost-effective under product effectiveness assumptions that were later 
proven ambitious[104]. Later evidence demonstrating that microbicides have poor 
effectiveness in many groups, alongside the development of oral PrEP products, has 
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shifted focus away from gel-based products to oral or intravaginal ring-based topical 
products, which are not dependent on coital use[105].  
Evidence demonstrating a lack of protection from microbicide gels has led to recent cost-
effectiveness work focusing on estimating the cost-effectiveness of oral PrEP. A 
systematic review in 2013 by Gomez et al.[29] identified 13 studies modelling the cost-
effectiveness of oral PrEP, concluding that it “has the potential to be a cost-effective 
addition to existing HIV prevention programmes in some settings” but noting that 
estimates are sensitive to model assumptions of PrEP cost, epidemic context, and PrEP 
programme coverage.  
Since 2013, modelling work among non-MSM populations has focused on characterising 
heterogeneity in the cost-effectiveness of PrEP, specifically studying populations of 
pregnant women[106], the HIV-negative partner in serodiscordant relationships[107, 
108], and other high-risk female groups[48, 50, 51]. Due to issues with product 
adherence, focus has begun to turn towards longer-acting ARV-based prevention which 
requires less frequent use. One analysis explores the cost-effectiveness of injectable 
products[109], one study assesses the value of a multipurpose intravaginal ring for HIV 
prevention[110], and one study estimates the cost-effectiveness of introducing multiple 
ARV-based HIV prevention products[49]. To date, no study has estimated the cost-
effectiveness of a range of MPT products.  
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Implications for thesis  
Justification of DCE use 
Given that this thesis aims to explore the potential impact of HIV prevention products 
that were not available at the time of conducting the research (and remain inaccessible 
to many), no revealed preference data were available. Although some trial data are 
available, we would require data from a programme introducing a range of MPT 
products where users could freely opt-in or opt-out of product use, which is not the 
design of successful clinical trials.  
To explore the impact of prevention products on the market for commercial sex, the ideal 
study design would be to randomise some women to receive PrEP and some to not. This 
was not possible given funding constraints, and would likely have been unethical given 
that PrEP has been shown effective in many groups. 
The ability of DCEs to predict the unconditional demand of products that do not exist, 
including substitution away from current condom use, makes them flexible and 
attractive tools to help inform infectious disease models. Both DCEs used in this thesis 
rely on the work of Lancaster [111] as they decompose choices into constituent 
attributes, allowing us to explore how respondents trade-off between positive and 
negative aspects. Grossman’s model of health as a stock held over a lifetime also informs 
our modelling of prevention products uptake as products are unlikely to confer 
immediate utility to a user. Instead, consumption of prevention products reduces the 
risk of a substantial, negative impact on health stock by preventing HIV infection.  
Modelling and cost-effectiveness 
All published studies identified have shown that ARV-based prevention could be cost-
effective, at least among some population groups or under favourable cost-assumptions. 
However, a consistent theme across the literature is that cost-effectiveness will depend 
on a number of highly variable factors, including: the extent to which antiretroviral 
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treatment is scaled up, the costs of new products, the extent to which products are used 
consistently by those at risk, and the extent to which existing programmes (including 
voluntary medical male circumcision (VMMC) and condom promotion) can be effectively 
scaled up. Only one study estimates the cost-effectiveness of an MPT[110] and, similarly, 
one study the cost-effectiveness of a range of different ARV-based prevention 
options[49].Thus, this chapter identifies a key gap in the modelling and cost-
effectiveness literature relating to the modelling of MPTs, which Paper R2 seeks to fill by 
assessing the potential cost-effectiveness of a range of candidate MPTs.  
The next chapter presents a literature review on the economics of sex work, the other 
key theme of this thesis. 
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Chapter 3: Economic influences on female sex 
worker choices: A literature review 
Overview of paper 
This chapter presents a review and synthesis of the literature exploring economic 
determinants of the choices and behaviours of female sex workers. This paper is being 
finalised for submission. 
The review proposes a conceptual framework which is used later in the thesis to identify 
important determinants of FSW risk and choices that the introduction of effective HIV 
prevention products might change. These form the long list of attributes which were 
refined for the FSW DCE as presented in paper R3.  
Although the review identifies some influences on the risks that FSWs face and the 
choices they make, the nature of the DCE study means that findings regarding individual-
level influences on choices are used in the attribute selection process.  
The paper is formatted to be submitted to Economics and Human Biology, and 
implications for this thesis are presented as a separate section, after the paper’s 
reference list.   
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Abstract 
Women who engage in commercial sex, or female sex workers (FSWs), face daily threats 
to their health and wellbeing. Although a great deal of literature has focused on the 
epidemiological determinants of FSW and client behaviour, economic work has also 
explored how operating in a competitive market may influence choices and behaviours. 
Although relevant to epidemiological and biomedical research, there is little crossover 
between literatures and economic work has not been comprehensively reviewed or 
synthesised to date. 4,470 potentially relevant studies were identified, of which 56 were 
included in a narrative synthesis. Results are presented through the construction of a 
conceptual framework, which categorised influences into act- and individual-level 
factors, system-level factors, and exogenous factors. There is strong evidence suggesting 
that economic factors play a substantive role in the choices of FSWs and client. These 
factors should be explicitly incorporated within epidemiological frameworks of risk.   
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Introduction 
There are a wide range of structural and social factors which influence whether and how 
female sex workers (FSWs) can protect themselves from acquiring HIV or STIs. The 
decisions of women who sell sex are also affected by operating in an environment where 
economic factors, such as financial incentives or market competition, can substantially 
affect the choices that FSWs make which ultimately form behaviours[1-5]. This review 
aims to inform a conceptual model of how economic and market forces can impact these 
choices, in addition to biological, social, and structural factors. It summarises and 
critically appraises the economic literature which has sought to explain how market 
influences might affect commercial partnerships, and highlights gaps where further 
research is needed. 
Early economic literature on sex work generally took one of two approaches, either to 
draw out the similarities of the sex work industry with other formal sectors or 
professions (for example [6, 7] cited in Cunningham and Kendall[8]), or study it as a form 
of criminality following economic work on relationship between criminality and human 
capital (for example [9-11]). Later work complements this market-level approach by 
exploring the role of act- and individual-level characteristics on FSW and client 
choices[12-14]. 
Shannon et al.’s systematic review of structural drivers of HIV risk among FSWs[5] 
illustrates the complexity of exploring HIV prevention among FSWs and documents the 
range of structural factors identified as influencing the likelihood a FSW will acquire HIV. 
Economic factors are considered to influence HIV risk among FSWs through 
macrostructural factors, referring to the vulnerability which women may face due to 
economic arrangements at a societal level, for example through poverty or income 
insecurity, power imbalances between FSWs and clients or non-commercial partners, 
and regulatory frameworks[15-18]. Further economic features are noted as influencing 
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the work environment, an acknowledgement that economic factors at the individual 
level also play an influential role in exposure to HIV and other health risks[19-21].  
Review Methods 
Aims 
This review aims to: 
1. Comprehensively review studies which identify economic influences on the 
choices of female sex workers, 
2. Describe and synthesise common themes in the literature, 
3. Critically appraise and identify gaps in the literature on the economics of sex 
work. 
Inclusion and Exclusion Criteria 
The scope of the review was deliberately broad. We sought to identify any published 
work describing economic influences on FSW choices, whether looking at financial 
incentives for different types of risk behaviour, or more generally the organisation and 
dynamics of the sex work market. This meant that papers exploring either the extensive 
(entry into sex work) or intensive (decisions on how much of what sex to supply) margin 
of the industry were considered. We consider any published study between 2000 and 
2016. Both theoretical and empirical work was included. 
Papers were excluded if they were only published in conference abstract form, not 
published in English, or only considered male sex-workers. Papers which only 
considered transactional sex (i.e. where payment is through gift-giving or other non-
monetary means) were not considered.  
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Literature Search Methodology 
It was identified early in the literature search that the language used to describe analyses 
of economic factors affecting sex-work varied substantially between journals of different 
fields, notably between applied economic and public health publications. Therefore, to 
capture differences in terminology, a parsimonious search strategy was designed to be 
more sensitive than specific. This meant that more irrelevant studies needed to be 
removed by hand, however, some papers were identified that a more restrictive strategy 
might have missed. Search terms were developed starting from the broad research 
question: “How do economic factors affect FSW choices?”, and divided into two concepts 
as shown in Table 1. Searches were run with the Boolean AND term between these 
concepts. Additional concepts to restrict the scope of searches (for example, to health or 
risk behaviours) were not included to avoid the omission of potentially relevant articles 
and to maintain the wide scope of the review. 
Where available, MeSH terms were used to identify articles missed in synonym searches. 
An iterative snowballing strategy was employed throughout where the references of 
relevant papers were examined for any potentially useful papers or search synonyms. In 
addition, studies citing included papers were obtained through Google Scholar and 
screened for relevance. Terms were applied to the EconLit, Science Direct, Medline, and 
EMBASE databases so that both economic and public health literatures were 
investigated.  
Table 1: Search strategy  
Concept Search Term 
Female sex workers (female AND sex AND work*) OR FSW OR 
prostitute* 
Economic factors Market OR compet* OR incentive* OR 
price* OR wage* OR income OR 
compensat* 
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Synthesis 
Articles are synthesised through a narrative overview, before allocation to three 
categories to synthesise key themes in the literature: act-level factors, system-level 
factors, and exogenous factors. These categories form the basis of a conceptual 
framework. 
Act-level factors are characteristics of the act, client, or FSW that may affect the agency 
and ability of FSWs to make optimal choices. Included in this category are studies 
exploring the determinants of act price, for example work drawing on the economic 
theory of compensating differentials, which explains the dependence of wage rates on 
risk or unpleasantness of a job. Applied in labour economics across many industries and 
contexts[22-26], compensating differentials stem from the work of Adam Smith[27]: 
“The whole of the advantages and disadvantages of the different employments of 
labour and stock must, in the same neighbourhood, be either perfectly equal or 
continually tending to equality”. (Smith, 1776. Book I, p. 111) 
In the context of heightened economic and structural inequities in many countries, FSWs 
may be highly financially dependent on sex work to support themselves and their 
families [28-30]. Therefore, we would expect act price (an advantage) to compensate sex 
workers fully for the disadvantage of bearing risk or unpleasantness in their work. 
Similarly, if HIV prevention products reduce the risk of providing services, we would 
expect the premium to fall. 
System-level factors are influences which are driven by the socio-legal framework 
within which FSWs operate, and this category includes potentially violent or exploitative 
relationships with clients or police and vulnerabilities due to the illegality of buying or 
selling sex commercially. FSWs often report violence and intimidation by clients and the 
police, with experience of violence strongly associated with inconsistent condom use 
and lower levels of participation in HIV and STI prevention activities[15, 18, 31]. Studies 
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which investigate competition between sex workers and market structure are also 
included in this category. 
Exogenous factors are unrelated events or factors occurring outside of the commercial 
sex market, but which affect the decisions of FSWs and clients. For example, drought, 
conflict, or political instability may induce more women to engage in commercial sex due 
to a lack of other income generating alternatives.  
Results 
Overview of included studies 
In total, 8,870 records were identified in searches, 17 records added through the 
snowballing process, and 3,831 duplicates removed. 56 papers were included in the 
review after full-text sifting. Notably, 9 of the papers identified via snowballing came 
from a recently published book, The Oxford Handbook of the Economics of Prostitution, 
which did not appear in database searches. Chapters of this book were omitted if they 
solely presented data published in paper form elsewhere. Details of the review process 
are given in the PRISMA diagram in Figure 1, and all included studies listed in table 2. 
Eleven studies were carried out in the USA and Canada, ten in sub-Saharan Africa, and 
seven in Asia and in Europe. 
Although some papers were strictly theoretical contributions, the majority of models 
were tested empirically in a single or later publication. The structure and scope of many 
models sought to answer a specific policymaking question, for example estimating the 
impact of deregulation on sex work[13, 32], or the impact of political instability on the 
dynamics of commercial sexual behaviours[33].  
We found no robust economic research into commercial sex until 2003, which Alberg 
and Jensen attribute to difficulties in collecting reliable data from FSW or client 
populations[34]. Figure 2 illustrates the publication of studies over time, with 2016 
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disproportionately represented due to the publication of the Oxford Handbook of The 
Economics of Prostitution. We observe a trickle of papers pre-2009, before an increase in 
work between 2010 and 2016.  
In general, the tone of the literature has changed over time, and later work presents a 
complex, more nuanced, and less value-laden view of sex-work than earlier research. 
Edlund and Korn developed the first theoretical model of sex work, and postulate that 
female career trajectories are limited to either housewifery or sex work[1] (generously 
described elsewhere as an “unsatisfactory” assumption[35]), whilst Cameron’s book 
title The Economics of Sin, provides insight into the value judgements some economists 
make about sex work[4]. By comparison, more recent work – notably all studies by 
authors Cunningham, Gertler and Shah – implicitly assumes agency on the part of sex 
workers at the extensive and intensive margins, albeit with different negotiating power 
than clients. Considerations of heterogeneity in sex work across individuals and 
geographies is a growing elem  
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Figure 1: PRISMA diagram of review process 
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Table 2: Summary of included studies 
Author Year Title Journal 
Act level 
pressures 
Systemic 
risks 
Exogenous 
factors 
Sample 
size 
Location 
Empirical               
Adriaenssens 
and Hendrickx 
[36] 
2012 Sex, price and preferences: accounting for unsafe 
sexual practices in prostitution markets 
Sociology of 
Health and Illness 
X   7,451 Netherlan
ds, 
Belgium 
Ahlburg and 
Jesnsen [34] 
1998 The Economics of the Commercial Sex Industry 
and its Implications for HIV/AIDS Prevention 
Policies 
Book chapter  X  SA* Sub-
Saharan 
Africa 
de Araujo [37] 2016 HIV/AIDS and Commercial Sex Work in the 
Developing World 
Book chapter X   SA* Sub-
Saharan 
Africa 
Arunachalam 
and Shah [38] 
2008 Prostitutes and Brides? American 
Economic 
Review: Papers & 
Proceedings 
X  X 4,100 Ecuador, 
Mexico 
Arunachalam et 
al. [39] 
2012 The Prostitute’s Allure: The Return to Beauty in 
Commercial Sex Work 
The B.E. Journal 
of Economic 
Analysis and 
Policy 
X X  4,100 Ecuador, 
Mexico 
Arunachalam et 
al. [40] 
2013 Compensated for Life: Sex Work and Disease Risk Journal of Human 
Resources 
X X  2833 Ecuador 
Cameron [41] 2016 Empirical Analysis of the Impact of Legal Status on 
Versatility and Efficiency in Prostitution Markets 
Book chapter X X  SA* UK 
Chang and Weng 
[42] 
2012 What is more important for prostitute price? 
Physical appearance or risky sex behavior? 
Economic Letters X   140 Taiwan 
Cunningham 
[43] 
2011 Monpolostic competiton with product 
differentiation in prostitution markets: explaining 
the returns to BMI 
 
 
Working paper X   94,000** USA 
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Author Year Title Journal Act level 
pressures 
Systemic 
risks 
Exogenous 
factors 
Sample 
size 
Location 
Cunningham and 
Kendall [44] 
2011 Prostitution 2.0: The Changing Face of Sex Work Journal of Urban 
Economics 
X   94,000** USA 
Cunningham and 
Kendall [45] 
2014 Prostitution, Education, and Moonlighting: A 
Demonstration of the Importance of Fixed and 
Variable Costs in Sex Worker Labor Supply 
Working paper X   685 USA 
Cunningham and 
Kendall [46] 
2014 Using Political Conventions to Estimate the 
Responsiveness of Prostitution Labor Supply 
Working paper X X  SA*** USA 
Cunningham and 
Kendall [47] 
2016 Prostitution Labor Supply and Education Working paper X  X 685 USA 
Cunningham and 
Kendall [48] 
2016 Examining the Role of Client Reviews and 
Reputation within Online Prostitution 
Book chapter X   72,104** USA 
de la Torre et al. 
[49] 
2010 Premium Sex: Factors Influencing the Negotiated 
Price of Unprotected Sex by Female Sex 
Workers in Mexico 
Journal of Applied 
Economics 
X   1,029 Mexico 
de Walque [50] 2014 Coping with risk: the effects of shocks on 
reproductive health and transactional sex in rural 
Tanzania 
Working paper x   1,076 Tanzania 
Dupas and 
Robinson [51] 
2012 Simulating the impact of regulation changes on 
the market for prostitution services 
European Journal 
of Law and 
Economics 
 X X 586 Kenya 
Ebstein and 
Sharygin [52]  
2016 The (hidden) costs of political instability: 
Evidence from Kenya's 2007 election crisis 
Journal of 
Development 
Economics 
X   SA* China 
Edlund, 
Engelberg, and 
Parsons [53] 
 
2009 The Wages of Sin Working paper  X X X  40,000 USA, 
Canada  
Egger and 
Lindenblatt [54] 
2015 Endogenous risk-taking and physical appearance 
of sex workers 
European Journal 
of Health 
Economics 
X   2,517 Germany 
Elmes et al [55] 2014 The Price of Sex: Condom Use and the 
Determinants of the Price of Sex Among Female 
Sex Workers in Eastern Zimbabwe 
Journal of 
Infectious 
Diseases 
X   311 Zimbabw
e 
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Author Year Title Journal Act level 
pressures 
Systemic 
risks 
Exogenous 
factors 
Sample 
size 
Location 
Gertler and Shah 
[32] 
2005 Risky Business: The Market for Unprotected 
Commercial Sex 
Journal of 
Political Economy 
 X  1,029 Mexico 
Gertler, Shah and 
Bertozzi [14] 
2011 Sex work and infection: what’s law enforcement 
got to do with it 
Journal of Law 
and Economics 
X   2,914 Ecuador 
Hakim [56] 2015 Economies of Desire: Sexuality and the Sex 
Industry in the 21st Century 
Economic Affairs X   SA* Europe, 
USA 
Holt, Blevins, 
and Fitzgerald 
[57] 
2016 Examining the Economics of Prostitution using 
Online Data 
Book chapter X   1,844**  
Islam and Smyth 
[58] 
2012 The Economic Returns to Good Looks and 
Risky Sex in the Bangladesh 
Commercial Sex Market 
Economics of 
Gender 
X   283 Banglade
sh 
 
 
 
Johnston et al. 
[59] 
2010 Offer of financial incentives for unprotected sex in 
the context of sex work 
Drug and Alcohol 
Review 
X   232 Vancouve
r, Canada 
Kwan [60] 2016 Decriminalizing Indoor Sex Work: Effect on 
Quantity of Transactions 
Thesis. University 
of California, 
Berkely 
 X X   238,501
** 
Rhode 
Island, 
USA 
Levitt and 
Venkatesh [12] 
2007 An empirical analysis of street level prostitution Working Paper X     4,400 Chicago, 
USA 
Li et al. [61] 2015 Does Competition Eliminate Discrimination? 
Evidence from the Commercial Sex Market in 
Singapore 
NBER Working 
Paper 
 x   176 Singapore 
Manda [62] 2013 Bang for Your Buck: STI Risk and Pregnancy Risk 
as Sources of the Price Premium for Unprotected 
Sex 
Working Paper X    192 Kenya 
Mannberg [63] 2011 Risky Sex in a Risky World: Sexual Behavior in an 
HIV/AIDS Environment 
The Scandinavian 
Journal of 
Economics 
X    SA** Sub-
Saharan 
Africa 
Moffatt and 
Peters [64] 
2004 Pricing Personal Services: An Empirical Study of 
Earnings in the UK Prostitution Industry 
Scottish Journal of 
Political Economy 
X    998+ UK 
Mondal and 
Gupta [65] 
2013 How costly is safe sex? An economic analysis of 
the commercial sex market in India 
Global Health 
Perspectives 
X    5,301 India 
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Author Year Title Journal Act level 
pressures 
Systemic 
risks 
Exogenous 
factors 
Sample 
size 
Location 
Muravyev and 
Talavera [66] 
2013 Unsafe sex in the city: Risk pricing in the London 
area 
European 
Economic 
Association and 
Econometric 
Society 
X    1,580 London, 
UK 
Ntumbanzondo 
et al. [67] 
2006 Unprotected intercourse for extra money among  
commercial sex workers in Kinshasa, Democratic 
Republic of Congo 
AIDS Care X    136 Kinshasa, 
DRC 
Peng [68] 2016 Economic Theories and Empirics on the Sex 
Market 
Book chapter X X     
Quast and 
Gonzalez [69] 
2016 Sex Work Regulation and Sexually Transmitted 
Infections in Tijuana, Mexico 
Health Economics   X   SA* Mexico 
Rao et al. [3] 2003 Sex workers and the cost of safe sex: the 
compensating differential for condom use among 
Calcutta prostitutes 
Journal of 
Development 
Economics 
X     608 Calcutta, 
India 
Robinson and 
Yeh [33] 
2011 Transactional Sex as a Response to Risk in  
Western Kenya 
American 
Economic Journal: 
Applied 
Economics 
X   192 Kenya 
Robinson and 
Yeh [70] 
2012 Risk-Coping through Sexual Networks: Evidence 
from Client Transfers in Kenya 
Journal of Human 
Resources 
  X 192 Kenya 
Sachsida and 
Moriera [71] 
2010 A theory of prostitution Economia e 
Desenvolvimento 
X   X 151 Brasilia, 
Brazil 
Shani and 
Shankar [72] 
2016 The Details Are in the Fine Print: Sex Work, Sex 
Workers, and Definitional Complications of 
Identity 
Book chapter X    3,424  
Sohn [73] 2016 Men’s Valuation of Temporal Proximity to Female 
Virginity: Evidence from Prostitutes 
Deviant 
Behaviour 
X    8,817 Indonesia 
Willman[74] 2010 Risk and reward in Managua’s commercial sex 
market 
Journal of Human 
Development and 
Capabilities 
X X   138 Managua, 
Nicaragua 
Theoretical               
Albert, Gomez 
and Franco [75] 
2007 Regulating Prostitution: A Comparative Law and 
Economics Approach 
    X     
72 
 
Author Year Title Journal Act level 
pressures 
Systemic 
risks 
Exogenous 
factors 
Sample 
size 
Location 
Cameron [4] 2002 Economics of Sin: rational choice or no choice at 
all? 
Book chapter   X     
Della Guista, Di 
Tomasso, Strom 
[76] 
2007 Who is watching? The market for prostitution 
services 
    X     
Edlund and 
Korn[1] 
2002 A Theory of Prostitution Journal of 
Political Economy 
  X     
Farmer and 
Horowitz [77] 
2013 Prostitutes, Pimps, and Brothels: Intermediaries, 
Information, and Market Structure in Prostitution 
Markets 
Southern 
Economic Journal 
  X     
Immordino and 
Russo [78] 
2015 Regulating prostitution: A health risk approach Journal of Public 
Economics 
  X     
Immordino and 
Russo [79] 
2016 Prostitution Policy Book chapter   X     
Lee and Persson 
[80] 
2016 Bargaining, Coercion, and Entry in Prostitution 
Markets: Implications for Prostitution Law 
Book chapter   X     
Peppet [81] 2012 Prostitution 3.0 Iowa Law Review   X     
SA*:  Secondary analysis of large household survey/epidemiological data 
** Data taken from sex work review website 
SA***: Secondary analysis of number of adverts posted on solicitation websites 
+: transaction-level data, number of individuals not listed
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Figure 2: Number of included studies by year published 
  
Synthesis of economic factors influencing FSW choices 
Papers are presented and synthesised by theme: 1) act- and individual-level factors, 2) 
system-level factors (further split into subcategories of decriminalisation, the extensive 
margin, and market structure), and 3) exogenous factors. Although largely mutually 
exclusive, when papers explore cross-category themes, they are included in all relevant 
sections. 
Act- and individual-level factors 
Work explaining the determinants of act price made up a substantial proportion of the 
literature, with 40 studies  (72%) exploring act- or individual-level factors[3, 12, 14, 33, 
36-49, 51-59, 61-65, 67, 68, 70-74]. Within this, the impact of condom use on the price 
of acts has been an important strand of research [3, 12, 14, 33, 36, 39, 40, 42, 43, 45, 47, 
49, 51, 54, 55, 58, 59, 61, 62, 64-67, 71, 73, 74]. The remaining literature in this category 
explores different pricing dynamics in the market for commercial sex, setting price as a 
dependent variable and exploring correlations with a range of factors including: 
interviewer-assessed FSW sociodemographic characteristics, interviewer-assessed 
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attractiveness, time and place of work, client characteristics, industry experience, and 
type of acts supplied (37, 38, 41, 44, 46, 48, 52, 53, 56, 58, 59, 57, 63, 65, 68, 70).  
Rao et al.’s seminal study [3] first applied the principle of compensating differentials to 
sex work by equating the disutility borne by a FSW in providing unprotected sex with 
the additional fee paid by the client. This study was the first to present convincing 
evidence of the existence of financial incentives in sex work, and a large empirical 
literature has since developed exploring variations in price, and defining the presence 
and magnitude of this condom differential. 
After Rao et al, the study most notable in advancing empirical research in the field was 
Gertler, Shah and Bertozzi[14], who were the first to apply concepts of game theory to 
the bargaining process between a FSW and a client. The authors use qualitative research 
to develop a Roth-Nash bargaining framework, which suggests that the magnitude of the 
price premium for unprotected sex depends on client disutility from condom use, FSW 
disutility from unprotected sex, and bargaining power between the two parties. The 
authors’ theoretical model is convincing, and is backed up empirically  through a FSW 
fixed-effects regression estimating a 23% price premium for unprotected sex, increasing 
to 40% if the FSW was deemed “attractive” by survey enumerators.  
Of these studies, many do not explore the implications of findings on individual or public 
health, instead focusing on the concordance between data and theoretical economic 
models (e.g. monopolistic [43] or perfect competition [61], and whether models are 
correct in inferring a trade-off between sex work and marriage [53]). Despite high levels 
of methodological robustness, many studies miss the opportunity to focus on distal 
outcomes of epidemiological value, and are instead limited to intermediate outcomes 
such as risky behaviours or pricing. 
By contrast, some studies use high-quality epidemiological data to estimate behaviours 
of clear public health importance. Two innovative studies explore the responsiveness of 
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the premium to epidemiological risk factors: Arunachalam and Shah[40] explore 
whether the condom differential is influenced more by intrinsic client preference for 
unprotected sex, or a 'true' compensating differential component which varies with the 
risk of STI or HIV acquisition. They find evidence that the latter drives the magnitude of 
the premium and estimate an 8% premium for unprotected vaginal sex, which increases 
substantially with the type of act and perceived risk of a client having an STI; 
unprotected anal sex with a risky client bears an additional 73% premium. Manda[62] 
estimates that 83% of the premium observed in Kenya can be explained by the sex-
worker bearing the risk of pregnancy, with the remaining 27% attributable to STI risk. 
These studies demonstrate that FSWs in these contexts (Kenya, Ecuador and Mexico) 
have sufficient information and agency on epidemiological risk factors to rationally 
adapt pricing models according to risk, and that the supply of unprotected sex is likely 
both higher-priced and lower in quantity than low prevalence areas. 
Among the largely methodologically robust literature, one paper stands out due to its 
estimation of a positive premium for protected intercourse after four years of a condom 
promotion campaign[65], yet its methodology is flawed.1 All other identified studies 
which do not correct for endogeneity biases find a positive price premium for 
unprotected sex. For example, Elmes et al.[55] estimate that clients in Zimbabwe paid 
43% more for unprotected sex, and Ntumbanzondo et al.[67] suggest that FSWs in 
Kinshasa charge up to 3.5 times more for unprotected intercourse. Since not adjusting 
for unobserved correlation between individual-level factors, which influence both 
condom use and price (e.g. by not accounting for unobservable elements of bargaining 
power), would bias estimates towards the zero, evidence of the existence of a condom 
differential is strengthened by findings of a significant premium in this literature. The 
                                                             
1 The paper uses a three-stage least-squares method to account for the reverse-causality between 
price and condom use, a potential source of endogeneity. However, this method does not tackle 
other sources of possible endogeneity for example omitted variable bias 
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methodological approach of many of papers is strong, using econometric methods to 
account for potential biases in estimating the impact of condom use on price, either using 
FSW fixed-effects models or taking an instrumental variable approach. The results of 
studies that do this are summarised in Figure 3, which displays the considerable 
heterogeneity in estimates of the price premium for unprotected sex. The number of 
studies is too small to assess variation statistically, however visual examination 
indicates a smaller price premium in high-income countries (between 7 and 18% in 
Europe and the USA) compared to low- and middle-income countries (up to 81%, though 
results are comparable in Kenya and among subgroups of “attractive” FSWs in Central 
and South America. There is no apparent correlation between HIV prevalence and the 
price premium across studies, yet variation in sampling methods and subsequent 
selection of different FSW populations makes comparison across contexts difficult. As 
noted above, within-sample evidence supports variation in the price premium according 
to epidemiological risk. 
Whilst earlier studies focused on proving the existence of a price premium for 
unprotected sex, as data and computational capacity have improved in recent years 
studies have begun to focus more intensively on heterogeneity in sex work, FSWs, and 
clients. Indeed, heterogeneity is a key theme emerging from the Oxford Handbook on the 
Economics of Prostitution. Cameron [41] explores the commercial sex market in North-
West England, with a particular focus on heterogeneity in client preferences. He argues 
that the assumption made in much of the economic literature on sex work, that there is 
a single market with perfect competition, does not hold as economies of scope conditions 
have “failed to develop to satisfy the demand for variety” in this area. The marked 
increase sample sizes of recent studies, using novel datasets that were previously non-
existent for example sex worker review websites[44, 48], will enable much more 
detailed analysis of heterogeneity within and across contexts.   
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Figure 3: Published econometric estimates of price premia for unprotected sex 
 
Circle area is proportional to the price premium. FSW HIV Prevalence estimates are also included for – Bangladesh [82], 
Belgium [83], Ecuador [84], India [85], Kenya [86], Netherlands [83], Mexico [87], USA [88]. Constructed with GIS 
Shapefile [89] using ArcGIS Desktop 10 [90]. Empirical Papers: Rao et al. [3], Adriaenssens and Hendrickx[36, 91], Levitt 
and Venkatesh (2007), Arunachalam and Shah [40], Robinson and Yeh [33], Gertler, Shah and Bertozzi [14], Islam and 
Smyth [58], Muravyev and Talavera [66]. 
Further research demonstrates that heterogeneity in pricing for services exists 
systematically across and within cities[57]. Edlund and Korn find support for theoretical 
models predicting a relationship between age and marital status [53]. Sahni and 
Shankar[72] show that future work could be improved by explicitly incorporating 
heterogeneity when analysing sex work markets, in particular being aware of differences 
between FSWs who are readily available to participate in research and those who are 
not.  
In general, the literature exploring individual- and act-level influences on FSW behaviour 
provides convincing evidence of a price premium for unprotected sex, found to be 
consistently present but varying in magnitude across context. Risks from HIV, other STIs, 
and pregnancy are shown to influence the magnitude of the price premium. In addition, 
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a number of studies note that considering heterogeneity is important to accurately 
reflect the complex dynamics of the commercial sex market. Edlund and Korn [53] find 
support for theoretical models predicting a relationship between age and marital status 
Although this literature gives a comprehensive overview of individual- and act-level 
influences on FSW behaviours, the extent that these factors affect overall risk and 
economics choices, are also shaped by macro-level, systemic structures; these are 
discussed in the next section. 
System-level factors 
System level risks were defined as the 1) legality (or otherwise) of sex work in different 
contexts, 2) factors affecting the extensive margin, and 3) the structure of the sex work 
market.  
Decriminalisation 
Sex work differs in legality across countries, and while there has been a substantial push 
in recent years for decriminalisation, many laws remain restrictive[5]. 16 studies were 
found to examine how the legality of sex work varies across contexts, through theoretical 
[1, 4, 34, 35, 75, 77-81, 92] or empirical means [32, 41, 60, 61, 69]. 
Two empirical studies in high-quality journals indicate that legalisation of sex work led 
to a fall in rates of STIs in Mexico and Ecuador[32, 69]. However, the other empirical 
study presents indicative evidence that decriminalisation may increase total health 
risks: a natural experiment from the legalisation of indoor sex work in Rhode Island 
between 2003 and 2009[60] found evidence that the policy increased the number of 
transactions five years after implementation, which persisted after re-criminalisation. 
However, this study was not able to assess the impact of decriminalisation on the 
riskiness of sex acts supplied, for example through changes in condom use. Excepting 
this single emprical study, all literature supports the legalisation or decriminalisation of 
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sex work, in terms of predicting a reduction in the quantity of sex sold, or reducing the 
proportion of acts which are risky.  
The lack of empirical data on decriminalisation has limited substantive empirical 
investigation. In its place, a theoretical literature – largely untested empirically – makes 
a number of predictions. Peppet[81] and Immordino and Russo[78][79] predict that 
legalising and taxing sex work would lead to lower levels of sex work than under optimal 
enforcement if made illegal, whereas regulation would minimise overall harms.  
The theoretical literature would be greatly strengthened with further empirical 
examination. Two studies seek to explain the lack of examples of sex work 
decriminalisation, in part explaining why examples and data are so limited in number. 
Lee and Persson[80] demonstrate how policymaking is complicated when voluntary sex 
work exists alongside involuntary sex work, whilst Della Guista[35] argues that the 
continued illegality of sex work may be due to policymakers seeking to maintain the 
status quo to preserve reputations, even while the same model demonstrates clear 
benefits from deregulation to sex workers and wider society.  
Factors affecting the extensive margin 
Although a number of studies listed above analyse the intensive margin of how economic 
factors affect FSW behaviour within the commercial sex industry, nine studies seek to 
formally explain the extensive margin or entry into and exit from sex work[1, 4, 8, 39, 40, 
46, 68, 74, 76]. This literature contains both theoretical and empirical contributions and, 
unlike the decriminalisation literature, all of the key theoretical contributions have been 
empirically tested for validity. 
Edlund and Korn’s seminal study[1] was the first to describe the relatively high rewards 
for sex work, despite a low training requirement. The authors suggest that FSWs trade-
off capital they hold in the marriage market to become FSWs and that women who 
choose sex-work instead of marriage require sufficient compensation for this in the form 
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of greater wages. However, this theoretical model faces a challenge from empirical 
evidence as Arunachalam and Shah[39] show that FSWs were more likely to be married 
than not. Neither study explores the validity of this tradeoff across contexts with 
different social constructions of marriage.  
A less critical inference of the model that a temporary increase in a male population 
would increase the propensity for women to choose sex-work over marriage was 
suggested to hold in a study by Cunningham and Kendall[46]. Finally, Peng [68] presents 
empirical evidence suggesting that the model’s predictions hold in reality: 1) that the 
amount of sex bought and sold reduces with male and female income, and 2) that there 
is a wage differential for a sex worker over a woman with similar characteristics in the 
general population.  
Cameron, in The Economics of Sin[4], presents a similar value-laden perspective of sex-
work but gives a more sophisticated explanation for high FSW wages. The author cites 
reasons including risk, social exclusion and anti-social working hours, but does not 
empirically test the effect of these. Della Guista and colleagues describe an alternative 
(but not incompatible) model of sex-work to that of Edlund and Korn and argue that 
their framework “makes no restrictive assumptions regarding the gender, pay, and 
nature of forgone earning opportunities of prostitutes and clients”[76]. Instead, they 
explore the impact of reputational effects, suggesting that stigma plays an important role 
in determining the price and quantity of sex supplied. By construction, the model 
suggests that exogenous factors which decrease the probability of detection may 
increase the market for sex work. This hypothesis was later empirically tested by 
Cunningham and Kendall and found to be, to an extent, reflective of empirical evidence 
as street-based FSWs (who bear associated risks) moved to indoor working 
environments[44].  
81 
 
Willman’s [74] approach models the commercial sex market from a different conceptual 
direction, however, presents similar findings. The paper uses a human capability 
approach to describe the unfreedoms, which FSWs face, on a daily basis from threats of 
disease and violence. The freedom to live a life free of disease and premature death is 
critical constituent part of the capability approach and is a key indicator in the United 
Nations Development Programme’s Human Development Index[93, 94]. The key 
message from Willman’s paper is, although many FSWs can command prices that include 
a sufficient monetary premium for risky acts, there is no reason to think that all FSWs 
have equal access to such premiums. In reality, depending on their location in the 
(segmented) labour market, FSW demand for compensation may be constrained by their 
mobility within the labour market resulting in differential compensation across 
segments. Thus, FSWs who have greater human capital and operate in more upscale 
market segments have fewer incentives to take risks; when these FSWs do take risks, 
they are compensated more generously than women are in other segments. Willman’s 
model presents a more nuanced view than much of the literature on risk premiums, 
where a heterogeneous labour force offers a differentiated product to different clients. 
Although disproved to some extent by empirical work showing disease risk was more 
influential than segmentation of demand[40], this has implications for STI and HIV 
prevention programmes which should first target those FSWs most at risk from market 
forces to maximise benefit from limited resources. 
Finally, Cunningham predicts that women who face lower variable costs of supplying 
commercial sex (for example reduced marriage market opportunities or social stigma) 
will enter into the market more frequently[8]. When applied empirically, the model 
indicates that women who faced larger fixed costs but decided to enter the market 
receive larger weekly earnings, however, they do not receive higher hourly wages.  
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In general, economic theory offers a restrictive view on decisions to enter the 
commercial sex market. In the models presented here, women must forgo other life 
opportunities, for example marriage [1], or perceive there to be sufficiently low levels of 
stigma around sex work[92]. In addition, women are assumed to act rationally and with 
agency, with the ability to accurately weigh up the individual risks and benefits of 
becoming a sex worker, fully predicting and accounting for social stigma and threats to 
health and wellbeing. Whilst there is some evidence that this may be the case in some 
contexts (e.g. Willman [74] shows that human capital is associated with agency), a large 
body of non-economic literature has shown that a wide range of micro- and macro-
influences affect engagement in sex work. Many of these are not considered by the 
studies presented here, including, but not limited to, trafficking, poverty, family 
demands, partner coercion or violence [5, 95-98]. 
Market structure 
Six studies explore how the structure of the market for commercial sex can affect FSW 
behaviours, with research largely focusing on how the presence of intermediaries (e.g. 
pimps/madams) interacts with FSW agency and ability to make healthy and rational 
choices. [44, 48, 52, 61, 77, 81] 
For example, Li et al.[61] demonstrate that FSWs in Singapore have a high degree of 
agency in the absence of intermediaries and are able to discriminate between clients, 
despite substantial competition in supply. Similarly, Farmer and Horotwitz[77] suggest 
that the presence of pimps in sex work markets dictates how much consumer surplus is 
present, but does not diminish supplier surplus (i.e. it will only affect client welfare if 
pimps are present). These two studies are in contrast with much of the empirical social 
epidemiology literature which suggests pimps can be symptomatic of exploitative sex 
work arrangements (e.g.[2, 99-101]).  
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Advances in technology, in particular the influence of the internet on increasing safety 
and information exchange in sex work markets, is tackled by Cunningham[44] and 
Peppet[81] who suggest that the internet has encouraged FSWs to move from recruiting 
clients from the street (an often unsafe working environment which can generate 
substantial negative externalities) to the virtual space where FSWs reportedly have 
more agency and influence over protection and risk behaviours. Thus, the rise of online 
solicitation has replaced a good deal of streetwalking, yet this augmentation of the 
commercial sex market appears to have only occurred among some age groups of FSWs 
in high-income countries. Furthermore, FSWs who have moved from on-street to virtual 
recruitment appear to mostly “carry” risky behaviours with them, potentially creating 
new disease risks in the (previously relatively safe) indoor-sector. In addition, 
Cunningham and Kendall [48] describe how internet-based soliciting makes previously 
unenforceable contracts between clients and FSWs enforceable, as online systems of 
client reviews act as a form of reputation mechanism, improving information exchange 
and increasing the implications of breaching agreements.  
Taking a different approach, Ebenstein and Sharygin [52] estimate how demographic 
trends in China, in particular an increasing adult population sex ratio (a larger number 
of men compared to women), will impact the structure of the market for commercial sex. 
Although the authors predict that competition in the marriage market will lead to an 
increase in demand for commercial sex, particularly in rural areas, they do not link this 
data with epidemiological risk variation (e.g. HIV/STI prevalence), or explore how 
technology or the role of intermediaries might interact with risk.  
This small but burgeoning literature on how the internet and mobile technology is 
changing the market for commercial sex is an example of the strength of using formal 
economic models to describe complex market interactions. In particular, the role of 
agency and information – both previously controlled by intermediaries between FSWs 
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and clients – are changing with the advent of review websites, which facilitate contact 
and information exchange between FSWs and clients. These structural changes to the 
market are beginning to substantively change the extensive and intensive margin of the 
commercial sex industry across contexts. Future research to understand how these 
changes affect the risks FSWs face, and choices they make, will be critical to understand 
and minimise risks to FSW and client health. There is a clear need to update models and 
assumptions made in literature published before the advent of internet-based 
solicitation, and renewed focus on information and agency will likely offer important 
insights. 
Exogenous factors  
Seven papers considered the impact of exogenous economic factors on the market for 
commercial sex [33, 37, 46, 50-52, 70]. Three of these explore the response of women to 
exogenous income or health shocks (which themselves require large expenditure), 
specifically measuring their impact on engagement with sex work and the mix of services 
provided. Robinson and Yeh[33] find that FSWs in Kenya, on days when a household 
member falls ill, or when she recovers from an STI (argued to be exogenous by the 
authors), women are much more likely to see a client and provide riskier services such 
as unprotected or anal sex. In a different paper analysing the same sample, Robinson and 
Yeh[70] find that women use regular clients as a financial safety-net, where men “act like 
husbands” to provide money for rent, school fees or funeral expenses. When FSWs fall 
ill, regular clients contribute around 25% of the income shortfall from time lost working 
and contribute substantially to funeral costs. Similarly, de Walque et al.[50] find that 
food insecurity causes women who do not usually sell sex to enter the market, though 
do not investigate the impact on services supplied by full-time FSWs.  
Finally, events in the political world have been shown to impact the market for 
commercial sex through two routes. Firstly, Cunningham and Kendall[46] reinforce 
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previously mentioned literature around the flexibility of the supply-side of the market. 
They use a natural experiment of political conventions in the US to show that the supply 
of commercial sex is responsive to demand – convention presence led to a more than 
40% increase in adverts for sex work on classified advertisement websites. Secondly, 
Dupas and Robinson[51] show that two months of political instability after national 
elections in Kenya in 2007, led to large reductions in income, expenditure and 
consumption. Unable to access “adequate insurance or consumption smoothing devices” 
to manage income losses, more FSWs provided more, riskier sex than before the crisis. 
de Araujo[37] also shows that stability, political and economic, affects the amount and 
type of sex sold in commercial markets. Finally, Ebenstein and Sharygin[52] show that 
migration for economic reasons, a male-weights sex ratio, and observed willingness of 
married FSWs to provide unprotected sex have the potential to increase HIV and STI 
incidence. 
Though this section of the literature is small, it is clear that exogenous factors can 
substantively impact the commercial sex market and, notably from a public health 
perspective, affect risky behaviours alongside economic pricing and supply factors. 
There are an almost infinite number of potential exogenous factors that may affect,  
positively or negatively, the choices of FSWs and clients; it is impossible to have a 
coherent public health response to all. Yet some, for example elections or public holidays, 
may be more predictable than others, and interventions could be designed to address 
predictable shocks to the commercial sex market. Increasing the availability of credit, or 
providing of cash transfers to aid earnings and consumption smoothing, may be one such 
approach to reduce short-term financial vulnerability and subsequent provision of more 
lucrative risky acts. More research is needed into the mechanisms underlying 
behavioural responses to exogenous events to identify vulnerability-reducing solutions. 
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Conceptual framework 
Figure 4 displays the conceptual framework derived through this review. Risk 
behaviours of clients and FSWs are influenced by factors in the three categories used to 
synthesise studies. Act-level factors are the most proximal to choices and include FSW 
and client characteristics (including differential bargaining power between parties), 
alongside the influence of financial incentives to bear risk. System-level factors influence 
choices indirectly by shaping act-level factors and include legal frameworks (which can 
restrict the ability of FSWs to work in safer indoor environments), the presence of 
intermediaries such as pimps or madams and subsequent reductions in agency, and the 
extent to which competition from other providers may influence bargaining power. 
Finally, exogenous factors can impact choices directly, such as through increasing the 
amount of unprotected sex a FSW provides after an income shock, or through influencing 
broader pressures of such as increased competition from new entrants to the market.  
Figure 4: Conceptual framework to explore choices and behaviours in commercial 
sex 
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Discussion 
Overview of literature 
This paper comprehensively reviews the literature on the influence of economic factors 
on the choices of FSWs. 56 papers were identified, many of which included some 
empirical work. The largest body of the literature sought to estimate the effect of various 
FSW, client, or act characteristics on price – particularly seeking to identify the condom 
differential, the price premium for unprotected sex, which was estimated to be between 
9% and 81% in different contexts. The second largest body of work analyses or simulates 
the effect of legalising (or decriminalising) sex work on the number of women engaged 
in the industry, and the number and type of acts supplied. A body of conceptual and 
largely theoretical studies modelled FSW decisions to engage in the commercial sex 
industry at all (the extensive margin). Finally, a small number of papers examined the 
effect of seemingly unrelated events on the market for commercial sex. These papers 
particularly highlighted the fragile economic circumstances of those on the periphery of 
the commercial sex market, and the potential unmeasured consequences of exogenous 
shocks on the quantity and type of sex sold.  
Strengths of literature 
This review identified a large number of methodologically robust and theoretically 
coherent contributions to the economics of sex work. A strength of basing empirical 
analyses on formal economic theory is theoretical validity across settings, as shown by 
the multitude of empirical work using similar theoretical models in estimating a 
compensating differential for condom use. Even where models differ structurally, such 
as predicting the impact of sex work decriminalisation, common predictions of positive 
outcomes from decriminalisation, including lower rates of STI and HIV transmission and 
improved FSW security, provide greater validity as a whole body of evidence than the 
sum of parts.  
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Furthermore, many elements of the economic literature identified here are consistent 
with wider sociological and epidemiological work around factors on FSWs. Individual 
studies focus on one or two narrow areas of research. However, economic work covers 
a very wide range of issues affecting FSWs and their choices. This is exemplified by 
economic work tackling every structural determinant identified in Shannon et al.[5], 
many of which combine to affect HIV/STI acquisition and transmission dynamics among 
FSWs.  
Limitations of literature  
No study was found to consider the impact that new HIV prevention products might have 
on the choices and behaviours of FSWs. In fact, the only method of HIV or STI prevention 
considered by the economic literature to date is condoms despite a number of trials and 
demonstration projects for PrEP in recent years. Although consistent condom use is 
encouraged to continue during PrEP use[102], there is a concern that condom use will 
be reduced due to diminished risks of unprotected sex alongside incentives to use 
condoms for protection[103]. There is a need for the economic literature to engage with 
outstanding questions around the potential impact of PrEP on FSWs and clients. 
Many of the theoretical and empirical models in this paper make assumptions around 
the agency of FSWs, particularly the structural literature which assumes that women a) 
can adjust their supply of commercial sex acts according to demand, b) that they are 
empowered agents who (albeit with sometimes lower bargaining power than clients) 
are able to opt-out of providing risky, or any, commercial acts, and c) that FSWs are a 
broadly homogeneous group either within studies, across studies, or both. These 
assumptions may not hold for a number of reasons. 
Firstly, FSWs may not be able to adjust their supply of commercial acts if an intermediary 
is forcibly making women work. Although trafficking forms a large part of the policy 
discourse around sex work, other evidence shows that the majority of women engaged 
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in the sex industry, particularly in higher income countries, have not been 
trafficked[104]. Nevertheless, little attention is paid in this literature to the possibility 
that exploitation could be occurring, nor its potential impact. Furthermore, exploitative 
arrangements are not considered as a potential outcome of models of legalising sex 
work. Although not considered a significant negative outcome of legalisation, trafficking 
and exploitation should be considered and monitored as possible unintended outcomes.  
Secondly, the ability of a FSW to opt-out of providing any commercial act at all depends 
on a range of factors, including the physical location where she meets clients and the 
potential for violence and abuse, alongside the wider financial situation she and her 
family faces. Evidence from India has shown that enhancing the social cohesion of FSWs 
as part of a HIV prevention programme improved the programme and empowered 
women to refuse services to bad clients[105, 106]. Nonetheless, street-based FSWs face 
a considerably riskier working environment than their indoor-based peers, are more 
likely to suffer from violence from clients of police, and are less likely to participate in 
community-led programmes. Economic and epidemiological literatures also disagree on 
the impact of intermediaries in sex work; studies in this review imply that 
intermediaries are value-adding, whilst epidemiological studies conclude the 
opposite[2, 99-101]. More research is needed to explore this nuanced relationship. 
Third, although later literature (e.g. [72]) argues for a greater consideration of 
heterogeneity within and across studies, the majority of the literature focuses on 
eliciting whole-sample averages. FSWs are a highly heterogeneous group; studies 
characterise populations by age, country of work, workplace, ethnic background, or 
experience in the industry – for example – but there is no generalisable taxonomy of sex 
work, nor will the risks of working on the street compared to indoors be comparatively 
similar across countries. Economic models seek to do exactly this and describe sex work 
in a formally defined, generalisable manner. This may be, in part, due to the traditional 
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use of empirical data to prove overarching economic theories, however, does not suit the 
huge variation in sex work contexts. More focus could be placed on the heterogeneity 
across different sex work contexts, including the agency of FSWs compared to clients, 
their negotiation power and ability, and the market power they hold relative to other 
FSWs.  
Finally, none of the literature identified literature satisfactorily explores the nature of 
the complex, two-way relationship between condom use and price. Isolating the effect of 
condom use on price is an interesting economic question, but the estimating effect of 
price changes on condom use would provide important data for programmes seeking to 
increase the economic empowerment of FSWs. For example, a Mexican programme gave 
male sex workers cash transfers conditional on remaining STI free, a proxy outcome for 
consistent condom use[107]. 
Strengths and limitations of review 
This study is the first to comprehensively review the literature assessing how the choices 
and behaviours of FSW may be impacted by economic factors. It used a systematic search 
strategy to identify potentially relevant papers, and provides a comprehensive overview 
of the research that has been conducted on the economics of sex work. 
Although the review identified a large body of work, the range of topics potentially 
relevant to the research question, alongside the variation in terminology used to 
describe aspects of studies, may mean that potentially relevant studies were omitted. 
Although the risk of omission was reduced through snowballing and screening lists of 
studies which cited included studies, we cannot guarantee that all relevant studies were 
included. For example, authors of epidemiological studies or those published in 
biomedical journals may not use the explicitly economic terminology of the search 
strategy, nor necessarily cite papers from economic journals. This may mean results are 
biased against the inclusion of epidemiological or biomedical research. 
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Conclusion 
This comprehensive review synthesises the results of 44 studies exploring a range of 
macro- and micro-level factors on the choices of FSWs. Identified studies were found to 
fit into three broad categories: act- and individual-level factors, system-level factors, and 
exogenous factors. The generalisability of economic models offers advantages, and the 
wide range of economic work carried out on commercial sex work is consistent with 
public health and epidemiological findings. However, no studies explore the potential 
impact of new HIV prevention products, while included studies require assumptions 
around FSW agency which may not hold in all contexts. 
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Implications for thesis 
This thesis has the opportunity to contribute substantively to the literature by exploring 
the impact of new HIV prevention products on the choices of FSWs. PrEP use may inhibit 
condom use directly where FSWs substitute away from condoms due to intrinsic 
preferences against their use. However, where a price premium exists for condomless 
sex as shown in many contexts, the additional monetary incentive may lead to an 
additional risk compensation, through a reduction in condom use or increase in 
commercial sexual activity. Also, client preferences may also change after the 
introduction of PrEP if they infer a lower risk from demanding unprotected intercourse, 
increasing their willingness to pay for unprotected sex.  
Papers R3 and R4 seek to explore if these scenarios might happen and if they could 
matter. The results of this review were used to refine the scope of the FSW DCE, and 
contribute to the long-list of potential attributes which were after refined during pre-
piloting and testing.  
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Chapter 4: How well do discrete choice 
experiments predict health choices? A 
systematic review and meta-analysis of 
external validity 
Overview of paper 
Because DCEs can be used to assess preferences for products or services which do not 
yet exist, they are frequently used to predict end-user uptake. However, DCE predictions 
are sometimes perceived as inaccurate, largely due to hypothetical bias where 
respondents are not faced with a choice in reality. For DCEs to be effectively used to 
predict real world behaviours – as they are employed in this thesis – it is important to 
quantify the extent to which they may give misleading results.  
This research paper systematically reviews the health literature for studies comparing 
DCE predictions to observed choices made by individuals and uses meta-analytic 
methods to synthesise estimates of the predictive ability of DCEs. This paper meets the 
methodological objective 6, to assess the reliability of DCEs to predict health-related 
choices. It has been revised and resubmitted to the European Journal of Health 
Economics.  
This chapter provides evidence on the validity of using DCEs to parameterise uptake and 
risk compensation parameters in models, as applied in results papers R2 and R4. It also 
meets research objective 6, which will be described in the next chapter, to assess the 
reliability of DCEs to predict health-related choices. 
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Abstract 
Discrete choice experiments (DCEs) are economic tools which elicit the stated 
preferences of respondents. Because of their increasing importance in informing the 
design of health products and services, it is critical to understand the extent to which 
DCEs give reliable predictions outside of the experimental context. We systematically 
reviewed the literature published DCE studies comparing predictions to choices made 
in reality; we extracted individual-level data to estimate a bivariate mixed effects model 
of pooled sensitivity and specificity. Eight studies met the inclusion criteria, and six of 
these gave sufficient data for inclusion in a meta-analysis. Pooled sensitivity and 
specificity estimates were 88% (95%CI: 81%, 92%) and 34% (95%CI: 23%, 46%) 
respectively, and the area under the SROC curve (AUC) was 0.60 (95%CI: 0.55, 0.64). 
Results indicate that DCEs can produce reasonable predictions of health-related 
behaviours. There is a great need for future research on the external validity of DCEs, 
particularly empirical studies assessing predicted and revealed preferences of a 
representative sample of participants. 
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Introduction 
Discrete choice experiments (DCEs) ask participants to make choices between 
hypothetical alternatives, using choice modelling methods to analyse data.  They are 
attractive tools for research and policy as they offer a flexible methodology to estimate 
which attributes are important in decision making. Participants are asked to choose their 
preferred of, generally, between two and five alternatives over a number of choice tasks 
(usually around ten). Data are analysed using discrete choice models [1], the results of 
which can be used to determine the relative importance of different attributes to 
respondent choices. Results can also be used to predict demand, termed as market 
shares in the marketing literature[2]. DCEs are being increasingly used in health to study 
patient and/or physician preferences in academic studies, health technology 
assessments, and regulatory risk-benefit assessment [3, 4]. Particularly useful is the 
ability to include products or attributes in DCEs which do not exist in reality, and for 
which no observational or trial data exist [5].  
In recent years, DCEs have proven increasingly popular in the health domain, whilst a 
large (mostly non-health) economic literature has developed around the design, analysis 
and application of DCEs [2, 6, 7]. Yet DCEs ask respondents to make hypothetical choices, 
and it is important to ensure that they measure what researchers think that they do. 
Disparities between revealed and stated preference data are, in part, due to the 
hypothetical nature of DCE tasks; this divergence is termed hypothetical bias. There has 
been no widely accepted theory to explain hypothetical bias which, following Beck et al. 
[8], we define in this paper as discrepancies between preferences exhibited in DCEs to 
those exhibited in reality. Hypothetical bias may originate when choice tasks do not fully 
reflect reality in the nature or characteristics of choices, when respondents have 
incomplete preferences, or if respondents perceive a vested interest in over- or under-
stating the importance of particular attributes. 
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Where the true attributes of a good or service are known, predicted probability analysis 
(PPA) uses DCE results to predict utility-maximising choices. Under the assumption that 
individuals are rational, DCEs can approximate which choice people would make given 
the option in reality [9, 10]. PPA is common outside of health  and is increasingly being 
applied by health economists to predict demand for a range of health-related choices, 
including HIV prevention products [11], contraceptive services [12], vaccination [13] 
and migraine treatments [9]. 
In the early stages of introducing health products or services, there is often a great deal 
of uncertainty around their potential impact and subsequent cost-effectiveness. DCE 
predictions can be particularly useful for estimating the uptake of new products or 
services where observational data, from trials or pilot projects, are not available [12, 13]. 
In the absence of observational data, for example in from a pragmatic trial or 
demonstration project, “expert opinion” is often used to generate uptake predictions 
which are then commonly used to inform impact or cost-effectiveness models [14]. In a 
previous paper, the authors of this study suggest that DCEs can provide a useful 
empirical alternative to expert opinion, whist also offering additional benefit through 
accounting for synergistic relationships between different product and service 
attributes and use, which are commonly ignored[15]. 
Background on validity in DCEs 
In health, around 60% of studies include internal theoretical validity checks, whilst non-
satiation and transitivity tests are applied less frequently[3]. A recent study 
demonstrated that, of the 112 health DCEs published in 2015, 49% included at least one 
internal validity check, yet there were substantial differences in how researchers dealt 
with indications of poor validity i.e. 46% of studies using a dominance test excluded 
respondents who failed the test[18]. 
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By contrast, external validity is concerned with ensuring the comparability of 
hypothetical and actual choices. Because respondents are not obliged in reality to make 
the choices they indicate in a DCE, hypothetical bias may reduce the usefulness of DCE 
results [19, 20]. There have been some substantive contributions to the methodological 
literature on the external validity of DCEs (e.g. [16, 21-23]), yet much of the focus in the 
literature has been on maximising the internal validity of DCEs. Whilst this is important, 
there has been very little empirical work assessing whether choices made in DCEs in fact 
reflect those made in reality, or the circumstances in which they may offer more or less 
reliable inference[16].  
This paper considers variations in external validity in health DCEs attributable to 
hypothetical bias, and is the first systematic review and meta-analysis assessing the 
ability of DCEs to predict health behaviours. Proving external validity is important to the 
practical application and use of DCEs, yet despite their growing popularity there has 
been little research on their external validity in the health domain [22, 23].  
There are many reasons why hypothetical bias may exist, including that people may be 
fundamentally rational but inconsistent in utility maximisation, e.g. when they are 
paying more or less attention to a decision context. Indeed, the choice architecture 
surrounding real-world and hypothetical choices has been shown to affect choices, 
including healthy eating, physical activity, and alcohol use[24-26]. Furthermore, if DCEs 
are not incentive compatible, respondents may try and answer strategically, for example 
to understate their willingness to pay for public services[27, 28]. Behavioural economic 
research challenges the theory that we are all variants of homo economicus, but there has 
been limited work exploring if behavioural heuristics influence preferences to a greater 
or lesser extent in stated preference tasks than in reality [29, 30]. Additional reasons 
why differences may exist in health fields include: difficulties in acquiring revealed 
preference data due to failures in healthcare markets; the lack of a market analogue for 
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many health decisions; or vested interests from researchers not wanting to reveal the 
ability (or lack thereof) of DCE models to accurately predict choices and behaviour [21, 
23, 31, 32]. 
We note that literature exists, mostly outside of a health context, evaluating the external 
validity of WTP estimates from stated preference exercises. These exercises are different 
from DCEs whereby, instead of participants choosing between a set of alternatives, 
people are presented with open-ended questions, for example how much they would be 
willing to pay to avoid a certain occurrence. The external validity of WTP estimates has 
been explored fully and recently in the literature, and we therefore do not include WTP 
studies in this review. This work explores the external validity of willingness-to-pay 
estimates from contingent valuations and conjoint analyses, mostly in transport fields 
[33-35], including three meta-analyses [36-38]. These studies conclude that 
hypothetical bias can be substantial, with median bias levels ranging from 25% to 300%. 
Furthermore, efforts to reduce hypothetical bias through a number of methods, such as 
increasing consequentiality of choices or “cheap-talk” strategies, have also been shown 
to have mixed results [26, 39-41]. 
Rationale for review and aim 
There has been no synthesis of the predictive abilities of DCEs in health, despite a 
substantive and recent increase in the number of studies using estimated choice 
probabilities from DCEs to predict choices, e.g. [9, 42]. These studies implicitly assume 
that DCEs have sufficient external validity to provide meaningful results. More generally, 
there has been no systematic review of studies exploring the external validity of any 
stated preference tasks in health. Existing reviews focus on summarising DCE 
applications [3, 7, 43], collating preference research on particular health or disease areas 
[44, 45], or synthesising methodological innovations to maximise internal validity [46]. 
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This review aims to systematically review studies comparing stated preference choices, 
as modelled through predicted probability models resultant from DCE data, to revealed 
preference choices as gathered through observational or survey means. We report 
published evidence, describe the quality of included studies using an adapted quality 
checklist, and quantitatively synthesise the predictive ability of DCEs. 
This review is the first to systematically evaluate and synthesise studies which observe 
participants’ stated and revealed preferences through comparing DCE data to real-life 
health choices. Its findings will enable researchers and policymakers to assess how 
useful DCEs might be in predicting individual choices.. 
Methods 
Search strategy  
We searched the following databases to ensure a comprehensive exploration of the 
health, economic and decision science literature: 1) PubMed/Medline; 2) EMBASE; 3) 
CINAHL; 4) Econlit; 5) Social Policy and Practice; 6) Science Direct. An iterative strategy 
was employed and the references of identified articles examined by hand for further 
relevant material. The search included all available years up to August 2015. The 
following keywords (alongside relevant MeSH terms where databases permitted) were 
used to build the search strategy: 
 Discrete choice experiments (“discrete choice* OR choice experiment* OR stated 
preference* OR DCE OR conjoint analysis”) 
AND 
 External validity (“external validity OR predict* OR hypothetical bias* OR market 
share* OR revealed preference*”) 
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Inclusion and exclusion criteria 
We included studies using a discrete choice experiment methodology to predict health-
related choices and compared these predictions with observed choices in real-life. 
Studies were not excluded by population or the nature of choice tasks presented to 
participants. Studies obtaining revealed preference data from lab-based studies were 
excluded as these may be subject to similar concerns over external validity as DCEs 
themselves. The term conjoint analysis was explicitly included in the search strategy, 
and studies incorrectly labelled as conjoint analyses, when they were in fact DCEs, 
included in the screening process. We excluded: 
1. Studies using a preference elicitation method other than a discrete choice 
experiment (for example, contingent valuation or conjoint analyses);  
2. Studies using “lab-based” experiments to elicit revealed preferences; 
3. Letters, general commentaries or perspectives; 
4. Studies without English language titles or abstracts. 
Screening of Studies for Eligibility 
We imported all identified references into reference management software[47] and 
removed duplicates. First, titles and abstracts were screened by one researcher and 
irrelevant articles excluded. Secondly, the full text of selected papers was screened 
independently by two researchers against the eligibility criteria. Any disagreements 
were resolved by discussion. Records of studies were kept as per the Preferred 
Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) checklist [48]. 
Data were then extracted into a predefined extraction form. Where information was 
lacking, attempts were made to contact corresponding authors to obtain the maximum 
quantity of data. 
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Assessment of Study Quality 
The characteristics of included studies were assessed by two reviewers against a tool of 
17 criteria based on that of Mandeville et al. [43] which is itself an adaptation of the 
“good-practice” checklist of Lancsar and Louviere [49]. The quality criteria tool used is 
presented in supplementary material S1. We remove the criteria of using an efficient 
design, since this may not be an indicator of study quality, and the criteria of ensuring a 
sufficient response rate due to the subjectivity of what may be considered sufficient. In 
addition, we amend the criteria that attribute and level choice should be “grounded in 
qualitative work with the target population”, to “grounded in piloting work with the 
target population”. Mandeville et al.’s method only assesses criteria which may 
substantively affect the quality of included studies, thereby avoiding common criticisms 
of quality checklists that they are poorly correlated with study validity and measure the 
quality of reporting rather than that of the underlying study [50]. 
The checklist of Lancsar and Louviere does not consider external validity, except through 
the broad question “Was internal or external validity investigated?”. Therefore, we drop 
this criterion in favour of five further criteria to assess the reliability of external validity 
assessment. We based four of these criteria on Lancsar and Swait [51] who specify some 
testable reasons that stated preference models might fail to be externally valid. Finally, 
we note the potential for selection bias in studies where observational data were 
gathered on a non-random subset of DCE participants and include an additional criterion 
to ensure that we account for potential selection bias in comparisons between predicted 
and actual choices. Both reviewers independently evaluated the quality of included 
studies by assessing whether the criterion for each study wass met or not. If the 
information available for a criterion was insufficient to evaluate its achievement, we 
noted this as a separate category.  
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Statistical Analysis 
Because DCE predictions are a form of binary classification test, to synthesise the 
outcomes of included studies we employ the array of methods used in assessing clinical 
diagnostic tests. In the context of DCE predictions, high sensitivity (true positive rate) 
would indicate reliability in predicting opting-in behaviours. We define an opting-in 
behaviour as a choice, in the DCE or a real-world context, to use a product or service that 
a respondent does not currently use. . High specificity (true negative rate) would indicate 
reliability in predicting opting-out behaviours, which we define as a respondent 
choosing not to use a product or service in the DCE or real-world context. 
Synthesising sensitivity and specificity estimates requires more sophistication than 
other quantitative syntheses, due to between-study heterogeneity, and the correlation 
between sensitivity and specificity estimates. When differences between studies are 
thought to be only due to sampling variation, it would be appropriate to pool estimates 
though sample size weighted averages of sensitivity and specificity. However, it is likely 
that variability beyond chance can be attributed to between study differences (e.g. study 
design, method of data collection, context, interviewer or self-administration). Due to 
the range of DCE methods and study contexts, we use a random effects model to attempt 
to account for explainable and unexplainable heterogeneity [52]. 
There is likely to be interdependence between sensitivity and specificity measures 
which requires specific consideration in meta-analytic models [53]. To account for this, 
we use bivariate mixed-effects logistic regression through the midas command in STATA 
14, which assumes independent binomial distributions for true positives and negatives 
conditional on the sensitivity and specificity in each study [54, 55]. By jointly modelling 
sensitivity and specificity, this method preserves the bivariate data structure of the data 
and is an improvement on the standard analysis method of applying the DerSimonian 
and Laird random effects model [52]. The potential for publication bias was assessed 
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through Egger’s test[56]. No test for publication bias is without methodological 
issue[57], yet Egger’s test for funnel plot asymmetry is recommended for use by PRISMA 
guidelines[58].  
Finally, we conduct bivariate multivariable meta-regression to explore heterogeneity by 
regressing sensitivity and specificity estimates on five study-level characteristics: mode 
of DCE administration (paper/computer), whether the DCE is related to a prevention or 
treatment choice, the number of DCE choice sets, the number of alternatives within a 
choice set, and the percentage of DCE respondents for whom revealed preference data 
were analysed. The effect of each covariate on sensitivity and specificity is estimated 
separately[54].   
 
Results 
Figure 1 details the flow of papers through the study. In total, 6,383 studies were 
identified through database searching and one additional study identified through its 
presentation at a health economics conference. The full text of 13 articles was reviewed 
for eligibility, eight were considered for a qualitative synthesis, and six included 
sufficient quantitative information for inclusion in a meta-analysis. Figure 2 shows 
publications identified by year. 
Notably, there were very few studies which directly assessed the external validity of DCE 
predictions. Of the studies that have been published (two were found in pre-publication, 
conference abstract stage, one of which was published whilst this study was under 
review[59]), 5 (63%) were published since 2015, suggesting that the external validity of 
DCEs is receiving more attention than in the past. Seven studies (88%) sought to predict 
the choices of patients over a broad range of health choices, from vaccination to sexually-
transmitted infection testing to prospective mother’s choice of birth location. One study 
sought to predict the choices of healthcare professionals as they appraised new 
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medicines. Six studies (75%) presented information at the individual level and are 
included in the meta-analysis. 
Assessment of quality of included studies 
Results from the quality assessment of included studies are presented in supplementary 
material S2. Overall, the quality of studies was high; the design and implementation of 
DCEs were often of good quality. However, the additional criteria we add to explore the 
robustness of study external validity indicate some notable weaknesses. 
When assessed by criteria outside of those exploring external validity, the included 
studies were of high quality. For example, most DCEs were piloted in a relevant target 
population and allowed participants to “opt-out” of making a choice. However, included 
studies may be subject to selection bias. The response rate of the DCE task was often low, 
while data on actual behaviour was not gathered for the full sample of people who 
completed the DCE. If participants who did not complete the DCE, or who did and were 
not followed-up, are non-randomly different from those who were included in final 
analyses, systematic bias would be introduced into results. If participants were more 
likely to be included in follow-up when they opted-in to a choice, this would overstate 
the predictive ability of DCEs. 
We note that two studies meeting the inclusion criteria, Mohammadi et al. [60] and  Chua 
et al. [61], were identified in conference abstract form. Although the former was 
published as a full paper during the review process of this study[59], the latter was not 
and does not include sufficient information to assess against all quality criteria.  
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Figure 1: PRISMA diagram of review process 
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Figure 2: Summary of publication date of included studies 
 
Quantitative synthesis 
Table 1 presents information on all included studies, while table 2 displays the data 
extracted to assess the predictive ability of DCEs. We consider 844 observations where 
opt-in or opt-out choices were correctly predicted 75% of the time; 65% of incorrect 
predictions were false positives. Figure 3 displays the sensitivity and specificity 
estimates for each study2. These estimates were calculated from the raw data. 
In this context, DCEs predict that an individual will either make or not make a particular 
choice in reality. Therefore, a higher sensitivity would indicate that DCEs are good at 
predicting when individuals would choose reality, while a higher specificity would 
indicate that DCEs reliably predict that individuals will not make a particular choice.  
We use a bivariate random-effects model to account for substantive heterogeneity 
between studies, and produce pooled estimates of sensitivity and specificity. Pooled 
estimation suggests that the sensitivity of DCE predictions was relatively high (0.88 95% 
CI: 0.81, 0.92), whilst specificity was substantially lower (0.34, 95% CI: 0.23, 0.46). These 
                                                             
2 One study (Krucien et al.) predicts the uptake of two treatments, and we present each separately 
in this analysis 
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results suggest that DCEs can be moderately informative for predicting future behaviour. 
Specifically, when DCE data suggest that somebody will behave in a certain way (for 
example, opting for a treatment or programme), this is a more reliable statement than 
when DCEs suggest somebody will not behave in a certain way (for example, they will 
not use a treatment or programme). There is no consistent pattern of the number of false 
positives outweighing the number of false negatives, however it is possible that 
imperfect sensitivity may result in DCEs over-predicting demand.  For the remainder of 
this paper, we will use the term "opt-in" to denote those participants who the DCE 
predicts would use a product or service.  
As sensitivity and specificity estimates are pooled through bivariate random effects 
modelling, we expect the two estimates to be interdependent. Supplementary material 
S3 shows a bivariate box plot which describes the extent to which sensitivity and 
specificity are interdependent with the inner oval representing the median distribution 
of estimates, and the outer oval the 95% confidence bound. These results indicate that 
there was a degree of heterogeneity between included studies, as three reside outside of 
the median distribution while one study tends towards being defined an outlier. There 
was no strong indication of a skew towards sensitivity or specificity. According to 
Egger’s test there was no evidence of publication bias (p=0.56), however the capacity for 
this test to detect publication bias from a limited number of small studies is limited [56]. 
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Table 1: Characteristics of included studies 
No. 
Authors 
Publication 
Year Title and Journal 
Place of DCE 
Deployment Sample Size* Survey Mode Study objective 
1 
Krucien et al. 
[62] 2015 
Empirical Testing of the 
External Validity of a Discrete 
Choice Experiment to 
Determine Preferred Treatment 
Option: The Case of Sleep 
Apnea, Health Economics 
Patient group in a 
French hospital's sleep 
unit 
SP: 140, RP: 138 
(99% follow-up) 
Face-to-face 
interview with 
trained nurse 
To explore patient 
preferences for alternative 
treatments for obstructive 
sleep apnea syndrome 
(OSAS) 
2 
Lambooij et 
al. [63] 2015 
Consistency between stated and 
revealed preferences: a discrete 
choice experiment and a 
behavioural experiment on 
vaccination behaviour 
compared, BMC Research 
Methodology 
Parents with child <2 
weeks old in The 
Netherlands 
SP: 906, RP:247 
(27% follow-up) 
Paper-based 
questionnaires, 
medical records 
To compare vaccination 
scenarios against hepatitis B 
among the parents of 
newborn children 
3 
Mohammadi 
et al. [59] 2015 
Testing the External Validity of 
a Discrete Choice Experiment 
Method: An Application to 
Latent Tuberculosis Infection 
Treatment, Value in Health.  
Patients diagnosed 
with latent TB 
infection attending TB 
clinics in British 
Columbia, Canada 
SP: 214, RP: 204 
(95% follow-up) 
Not reported in 
abstract 
To explore patient 
preferences for latent TB 
treatment, and predict 
uptake  
4 
Salampessy 
et al. [64] 2015 
The Predictive Value of Discrete 
Choice Experiments in Public 
Health: An Exploratory 
Application, Patient 
Patient group in 
Utrecht, The 
Netherlands 
SP: 206, RP: 54 
(26% follow-up) 
Paper-based 
questionnaires, 
medical records 
To assess the willingness of 
Type 2 diabetes mellitus 
patients to participate in a 
combined lifestyle 
intervention 
5 
Ryan and 
Watson [65] 2009 
Comparing welfare estimates 
from payment card contingent 
valuation and discrete choice 
experiments, Health Economics 
Attendees of a family 
planning clinic, UK 
SP: 142, RP: 111 
(78% follow-up) 
Paper based 
questionnaire 
To assess the willigness to 
pay of women to receive 
chlamydia screening 
6 
Chua et al. 
[61] 2016 
External validity of discrete 
choice experiment: findings 
from a field experiment. 
Conference paper.  
Attendees of 
pharmacies in UK 
SP: 423 RP: 258 
(61% follow-up) Computer tablet 
To explore patient 
preference for pharmacy-
based health checks 
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7 
Kruk et al. 
[66] 2009 
Women's preferences for place 
of delivery in rural Tanzania: a 
population-based discrete 
choice experiment, American 
Journal of Public Health 
General population 
survey (household), 
Kasulu District, 
Tanzania SP: 1,205 
Paper-based 
questionnaires. RP 
data from census 
To evaluate health-system 
factors which influence 
women's delivery decisions 
8 
Linley and 
Hughes [67] 2013 
Decision-makers' preferences 
for approving new medicines in 
Wales: a discrete-choice 
experiment with assessment of 
external validity, 
Pharmacoeconomics 
Past and present 
members of the All 
Wales Medicines 
Strategy Group 
(AWMSG) SP: 41 
Anonymous online 
questionnaire 
To explore the preferences 
of the AWMSG appraisal 
committee and appraisal 
sub-committee for specific 
new medicines adoption 
criteria 
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Table 2: Extracted data for individual-level meta-analysis 
No. Authors Outcome 
True 
Positives 
True 
Negatives 
False 
Positives 
False 
Negatives Accuracy Sensitivity Specificity PPV NPV 
1 Krucien et al. CPAP 37 1 2 9 0.78 0.80 0.33 0.95 0.10 
2 Krucien et al. OAs 36 1 1 13 0.73 0.73 0.50 0.97 0.07 
3 Lambooij et al. All Outcomes 191 6 33 17 0.80 0.92 0.15 0.85 0.26 
4 Mohammadi et al. All Outcomes 147 21 30 6 0.82 0.96 0.41 0.83 0.78 
5 Salampessy et al. All Outcomes 36 4 9 5 0.74 0.88 0.31 0.80 0.44 
6 Ryan and Watson All Outcomes 88 2 2 19 0.81 0.82 0.50 0.98 0.10 
7 Chua et al. All Outcomes 30 36 58 4 0.52 0.88 0.38 0.34 0.90 
8 Kruk et al. All Outcomes N/A N/A N/A N/A  N/A   N/A   N/A   N/A   N/A  
9 
Linley and 
Hughes All Outcomes 25 12 N/A N/A 0.64  N/A   N/A   N/A   N/A  
N.b. Kruk et al. and Linley and Hughes do not contain sufficient data for inclusion in a meta-analysis
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Figure 3: Synthesis of Sensitivity and Specificity of DCE predictions  
 
 
Visual examination of results, shown in Figure 3, suggests that there was substantial 
between-study variation. The quantity I2 statistic describes the percentage of total 
variation across studies which can be attributed to heterogeneity rather than due to 
chance, where an I2 of 0% indicates that there was no heterogeneity between studies 
while an I2 of above 50% suggests substantial heterogeneity [54, 68]. The I2 estimates 
for sensitivity and specificity are 64% and 58% respectively, indicating that while there 
was substantial heterogeneity in both measures, estimates of sensitivity were subject to 
greater variation. Finally, we assessed publication bias through Egger’s test which 
suggests no evidence of publication bias (p=0.56). However the capacity for this test to 
detect publication bias from a limited number of small studies is limited [56]. 
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Under the presence of heterogeneity, summary receiver operating characteristic (SROC) 
curves can be used to display the results of syntheses where the higher the combined 
sensitivity and specificity of a test (i.e. the greater true positive rate), the closer the SROC 
curve will be to the top left of the SROC space [53]. Figure 4 shows the SROC for included 
studies, where the curve represents the relationship between the true and false positive 
rates across studies and was fitted to the data through least-squares regression [69]. The 
area under the SROC curve (AUC) can be a useful summary statistic of predictive ability, 
and the AUC we present in Figure 4 (0.60 [95%CI: 0.55, 0.64]) provides further evidence 
that DCEs have a moderate ability to predict choices; although there are no firm limits 
for “good” AUCs, meta-analyses of diagnostic tests infer a similar conclusions [70, 71].  
Figure 4: Summary Receiver-Operator Curve (SROC) of included studies 
 
Finally, the results of univariable meta-regression are presented in Figure 5 and show 
that, even among the small number of studies, the specificity of DCE predictions is 
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significantly and positively associated with the SP/RP response rate, alongside the 
number of alternatives shown in choice tasks. No factor is significantly associated with 
greater or lower sensitivity. These results will become more precise and allow greater 
influence as more studies are published assessing the predictive ability of DCEs. 
Figure 5: Meta-regression results 
  
Paper-based
Computer-based
Treatment-related
Prevention-related
No. choice sets
No. alternatives
RP/SP responses
0.41 0.97
Sensitivity(95% CI)
*p<0.05, **p<0.01, ***p<0.001
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Computer-based
Treatment-related
Prevention-related
No. choice sets
*No. alternatives
*RP/SP responses
0.13 0.96
Specificity(95% CI)
*p<0.05, **p<0.01, ***p<0.001
Univariable Meta-regression & Subgroup Analyses
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Discussion 
This paper reports the results of a systematic literature review and meta-analysis and 
proposes a method to strengthen predictions made from DCE data. The systematic 
review identified seven studies as meeting the inclusion criteria. The meta-analysis of 
six studies with individual-level data found that DCEs have moderate, but not 
exceptional, accuracy when predicting health-related choices. Pooled sensitivity and 
specificity estimates were 88% (95%CI: 81%, 92%) and 34% (95%CI: 23%, 46%) 
respectively. All DCEs included in this review were exploring opting-in behaviours, and 
the mean observed uptake of options across all studies in this review was high at 76% 
(638 out of 844 observations). Only one study reported a measure of uncertainty around 
uptake predictions. The sensitivity of predictions was found to be greater than their 
specificity, suggesting that DCEs are better at predicting who would opt-in to a health-
related decision rather than who would not. Overall, the review found very few studies 
comparing DCE predictions to observed choices at an individual level, and this is a key 
priority for future research. 
We explored heterogeneity through use of meta-regression by incorporating study-level 
characteristics into bivariate mixed effects models, and found evidence that the RP/SP 
follow-up rate and the number of alternatives presented to respondents were positively 
associated with estimates of specificity, but not sensitivity. This study, being the first to 
synthesise evidence on the predictive ability of DCEs, is the first to show the extent of 
the heterogeneity in specificity when predicting behaviours, and care is needed when 
interpreting the results of DCE predictions. Due to the low number of studies in the 
literature, this analysis was underpowered and future research should focus on 
identifying the determinants of DCE external validity in order that DCEs and prediction 
methods give predictions with the greatest accuracy.  
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The finding that opt-in predictions from DCEs are reliable is useful for planning 
interventions and programmes. This quantification of how well DCEs predict behaviour 
could be used to explicitly account for uncertainty in DCE predictions, for example by 
using the pooled sensitivity point estimate and confidence intervals from this study to 
give upper- and lower-bounds of opting-in behaviours. Accounting for the variation in 
DCE prediction accuracy in this manner would make for more robust uptake and impact 
models. Although the pooled specificity estimate suggests that DCEs are not good 
predictors of opting out behaviour (i.e. should not be trusted when predicting that 
someone will not uptake a product or service), the pooled sensitivity estimate was 
relatively high and precise making it suitable for this application. 
When considering how useful DCEs are in predicting behaviour, we must consider the 
alternative data sources available to decision makers. When predicting the demand for 
new health products or services, there is likely to be almost no information to base these 
forecasts on. One option is to run a pilot study or demonstration project; however, even 
on a small-scale, these can be both expensive and time-consuming. Another option 
would be to canvass expert opinion; however, even experts with the best of intentions 
can be incorrect or biased in their estimates. In such instances, DCEs can provide a 
relatively accurate and cost-effective option to predict individual choices. DCEs have 
been proposed for use to parameterise uptake and use parameters in health economic 
modelling[15], and if used for this purpose, parameter uncertainty could be partly 
accounted for using estimates from this review to adjust uptake estimates.  
There may be some reasons why observed choices may be different to those predicted 
by DCEs. Firstly, the information presented in DCE choice tasks is necessarily a 
simplification of reality. Even in the case of high-quality DCEs, there are likely to be 
unobserved attributes present in real life decisions that were not, or poorly, accounted 
for in the DCE. Where these unobserved attributes influence the decisions of 
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participants, stated and revealed preferences will be based on heterogeneous choice 
attributes and may diverge. Even high-quality DCEs are unlikely to fully capture all 
relevant attributes of choice. 
Secondly, DCE predictions may suffer from the intention-behaviour gap where 
individuals do not always ultimately behave in ways which they might intend to [72, 73]. 
For example, when people are a long way ahead of making a choice, they are more likely 
to commit to a substantial course of action (such as giving up smoking), however as they 
move closer to the choice situation they are more likely to choose the smaller reward 
(have a cigarette). This hyperbolic discounting suggests the passage of time changes the 
perception of the situation and choices, potentially explaining variation between DCE 
predictions and actual behaviour . 
Results assume that there is a generalisable and measurable concept of DCE external 
validity. However this review was limited by the small number of studies identified 
which met the inclusion criteria. This meant that we were unable to undertake a 
meaningful analysis of where DCEs may provide more or less accurate predictions. For 
example, Ryan and Watson [65] find that a DCE for chlamydia screening has a high false 
negative rate (where more people screened in reality than predicted in the DCE), 
whereas Mohammadi et al. [59] find a high false positive rate of DCEs predicting 
treatment for tuberculosis (where the DCE over-predicted successful treatment). With a 
larger number of studies, it would have been interesting to explore whether such 
divergent results may have been down to study context (treatment requires continued 
adherence and not just a one-off action), cognitive biases (perhaps social desirability 
bias to predict successful treatment or not disclose demand for a chlamydia test outside 
of a consultation environment), or other reasons. 
The meta-analytic tools used in this review are often employed to assess diagnostic tests, 
with the data normally used to assess these tests gathered in strictly controlled 
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environments. In contrast, the DCEs in this study cover a range of health choices across 
a broad range of populations, and it is perhaps no surprise that there was substantial 
heterogeneity between studies. Finally, predicted probabilities are just one 
interpretation of DCE results. Although probabilities are calculated using the coefficients 
of DCE models, this review explores just one interpretation of DCE results. 
When compared against existing quality assessment tools, the quality of the included 
studies was high. However, when assessed against the additional external validity 
criteria, all but two studies were substantially prone to selection bias. As none of these 
studies gave any detail as to how participants were selected for follow-up, we are unable 
to fully assess how reliable these estimates might be.  
A limitation of this review is the assessment of DCE predictive ability, which is just one 
facet of external validity. Assessing the external validity of WTP estimates was beyond 
the scope of this review, whilst the external validity of WTP estimates have been robustly 
assessed in three systematic reviews and meta-analyses since 2004 [36-38]. In addition, 
included studies must have been able to define participants’ choice sets in the real world, 
implicitly limiting the scope of this review to predictions of choices within choice sets 
which can be represented consistently in a stable manner across real-world and 
hypothetical tasks e.g. uptake of a test, but not adherence to a treatment over time.  
Although the sample size of included studies was incorporated in the standard error 
around pooled estimates, we are not able to account for potential publication or 
selection biases. The pooled sensitivity estimates are based on a multi-stage follow-up – 
participants must initially consent to participate in a DCE, then be successfully followed 
up to ascertain whether or not they engaged in a predicted behaviour. A recent meta-
analysis indicates that the response rates to DCE surveys is often relatively low, and 
varies according to contextual factors such as the number of attributes or population 
surveyed [74]. This review could not incorporate divergent choices from those who did 
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not respond to DCEs in these samples, nor those who were lost to follow-up. Non-
responders or those lost to follow-up may be systematically different from the included 
sample. Finally, we did not assess the internal validity of included studies. Although DCEs 
may vary in their predictive power absolute terms, the choice modelling literature 
suggests that their ability to give reliable data on the relative impact of some factors on 
choices is much more robust.  
Conclusion 
This study sought to systematically review the external validity of DCEs and is the first 
to synthesise studies assessing the predictive ability of DCEs in health. Seven studies 
were identified as meeting the inclusion criteria, and a meta-analysis of six studies with 
individual-level data found that DCEs have moderate, but not exceptional, accuracy 
when predicting health-related choices. Pooled sensitivity and specificity estimates were 
88% (95%CI: 81%, 92%) and 34% (95%CI: 23%, 46%) respectively. This review and 
meta-analysis suggests that DCEs can be useful in predicting real-world behaviour, and 
provides important estimates of sensitivity and specificity which can be explicitly 
incorporated into impact and economic models. There is a substantial need for more 
evidence on how DCE predictions compare to real-world choices.
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Supplementary material S1: Criteria for assessment of study quality 
Section Criteria Justification 
Choice Task 
Design 
Choice of attributes and levels 
grounded in qualitative work with 
target population 
Attributes and levels should be salient to the target population to ensure comprehension 
and engagement with the choice task 
Choice Task 
Design 
No conceptual overlap between 
attributes 
Attributes should be conceptually distinct and vary independently of each other, otherwise 
effects will not be independent 
Choice Task 
Design Uni-dimensional attributes 
Attributes that encompass several aspects of an attribute introduce variability into the 
choice process as participants may focus on different aspects and the resulting preferences 
can only be interpreted as being for all dimensions 
Choice Task 
Design 
Inclusion of an opt-out or status quo 
option or justification of forced choice 
Choices that force participants to accept an unappealing choice are likely to lead to 
overestimation of preferences 
Conduct 
Piloting conducted amongst target 
population 
Validity of choice task design and questionnaire features should be tested with participants 
from target population and subgroups 
Conduct 
Target population(s) appropriate for 
research objective Preferences of target population should be sufficient to answer research objective 
Conduct 
Sampling frame representative of 
target population Sampling frames that exclude part of the target population may lead to bias in preferences 
Analysis 
Any pooled analysis from different 
subgroups appropriate 
Pooled analyses from very heterogeneous subgroups may mask marked differences in 
preferences 
Analysis 
Econometric model appropriate for 
choice task design 
Model should be appropriate for the choice task and number of alternatives presented to 
participants 
Analysis 
Econometric model accounts for serial 
correlation of choices 
As multiple observations are obtained from each participant, the econometric model 
should take account of panel nature of data to avoid overestimation of the differences 
between preferences 
Analysis 
Relative attribute effects compared 
using a common metric 
Preferences for different attributes cannot be compared directly using parameter 
estimates due to confounding with the underlying utility scales 
External 
validity  
The same available set of alternatives 
are available in both environments 
For predictions to be valid, participants must have the opportunity to choose from the 
same alternatives in both RP and SP choices 
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Section Criteria Justification 
External 
validity  Linear-in-parameters evaluations Models which are non-linear in parameters may give misleading results 
External 
validity  
Using the identical full information set 
of attributes in both environments 
If participants are presented with more or less information in RP or SP tasks, this may bias 
results 
External 
validity  
Common utility maximising decision 
rule implicit in the MNL formation 
To remain grounded in random utility theory (RUT), the participants must be assumed to 
make decisions based on the alternative which gives them the greatest utility 
External 
validity  
Revealed preferences are obtained for 
all, or from a random subset, of 
respondents 
Where revealed preferences are elicited from a non-random subsample of participants, 
selection bias may distort results 
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Supplementary material S2: Quality assessment 
 
 
  
Section Criteria Krucien et al. Lambooij et al.
Salampessy
 et al.
Ryan and 
Watson
Mohammadi et 
al. Chua et al. Kruk et al.
Linley and 
Hughes
Choice Task Design
Choice of attributes and levels grounded in 
qualitative work with target population
Choice Task Design No conceptual overlap between attributes
Choice Task Design Uni-dimensional attributes
Choice Task Design
Inclusion of an opt-out or status quo option or 
justification of forced choice
Conduct Piloting conducted amongst target population
Conduct
Target population(s) appropriate for research 
objective
Conduct
Sampling frame representative of target 
population
Analysis
Any pooled analysis from different subgroups 
appropriate
N/A (no 
subgroups)
N/A (no 
subgroups)
N/A (no 
subgroups)
N/A (no 
subgroups)
N/A (no 
subgroups)
N/A (no 
subgroups)
N/A (no 
subgroups)
N/A (no 
subgroups)
Analysis
Econometric model appropriate for choice task 
design
Analysis
Econometric model accounts for serial 
correlation of choices
External validity 
The same available set of alternatives are 
available in both environments
N/A (unlabelled 
DCE)
External validity Linear-in-parameters evaluations
External validity 
Using the identical full information set of 
attributes in both environments
External validity 
Common utility maximising decision rule 
implicit in the MNL formation
External validity 
Revealed preferences are obtained for all 
participants, or from a random sample of 
respondents N/A N/A
Meets criteria
Unclear 
Does not meet criteria
N/A Not applicable
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Supplementary material S3: Bivariate boxplot of sensitivity and specificity 
estimates 
 
 
 
  
1
2
6
4
5
3
1
2
3
4
L
o
g
it
(S
e
n
s
it
iv
it
y
)
-2 -1 0 1
Logit(Specificity)
Bivariate Boxplot
130 
 
References 
1. McFadden, D., Conditional logit analysis of qualitative choice behaviour, in 
Frontiers in econometrics, P. Zarembka, Editor. 1974, Academic Press: New York. 
2. Hensher, D., J. Rose, and W. Greene, Applied Choice Analysis: Second Edition. 2015, 
Cambridge: Cambridge University Press. 
3. Clark, M.D., et al., Discrete choice experiments in health economics: a review of the 
literature. Pharmacoeconomics, 2014. 32(9): p. 883-902. 
4. Muhlbacher, A.C., et al., Preferences for antiviral therapy of chronic hepatitis C: a 
discrete choice experiment. Eur J Health Econ, 2017. 18(2): p. 155-165. 
5. Louviere, J.J. and E. Lancsar, Choice experiments in health: the good, the bad, the 
ugly and toward a brighter future. Health Econ Policy Law, 2009. 4(Pt 4): p. 527-
46. 
6. Ben-Akiva, M.E. and S.R. Lerman, Discrete Choice Analysis: Theory and Application 
to Travel Demand. 1985, Boston: MIT Press. 
7. de Bekker-Grob, E.W., M. Ryan, and K. Gerard, Discrete choice experiments in 
health economics: a review of the literature. Health Econ, 2012. 21(2): p. 145-72. 
8. Beck, M.J., S. Fifer, and J.M. Rose, Can you ever be certain? Reducing hypothetical 
bias in stated choice experiments via respondent reported choice certainty. 
Transportation Research Part B: Methodological, 2016. 89: p. 149-167. 
9. Bingham, M.F., F.R. Johnson, and D. Miller, Modeling choice behavior for new 
pharmaceutical products. Value Health, 2001. 4(1): p. 32-44. 
10. McFadden, D.L., Chapter 24 Econometric analysis of qualitative response models, 
in Handbook of Econometrics, G. Zvi and D.I. Michael, Editors. 1984, Elsevier. p. 
1395-1457. 
11. Quaife, M., et al., The cost-effectiveness of multipurpose HIV and pregnancy 
prevention technologies in South Africa. Journal of the International AIDS Society, 
2018. 
12. Fiebig, D.G., et al., Preferences for new and existing contraceptive products. Health 
Econ, 2011. 20 Suppl 1: p. 35-52. 
13. Hall, J., et al., Using stated preference discrete choice modelling to evaluate the 
introduction of varicella vaccination. Health Econ, 2002. 11(5): p. 457-65. 
14. Terris-Prestholt, F., et al., How much demand for New HIV prevention technologies 
can we really expect? Results from a discrete choice experiment in South Africa. 
PLoS One, 2013. 8(12): p. e83193. 
15. Terris-Prestholt, F., M. Quaife, and P. Vickerman, Parameterising User Uptake in 
Economic Evaluations: The role of discrete choice experiments. Health Economics, 
2016. 25: p. 116-123. 
16. Lancsar, E. and J. Swait, Reconceptualising the External Validity of Discrete Choice 
Experiments. Pharmacoeconomics, 2014. 32((Lancsar) Centre for Health 
Economics, Monash University, Melbourne, Australia): p. 951-965. 
17. Lancsar, E. and J. Louviere, Deleting 'irrational' responses from discrete choice 
experiments: a case of investigating or imposing preferences? Health Econ, 2006. 
15(8): p. 797-811. 
18. Schmidt-Ott, T., et al. Rationality tests in Discrete Choice Experiments ‐ the pros 
and cons of testing dominant alternatives. in 7th Meeting of the International 
Academy of Health Preference Research. 2017. Glasgow, UK. 
19. Mitchell, R.C. and R.T. Carson, Using surveys to value public goods: the contigent 
valuation method. 1989: Hopkins University Press. 
20. Cummings, R.G., S. Brookshire, and W.D. Schulze, Valuing Environmental Goods: 
A State of the Arts Assessment of the Contingent Valuation Method, Volume I.B of 
Experimental Methods for Assessing Environmental Benefits. 1986, Rowman and 
Allanheld: Totowa, NJ. 
131 
 
21. Hensher, D.A. Hypothetical Bias, Choice Experiments and Willingness to Pay. 2010 
July 2010// [cited 44; 6:[735-52]. 
22. Ryan, M. and K. Gerard, Using discrete choice experiments to value health care 
programmes: current practice and future research reflections. Appl Health Econ 
Health Policy, 2003. 2(1): p. 55-64. 
23. Telser, H. and P. Zweifel, Validity of discrete-choice experiments evidence for 
health risk reduction. Applied Economics, 2007. 39(1): p. 69-78. 
24. Hollands, G.J., et al., Altering micro-environments to change population health 
behaviour: towards an evidence base for choice architecture interventions. BMC 
Public Health, 2013. 13(1): p. 1218. 
25. Barrage, L. and M.S. Lee. A Penny for Your Thoughts: Inducing Truth-Telling in 
Stated Preference Elicitation. 2010 February 2010// [cited 106; 2:[140-42]. 
26. Bosworth, R. and L.O. Taylor. Hypothetical Bias in Choice Experiments: Is Cheap 
Talk Effective at Eliminating Bias on the Intensive and Extensive Margins of 
Choice? 2012 January 2012// [cited 12; 1:[ 
27. Lusk, J.L. and T.C. Schroeder, Are Choice Experiments Incentive Compatible? A Test 
with Quality Differentiated Beef Steaks. American Journal of Agricultural 
Economics, 2004. 86(2): p. 467-482. 
28. McCartney, A. and J. Cleland, Choice Experiment Framing and Incentive 
Compatibility: observations from public focus groups. 2010. 
29. Neuman, E., Reference-dependent preferences for maternity wards: an exploration 
of two reference points. Health Psychology and Behavioral Medicine, 2014. 2(1): 
p. 440-447. 
30. Howard, K. and G. Salkeld, Does Attribute Framing in Discrete Choice Experiments 
Influence Willingness to Pay? Results from a Discrete Choice Experiment in 
Screening for Colorectal Cancer. Value in Health, 2009. 12(2): p. 354-363. 
31. Lancsar, E. and J. Swait. Reconceptualising the External Validity of Discrete Choice 
Experiments. 2014  [cited 32 (Lancsar) Centre for Health Economics, Monash 
University, Melbourne, Australia]; 10:[951-965]. Available from: 
http://rd.springer.com/journal/40273 
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&NEWS=N&A
N=2015639269. 
32. Vossler, C.A. and S.B. Watson, Understanding the consequences of 
consequentiality: Testing the validity of stated preferences in the field. Journal of 
Economic Behavior & Organization, 2013. 86: p. 137-147. 
33. Brownstone, D. and K.A. Small, Valuing time and reliability: assessing the evidence 
from road pricing demonstrations. Transportation Research Part A: Policy and 
Practice, 2005. 39(4): p. 279-293. 
34. Isacsson, G., The trade off between time and money: Is there a difference between 
real and hypothetical choices? 2007. 
35. Loomis, J. What's to Know about Hypothetical Bias in Stated Preference Valuation 
Studies? 2011 April 2011// [cited 25; 2:[363-70]. 
36. Murphy, J.J., et al. A Meta-analysis of Hypothetical Bias in Stated Preference 
Valuation. 2005 March 2005// [cited 30; 3:[313-25]. 
37. List, J. and C. Gallet, What Experimental Protocol Influence Disparities Between 
Actual and Hypothetical Stated Values? Environmental and Resource Economics, 
2001. 20(3): p. 241-254. 
38. Little, J. and R. Berrens, Explaining disparities between actual and hypothetical 
stated values: further investigation using meta-analysis. Economics Bulletin, 
2004. 3(6): p. 1-13. 
39. Alpizar, F., F. Carlsson, and O. Johansson-Stenman, Does Context Matter More for 
Hypothetical Than for Actual Contributions? Evidence from a Natural Field 
Experiment. Experimental Economics, 2008. 11: p. 299-314. 
132 
 
40. Silva, A., et al. Can Perceived Task Complexity Influence Cheap Talk's Effectiveness 
in Reducing Hypothetical Bias in Stated Choice Studies? 2012 November-
December 2012// [cited 19; 16-18:[1711-14]. 
41. Ready, R.C., P.A. Champ, and J.L. Lawton. Using Respondent Uncertainty to 
Mitigate Hypothetical Bias in a Stated Choice Experiment. 2010 May 2010// [cited 
86; 2:[363-81]. 
42. Viney, R., E. Lancsar, and J. Louviere, Discrete choice experiments to measure 
consumer preferences for health and healthcare. Expert Rev Pharmacoecon 
Outcomes Res, 2002. 2(4): p. 319-26. 
43. Mandeville, K.L., M. Lagarde, and K. Hanson, The use of discrete choice 
experiments to inform health workforce policy: a systematic review. BMC Health 
Serv Res, 2014. 14: p. 367. 
44. Purnell, T.S., et al., Patient Preferences for Noninsulin Diabetes Medications: A 
Systematic Review. Diabetes Care, 2014. 37(7): p. 2055-2062. 
45. Lewis, R.A., et al., Patients' and healthcare professionals' views of cancer follow-
up: systematic review. Br J Gen Pract, 2009. 59(564): p. e248-59. 
46. Harrison, M., et al., Risk as an attribute in discrete choice experiments: a systematic 
review of the literature. The Patient-Patient-Centered Outcomes Research, 2014. 
7(2): p. 151-170. 
47. Thompson Reuters, EndNote X7. 2013. 
48. Moher, D., et al., Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med, 2009. 6(7): p. e1000097. 
49. Lancsar, E. and J. Louviere, Conducting discrete choice experiments to inform 
healthcare decision making: a user's guide. Pharmacoeconomics, 2008. 26(8): p. 
661-77. 
50. Juni, P., et al., The hazards of scoring the quality of clinical trials for meta-analysis. 
Jama, 1999. 282(11): p. 1054-60. 
51. Lancsar, E. and J. Swait, Reconceptualising the external validity of discrete choice 
experiments. Pharmacoeconomics, 2014. 32(10): p. 951-65. 
52. Hamza, T.H., H.C. van Houwelingen, and T. Stijnen, The binomial distribution of 
meta-analysis was preferred to model within-study variability. J Clin Epidemiol, 
2008. 61(1): p. 41-51. 
53. Harbord, R.M., et al., A unification of models for meta-analysis of diagnostic 
accuracy studies. Biostatistics, 2007. 8(2): p. 239-51. 
54. Dwamena, B., MIDAS: Stata module for meta-analytical integration of diagnostic 
test accuracy studies. 2009. 
55. StataCorp, STATA 14. 2014. 
56. Egger, M., et al., Bias in meta-analysis detected by a simple, graphical test. BMJ, 
1997. 315(7109): p. 629-634. 
57. Bland, M., Meta-analysis: heterogenity and publication bias. 2006. 
58. Liberati, A., et al., The PRISMA Statement for Reporting Systematic Reviews and 
Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation 
and Elaboration. PLOS Medicine, 2009. 6(7): p. e1000100. 
59. Mohammadi, T., et al., Testing the External Validity of a Discrete Choice 
Experiment Method: An Application to Latent Tuberculosis Infection Treatment. 
Value Health, 2017. 20(7): p. 969-975. 
60. Mohammadi, T., Exploring the External Validity of Discrete Choice Experiment 
Using Hierarchical Bayes Mixed logit: An Application to Latent Tuberculosis, in 
International Health Economics Association Congress. 2015: Milan, Italy. 
61. Chua, G.N., et al., External validity of discrete choice experiments: findings from a 
field experiment, in Health Economists' Study Group (HESG) Meeting. 2016: 
University of Manchester, Manchester, UK. 
133 
 
62. Krucien, N., A. Gafni, and N. Pelletier-Fleury, Empirical Testing of the External 
Validity of a Discrete Choice Experiment to Determine Preferred Treatment Option: 
The Case of Sleep Apnea. Health Econ, 2015. 24(8): p. 951-65. 
63. Lambooij, M.S., et al., Consistency between stated and revealed preferences: a 
discrete choice experiment and a behavioural experiment on vaccination 
behaviour compared. BMC Med Res Methodol, 2015. 15: p. 19. 
64. Salampessy, B.H., et al., The Predictive Value of Discrete Choice Experiments in 
Public Health: An Exploratory Application. Patient, 2015. 
65. Ryan, M. and V. Watson, Comparing welfare estimates from payment card 
contingent valuation and discrete choice experiments. Health Econ, 2009. 18(4): 
p. 389-401. 
66. Kruk, M.E., et al., Women's preferences for place of delivery in rural Tanzania: a 
population-based discrete choice experiment. Am J Public Health, 2009. 99(9): p. 
1666-72. 
67. Linley, W.G. and D.A. Hughes, Decision-makers' preferences for approving new 
medicines in Wales: a discrete-choice experiment with assessment of external 
validity. Pharmacoeconomics, 2013. 31(4): p. 345-55. 
68. Higgins, J.P., et al., Measuring inconsistency in meta-analyses. BMJ, 2003. 
327(7414): p. 557-60. 
69. Walter, S.D., Properties of the summary receiver operating characteristic (SROC) 
curve for diagnostic test data. Stat Med, 2002. 21(9): p. 1237-56. 
70. Engels, E.A., et al., Meta-analysis of diagnostic tests for acute sinusitis. Journal of 
Clinical Epidemiology, 2000. 53(8): p. 852-862. 
71. Lee, A., et al., A Systematic Review (Meta-Analysis) of the Accuracy of the 
Mallampati Tests to Predict the Difficult Airway. Anesthesia & Analgesia, 2006. 
102(6): p. 1867-1878. 
72. Sheeran, P., Intention—behavior relations: A conceptual and empirical review. 
European review of social psychology, 2002. 12(1): p. 1-36. 
73. Ajzen, I., The theory of planned behavior. Organizational behavior and human 
decision processes, 1991. 50(2): p. 179-211. 
74. Watson, V., F. Becker, and E. de Bekker-Grob, Discrete Choice Experiment 
Response Rates: A Meta-analysis. Health Economics, 2016. 
 
  
134 
 
Results from updated search in January 2018 
The searches conducted for this paper were re-run in January 2018. No additional 
studies were found comparing revealed and stated preferences within individuals in a 
health context. A number of changes were made to the paper during the peer-review 
process, including the updating of references for Chua et al. and Mohammadi et al. which 
were initially included in the review as conference presentations, but later updated. A 
meta-regression was also included. 
In this update, an additional 1,913 studies were identified (PubMed: 157, EMBASE: 66, 
CINAHL: 169, Econlit: 143, Social Policy and Practice: 2, and Science Direct: 1,376). Of 
these, 254 were duplicates. None of the remaining 1,659 studies met the inclusion 
criteria, with 1,253 omitted at title screen and 406 at abstract screen. 
Implications for thesis 
The most substantive implication of these for this thesis is that DCE predictions can be 
used to predict health-related behaviours. We use this approach in results paper R1 to 
predict the uptake of a range of MPTs, and in results paper R3 to predict risk 
compensation among FSWs using an effective HIV prevention product. In both cases, we 
take care to conduct sensitivity analyses of parameters taken from DCE predictions to 
ensure that model results are not unduly influenced by uncertainty arising from DCE 
predictions. 
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Chapter 5: Additional information on the 
formative phase of DCE development 
Development of the products DCE 
The preceding protocol paper gives an overview of the formative work conducted for the 
development of the products DCE, alongside survey implementation methods. This 
section gives additional information on how the final design of the products DCE was 
created. The next section describes the design process for the second FSW DCE. 
Development of attribute long-list 
Results from qualitative work carried out for a 2005 study[1] were used alongside 
lessons learnt in the development and application of this earlier DCE[2] to identify a set 
of product attributes which are likely to be important to people, albeit ten years later. 
The FGDs mentioned in the protocol were carried out among FSWs; however, focused 
on the development of a completely new second DCE presented in this thesis and did not 
explicitly cover product attributes. Instead, substantial piloting and engagement work 
was carried out which is described here. 
A long list of nine potential attributes was developed. All attributes found to be 
consistently statistically significant in the 2005 analysis were included (HIV protection, 
pregnancy protection, ability to use in secret, and price). Through meetings with 
academic and fieldwork staff, I drew on the experience of collaborators to identify 
additional relevant attributes for different populations. Finally, I carried out a 
comprehensive literature review exploring:  
1. What types of ARV-based prevention products have been developed or are under    
development? 
2. What factors influence the success or failure of products already tested? 
3. What are the key research areas for the next ten years?  
A summary of this work forms the background material in chapter 1 of this thesis.  
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The 2005 study found that the most important factors in women's use of HIV prevention 
products was the extent to which they protected from HIV infection and pregnancy. 
Furthermore, there was notable variation in the utility these attributes offered to women 
in different life situations. Due to the strength of preference women displayed for both 
attributes, we opted to include them in this DCE. 
As described in the correspondence published in the Lancet Infectious Diseases, 
presented earlier in this thesis, recent developments in HIV prevention have led to 
optimism that candidate MPTs may soon be developed[3-7]. We explicitly focused on the 
potential for MPTs in developing this DCE. Three levels of HIV protection were used – 
55%, 75%, and 95% – reflecting variation observed in efficacy trials of products, 
alongside idealised products used in modelling exercises[8]. Pregnancy protection was 
represented by a two-level attribute (yes/no). Ideally, we would have included both as 
multi-level, continuous attributes but opted to display pregnancy protection as a binary 
attribute to reduce complexity, after comments during piloting.  
The "ability to use in secret" attribute was included in 2005 due to qualitative data 
suggesting that this was important to respondents. However, quantitative DCE results 
suggested that the significance of the secrecy attribute coefficient depended on the 
model specification used, and whilst the influence of the secrecy attribute on choices was 
small relative to others. Because the current study explores preferences for products 
with vastly different usage regimens and frequencies, I opted to fix the secrecy 
characteristic by product (giving participants information on whether a product could 
be used without a partner's knowledge in the explanation of products through an 
information sheet given to all participants). Therefore, the utility which is offered by 
using a product with or without a partner's knowledge is contained in the product-
specific coefficient. This is a limitation of this study as it is not possible to separate the 
utility that secrecy may add in addition to that given intrinsically by products, for 
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example, how much more attractive a vaginal ring would be which allowed covert use. 
However, the nature of the products in development mean that it is impossible for 
secrecy to vary across products.  
Frequency of use was considered an important characteristic because there is 
substantial variation across products. In addition, low levels of adherence to oral PrEP, 
microbicide gel, and vaginal ring products in PrEP trials to-date[9-11], particularly 
among younger women, mean that supporting adherent use has been identified as a 
critical part of the prevention cascade[12]. The decision to include frequency therefore 
came from the research question and potential implications for product development, 
rather than from inductive qualitative work. 
Finally, side effects have been identified as a key driver of non-adherence among 
treatment users, and since the active ARV ingredient is similar in prevention (which to 
date is mostly based on tenofovir), it is thought that similar side effects might drive 
adherence (or non-adherence) in preventative products[4, 13]. The side effects attribute 
was particularly difficult to represent to respondents in a one-dimensional manner, and 
questions were raised around the severity of side effects to include (short-term, non-
severe conditions such as dizziness, or long-term severe conditions such as liver failure) 
alongside the frequency with which these might occur. A number of iterations of the side 
effect attribute were explored in piloting with different representations of severity and 
frequency in written and pictorial form. Participants in pilot interviews were asked after 
carrying out the pilot DCE, a) whether shorter-term, less-severe side-effects were more 
important to their product choice than longer-term, more-severe side-effects, and b) 
which representations of potential side-effects were clearer to them, and for their 
suggestions to how side-effects could be accurately and consistently represented to a 
range of their peers. The development of the side-effects attribute can be seen in Figure 
1. 
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Ultimately, respondents suggested that a) specific side-effects were clearer to 
understand than “mild/moderate/severe” side effect labels, b) that more immediate 
side-effects (such as stomach cramps or nausea) were more influential in choices than 
the more rare longer-term but more severe side-effects, and c) male- and female-specific 
images of side-effects were better understood than non-gendered, stick figure 
representations. 
Refinement of attribute shortlist and selection 
The long-list of attributes was reduced through intensive discussion with HIV and DCE 
experts at LSHTM, the University of the Witwatersrand (School of Public Health and Wits 
RHI), Bristol University, and PATH. Because of the necessity to reduce the number of 
attributes, the long list was reduced to five for further development and pre-piloting. 
Ultimately, these five attributes were used in the final DCE, however, throughout piloting 
we asked participants whether there were any important factors omitted and revised 
the presentation of attributes and levels a number of times. 
The question of how many attributes is too many for participants to consider has had 
considerable attention in the DCE literature[14]. Including too few attributes increases 
the likelihood that important factors have been omitted. However, including too many 
may be cognitively demanding for respondents to consider all pieces of relevant 
information, increasing the likelihood of attribute nonattendance, or leading to protest 
responses as participants disengage with choice tasks[15, 16]. Although there has been 
a recent trend towards DCEs with greater numbers of attributes, the majority (70%) of 
DCEs identified in a 2012 systematic review contained between four and six 
attributes[14]. A practical limitation on the number of attributes came from the 10-inch 
screen of the tablet computers used in data collection, on which all alternatives and 
attributes had to be simultaneously displayed. This also constrained the choice between 
a labelled and unlabelled design, as discussed elsewhere. 
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A price attribute was not included as it became apparent during research that any roll-
out of ARV-based prevention products would be provided free of charge by the South 
African Department of Heath[17]. This is a limitation to this study as willingness-to-pay 
for PrEP products cannot be inferred from the data collected, however this increased the 
realism of choice tasks potentially increasing external validity.  
An important consideration in choosing attributes is that of intra-attribute correlation, 
where different attributes are correlated perceptually by decision makers. For example, 
the price-quality heuristic suggests that decision makers may assume that higher priced 
alternatives display higher levels of quality, even though the two attributes may be 
statistically uncorrelated[15]. As the number of attributes were reduced from the long 
to the short list, we considered potential sources of inter-attribute correlation and tried 
to ensure that the final set of five attributes were conceptually independent from each 
other so that one is unlikely to act as a proxy for another.  
Further considerations on the use of a labelled or unlabelled design 
Including a label in DCEs adds a degree of realism to choices, as consumers do not select 
from a number of generic alternatives in real-life, but from among a labelled set of brands 
or types of good[15]. A recent study suggests that 22% of all choices in a cancer 
screening DCE were made on the label alone[18]. 
Though a design using product labels would be theoretically most appropriate for this 
study, this would have required six alternatives (five new products plus one opt-out) to 
be presented at one time on a small tablet screen. There was consensus during 
discussions with the project team that asking respondents to choose between six 
alternatives would make for a complex and tiring choice experiment. Therefore, we 
opted to reduce the number of alternatives presented to respondents to three (plus an 
opt-out), where one attribute represented product type. Product labels entered the DCE 
as levels of this attribute, rather than separate labelled alternatives.  
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This strategy means some loss of precision in estimates of product-specific constants as 
fewer choice data are collected for each label (now represented by the coefficient for 
each level of the effects-coded product attribute, instead of an alternative-specific 
constant), however, this may provide data of better quality overall through reducing 
participant fatigue. 
Feedback and iteration 
Once the short-list and early mock-up of representations (version 1 in Figure 2) had been 
generated, feedback was obtained from DCE experts at LSHTM (Mylene Lagarde) and the 
University of the Witwatersrand (Duane Blaauw). Feedback suggested a) exploring 
different representations of the HIV protection attribute (comparing a visual array of 
“people” to a pie-chart representing the degree of protection a product offers), b) 
representing pregnancy and STI protection as two-level attributes to reduce complexity, 
and c) explore different representations of side-effect severity and probability. Changes 
to the DCE as a result of these comments can be seen in version 2. 
Version 2 of the DCE was presented in a research seminar to around 20 researchers 
(working mostly in HIV) at Wits RHI in Johannesburg in June 2015. There was a 
consensus that the five short-listed attributes were relevant and meaningful to the 
choice task in that context, whilst the mix of attributes chosen would provide interesting 
policy and product developmental insights. There were a range of views on the side-
effects attribute, with specific concerns covering a) how to represent the frequency and 
severity of side-effects as a one-dimensional attribute as recommended in the 
literature[19]; b) what side effects might impact demand for a product (severe but rare 
side effects such as liver failure, or milder and more common side effects such as nausea 
or stomach cramps); and c) how best to represent side-effects (visually or through 
words).  
141 
 
Further feedback was taken on the visual representation of some attributes, particularly 
that HIV protection would be best represented as a risk array, which is the most popular 
means of representing risk in published DCEs[20]. In addition, local experts suggested 
that the acronym "STI" would be understood well, and be more meaningful to 
participants than "other infections" – this later turned out to be the case in piloting. 
Because of suggestions from this meeting, we produced version 3 of the DCE in Figure 2, 
which was used for pre-piloting. 
Pre-piloting 
Pre piloting was carried out in the general population in two rounds among 8 adult 
females, 5 adult males and 4 adolescent females, described in Table 1: 
Table 1: Pre-pilot dates and participants 
Pre-pilot 
round 
Dates Participants 
Round 1 26th-27th August 
2015 
6 adult females, 3 adult males 
Round 2 3rd September 
2015 
2 adult females, 2 adult males, 4 adolescent 
females 
Pilot participants were identified from a convenience sample of participants from the 
three groups. FSWs were not specifically sampled in this pre-piloting stage. Because 
FSWs are a subset of the adult female population, FSW programme experts indicated 
that the insights of pre-piloting among this group would be sufficient to negate the need 
for pre-piloting among FSWs. Nevertheless, during the later FSW-specific pilot, we 
ensured that respondent understanding was comprehensively explored and ensured 
there was time and resources available to re-design the product DCE for this population 
if required. 
At this point, after discussion with fieldworkers and pilot participants, we opted for 
interviewer administration of the survey, as opposed to respondents entering data 
directly into the tablet computer. Although this may increase acceptability biases in 
142 
 
reporting of sensitive behaviours (such as age at first sex, condom use, or number of 
sexual partners[21-23]), interviewers were able to thoroughly explain the DCE task and 
ensure that participants were making careful and informed decisions. Through 
encouraging participants to “think aloud” through all choices (shown elsewhere to 
increase the external validity of stated preference tasks[24, 25]), interviewers were able 
to assess the degree to which participants were understanding and engaging with choice 
tasks. 
The resilience of this method was shown in final piloting. For example, a female 
respondent chose the condom opt-out in all but one choice set. When probed by the 
interviewer, the respondent said that she wanted the full protection that condoms 
offered across all attributes. She still looked at every alternative but chose condoms 
eventually, except when a vaginal ring offered the same protection and side-effects 
profile with a reduced frequency of use. In another instance, one male appeared to be 
choosing oral PrEP in each task, regardless of how attributes compared to that of an 
injectable. When asked to “think-aloud” through his decision-making process, the 
respondent revealed a substantial dislike for injections, over and above the importance 
of other product characteristics. Where one choice set had three injection alternatives 
with an unprotected opt-out, the respondent chose the highest HIV efficacy. 
Also at this stage, I opted to reduce the number of choice tasks presented to participants 
from 15 to 10 after interviewer feedback that the tasks became boring to participants 
after 8-10 choice tasks. Interviewers reported that participants were, in the most part, 
engaged with the first 8-12 choice sets, however became fatigued with the tasks towards 
the end of the DCE, either making choices based on just 1-2 attributes, or by choosing 
largely at random.  
Decreasing the number of tasks reduced the quantity of choice information gathered 
from each respondent, resulting in less precise preference estimates. However, 
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minimising tedium in the choice tasks could have increased the quality of information 
captured. Ignoring some attributes in a choice task, termed attribute non-attendance, is 
an example of choice behaviour which violates the axioms underpinning random utility 
theory (that participants choose the alternative offering the greatest utility as a sum of 
its individual attributes)[15]. Choosing responses at random can be considered an 
extreme form of attribute non-attendance. Either behaviour will bias choice model 
parameters towards the null, reducing the efficiency of models and the information 
gained from the DCE[15, 26]. 
However, reducing the number of DCE tasks also reduces the amount of information 
obtained from each participant. To assess if the reduction in precision as a result of 
reducing the number of choice tasks could meaningfully reduce the statistical power of 
the DCE, D-error minimising designs with 10 and 15 tasks were generated in NGENE 
software[27], and the Sp value examined – an estimate of the minimum sample size 
required to obtain statistically significant parameters in a discrete choice model using 
parameter priors normally obtained from piloting work. Appendix V shows the NGENE 
output from both designs; the 15-task design has an expected sample size needed for 
significant parameters of 63 participants, whilst the 10-task design would require a 
sample size of 134. Since the total sample size in each survey group was 200, the 10-task 
DCE was deemed sufficient on this basis. 
A number of changes to attribute presentation were made during piloting. Firstly, the 
use of a red cross to signify no STI protection was found to be confusing when compared 
to the use of a similar red cross to signify contraceptive properties in the pregnancy 
attribute. Interviewers themselves suggested incorporating a tick, separate from an 
image of a non-pregnant woman, to represent contraceptive properties. This was in 
contrast to a red cross alongside an image of a pregnant woman to indicate a lack of 
contraceptive protection. Feedback from piloting suggested that interviewers and 
144 
 
participants found this representation (Figure 1 – panel B) easier to explain and 
understand than previously (Figure 1 – panel A). 
Figure 1: Changes to representation of contraceptive attribute 
Panel A – Initial representation  
 
Panel B – Final representation after changes 
 
The frequency of use attribute was further refined through a) changing the denominator 
of use to be consistent across non-coital usage as "number of uses in a year", and b) text 
being placed inside a box and highlighted such that the attribute stood out alongside 
pictorial representations of others. We explored the use of graphics representing 
frequency of use, however, participants indicated that the text representation simpler to 
understand, and it was not possible to unambiguously represent coital use in this 
manner. A limitation of the analyses presented in this thesis is that they do not explore 
the potential for attribute non-attendance to occur, where text attributes are ignored by 
participants in favour of those represented by pictures.  
Finally, representing side-effects well was a challenge throughout the design process. 
Because of comments from local experts, we included a categorical four-level side-effects 
attribute: no side effects, dizziness, stomach cramps, and nausea. These were a) reported 
side effects of tenofovir use, b) symptom based and therefore easily understood, and c) 
familiar to most participants thus requiring less abstract reasoning during the DCE. 
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These were chosen instead of longer-term side-effects such as liver complications or 
reductions in bone density, which have also been recorded with tenofovir use[28, 29]. 
This was largely because long-term side effects require a substantial amount of abstract 
thinking on the part of respondents, which would have been challenging for respondents 
as part of an already complex DCE. In addition, to adhere to DCE best practice and only 
include one-dimensional attributes[19], each long-term condition would require four 
separate attributes to represent the severity, probability and nature of side-effects.  
This decision also meant that, rather than including multiple attributes to represent 
different side-effect aspects, a single attribute was required to convey the symptoms of 
each side-effect. Although the reported frequency of side-effects varied slightly across 
the three included, we opted to fix the frequency at which all three would "occur" as the 
most frequent reported in the literature[29]. In round one of pre-piloting this was just 
explained to participants by interviewers, however, some respondents repeatedly 
clarified this point throughout the tasks As a result, for later rounds of the pilot, and in 
the final DCE, we included a frequency array (as displayed in version 4). This served to 
make the 1/60 chance of side effects occurring more salient to participants, whilst the 
fixed frequency across side effect levels meant the attribute was still one dimensional.  
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Figure 2: Iterations of DCE formatting 
Version 1: 
Version 2: 
 
  
Choice: A B C D E F
Product
Oral PrEP Diaphragm and microbicide gel Microbicide gel Vaginal ring Injection
HIV protection
75% risk reduction
15 of 20 women remain HIV negative
75% risk reduction
15 of 20 women remain HIV negative
75% risk reduction
15 of 20 women remain HIV negative
95% risk reduction
19 of 20 women remain HIV negative
95% risk reduction
19 of 20 women remain HIV negative
Pregnancy prevention
55% reduction in pregnancies
9 of 20 women become pregnant
55% reduction in pregnancies
9 of 20 women become pregnant
55% reduction in pregnancies
9 of 20 women become pregnant
Does not prevent pregnancy
All 20 women become pregnant
Does not prevent pregnancy
All 20 women become pregnant
Frequency of use
Twice every week Every time you have 
sex
Every time you have 
sex
Once every month Once every 3 months
STI protection Prevents half of STIs Prevents no STIs Prevents half of STIs Prevents no STIs Prevents no STIs
Side effects
Some side effects
5 of 20 people feel side effects
Few side effects
1 of 20 people feel side effects
Few side effects
1 of 20 people feel side effects
Some side effects
5 of 20 people feel side effects
Few side effects
1 of 20 people feel side effects
Neither,
I would 
do the 
same as
the last
time I 
had sex
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Version 3: 
Version 4 (female): 
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Version 4 (male): 
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Table 2: Attributes included in products DCE 
Attribute Levels Source Reason 
Products Oral PrEP,  
microbicide gel,  
SILCS diaphragm 
and gel,  
vaginal ring,  
injection 
Literature, expert 
opinion 
Current and future 
product pipeline. 
Different time 
horizons for each 
product's development 
(i.e. injection ~10 
years whilst PrEP is 
available in South 
Africa today) 
HIV Protection 55%,  
75%,  
95% 
2005 DCE Focus of study. 
Important determinant 
of demand in 2005 
DCE 
Pregnancy 
Protection 
Yes,  
no 
2005 DCE, expert 
opinion 
Important determinant 
of demand in 2005 
DCE. Reclassified as 
binary for simplicity in 
presentation.  
Frequency of use Coitally,  
daily,  
weekly,  
monthly,  
three-monthly,  
six-monthly,  
annually 
Literature, expert 
opinion 
Seen as important 
factor in studies 
exploring low 
adherence in ARV-
based prevention 
trials[30]  
STI Protection Yes,  
no 
Literature, expert 
opinion 
Important in literature 
exploring the potential 
for MPTs[3, 4, 31]  
Side Effects Nausea,  
dizziness,  
stomach cramps 
Literature, reports 
from PrEP studies 
Concerns that 
adherence to 
prevention products 
might be inhibited by 
observable side-effects 
(i.e. shorter-term, non-
sever events rather 
than longer-term 
severe side-effects 
such as liver failure). 
Levels taken from HIV 
treatment studies and 
trial reports[29, 32, 
33] 
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Table 3: Attributes excluded from products DCE 
Attribute not 
included 
Potential levels Source Reason 
Secrecy Can be used in 
secret, 
Cannot be used in 
secret 
2005 DCE Levels likely to be 
fixed by product - a 
gel will always 
require partners' 
knowledge, whilst an 
injection could 
always be obtained 
covertly 
Mode of delivery Oral, 
vaginal, 
injection 
Literature 
review 
Fixed by product 
Monitoring None, 
weekly, 
monthly, 
quarterly 
Literature 
review 
Not identified as 
important by experts, 
or during piloting 
work 
Forgiveness in 
regimen 
High, 
medium, 
low 
Literature 
review 
Difficult for 
respondents to 
conceptualise and 
represent in DCE 
tasks, so dropped 
early in piloting 
Purchasing location Clinic, 
spaza shop, 
community 
outreach worker, 
pharmacy 
2005 DCE Since product 
distribution likely to 
only be through 
public clinics in the 
first instance, this 
was omitted to keep 
the number included 
low 
Price  2005 DCE In many DCEs, price 
attributes have 
dominated choice 
behaviours.[15] This 
was omitted to avoid 
this, and also 
represent the fact 
that products will 
likely be provided 
free of charge in 
South Africa.  
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Estimating unconditional demand 
To improve uptake estimates in the cost-effectiveness analysis, paper R2, an opt-out 
alternative was included in choice tasks, allowing the estimation of unconditional 
demand. If we had not included an opt-out, and instead calculated conditional demand 
through forcing a choice between new products, we would have had greater precision in 
attribute coefficient estimates but not be able to predict uptake. 
As mentioned briefly in the protocol, the opt-out alternative was presented as the 
characteristics of a male condom, or for using nothing, depending on whether or not a 
condom was used in the last sex act. This made the choice scenario more realistic, as its 
framing and choice set was based on the last sex act, but in doing so we assumed that 
condom users always preferred a condom over unprotected sex, and did not allow non-
condom users to choose a condom. This may have led to underestimation of condom use, 
and biased estimates of new product cost-effectiveness towards being more cost-
effective. 
Estimation of condom substitution 
Knowing whether the users of new products are also consistent condom users is critical 
to estimate their impact[34]. For example, if demand for new prevention products is 
solely among current condom users, the additional impact of new products will be 
minimal, particularly if users choose to use a new product instead of a condom. 
Conversely, if demand for new products is largely among non-condom users, the 
potential for additional benefit is high. 
There are three steps to ensuring that this DCE captures sufficient information on 
respondents to estimate impact accurately, displayed in Figure 3. Firstly, the opt-out 
presented to participants is tailored to the product they report using in their last sex-act. 
This was carried out by programming the tablet computer to display a different opt-out 
alternative depending on a participant’s answer to the question “the last time you had 
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sex, did you use a condom?” If yes, participants were shown an opt-out for each choice 
task containing the attributes of a male condom. If participants reported that a condom 
was not used, they could not remember, or did not wish to say, they were presented with 
an opt out of “nothing” with a set of attributes representing no protection against HIV, 
pregnancy or STIs and with no side-effects or frequency of use.  
Figure 3: Representation of opt-out alternatives 
 
When participants who reported using a condom in their last sex act chose one of the 
new products over the condom opt-out, they were asked a further question of “if 
available, would you have used this the last time you had sex?”. If the answer to this 
question was yes, respondents were then asked “would you have used this instead of a 
condom, or would you have used both together?”. With these data, it is possible to 
estimate substitution from condoms to new products, alongside uptake amongst non-
condom users, however acknowledge that dual use of condoms with new products may 
be unrealistic.  
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Development of the FSW DCE 
This section describes the development of the FSW DCE, a DCE to assess whether HIV 
prevention products will change FSW preferences for the supply of condomless 
commercial sex. Although a protocol was not published for this DCE, data collection was 
fully integrated within the FSW sample described earlier. Furthermore, many of the 
methods used are described in the results paper for this DCE, paper R3. Therefore, in 
this section I only provide information about the development of this DCE which is not 
included elsewhere, notably an overview of the qualitative work and piloting process, 
and refer the reader to the results paper (chapter 8 – Paper R3) and study protocol 
(Appendix IX) for further details.  
The earlier literature review summarised economic evidence suggesting that there was 
a price premium for unprotected sex among female sex workers in multiple countries 
and contexts. Just one of these studies was in Africa (Kenya[35]), and there has been no 
work exploring the economics of commercial sex in South Africa. Furthermore, there has 
been no work in any context exploring the potential impact of effective new HIV 
prevention products on the market for commercial sex in any context.  
This DCE was designed to elicit FSW preferences towards key client and commercial sex-
act characteristics. We employ a repeated DCE design, where the same DCE is presented 
to each respondent twice – once with no framing, and a second time asking participants 
to choose as if they were fully protected from HIV.  
Because a number of additional data on commercial sex acts were gathered among the 
FSW population, the survey was expected to take much more time among this 
population. Furthermore, the opportunity cost of FSW time was estimated to be greater 
than other populations due to their comparatively greater earnings. Therefore, the 
primary design consideration for this DCE was to minimise the time required to 
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complete the DCE, whilst making the choice scenarios engaging and easily understood 
to ensure good quality choice data. 
The development process of the FSW DCE aimed to 1) identify what client and act 
characteristics are important to FSWs’ decisions to engage in protected or unprotected 
intercourse; 2) explore how to best represent these attributes in a DCE; and 3) maximise 
efficiency in DCE data collection. Firstly, a long list of attributes was generated through 
a thematic analysis of two focus group discussions, with thirteen participants in each 
(two further focus group discussions were held during data collection to inform the 
analysis and interpretation of results). The attribute long list was supplemented and 
refined with the results of the literature review presented earlier in this thesis, alongside 
input from UK and South African experts in DCE methods and FSW populations.  
Attribute and level development 
Development of attribute long list 
Qualitative focus group discussions 
We carried out four focus group discussions (FGDs) with a heterogeneous mix of 9-13 
participants in each. Participants were purposively sampled to obtain a mix of women 
working in hotels and on streets with the intention of stimulating a broad discussion. A 
thematic analysis of these FGDs led to the identification of important attributes in the 
choice context, specifically around client characteristics, and to explore which attributes 
may be affected by the introduction of effective products. The specific aims of the FGDs 
were to: 
1. Explore how women conceptualise "good" or "bad" clients  
2. Understand how condom use and price is negotiated with different types of 
client 
3. Explore how perceived negotiation power in commercial acts relates to condom 
use and price agreements 
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To ensure that we obtained sufficient data from FGDs, considerable time was spent 
developing a concise and informative focus group discussion guide, which is presented 
in appendix VII. Developing the guide was an iterative process where the content and 
wording of each draft was tested and reviewed among members of the project team, 
before a final draft was reviewed by the FGD moderator from Progressus Research and 
Development.  
Focus group discussion recruitment and procedures 
In total, four FGDs were held among members of the target population for the DCE. FGDs 
in Springs and Brakpan were used to develop the DCE and survey, whilst two subsequent 
FGDs in Boksburg were used to give greater depth to the data alongside informing 
analysis and interpretation of data.  
We used existing peer-outreach networks to recruit participants. Our collaborating 
institution, Wits RHI, provided mobile clinic services for FSWs in Ekurhuleni. The clinic 
travelled to a different location every Thursday, cycling through six locations. Active 
FSWs were referred to the Wits RHI clinic by peer educators in the area, who were 
themselves employed by an NGO, Center for Positive Care (CPC). With an introduction 
from Wits RHI, we approached the local CPC management and explained the objectives 
and method of our study. We were given permission to ask CPC peer-educators to a) 
assist in recruiting FSWs for the focus group discussions, and b) for a small number to 
participate in discussions themselves, as previous work by our data collection partners 
found the presence of peer-educators conducive to open and frank conversation. 
An important aim of recruitment was to ensure a range of experiences in each discussion, 
and we recruited women of a range of ages and working environments (street-based and 
hotel-based workers). The literature suggests that the risks and rewards of sex work can 
vary substantially by context, whilst a heterogeneous set of focus group participants has 
been shown to encourage a nuanced discussion, with participants more likely to agree 
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on a common identity (i.e. belonging to the group of "female sex workers") whilst 
highlighting differences in their experience of that identity.[36, 37] Brown[38] suggests 
that the number of FGD participants should increase with the degree of heterogeneity 
between participants, with a maximum of around twelve. Because of the busy and 
transitory nature FSWs' working lives, we opted to invite more respondents than 
required to allow for some non-attendees. Ultimately, relatively high levels of attendance 
meant we had a maximum of 13 and a minimum of 9 participants in each FGD. The data 
from the FGD with 13 participants did not inhibit conversation or the quality of data.  
We initially planned to integrate the FGD work alongside outreach clinic activities, 
however, were advised by peer educators that women would not be willing to give up 
more productive time on the days the clinic was present. Furthermore, we were advised 
that many FSWs would be busy working between Thursday evenings and Monday 
morning. We therefore scheduled focus groups midweek when a clinic was not present. 
To conduct the FGDs, we utilised the same location where outreach activities occurred; 
these offered a safe, confidential and secure space in which to carry out FGDs.  
Once we had set a location and time for the FGD, peer-educators were asked to recruit 
women based on their schedule of providing outreach services that day. Through 
selecting which peer educators recruited for each group, we were able to achieve a mix 
of street- and hotel-based participants. We ensured that free transport was available for 
potential participants, however this was not required for any participant as FGDs were 
held in convenient locations.  
As participants arrived at the FGD location, they were welcomed by a survey team 
member who offered refreshments. When the group were together the moderator 
explained the study in general; read out the guidelines for the discussion, as on the front 
of the FGD guide (i.e. speaking up when they felt they had something to say, not 
interrupting other participants); introduced specific topics for discussion; explained 
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why we had specifically asked for participants to attend; and that we were interested in 
their honest thoughts and opinions on the discussion topics. The informed consent form 
was distributed to participants and read out loud by the moderator; this form is included 
in appendix VI.  
Participants were told that the discussions were confidential, that they could rely on the 
survey staff not to disclose what they said, and that the views that others express during 
the discussion should not be discussed outside of the group. The moderator told the 
group that they could use whatever name or nickname they wished, and we did not need 
to know their real identity. Finally, the moderator explained the presence and purpose 
of the two audio recording devices. If participants were still willing to participate in the 
discussion, the moderator and an additional survey team member went around the 
group individually, answering any further questions and, if required, assisted 
participants in completing the informed consent form.  
The moderator informed participants that the audio recorders would turn on, explained 
once more that the discussion was recorded from this point, and obtained a verbal 
acknowledgement from the group. The moderator then began the discussion, first 
choosing which language(s) were most comfortable for people to speak in. Conversation 
was broadly framed around the discussion guide, with the moderator ensuring 
conversation flowed naturally whilst covering all relevant points. When the discussion 
ended, the tape was switched off and participants offered refreshments. As a token of 
thanks for their time, participants were provided with a R50 (approx. £2.50) voucher.  
Role of candidate in FGDs 
FGDs were carried out by a data collection consultant, Motlalepule Tsepe, a senior 
partner at Progressus Research and Development with over ten years of fieldwork 
experience. Although I did not attend the FGDs, I wrote the FGD discussion guide and 
worked intensively with the FGD moderator in days before each FGD to ensure the FGDs 
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were carried out correctly. Directly after each FGD, the moderator and I had a debriefing 
where we identified topics that were missed, alongside those which were discussed at 
too much length. The topic guide was not altered during data collection. 
Analysis of FGD data 
Due to time constraints between the completion of FGDs and the requirement to submit 
a final version of the DCE survey for final ethical review, a full analysis of the FGDs was 
not possible. Instead, a preliminary framework analysis was carried out in partnership 
with Robyn Eakle, a qualitative researcher at Wits RHI, who identified the following 
themes from the data. A fuller analysis of the FGDs was presented as a poster at the HIV 
Research for Prevention Conference in Chicago, USA on the 2016, which is included as 
Appendix X. 
Refinement of attribute shortlist and selection 
As with the refinement of the products DCE described above, the attribute long list for 
the FSW DCE was reduced through presentation to experts. The background survey 
among FSWs included additional questions on commercial sexual behaviour which were 
not asked to the general population. This meant that the DCE had to be intuitive and 
relatively quick to complete, particularly as it was being carried out twice with each FSW 
participant in addition to the products DCE.  
Due to delays in finding local collaborators who could facilitate access to the FSW 
population, the development of the FSW DCE occurred after the products DCE had been 
finalised. We used this to our advantage by applying the lessons learnt in the 
development of the products DCE in our target population, notably that more than five 
attributes were difficult to represent clearly on the tablet screen, and that more than ten 
choice tasks in a DCE led to participant fatigue. The DCE lent itself to an unlabelled design 
due to the lack of overarching concepts of clients that FSWs choose between. Also at this 
stage, we decided to include an opt-out alternative to allow the estimation of 
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unconditional demand, and enable the simulation of choices to parameterise the 
dynamic transmission model in paper R4. Tables 3 and 4 detail the attributes included 
the final DCE and those omitted, respectively.  
Table 4: Attributes included in FSW DCE 
Attribute Levels Source Reason 
Price  R100,  
 R200,  
 R400,  
 R800 
Economic 
literature, work in 
other SA FSWs[39], 
qualitative work 
Primary research 
question to explore 
how price and 
condom choices 
change with PrEP 
introduction 
Condom use Male or female 
condom, no 
condom 
Economic and 
social 
epidemiologic 
literature, 
qualitative work 
Primary research 
question to explore 
how price and 
condom choices 
change with PrEP 
introduction 
Type of sex Vaginal, anal Economic 
literature, pilot 
with peer-
educators 
Initially left out, but 
included after 
piloting comments. 
Different prices[40, 
41] and HIV 
risk[42] associated 
with sex type 
Perceived client 
HIV risk 
You think this 
client has HIV, you 
don't think this 
client has HIV 
Economic 
literature, expert 
input, piloting 
Concordance with 
study aims, allows 
assessment of 
framing effect 
Perceived client 
STI risk 
You think this 
client has and STI, 
you don't think 
this client has an 
STI 
Economic 
literature, 
qualitative findings 
piloting 
Concordance with 
study aims, 
identified as 
relevant during 
qualitative 
work[43] 
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Table 5: Attributes excluded from FSW DCE 
Attribute not 
included 
Potential levels Source Reasons omitted 
Handsome client Handsome client, 
non-handsome 
client 
Economic 
literature 
Subjectivity of 
handsomeness, not 
identified as relevant 
during qualitative 
work, lack of 
relevance to study 
aims 
Drunk client Client seems 
drunk, client seems 
sober 
Expert input, 
FGD results 
Subjectivity of what 
"drunk" means, 
ubiquity of alcohol 
use in some settings, 
conflated with 
perceived STI/HIV 
risk  
Client age Client <25 years, 
client 26-40 years, 
client >41 years 
Economic 
literature, 
expert input 
Was not identified as 
relevant during 
qualitative work 
Repeat client Regular client, 
occasional client, 
new clients 
Expert input, 
FGD results 
Was identified as 
important during 
qualitative work, but 
conflated with 
perceived STI and 
HIV risk 
Client risk Client seems risky, 
client does not 
seem risky 
Expert input, 
economic 
literature, FGD 
results 
Separated after 
piloting to HIV and 
STI risk, conflated 
with risk of 
perpetrating violence 
 
Estimating the impact of HIV prevention product use on act price and condom use were 
the primary objectives of the study. Condom use was included as a binary variable 
denoting male condom use or unprotected sex; female condoms were omitted here due 
to low reported use among FSWs during FGDs. The four levels of the price attribute were 
obtained from FGD information, alongside quantitative data collected in 2010 by Richter 
et al.[44].   
We considered including several client characteristics as separate attributes: 
attractiveness, perceived inebriation, age, whether the client was new or a repeat client, 
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and client risk. As with the products DCE, the long list of attributes was presented in 
seminars at LSHTM and Wits RHI, where comments from experts led to the development 
of a four-attribute draft task from the long list of nine attributes.  
We considered using images of client faces to represent client attractiveness, however, 
it was not possible to generate a set of faces to represent a scale of attractiveness which 
was consistent across potential respondents. The subjectivity of the client attractiveness 
attribute, alongside difficulties in justifying its inclusion when not directly contribution 
to a research question, meant that this was dropped before piloting. Client age was found 
to be a significant influence on behaviours in the empirical literature, however was not 
identified as important by women during the FGDs, so was removed.  
An attribute representing whether a client was drunk was identified during these 
seminars as being a proxy factor for assessing a client’s risk profile, and for the draft task 
client regularity and perceived risk were both included. To minimise complexity, we 
initially opted to frame the task around a vaginal sex act, however later changed this as 
a result of comments from piloting. 
Figure 4: Draft choice task initially presented to sex worker community advisory 
board 
 
162 
 
This draft task in Figure 4 was presented to the twelve-person sex worker community 
advisory board of Wits RHI in October 2015 who advised that all attributes were 
meaningful and relevant to the choice task. One round of piloting took place with a 
sample of ten peer-educators at Wits RHI working in central Johannesburg and were 
part of a population which was not in the final sampling frame. 
This piloting process led to a substantial reshaping of the DCE. The price and condom 
attributes remained, however client type was identified by many pilot participants as 
unimportant relative to the other attributes – this was reinforced by analysis of this pilot 
data. Instead, participants unanimously recommended focusing on the type of sex being 
supplied – vaginal or anal – which would have a much greater bearing on decision 
making. This also allowed analysis to be broadened to estimate a price differential for 
different types of sex, as in evidence suggesting that different types of commercial sex 
commanded different prices, with anal sex consistently selling for a greater price than 
vaginal sex[40, 45]. Both choice task framings – current practice and HIV protection 
under PrEP use – was thought to be very clear, and was not changed. 
The client risk attribute also received attention during piloting, and the meaning of “risk” 
was considered ambiguous by participants. Through discussion with pilot participants 
and re-examination of FGD data, we opted to a) limit the description of risk to exposure 
to HIV or STIs, and not the potential of violence from clients, and b) separate HIV and STI 
risk. Participants reported the differing consequences of STI and HIV infection, where 
STI acquisition was perceived as a small health impact but a large potential to negatively 
affect earnings in the short-medium term, whilst HIV infection was perceived a larger 
longer-term risk, with negative implications occurring after women aimed to leave sex 
work[43].  
Time pressure to complete data collection, particularly with the uncertainty over the 
length of time required to reach sample size through the RDS process used in FSW data 
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collection, meant that a full second round of piloting with the revised task was not 
possible. Instead, the final task design and appearance was tested individually with five 
of the pilot participants. Participants reported that the explicit representation of STI risk 
was very clear, whilst interviewers reported throughout the survey that the slightly 
humorous nature of this attribute worked to relax participants, and break down the 
barrier between interviewer and respondent. 
Final input on the appearance of the FSW DCE was obtained from fieldworkers during 
their training. The only change at this stage was the representation of a client who was 
not perceived to have HIV, where a green ribbon was used in contrast to the red AIDS 
ribbon, which is widely used in South Africa to denote AIDS-related issues. Although 
meaningless outside of the context of this study, this representation of the absence of 
HIV risk was reported by interviewers to be particularly clear to explain, and resonated 
among respondents. The final presentation of the task is shown in Figure 5. 
Figure 5: Example of final choice task (without HIV protection framing) 
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Chapter 6: Paper R1 – Divergent preferences for 
HIV prevention: A discrete choice experiment 
for multipurpose HIV prevention products in 
South Africa 
Overview of paper R1 
As identified in chapter 1, the development of candidate MPT products offers optimism 
for increased coverage of HIV prevention in general and high-risk populations. This 
paper describes the design, implementation, and results of a DCE assessing preferences 
for five new products among four population groups: adult men and women in the 
general population (aged 18-49), adolescent girls (aged 16-17), and self-identifying 
female sex workers (aged 18-49).   
This work undertaken in this thesis was reviewed and approved by the Human Research 
Ethics Committee (HREC) at the University of the Witwatersrand, and the Research 
Ethics Committee at LSHTM. Approval letters from these committees are presented in 
Appendix IV. Full informed consent was obtained from all participants during qualitative 
and quantitative data collection. Appendix VI contains the information sheets and 
informed consent forms used in this process, Appendix VII presents the FGD discussion 
guide, and Appendix VIII the information given to participants on the new HIV 
prevention products shown to them.  
Appendix IX contains a paper, published in 2016 in BMJ Open, describing the 
development of this DCE, and gives additional information on data collection methods 
over and above that detailed in this chapter. 
Data were analysed using multinomial (MNL), latent class (LC) and mixed multinomial 
logit (MMNL) models. As noted in the paper, although commonly applied in choice 
modelling, the MNL requires restrictive assumptions of the underlying preferences of 
respondents – notably, that every individual in the population has identical preferences. 
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This assumption is relaxed by the use of a semi-parametric LC model to separate 
respondents into different groups based on similarity of preferences, with group 
membership predicted by observable characteristics. The MMNL model is also used, 
which allows preferences to vary across individual, incorporating taste heterogeneity 
through the introduction of random parameters.  
The paper is presented as accepted to the journal Medical Decision Making in July 2017, 
including the superscript referencing style. Permission to include in this thesis was not 
obtained before submission, so the accepted version is presented here. A supplementary 
section immediately following the paper details an additional analysis using observable 
characteristics as interaction terms in a MNL model, which was not included in the final 
paper.  
This paper fulfils research objective 1 to quantify the determinants of demand for new 
HIV prevention technologies among adult men, women, and adolescent girls in the 
general population, and female sex workers. The results are also used to predict product 
uptake in the cost-effectiveness model in paper R2, so therefore also contribute to 
objective 2. 
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Abstract: The development of antiretroviral (ARV)-based prevention products has the 
potential to substantially change the HIV prevention landscape, yet little is known about 
how appealing these products will be - compared to existing options - outside of clinical 
trials. We conducted a discrete choice experiment (DCE) to measure preferences for five 
new products among four important populations in the HIV response: adult men and 
women in the general population (aged 18-49), adolescent girls (aged 16-17), and self-
identifying female sex workers (aged 18-49). We interviewed 661 self-reported HIV 
negative participants in peri-urban South Africa, who were asked to choose between 
three unique, hypothetical products over ten choice sets. Data were analysed using 
multinomial, latent class and mixed multinomial logit models. HIV protection was the 
most important attribute to respondents; however, results indicate significant demand 
among all groups for multipurpose prevention products which offer protection from HIV 
infection, other STIs, and unwanted pregnancy. All groups demonstrated a strong 
preference for long-lasting injectable products. There was substantial heterogeneity in 
preferences within and across population groups. These results suggest that stimulating 
demand for new HIV prevention products may require a more a nuanced approach than 
simply developing highly effective products. No one product is likely to be equally 
attractive or acceptable across different groups. This study strengthens the call for 
effective and attractive multipurpose prevention products to be deployed as part of a 
comprehensive combination prevention strategy. 
Ethical Statement: The study was reviewed and approved by the University of the 
Witwatersrand Human Research Ethics Committee (M140614) and the Research Ethics 
Committee at the London School of Hygiene and Tropical Medicine (8541-2). All 
participation in the DCE and supporting qualitative studies was voluntary and subject to 
completion of a written informed consent process. Adolescent participants were asked 
for written assent, in addition to written consent provided by a parent or guardian per 
South African law. A comprehensive distress protocol adopted as standard study 
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procedure ensured that participants who answered in the affirmative to questions about 
violence and/or other potentially distressing situations were referred to named persons 
at local clinics and NGOs for additional support. 
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Introduction  
South Africa has the largest HIV epidemic in the world, but the health and economic 
burden of HIV infection is not borne equally.1 Women are 40% more likely to be living 
with HIV than men, whilst adolescent girls (aged 15-19 years) face an 80% cumulative 
lifetime risk of HIV acquisition.2, 3 Female sex workers (FSW) are designated as a key 
population for HIV treatment and prevention and estimates suggest that the HIV 
prevalence among this group in Johannesburg is 72%.4  
Recent technological developments have led to a number of candidate products for 
antiretroviral (ARV)-based HIV prevention.5 Yet before these are introduced, it is 
important to understand who will use them to reliably estimate their impact and best 
plan their introduction. Where different population groups have different preferences 
for products it is critical that this heterogeneity is identified to ensure that relevant 
products are made available to potential users. Even if only a small proportion of the 
population only uses products, they may still be cost-effective if used consistently and 
effectively among those at risk of HIV acquisition. ARV-based pre-exposure prophylaxis 
(PrEP) has been shown to offer varying degrees of protection to HIV negative persons 
when delivered via daily or intermittent oral tablet6, 7 or long-lasting intravaginal ring8, 
9. However, product protection has been variable during clinical trials as microbicide 
gels and vaginal rings were found to confer substantially less protection to younger users 
than to older women primarily due to adherence issues.8, 10 This is particularly 
concerning as adolescent girls and young women (AGYW) face a far greater risk of HIV 
acquisition than older women, or men of any age.3, 10  
A promising field in HIV prevention is the development of multipurpose technologies 
(MPTs), products which simultaneously provide protection from two or more of HIV, 
other STIs, and unintended pregnancy.11, 12 Current MPTs in development include: (1) 
long-acting drug delivery systems such as intravaginal rings designed to protect from 
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HIV infection and pregnancy (currently in a phase-I trial, ClinicalTrials.gov Identifier: 
NCT02235662); (2) pericoital drug delivery systems such as vaginal gel, tablets and 
films designed to protect from HIV; and (3) a combination of products such as a 
contraceptive diaphragm used with microbicide gel designed to protect from HIV, STIs 
and pregnancy.11, 13 Although MPT development is likely to be costly and complex, their 
benefits may also be large. Firstly, products offering more than one indication may be 
more attractive to potential users than single-purpose products. Secondly, MPT use 
could crowd-in protection from lesser valued attributes. For example, where users value 
contraceptive properties more than they do HIV prevention, additional HIV protection 
would be a positive externality from the use of a dual-protective product. Thirdly, the 
multipurpose nature of MPTs may reduce the stigma of accessing HIV prevention tools, 
which has been shown to be a substantive barrier to use, and prevent products from 
being perceived as for certain populations only.14, 15 
Accounting for the perspectives of end-users in product formulation and delivery could 
lead to more attractive products, greater uptake and adherence, and increased 
population protection. This study uses a discrete choice experiment (DCE) to elicit the 
preferences for five HIV prevention products (oral PrEP, a microbicide gel, a SILCS 
diaphragm used in concert with gel, an intravaginal ring, and an injectable) from four 
population groups (adult men and women aged 18-49, adolescent girls aged 16-17 and 
self-identifying female sex workers aged 18-49) in Vosloorus, a township in peri-urban 
Ekurhuleni, around 30km from Johannesburg in the Gauteng province of South Africa. 
Because there are no observed data for many of these products, we gathered primary 
stated preference data using the DCE, an end-user focused approach to identifying key 
determinants of demand.16, 17 DCEs ask respondents to choose their preferred product 
or service from a set of alternatives over a number (usually between 8-10) of choice 
tasks. By looking at how respondents choose across repeated scenarios allows 
researchers to quantitatively elicit the key drivers of decision making.18 Although men 
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who have sex with men (MSM) are a high-risk group in South Africa, they were not 
purposively sampled in this study a) because the contraceptive indication of interest 
would have little relevance among MSM practicing solely same-sex intercourse, b) the 
stigma associated with same-sex activity was considered to place interviewers or 
participants at risk, and c) the small number of MSM likely to be in the geographical 
location of the survey coupled with the intensive resources required to reach adolescent 
and FSW groups. Where a small number of MSM were identified the household survey, 
they were not excluded from data collection or analysis based on reported same-sex 
activity. 
Already popular in the health literature19, DCEs are being increasingly applied in the HIV 
and sexual health fields. Previous work conducted in South Africa found HIV prevention 
efficacy to be a key driver of demand for a microbicide, a diaphragm or female condom.20 
A DCE was used to indicate that a rectal microbicide was acceptable among MSM in 
Thailand, with male sex workers more likely to use an efficacious product than other 
men.21 A DCE in Tanzania showed that different population groups had markedly 
different preferences for HIV testing interventions among respondents who had been 
tested previously.22 Two DCEs in Malawi found heterogeneity in the preferences of 
young people for HIV, sexual health, and family planning services.23, 24 Finally, a conjoint 
analysis in seven countries found PrEP to be broadly acceptable to potential end-users.25 
To our knowledge, this is the first study to explore how preferences for new HIV 
prevention products vary across general and key population groups, and provides 
important information on a) preferences among different groups, b) variation in 
preferences within groups, and c) whether new products will be used alongside or 
instead of condoms. Such “condom substitution” has been a concern in the design of PrEP 
programmes and demonstration projects, yet evidence is mixed as to whether 
condomless sex will increase after PrEP introduction.6, 26-28 
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Methods 
Study context 
Primary data collection was carried out in the town of Vosloorus, around 30km south-
east of Johannesburg, South Africa. Vosloorus contains a broad range of residential 
contexts representing a range of demographic, socioeconomic and cultural 
characteristics. Formative research took place between August and September 2015, 
and the survey ran from October to December 2015. Further details on study context 
and methods have been published in the study protocol29 3 and no changes were made 
to the study design or analysis plan.  
Development and design of the discrete choice experiment 
The DCE was developed through an analysis of a previous DCE and focus groups 
discussions carried out in previous research18, 21, specifically identifying important 
characteristics of prevention products and exploring optimal ways to present these in a 
clear and relatable manner to participants. This was supplemented by a scoping 
literature review to identify new products and additional attributes which could be 
important to respondents, which was added to and refined through piloting. We opted 
to show three alternatives of new products in each task using an unlabelled design where 
each alternatives represent a generic product within which all characteristics can change 
as prescribed by the statistical design. Though an unlabelled design, were each 
alternative represents a fixed product category, would have led to greater statistical 
efficiency, feedback from piloting was that a choice task with five labelled alternatives 
plus an opt-out was too complex. The opt-out alternative displayed characteristics of a 
male condom or non-protection, depending on what the respondent reported using in 
their last sex act.  
                                                             
3 Chapter 7 of this thesis 
177 
 
The DCE was pre-piloted among 17 respondents from across the target populations. A 
separate design was generated for male and female groups as men can only initiate use 
of two of the five potential products (the injectable and oral PrEP). The full survey and 
DCE was then piloted among 45 respondents from the target sampling frame. Few 
changes were made to the DCE after piloting, except to the side-effects attribute where 
minor and frequent side-effect symptoms of nausea, stomach cramps, and dizziness 
were included over major, less frequent side-effects such as reduction in bone mineral 
density or liver toxicity. This is a limitation of this study, but was necessary due to 
difficulties in participant comprehension of a) varying probabilities of side-effects and 
b) medical implications of more serious conditions in a brief DCE interview. Priors from 
analysis of pilot data (n=17) were used in NGENE software30 to generate a single D-
efficient design with ten tasks, which avoided dominated or duplicated alternatives as 
recommended31. A D-efficient design was chosen with the aim of improving precision in 
final model estimates whilst accounting for design constraints arising from restrictions 
on the frequency that products could be used. The final six attributes of the DCE and their 
levels are shown in Table 1, and Figure 1 shows an example of how choice tasks were 
presented to respondents who reported using a condom in their last sex-act. For 
participants who reported not using a condom at last sex, the final column showed a 
“nothing” alternative, whilst male respondents saw identical side-effects images but 
with male characters. The final design incorporated ten choice tasks, with one additional 
task a repeat to check the consistency of responses. 
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Table 1: Attributes and levels 
Attribute Levels 
Product Oral pre-exposure prophylaxis, 
Microbicide gel, Microbicide gel with 
SILCS diaphragm, Vaginal ring, Injectable 
pre-exposure prophylaxis 
HIV protection 55%, 75%, 95% 
Pregnancy prevention Prevents pregnancy, Does not prevent 
pregnancy 
Frequency of use4 Every time you have sex, Once per day, 
Once per week, Once per month, Once 
per three months, Once per six months, 
Once per year 
Protection against other STIs Protects against other STIs, Does not 
protect against other STIs 
Side-effects (probability of occurrence 
fixed) 
Stomach cramps/pain, Nausea/feeling 
sick, Dizziness, None 
 
Figure 1: Example of DCE task as shown to a female who used a condom at last sex 
 
  
                                                             
4 Because no product can be used at all frequencies, the design contained constraint terms where 
only relevant frequencies were presented alongside products. Frequencies were chosen to be 
informative for product development: Oral PrEP – Daily, weekly, monthly; Microbicide Gel – 
coitally; SILCS diaphragm and microbicide gel – coitally, daily; Vaginal ring – weekly, monthly, 
three monthly, six monthly; Injection – three monthly, six monthly, annually 
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Survey methods 
A household survey sampled adult men and women (aged 18-49), and adolescent girls 
(aged 16-17) randomly. Clusters of dwellings (census enumeration areas) within 
Ekurhuleni were selected at random using municipal data and aerial photographs, and 
interviewers contacted every second property after a random start. All eligible 
participants were interviewed within selected households. The DCE and background 
survey was administered in English, Zulu and Khosa languages using Open Data Kit 
(https://opendatakit.org) software on tablet computers, and participants were given 
ZAR 50 (GBP £2.50) vouchers as compensation for their time. A team of twelve 
experienced interviewers from a specialist local data collection firm, Progressus 
Research and Development (http://www.progressus.co.za) implemented the survey.  
FSWs are a hard to reach population and we used respondent-driven sampling (RDS) to 
sample 203 active FSW participants.32 Peer educators, most of whom were practicing 
sex workers, were used to locate ‘hotspots’ in Ekurhuleni. First, 12 were asked to act as 
‘seeds’ to start RDS chains in different areas (i.e. women working in brothels, hotels or 
on the street). Seeds were invited to complete the survey and received the same ZAR 50 
(GBP £2.50) compensation as participants in the general population. Women were then 
given four coupons containing study information to distribute to colleagues. When each 
referred colleague attended for interview, their recruiter received a small incentive in 
the form of a ZAR 20 (GBP £1) voucher. 
Choice Modelling 
We model choices using random utility models, choosing this approach over alternative 
methods (random regret minimisation for example) due to its proven consistency in 
explaining choice behaviour in health applications. We assume that that individual 
i(i=1,…,N) makes choices such that they maximise utility over the four alternatives 
presented (j=1,2,3,4). Their axiomatic utility function Uij is decomposed into an 
180 
 
explainable systematic component Vij and a random component εij, and we specify an 
indirect utility function for the utility of respondent i from choice j in choice set c as the 
linear combination of attributes and an error term: 
𝑉𝑖𝑗𝑐 = 𝑋𝑖𝑗𝑐𝛽 + 𝜀𝑖𝑗𝑐  (1) 
With 𝑉𝑖𝑗𝑐 the utility derived from a choice, 𝑋𝑖𝑗𝑐
′ 𝛽 the component of utility that is captured 
by DCE attributes, and 𝜀𝑖𝑗𝑐  a stochastic (random) component of utility. We specify the 
vector 𝑋𝑖𝑗𝑐  as the set of product attributes: 
𝑋𝑖𝑗𝑐𝛽𝑗 = 𝛽0 +  𝛽1𝑃𝑟𝑜𝑑𝑢𝑐𝑡𝑗 + 𝛽2𝐻𝐼𝑉𝑗 + 𝛽3𝐶𝑜𝑛𝑡𝑟𝑎𝑐𝑒𝑝𝑡𝑖𝑜𝑛𝑗 + 𝛽4𝑆𝑇𝐼𝑗 + 𝛽5𝐹𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦𝑗
+ 𝛽6𝑆𝑖𝑑𝑒𝐸𝑓𝑓𝑒𝑐𝑡𝑠𝑗 
(2) 
 
Where 𝑃𝑟𝑜𝑑𝑢𝑐𝑡𝑗 , 𝐻𝐼𝑉𝑗 ,  𝐶𝑜𝑛𝑡𝑟𝑎𝑐𝑒𝑝𝑡𝑖𝑜𝑛𝑗 , 𝑆𝑇𝐼𝑗 , 𝐹𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦𝑗 , and 𝑆𝑖𝑑𝑒𝐸𝑓𝑓𝑒𝑐𝑡𝑠𝑗  are the 
design attributes of the DCE, and 𝛽0 a constant. We first estimate equation (1) using a 
multinomial (or conditional) logit model (MNL) which estimates the probability of 
individual i choosing alternative j among the set of options c as a probabilistic function 
of design attributes: 
𝑃𝑖𝑗𝑐 =
exp (𝑋𝑖𝑗𝑐𝛽)
∑ exp (𝐽 𝑋𝑖𝑗𝑐𝛽)
 
(3) 
Although described as the workhorse of discrete choice modelling, the MNL requires two 
restrictive assumptions: the IIA assumption of independence of irrelevant alternatives 
(concordant with the IID distribution of the disturbance), and homogenous preferences 
across individuals where every individual is assumed to have the same tastes as the 
sample average, which does not allow us to uncover differences in preferences that are 
important in guiding policy.18 We assume that individuals choose the service associated 
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with the highest utility such that the probability that individual i chooses alternative j 
over k is given as: 
Pr 𝑗𝑖 = Pr(𝑈𝑗𝑖 > 𝑈𝑘𝑖) = Pr(𝑉𝑗𝑖 + 𝜀𝑗𝑖 >  𝑉𝑘𝑖 + 𝜀𝑘𝑖) = Pr(𝑉𝑗𝑖 − 𝑉𝑘𝑖 > 𝜀𝑗𝑖 − 𝜀𝑘𝑖) (4) 
In this paper, as different MNL models are estimated for each population, the assumption 
required is homogeneity of preferences within each group. As groups are more 
homogenous in nature due to separate inclusion criteria, assuming identical preferences 
across members within each group may be less restrictive than assuming this across the 
range of populations in our sample.  
Nevertheless, to recognise that individuals within groups may have different 
preferences, we apply a random parameter logit (MMNL or mixed logit random 
parameter) model. The MMNL allows for preference (taste) heterogeneity within groups 
so does not require the IIA assumption to hold. Briefly, the MMNL extends the MNL 
model by decomposing the error term into two components: 
𝑈𝑖𝑗 = 𝑉𝑖𝑗 + [𝛤𝑖𝑗 + 𝜀𝑖𝑗] (5) 
Which, when the distribution of the random component 𝛤𝑖𝑗  is specified by the analyst, is 
used to estimate individual-level coefficients: 
𝛽𝑖𝑘 = 𝛽𝑘 + 𝛿𝑘𝑍𝑖 + 𝛤𝑘𝑣𝑖𝑘 (6) 
Where 𝛿𝑘𝑍 reflects observable heterogeneity, and 𝛤𝑘𝑣𝑖𝑘 unobservable heterogeneity.  
Finally, we use a latent class approach to explore unobserved heterogeneity in choice 
data. A semi-parametric approach, a latent class model assumes the existence of 
underlying subgroups (classes) of respondents whose membership of each class is 
characterised by unobserved, or latent, variables. A posterior probability is assigned to 
each participant for membership to each class, and when participants are allocated to 
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classes based on their highest probability it is possible to compare the observable 
characteristics of participants across classes 18, 34. 
Latent class modelling offers a different approach to relaxing the IIA assumption of the 
MNL model. Furthermore the basic latent class model does not require parametric 
distributional assumptions to be imposed by the analyst, whilst results have been shown 
less sensitive to computational variations in estimation, such as starting values or 
optimisation algorithms which can vary across software packages.35, 36 A latent class 
approach estimates separate parameter vectors for different classes of the sample with 
MNL models. The model relaxes the IIA assumption by assuming that preferences are 
homogenous within, but not across, classes. Thus the probability of respondent i 
choosing alternative j in choice set c conditional on class membership k is: 
𝑃𝑖𝑐(𝐽|𝛽𝑘) =  ∑ 𝜋𝑖𝑘
𝐾
𝑘=1
exp (𝑋𝑖𝑗𝑐𝛽𝑘)
∑ exp (𝐽 𝑋𝑖𝑗𝑐𝛽𝑘)
 
(7) 
The probability of respondent i belonging to class k is 𝜋𝑖𝑘 . Class membership is 
unobservable, however, we can regress the probability of class membership on a set of 
observable characteristics such that: 
𝜋𝑖𝑘 =
exp (𝑍𝑖
′𝛿𝑘)
∑ exp (𝑍𝑖
′𝛿𝑘)
𝐾
𝑘=1
 
(8) 
With Zi a vector of individual characteristics, and 𝛿𝑘  a vector of parameters to be 
estimated. 
We run latent class logit models on the male sample, alongside a pooled sample of all 
three female groups. This approach removes the implicit assumption that women’s 
preferences will differ by their sample category, and instead allows the data to drive 
evidence of variation and similarity among subgroups. By pooling we lose 
generalisability from the results of this specification; however, results from the pooled 
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analysis are useful to identify important subgroups of the female population. We assess 
the optimal number of classes through comparison of model fit via log-likelihood 
function and Akaike Information Criteria (AIC). 
Heterogeneity 
We use two approaches to explore heterogeneity in preferences. First, we examine the 
distribution parameters of the MMNL model to see where variation remains in addition 
to that captured by the random parameters. Secondly, we estimate the latent class model 
(equation 8) and explore how preferences vary by class, specifying several observable 
characteristics which influence the probability of class membership.  
Our rationale for including these observable characteristics is as follows. Age is strongly 
associated with HIV and pregnancy risk37, 38, yet little is known about the effect of age on 
preferences for protection against HIV or pregnancy. Structural drivers are legal, 
economic and social factors which shape HIV risk.39 Exposure to intimate partner 
violence (IPV) has been shown to be associated with increased HIV risk in many 
contexts40, 41, whilst limited livelihood opportunities, and unrestricted alcohol 
availability alongside drinking norms are also significant factors in HIV risk.42-45 Finally, 
life circumstances play an important role in the extent to which people place themselves 
at, or are able to protect themselves from, HIV risk.46, 47 We therefore explore attitudes 
towards pregnancy among women and how preferences may be affected by male 
circumcision, which reduces the likelihood of a male acquiring HIV.48, 49 Finally, we 
explore associations with protective attributes, having an external partner in the 
previous three months, and having high HIV knowledge as assessed by the number of 
correct answers on a knowledge tool.50  
Model estimation 
Models were estimated in NLOGIT 551 through a maximum likelihood approach and 
MMNL models were estimated using 500 Halton draws with start values obtained from 
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a MNL model. All parameters were generic across three unlabelled alternatives, with 
labels entering the DCE through an attribute level. All design attributes were specified 
as random with parameters following a normal distribution to characterise our 
uncertainty in the nature and direction of heterogeneity around coefficients. Triangular 
and lognormal distributions were tested and did not change the sign or significance of 
the main effects. General population samples were analysed with survey weighting such 
that age and sex characteristics matched those of the general population. FSW RDS data 
were weighted using age characteristics using RDSAT software.52 All attribute levels 
were effects coded5, except for HIV protection which was estimated linearly.53 
Results 
Sample characteristics and generalisability 
In the household survey, of 2271 persons identified door-to-door, 650 were eligible 
(29%). Of those, 30 (5%) were not found after five attempts and 11 (2%) refused to be 
interviewed, leading to 609 (94%) completed interviews. In total 661 interviewees met 
the DCE eligibility criteria across the four populations. Notably, 126 (62%) of adolescent 
girls reported not being sexually active whilst self-reported HIV prevalence was broadly 
comparable across and within populations to that of other representative surveys.3, 4 The 
inclusion criteria for adolescent girls did not require sexual activity because adolescent 
girls face substantial and immediate risk of HIV at sexual debut, whilst HIV prevention 
programmes do not target based on reported sexual activity. The preferences of non-
sexually active adolescent are important for ensuring that attractive products are made 
available at the earliest possible exposure to HIV risk. In addition, if sexual activity was 
an explicit inclusion criterion for adolescents, confidentiality could have been breached 
if other members of the household knew that an interview did, or did not, take place.   
                                                             
5 Effects coding is similar to dummy coding in that it allows for non-linear effects in attribute 
levels, but does not perfectly confound the base attribute level with the grand mean of the utility 
function. Coefficients are therefore interpreted as divergence from the mean for that attribute 
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Table 2: Descriptive statistics for DCE respondents by population 
 Adult Males Adult Females Adolescent Girls 
Female 
Sex 
Workers 
Participation         
Recruited for survey 202 203 204 203 
HIV positive 16 (8%) 35 (17%) 5 (2%) 81 (40%) 
Not sexually active 4 (2%) 10 (5%) - 0 
Eligible and completed DCE 182 (90%) 158 (78%) 199 (98%) 122 (60%) 
Socio-demographic 
variables 
N (%), Mean 
(SD) 
N (%), Mean 
(SD) 
N (%), Mean 
(SD) 
N (%), 
Mean (SD) 
Age 29 (7.6) 29 (7.83) 17 (0.49) 31 (6.17) 
Education: Primary or less 18 (12%) 29 (16%) 51 (28%) 36 (20%) 
    Finished secondary 127 (70%) 1234 (68%) 129 (71%) 138 (76%) 
    College or higher 33(18%) 29 (16%) 2 (1%) 5 (3%) 
Employment: Full time 58 (32%) 38 (21%) 0 (0%) 66 (36%) 
    Part time 36 (20%) 35 (19%) 4 (2%) 29 (16%) 
    Student/scholar 24 (13%) 27 (15%) 164 (90%) 0 (0%) 
    Work seeker/unemployed 47 (26%) 71 (39%) 13 (7%) 40 (22%) 
    Other 15 (8%) 11 (6%) 0 (0%) 46 (25%) 
In a stable relationship 131 (72%) 157 (86%) 160 (88%) 118 (65%) 
Cohabiting 40 (22%) 53 (29%) 0 (0%) 29 (16%) 
Household monthly income: 
<R5,000 133 (73%) 127 (70%) 113 (62%) 113 (62%) 
     R5,000-15,000 42 (23%) 40 (22%) 60 (33%) 55 (30%) 
     R15,000+ 5 (3%) 7 (4%) 7 (4%) 15 (8%) 
Sexual history variables     
Age at first sex 16.55 (3.4) 17.88 (1.98) 15.68 (1.09) 
17.96 
(2.57) 
Number of lifetime partners 13.06 (25.94) 4.55 (3.53) 2.14 (1.69) 
1626.54 
(2185.95) 
Number of partners in 
previous year 2.51 (4.45) 1.24 (1.49) 1.34 (0.85) 
462.83 
(556.59) 
Current regular sexual 
partner 131 (72%) 157 (86%) 160 (88%) 118 (65%) 
Condom use at last sex with 
regular partner 124 (68%) 78 (43%) 118 (65%) 166 (91%) 
Currently using any form of 
contraception 140 (77%) 126 (69%) 149 (82%) 149 (82%) 
Ever received an HIV test 131 (72%) 157 (86%) 160 (88%) 118 (65%) 
External sexual partner in 
prior 3 months 36 (20%) 9 (5%) 9 (5%) 166 (91%) 
Circumcised 118 (65%)    
Nb. Values of continuous variables italicised   
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Table 2 displays the descriptive statistics for eligible respondents in each population. 
Comparability is limited across groups due to varying inclusion criteria for adolescent 
girls and FSWs, the latter also sampled through RDS. The mean age across adult groups 
was similar and whilst a large number of respondents in each group reported being in a 
relationship, many fewer reported cohabiting with a sexual partner. Reported lifetime 
sexual partners among adult males (13.06) were higher than among adult females 
(4.55). Reported condom use at last sex with a regular partner was significantly lower 
among adult females (43%) than any other group, though this Figure is comparable with 
that of 34% from a nationally representative survey.3, 4  
The DCE was well understood by participants; just 2% of respondents reported finding 
the DCE quite difficult or very difficult, whilst 81% of respondents chose the same 
alternative twice in the repeated choice task. 61% of respondents chose the product (or 
one of the products when values were duplicated) with the highest HIV protection in 
every choice set. 
Analysis of preference data 
Table 3 shows MMNL results and reports the coefficients of each attribute level 
parameter. Results from the MNL model are given in supplementary Table 2.   
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Table 3: MMNL main effects results 
 
 Adult Males  
Coeff. (SE) 
 Adult Females  
Coeff. (SE) 
 Adolescent Girls  
Coeff. (SE) 
 FSW  
Coeff. (SE) 
Products: Oral PrEP -2.52 (1.284)** -0.45 (0.15)*** -0.31 (0.11)*** -1.09 (0.169)*** 
         Microbicide Gel - -0.29 (0.19) -0.17 (0.14) -1.03 (0.21)*** 
         Vaginal Ring - -0.23 (0.15) -0.16 (0.11) -0.13 (0.149) 
         SILCS Diaphragm - -0.23 (0.28) -0.16 (0.27) -0.28 (0.265) 
         Injectable 2.52 (1.284)** 1.21 (0.28)*** 0.8 (0.28)*** 2.52 (0.35)*** 
Protection: HIV protection 
(100%) 5.32 (1.650)*** 3.14 (0.77)*** 2.33 (0.53)*** 2.78 (0.694)*** 
          Pregnancy prevention 0.16 (0.066)** 0.34 (0.08)*** 0.16 (0.05)*** 0.43 (0.087)*** 
          STI protection 0.75 (0.211)*** 0.41 (0.1)*** 0.22 (0.06)*** 1.04 (0.105)*** 
Frequency of use: Daily -6.91 (0.227) 0.32 (0.16) 0.17 (0.16) 0.3 (0.213) 
          Coitally - 0.13 (0.29)* 0.14 (0.23) 0.25 (0.281) 
          Weekly 3.77 (2.207)* 0.29 (0.17)** 0.15 (0.13) 0 (0.173) 
          Monthly -0.89 (1.913) 0.4 (0.16) 0.4 (0.12)*** 0.52 (0.155)*** 
          Every 3 months -1.16 (1.825) 0.26 (0.17) 0.06 (0.13) -0.02 (0.181) 
          Every 6 months 4.14 (2.32)* 0.14 (0.2) 0.01 (0.15) 0.23 (0.177) 
          Annually 1.06 (2.164) -1.53 (0.5)*** -0.93 (0.45) -1.28 (0.453)*** 
Side-effects: Dizziness 2.42 (2.318) -0.16 (0.07)* -0.13 (0.07)* -0.37 (0.108)** 
          Stomach cramps -1.98 (-1.291) 0.09 (0.11) 0.07 (0.08) 0.09 (0.127) 
          Nausea -4.19 (-2.277)* -0.06 (0.1) 0.02 (0.08) 0.16 (0.103) 
          No side-effects 5.06 (1.792)*** 0.13 (0.08) 0.05 (0.09) 0.11 (0.093) 
          Opt out 42.2 (14.783)*** 3.01 (0.65)*** 2.05 (0.4)*** 1.2 (0.598)** 
          Male condom (opt out) 1.34 (1.275) 2.77 (0.59)*** 0.6 (0.09)*** 2.86 (0.32)*** 
Distribution parameters     
          Oral PrEP 14.06 (4.661)*** 0.81 (0.13)*** 3.77 (5.14) 1.51 (0.13)*** 
          Microbicide Gel - 0.79 (0.14)*** 11.4 (6.37)* 1.08 (0.179)*** 
          Vaginal Ring - 0.38 (0.19)** 3.06 (5.28) 0.47 (0.102)*** 
          Injectable 14.06 (4.661)*** 0.36 (0.09)*** 36.42 (8.69)*** 1.39 (0.146)*** 
          SILCS Diaphragm - 0.92 (0.16)*** 7.29 (2.37)*** 0.73 (0.237)*** 
          HIV protection (100%) 0.28 (0.094)*** 0.04 (0.01)*** 0.17 (0.07)*** 0.05 (0.003)*** 
          Pregnancy protection 2.58 (2.966) 0.42 (0.07)*** 3.23 (2.78) 0.76 (0.07)*** 
          STI protection 10.85 (3.953)*** 0.89 (0.09)*** 21.58 (5.18)*** 1.16 (0.085)*** 
          Daily 10.67 (10.617) 0.3 (0.53) 1.12 (8.21) 1.24 (0.153)*** 
          Coitally - 0.19 (0.63) 0.19 (6.26) 1.64 (0.216)*** 
          Weekly 2.81 (4.202) 0.01 (0.12) 17.7 (7.6)** 0.09 (0.157) 
          Monthly 0.77 (4.73) 0.12 (0.2) 15.56 (7.07)** 0.13 (0.113) 
          Every 3 months 2.99 (4.446) 0.43 (0.14)*** 34.98 (10.49)*** 0.66 (0.185)*** 
          Every 6 months 2.22 (4.935) 0 (0.17) 14.26 (6.73)** 0.26 (0.194) 
          Annually 21.4 (7.74)*** 0.15 (0.27) 1.01 (0.2)*** 1.01 (0.199)*** 
          Dizziness 0.96 (0.342) 0.54 (0.34) 5.15 (6.84) 0.42 (0.075)*** 
          Stomach cramps 0.32 (3.121) 0.15 (0.16) 7.56 (4.07)* 0.6 (0.11)*** 
          Nausea 2.38 (3.795) 0.05 (0.17) 23.01 (6.61)*** 0.01 (0.108) 
Opt out:  No side-effects 2.09 (2.943) 0.17 (0.13) 0.28 (0.08)*** 0.28 (0.083)*** 
          Male condom (opt out) 29.9 (9.716)*** 2.97 (0.44)*** 30.9 (8.58)*** 0.62 (0.138)*** 
Log-likelihood -2041.3 -1758.92 -2107.8 -2457.68 
AIC 4136.7 3585.9 4251.7 4985.4 
***, **, * ==> Significance at 1%, 5%, 10% level. Models for each population analysed separately, and indicated as 
significant if different from zero. 
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Where coefficients are significantly greater than zero, an attribute can be interpreted as 
having a relatively positive impact on participant utility. The magnitude of coefficients 
can be directly compared within each model. The significance of coefficients (i.e. what is 
important to people’s choices) can be compared across populations, but due to possible 
differences in the scale of choice data across groups, coefficients cannot be directly 
compared across populations. In both specifications and across all groups HIV 
protection was the strongest determinant of choice, whilst protection against pregnancy 
and other STIs was also significantly attractive. The absence of side-effects was 
important to adult men but not to any female groups, although FSWs found nausea 
significantly worse than other side-effects. There was no clear pattern of demand around 
frequency of use across groups. 
There are some differences between the product coefficients in the MNL and MMNL 
models, indicating that tastes vary within populations – this is also highlighted by the 
positive distribution parameters. In both specifications adult women and FSWs 
significantly dislike oral PrEP and favour injectable products, with FSWs additionally 
disliking microbicide gels. Among adolescent girls, the MNL indicates a significant dislike 
for the vaginal ring which is insignificant in the MMNL model, whilst the MMNL model 
shows the same pattern of statistically significant preferences for oral PrEP and 
injectable products as other female groups.  
Preference Heterogeneity 
Latent class specification 
Latent class models are presented for female and male respondents in panels A and B of 
Table 4 respectively, and were computed without survey weighting.  
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Table 4: Latent class logit: Pooled samples 
 
 
Panel A: 
All females (adult women, adolescent girls, FSWs) 
Panel B: 
All males 
 
Class 1 
34% of sample  
Coeff. (SE) 
Class 2 
19% of sample  
Coeff. (SE) 
Class 3 
48% of sample  
Coeff. (SE) 
Class 1 
42% of sample  
Coeff. (SE) 
Class 2 
58% of sample  
Coeff. (SE) 
Products: Oral PrEP 0.12 (0.31) -0.14 (0.23) -0.04 (0.1) 0.37 (0.19)* -0.04 (0.1) 
         Microbicide Gel 0.01 (0.32) 0.02 (0.38) 0.05 (0.14) - - 
         Vaginal Ring -0.27 (0.34) -0.37 (0.25) -0.21 (0.11)* - - 
         SILCS Diaphragm -0.15 -0.18 0.21 - - 
         Injectable 0.28 (0.69) -0.24 (0.67) 0.01 (0.31) -0.37 0.04 
Protection: HIV protection (100%) 0.53 (1.79) 7.59 (1.05)*** 3.28 (0.64)*** 5.79 (1.45)*** 3.44 (0.64)*** 
          Pregnancy prevention 1.33 (0.19)*** 0.27 (0.12)** 0.26 (0.06)*** 0.37 (0.11)*** -0.02 (0.06) 
          STI protection 1.34 (0.21)*** 0.21 (0.13) 0.29 (0.06)*** 0.48 (0.11)*** 0.51 (0.07)*** 
Frequency of use: Daily -0.45 (0.52) -0.5 (0.35) -0.15 (0.17) 0.48 (0.34) -0.22 (0.16) 
          Coitally 0.28 (0.56) -1.06 (0.54)** -0.22 (0.24) - - 
          Weekly -0.65 (0.42) 0.03 (0.31) -0.21 (0.16) 0.24 (0.34) -0.08 (0.15) 
          Monthly -0.34 (0.44) 0 (0.32) 0.21 (0.14) -0.17 (0.2) 0.04 (0.1) 
          Every 3 months 1.06 (0.56)* -0.3 (0.31) -0.06 (0.14) -0.49 (0.24)** 0.01 (0.12) 
          Every 6 months 0.42 (0.44) 0.29 (0.48) 0.34 (0.17)** -0.02 (0.24) 0.17 (0.14) 
          Annually -0.32 1.53 -0.31 -0.04 0.08 
Side-effects: Dizziness 0.35 (0.32) 0.04 (0.15) -0.03 (0.08) -0.04 (0.14) 0.06 (0.09) 
          Stomach cramps -1.23 (0.54)** -0.3 (0.21) 0.01 (0.09) -0.07 (0.16) -0.01 (0.09) 
          Nausea 0.77 (0.27)*** -0.06 (0.19) -0.06 (0.09) -0.26 (0.24) -0.44 (0.23)* 
          No side-effects 0.10 0.31 0.09 0.38 0.39 
Opt out: Opt out 3.94 (1.35)*** 1.02 (1.15) 1.81 (0.19)*** 6.39 (1.48)*** 0.51 (0.52) 
          Male condom (opt out) 0.53 (0.04)*** -5.45 (1.15) 1.33 (0.21)*** 0.13 (0.27) 0.86 (0.35)** 
Class membership probabilities      
Constant 0.23 (0.93) -1.09 (1.17)  0.94 (1.56)  
190 
 
Female sex worker 1.98 (0.77)** 1.83 (0.96)*  -  
Adolescent 0.99 (0.46)** 1.42 (0.65)**  -  
Age -0.06 (0.03)** -0.02 (0.04)  -0.04 (0.07)  
Experience of IPV in last 12 months -0.14 (0.17) -0.19 (0.23)  -  
Unhappy if self/partner became pregnant 0.03 (0.14) 0.16 (0.19)  0.06 (0.22)  
High HIV knowledge -0.47 (0.15)*** -0.56 (0.21)***  -0.15 (0.28)  
Alcohol use at last sex 0.34 (0.34) 1.01 (0.33)***  0.25 (0.46)  
Report external partners in last 3 months 0.03 (0.36) -0.12 (0.44)  -0.02 (0.21)  
Unemployed 0.10 (0.18) 0.03 (0.24)  0.08 (0.21)  
Log-likelihood -4608.94   -1971.39  
AIC 9365.90   4012.80  
Nb. Standard errors not retrievable in latent class specification for base categories "SILCS diaphragm", 
“Injectable”, "Annually", and "No side-effects". ***, **, * ==> Significance at 1%, 5%, 10% level. Models 
for each population analysed separately, and indicated as significant if different from zero. 
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HIV knowledge (as assessed through the tool presented in Supplementary Material 1) is 
a key driver of demand for HIV protection as Class 1 members (34% of the female 
sample) show strong preferences for STI and pregnancy protection but do not value HIV 
protection in a new product. Class membership is additionally predicted by being of 
younger age, a FSW, or an adolescent, indicating that there is significant variation in 
preferences among female groups. A HIV preventive MPT would offer substantial benefit 
to this group of women, as contraceptive or STI preventative products could be bundled 
with HIV protection, offering additional protection. 
In contrast, members of class 2 (19% of the sample) display very strong preferences for 
HIV protection, valuing it more than twice as highly as other classes. Class 2 members 
also value pregnancy protection, but do not find STI protection appealing. Class 2 
appears to be a high-risk group as, relative to class 3, members are more likely to have 
used alcohol the last time they had sex, and have lower HIV knowledge. Finally, class 2 
members are more likely to be FSW or adolescent girls than class 3 members, and 
indicate a dislike for coitally-specific products. Class 3 members (48% of the sample) 
strongly value protection from HIV, pregnancy and STIs, and indicate a dislike for the 
vaginal ring product. This group is likely to comprise of adult women in the general 
population. 
Among adult males, membership of either class (42%) is not significantly predicted by 
the characteristics we define, indicating that drivers of preference heterogeneity differ 
between men and women and that male preferences are not shaped by structural risks 
in the same manner as female preferences. However, there is still evidence of 
heterogeneity in preferences among adult men. The most notable variation between the 
two groups is the non-significance of the pregnancy prevention parameter among class 
2 men indicating that, in order to make HIV prevention products attractive to these men, 
potential HIV and STI prevention properties should be emphasised. Men in class 1 
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strongly prefer oral PrEP, whilst the strongly significant opt-out parameters in both 
groups show an inclination to continue current practice suggesting that the expected 
reporting bias towards switching to new products may not be as strong as hypothesised.  
Marginal effects 
DCEs estimate the relative strength of preferences, and therefore we cannot simply 
compare the magnitude of coefficients across groups. However, the ratios of coefficients 
are comparable across populations and show the variation in trade-offs across groups. 
The marginal effects of factors relative to the common denominator of HIV protection 
are provided in supplementary Table 3, computed from the coefficients in Table 3. Adult 
men are only willing to forgo 3% HIV protection for a contraceptive product, but adult 
women are willing to forgo 11%. Results suggest that all female groups value the male 
condom substantially more than men, and that preferences for STI protection is broadly 
comparable to pregnancy protection across female groups. Men value the absence of 
side-effects much more than women and FSWs value STI protection almost three times 
greater than any other group. 
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Discussion 
This study assessed preferences for new HIV prevention products among adult men and 
women, adolescent girls, and female sex workers. Consistent with prior expectations HIV 
protection was the most important attribute to respondents, particularly those with high 
levels of HIV knowledge, however, results suggest that demand would increase for all 
groups if multipurpose protection was incorporated. There was relatively little variation 
in preferences for oral PrEP, microbicide gel, the SILCS diaphragm and the vaginal ring 
when compared to strong preferences for a long-lasting injectable ARV. This could be 
influenced by the strong awareness and use of injectable contraceptives in South 
Africa.54 
This study also provides evidence to explain data from clinical trials of new HIV 
prevention products. Neither adult women nor adolescent girls found the vaginal ring 
appealing, whilst an injectable product was favoured by all groups. In the context of trial 
data suggesting that younger women were not able to adhere to vaginal ring use to the 
same extent as older women8, 9, these results suggest that younger women in particular 
do not favour a vaginal ring prevention system. Incorporating multipurpose properties 
to a vaginal ring could mitigate some of the intrinsic dislike of this product, however, 
these data suggest that a vaginal ring product will not be an attractive offering for 
younger populations. 
Importantly this study suggests that, in order to fully catch the attention of AGYW, 
products must not be single-purpose but provided to offer multipurpose prevention 
against HIV, pregnancy, and other STIs. AGYW have been identified as key populations 
in HIV prevention, and it is critical that new biomedical products are made to be 
attractive and easy for these women to use.3 Although MPT products are generally at the 
concept stage of development, bundling PrEP with other sexual and reproductive health 
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services may make it more attractive than vertical programmes until such time as an 
MPT is licensed. 
Although there are some similarities across groups, the divergence in preferences shown 
here can provide useful information for programming. Adolescent and adult females are 
unlikely to be put off by minor side-effects and demonstrate comparable, statistically 
significant preferences for STI and pregnancy protection. Adult women, however, are 
much more likely to find the male condom appealing relative to new products, indicating 
that demand for ARV-based prevention may be less among older, lower-risk women who 
may prefer on-demand methods. Products rolled out into higher-risk groups (such as 
AGYW) are more likely to be cost-effective – as long as they can be used consistently and 
effectively.55 Findings from the latent class analysis show notable segments in the 
market for PrEP, with some women very concerned about HIV and STI protection, and 
others who are not at all. In addition, female sex workers demonstrate a much stronger 
preference for STI protection than any other group, perhaps because STI acquisition is 
more likely to immediately affect earnings than HIV or pregnancy.56  
Finally, these results suggest that a one size-fits all HIV prevention package will not be 
an effective or efficient use of resources. This is consistent with recent trajectories of 
contraceptive and HIV research where it has been recognised that a range of options can 
optimise uptake and adherence.57 Because groups have different preferences and needs, 
further highlighted by these results, there is a strong case for greater tailoring of 
prevention services, for at risk young women in particular. 
This study has some limitations. Firstly, DCEs are hypothetical tools and may not 
correlate perfectly with real-world choices. However, recent evidence shows that DCEs 
conducted in health fields predict real world choices with a relatively high sensitivity, 
suggesting a reasonable degree of external validity.58 Overall, the random sample of the 
general population survey design and the similarity of sample descriptive statistics with 
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other representative surveys mean findings may have relevance for other South African 
settings. Self-reported rates of condom use among males and adolescent girls were 
higher than other representative surveys and may indicate acceptability biases in 
reporting, or that condoms were more readily available to this group than others. This 
study did not include a price attribute, and therefore does not enable the calculation of 
willingness to pay estimates for different products. However, given the South African 
context where prevention products will likely be free-of-charge to potential users in the 
public sector, including a price element would have made the choice task unrealistic. 
Product profiles in the DCE do not perfectly match with candidate products in 
development, for example injectable trials are based on administration every eight 
weeks rather than every four or twelve explored in this DCE, whilst rare but serious side-
effects were not included in the choice tasks. In addition, injectable products may be 
more likely to initiate drug resistance as they have been shown to remain in the body at 
a low level59, and this is not included here. Finally, there is a lively literature discussing 
the reliability of RDS to generate generalisable samples suggesting that, at worst, RDS is 
a superior form of convenience sampling for hard-to-reach populations and, at best, 
produces bias-free and generalisable samples.32, 60  
Further research is needed to estimate the impact and cost-effectiveness of potential 
single- and multi-purpose HIV prevention products. If models do not incorporate the 
variation in product preferences that we observe here and instead assume an average 
uptake across groups, they may give misleading results. Because models are used to 
generate impact predictions for investment cases in low- and middle-income countries 
(e.g. in South Africa61), inaccurate predictions could result in reduced efficiency in the 
allocation of resources, and large opportunity costs in terms of benefits forgone. This 
paper shows that particular attention should be paid to the perspectives of different 
groups of end-users. 
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Conclusion 
This study involved a discrete choice experiment among four groups in Ekurhuleni 
Municipality in South Africa. In general, respondents indicated a strong desire for 
products that are highly effective in preventing HIV infection. However, there was strong 
demand across all groups for multipurpose prevention products to protect against other 
STIs and pregnancy. Further analysis shows substantive heterogeneity across and 
within groups, suggesting that a variety of prevention methodologies are required to 
meet the demands of different groups. These results strengthen the call for effective and 
attractive multipurpose prevention technologies to be deployed as part of a 
comprehensive combination prevention strategy. 
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Supplementary file 1: HIV Knowledge tool 
Here are some statements about protection against HIV. For each statement please tell 
me whether you think it is true or not.  
 
1. Coughing and sneezing openly DOES NOT spread HIV. 
2. A person can get HIV by sharing a glass of water with someone who has HIV. 
3. A woman can get HIV if she has anal sex with a man 
4. Showering, or washing one’s genitals/private parts, after sex keeps a person 
from getting HIV. 
5. It is possible for a HIV positive mother to give birth to a HIV negative child 
6. A person can get HIV by sitting in a hot tub or a swimming pool with a person 
who has HIV. 
7. Being circumcised reduces a man's chance of getting HIV from a woman 
8.  If a HIV positive person takes HIV treatment regularly, they are less likely to 
transmit HIV to a sexual partner  
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Supplementary Table S1: Exploring heterogeneity 
Segment type (concepts) Variables 
Anticipated 
effect on 
HIV/pregnancy 
Sociodemographic 
Sub-population membership (FSW, 
Adolescent)* 
?/? 
 Age ?/? 
Structural drivers of HIV risk Exposure to IPV in previous 12 months* +/+ 
 Unemployed ?/? 
 Alcohol use at last sex +/+ 
Lifestyle and risk Would be unhappy if became pregnant* ?/+ 
 External partner in previous 3 months +/+ 
 High HIV knowledge +/? 
 Circumcised˥ +/? 
* => Applicable to female groups only  
˥ => Applicable to male groups only  
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Supplementary Table S2: MNL main effects results 
 
 Adult Males  
Coeff. (SE) 
 Adult Females  
Coeff. (SE) 
 Adolescent Girls  
Coeff. (SE) 
 FSW  
Coeff. (SE) 
Products: Oral PrEP -0.11 (0.074) -0.31 (0.11)*** 0.09 (0.19) -0.41 (0.097)*** 
         Microbicide Gel  -0.17 (0.14) -0.12 (0.23) -0.38 (0.119)*** 
         Vaginal Ring  -0.16 (0.11) -0.28 (0.18)** 0.03 (0.099) 
         SILCS Diaphragm  -0.16 (0.21) -0.19 (0.33) -0.38 (0.178)** 
         Injectable 0.11 (0.074) 0.8 (0.28)*** 0.5 (0.16) 1.14 (0.214)*** 
Protection: HIV protection 3.53 (0.289)*** 2.33 (0.53)*** 2.59 (0.88)*** 2.19 (0.425)*** 
          Pregnancy prevention 0.11 (0.034)*** 0.16 (0.05)*** 0.48 (0.09)*** 0.14 (0.044)*** 
          STI protection 0.48 (0.046)*** 0.22 (0.06)*** 0.44 (0.1)*** 0.36 (0.048)*** 
Frequency of use: Daily -0.05 (0.112) 0.17 (0.16) 0.05 (0.28) 0.21 (0.136) 
          Coitally  0.14 (0.23) 0.47 (0.37)** 0.18 (0.193) 
          Weekly 0.08 (0.116) 0.15 (0.23) -0.27 (0.25)* -0.18 (0.122) 
          Monthly 0.03 (0.078) 0.4 (0.13)*** 0.17 (0.22) 0.27 (0.105)*** 
          Every 3 months -0.19 (0.096)** 0.06 (0.12) 0.03 (0.24) -0.11 (0.113) 
          Every 6 months 0.11 (0.106) 0.01 (0.13) -0.12 (0.26) -0.07 (0.117) 
          Annually 0.02 (0.029) -0.93 (0.15)** -0.34 (0.26) -0.3 (0.285) 
Side-effects: Dizziness 0.01 (0.063) -0.13 (0.07)* -0.12 (0.13) -0.18 (0.061)*** 
          Stomach cramps -0.03 (0.063) 0.07 (0.08) 0.11 (0.16) -0.01 (0.077) 
          Nausea -0.27 (0.113)*** 0.02 (0.08) 0.01 (0.13) -0.17 (0.067)** 
          No side-effects 0.29 (0.078)*** 0.05 (0.05) 0.01 (0.07) 0.02 (0.023) 
Opt out:  Opt out 3.06 (0.244)*** 2.05 (0.4)*** 2.95 (0.41)*** 1.68 (0.362)*** 
          Male condom  0.01 (0.054) 0.6 (0.09)*** 0.16 (0.09)* 1.2 (0.174)*** 
Log-likelihood -2317.7 -2107.85 -1998.34 -3240.41 
AIC 4663.5 4251.7 4032.7 6516.8 
***, **, * ==> Significance at 1%, 5%, 10% level. Coefficients for omitted categories retrieved 
through calculating -1*∑(coeffs.). Models for each population analysed separately, and indicated 
as significant if different from zero. 100% HIV protection modelled. 
 
Supplementary Table S3: MMNL marginal effects relative to HIV 
  Adult Males  Adult Females Adolescent Girls  FSW  
Pregnancy protection 3% 11% 7% 15% 
STI protection 14% 13% 10% 38% 
No side-effects 10% 4% 2% 4% 
Male condom 3% 88% 26% 103% 
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Supplementary file 2 
The following section presents the results of a brief further analysis carried out on the 
DCE survey data, including interaction specifications to explore observable 
heterogeneity among participants. We interact a number of respondent characteristics 
with DCE attributes to explore associations between observable characteristics and 
preferences for HIV and pregnancy protection. 
MNL Interaction Specification 
We explore observable heterogeneity among the four populations by running separate 
MNL models with interaction terms between HIV, STI, and pregnancy protection 
alongside individual characteristics. Results are presented in supplementary Table S4, 
and show a great deal of variation in how sociodemographic characteristics affect 
preferences across groups. For example, exposure to intimate partner violence increases 
the importance of HIV protection to adult women, but not adolescents or FSWs. Alcohol 
use at last sex is associated with an increased importance of HIV protection among men 
and sex workers, but a decreased importance among adult and adolescent women. 
Having high HIV knowledge increases utility gained from HIV protection among 
adolescent girls, but there is no significant effect in other populations. Adult men who 
are circumcised value HIV protection from a new product less than uncircumcised men. 
Preferences for contraceptive properties are higher among adolescents not in work 
(including those still in education). Exposure to IPV has a mixed effect between FSWs 
and adolescents, increasing preferences for contraceptive properties among FSWs but 
diminishing their importance among adolescents. Adolescents and FSWs who reported 
that they would be unhappy if they fell pregnant today valued contraceptive properties 
more than those who would be happy or indifferent, however there was not association 
among adult women. 
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The design interactions, between HIV, STI and pregnancy protection, indicate a 
substantial preference for multipurpose pregnancy and STI products across all female 
groups indicating intrinsic benefits from multipurpose prevention. There is evidence 
that preferences for multipurpose products vary across groups with evidence that 
demand may reduce for products offering HIV and STI protection among adult males and 
females.  
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Supplementary Table S4: MNL model with interaction effects 
  Adult Males   Adult Females  Adolescent Girls  FSW  
Products: Oral PrEP -0.21 (0.111)* -0.19 (0.12) 0.24 (0.13)* -0.43 (0.109)*** 
         Microbicide Gel  -0.12 (0.16) 0.15 (0.16) -0.24 (0.133)* 
         Vaginal Ring  -0.33 (0.11)*** -0.39 (0.13)*** -0.09 (0.111) 
         Injectable  0.05 0.11 -0.31 
         SILCS Diaphragm  0.59 (0.36) -0.1 (0.35) 1.07 (0.284)*** 
Protection: HIV protection (100%) 4.61 (0.533)*** 1.75 (0.71)** 0.56 (2.53) 3.75 (0.649)*** 
          Pregnancy prevention -0.06 (0.298) -0.03 (0.45) 1.49 (1.41) 1.52 (0.393)*** 
          STI protection 1.66 (0.255)*** 1.03 (0.29)*** 0.51 (0.3)* 0.73 (0.235)*** 
Frequency of use: Daily 0.12 (0.136) -0.22 (0.21) -0.57 (0.2)*** -0.42 (0.171)** 
          Coitally  -0.2 (0.25) 0 (0.25) -0.29 (0.225) 
          Weekly 0.23 (0.141)* 0.14 (0.15) -0.29 (0.17)* -0.54 (0.134)*** 
          Monthly 0.12 (0.09) 0.3 (0.17)* 0.12 (0.19) 0.8 (0.147)*** 
          Three-monthly -0.35 (0.141)** 0.28 (0.15)* 0.03 (0.17) -0.35 (0.134)*** 
          Six-monthly -0.11 (0.129) 0.19 (0.17) 0.18 (0.17) 0.25 (0.125)** 
          Annually -0.01 -0.49 0.54 0.55 
Side effects: Dizziness -0.03 (0.066) -0.1 (0.09) -0.05 (0.09) -0.31 (0.081)*** 
          Stomach cramps -0.11 (0.066)* 0.05 (0.09) 0.05 (0.1) -0.01 (0.085) 
          Nausea -0.07 (0.127) 0 (0.09) -0.02 (0.1) 0.28 (0.088)*** 
          No side effects 0.21 0.05 0.03 0.04 
Opt out: Opt out 3.14 (0.264)*** 1.9 (0.41)*** 3.13 (0.41)*** 2.35 (0.385)*** 
          Male condom (opt out) 0.06 (0.056) 0.54 (0.1)*** 0.5 (0.11)*** 1.26 (0.175)*** 
Design interactions     
          HIV*STI -0.03 (0.006)*** -0.02 (0.01)*** -0.002 (0.01) -0.005 (0.006) 
          Pregnancy*STI 0.11 (0.125) 0.3 (0.13)** 0.74 (0.13)*** 0.78 (0.098)*** 
          Pregnancy*HIV 0.005 (0.003) -0.0002 (0.01) 0.002 (0.01) -0.02 (0.004)*** 
Sociodemographic interactions     
          Age*HIV 0.02 (0.08)** 0.04 (0.002)*** 0.06 (0.14) 0.02 (0.011) 
          IPV exposure in last year*HIV  0.43 (0.12)*** -0.06 (0.13) 0.03 (0.062) 
          Unemployed*HIV -0.04 (0.072) 0.13 (0.08) -0.27 (0.16)* 0.04 (0.06) 
          Alcohol use at last sex*HIV 0.28 (0.093)*** -0.01 (0.14)*** -1.77 (0.7)** 0.84 (0.085)*** 
          External partners*HIV -0.15 (0.082)* -0.09 (0.08) 0.7 (0.26)*** -0.43 (0.088)*** 
          High HIV Knowledge*HIV -0.08 (0.065) 0.06 (0.08) 0.2 (0.07)*** -0.04 (0.052) 
          Age*pregnancy -0.01 (0.004)*** -0.001 (0.004) 0.09 (0.07) -0.01 (0.006) 
          IPV exposure in last year*pregnancy  0.01 (0.04) -0.24 (0.06)*** 0.13 (0.035)*** 
          Unemployed*pregnancy -0.01 (0.036) 0.05 (0.03) 0.24 (0.09)*** 0.03 (0.034) 
          Alcohol use at last sex*pregnancy -0.03 (0.042) -0.08 (0.07) 0.16 (0.49) -0.04 (0.038) 
          External partners*pregnancy -0.07 (0.041)* -0.04 (0.04) -0.14 (0.11) -0.01 (0.048) 
          Unhappy if fell pregnant mmm  
mmmmmnow*pregnancy  -0.11 (0.07) 0.37 (0.08)*** 0.11 (0.045)** 
          Circumcised*HIV -0.001 (0.001)**    
Log Likelihood -2291.17 -2070.14 -1940.97 -3099.83 
AIC 4636.3 4206.3 3947.9 6265.7 
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Conclusions from paper R1 
The results presented in this paper offer important insights into preferences for MPTs 
among different South African population groups. In particular, they suggest that MPTs 
will be attractive options for many women, but preferences vary across – and within – 
different groups. Yet it is necessary to go beyond these results to fully inform policy, as 
the potential benefit of these products cannot be extrapolated from these data. For 
example, the alternatives shown were restricted to those available to male or female 
participants, which meant that choices reflect preferences under perfect agency to 
choose. Yet, due to a range of cultural and socio-economic reasons, the choices of women 
in many contexts are restricted by the preferences of their male partners, which we did 
not capture. 
The next paper uses these DCE results to predict product uptake among female groups 
to assess the potential impact and cost-effectiveness of a range of MPT introduction 
scenarios. 
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Chapter 7: Paper R2 – The cost-effectiveness of 
multipurpose HIV and pregnancy prevention 
technologies in South Africa 
Overview of paper R2 
Although paper R1 demonstrates that MPTs are likely to be attractive products in South 
Africa, in isolation these results are not sufficient to support continued investment in 
MPT development. This paper estimates the cost-effectiveness of combinations of 
candidate multipurpose prevention technologies (MPTs), which could be co-formulated 
or co-provided for dual HIV and pregnancy protection, in South Africa among general 
population women and female sex workers (FSWs).  
Uptake predictions from the DCE are used to parameterise a simple, static product 
impact model for five potential MPTs: intravaginal ring, injectable ARV, microbicide gel, 
and SILCS diaphragm used in concert with gel. A cost model was created to estimate the 
health system costs of product delivery, including product and staff costs for MPT 
delivery and averted costs from averted HIV infections and unintended pregnancies. 
Product benefit was estimated in disability-adjusted life years (DALYs) averted. Benefits 
from contraception were incorporated through adjusting the uptake of these products 
based on the DCE and through estimating the costs averted from avoiding unwanted 
pregnancies. 
The paper is presented as submitted to The Journal of the international AIDS Society in 
May 2017. A range of supplementary materials, including the description of the cost 
model, are included immediately after the paper. These are not presented in the 
manuscript itself due to the journal’s word limit.  
This paper fulfils research objective 2 to estimate the impact and cost-effectiveness of 
new HIV prevention products among South African men, women, adolescent girls and 
FSWs.  
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Abstract 
Introduction: multi-purpose 
A number of antiretroviral HIV prevention products are efficacious in preventing HIV 
infection. However, the sexual and reproductive health needs of many women extend 
beyond HIV prevention and research is ongoing to develop multi-purpose prevention 
technologies (MPTs) that offer dual HIV and pregnancy protection. We do not know if 
these products will be an efficient use of constrained health resources.  In this paper we 
estimate the cost-effectiveness of combinations of candidate multi-purpose prevention 
technologies (MPTs), in South Africa among general population women and female sex 
workers (FSWs). 
Methods: We combined a cost model with a static model of product impact based on 
incidence data in South Africa to estimate the cost-effectiveness of five candidate co-
formulated or co-provided MPTs: oral PrEP, intravaginal ring, injectable ARV, 
microbicide gel, and SILCS diaphragm used in concert with gel. We accounted for the 
preferences of end-users by predicting uptake using a discrete choice experiment (DCE). 
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Product availability and protection were systematically varied in five potential rollout 
scenarios. The impact model estimated the number of infections averted through 
decreased incidence due to product use over one year. The comparator for each scenario 
was current levels of male condom use, while a health system perspective was used to 
estimate discounted lifetime treatment costs averted per HIV infection. Product benefit 
was estimated in disability-adjusted life years (DALYs) averted. Benefits from 
contraception were incorporated through adjusting the uptake of these products based 
on the DCE and through estimating the costs averted from avoiding unwanted 
pregnancies. We explore the additional impact of STI protection through increased 
uptake in a sensitivity analysis. 
Results: At central incidence rates, all single- and multi-purpose scenarios modelled 
were cost-effective among FSWs and women aged 16-24, at a governmental willingness-
to-pay threshold of $1,175/DALY averted (range: $214 to $810/DALY averted among 
non-dominant scenarios), however none were cost-effective among women aged 25-49 
(minimum $1,706/DALY averted). The cost-effectiveness of products improved with 
additional protection from pregnancy. Estimates were sensitive to variation in incidence 
assumptions, but robust to other parameters. 
Conclusions: To our knowledge, this is the first study to estimate the cost-effectiveness 
of a range of potential MPTs; suggesting that MPTs will be cost-effectives amongst higher 
incidence FSWs or young women but not lower incidence older women. More work is 
needed to make attractive MPTs available to potential users who could use them 
effectively.  
214 
 
Introduction 
Over the past six years, clinical trials have shown that antiretroviral (ARV)-based pre-
exposure prophylaxis (PrEP) can be efficacious in preventing the transmission of human 
immunodeficiency virus (HIV)1-5. However, protection has been variable during clinical 
trials and different PrEP modalities have conferred substantially less protection to 
younger women than older women4 6. Both oral and topical PrEP products have been 
more effective in male populations than females7 8, partly explained by adherence, and 
partly by pharmacokinetic data indicating higher drug colorectal drug concentrations 
than in the female lower genital tract6 9.  
It is likely that more than one effective prevention option will be needed to achieve 
population coverage amongst women10. One option to increase impact whilst making 
products more desirable to potential users is to develop multi-purpose prevention 
technologies (MPTs), which simultaneously provide protection from two or more of HIV, 
other STIs and unintended pregnancy11-14. Current MPTs in development include: 1) 
long-acting drug delivery systems such as intravaginal rings, designed to protect from 
HIV infection and pregnancy (currently in phase-1 trial, ClinicalTrials.gov Identifier: 
NCT02235662); 2) pericoital drug delivery systems such as vaginal gels, tablets and 
films (not currently being trialled); and 3) co-provision of a combination of products, 
such as a contraceptive diaphragm with microbicide gel (currently feasible but not 
widely implemented)11 15. In the medium term, the co-provision of contraceptive and HIV 
preventative products could be an intermediate step to the development of a MPT. As 
HIV prevention products come to market, provision alongside contraceptives – 
particularly when products are of the same modality – could facilitate uptake and 
adherence, and gauge demand for potential MPTs in the future.  
Despite large variations in effectiveness and cost assumptions, previous studies have 
broadly found single-purpose PrEP to be cost-effective when delivered to populations at 
high risk of HIV infection16-20. Although the financial and regulatory burden of MPT 
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development is likely to be high, their benefits may also be large, not least because of 
synergistic impacts across health outcomes. Firstly, products offering more than one 
indication may be more attractive to some potential users than single-purpose products, 
particularly the combination of contraceptive and HIV prevention properties21 22. 
Secondly, MPT use could crowd-in protection from lesser valued attributes. For example, 
where users value contraceptive properties strongly, additional HIV protection would 
be a positive externality from the use of a dual-protective product. In addition, we can 
use lessons learnt in contraceptive provision for different female populations to 
optimise MPT or co-provision modalities23. Thirdly, the contraceptive properties of 
MPTs may reduce the stigma associated with accessing HIV prevention tools, shown to 
be a substantive barrier to use24 25. 
Unlike other PrEP impact models which use expert opinion to inform uptake 
assumptions, we take a data-driven approach by using a discrete choice experiment 
(DCE) to predict product uptake among different groups26. DCEs are economic tools 
which ask people to choose between hypothetical alternatives, and have been shown 
reliable when predicting real-world choices27 28. Although relying on hypothetical 
choices, a DCE is useful because preferences can be elicited for products which do not 
exist yet, thus we can estimate demand for co-formulated or co-provided products 
containing contraceptive properties. DCEs are objective, end-user focused tools which 
may be less biased than predictions based on expert opinion22 29. 
This paper presents a cost-effectiveness analysis which estimates the incremental 
benefits and health system costs of single and multi-purpose prevention products, 
compared to current practice of condom use and male circumcision prevalence. Cost-
effectiveness is modelled across three female groups due to differences in epidemiology 
and HIV risk in each: younger women (aged 16-24), older women (aged 25-49), and 
female sex workers (FSWs).  
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Methods 
Analytic overview 
This analysis builds on previous work using a DCE to elicit preferences for new HIV 
prevention products in South Africa22. Figure 1 displays our approach to estimate the 
cost-effectiveness of the five single and multi-purpose prevention products considered: 
oral PrEP, intravaginal rings, injectable ARVs, microbicide gels, and SILCS diaphragms 
used in concert with gel. A full list of parameters used in the model is presented in 
supplementary file S1. In this paper, we focus on contraceptive MPTs (considering STI 
prevention in a sensitivity analysis) because no STI-specific MPT is in development 
whilst there are limited data on the efficacy of MPT products to prevent STIs. We model 
cost and benefits associated with one-year’s products use, and therefore do not consider 
variations over time such as increasing economies of scale or diminishing adherence 
patterns.  
Figure 6: Modelling schematic 
 
Estimating uptake 
DCE data were gathered in Ekurhuleni Municipality, South Africa between September 
and December 2015 from 484 self-reported HIV negative women: 362 from the general 
population and 122 FSWs. We use DCE data to simulate uptake for different scenarios of 
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MPT characteristics (Table 1) in each population. In the model, users choose one product 
(or continue current practice) from a set, where availability is defined by different policy 
scenarios set out in the next section. The DCE protocol and results are described in detail 
elsewhere 26 30, whilst further information is given in supplementary file S2.  
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Table 1: Product characteristics 
Product 
characteristics 
HIV efficacy 
(%, Ex),  
[PSA 
bounds] 
Contraceptive 
protection 
Freq. of 
use 
Product cost 
assumptions 
($USD) 
Source 
Single-purpose      
Oral PrEP 61 [40-75] N Daily 
75 [70-130] 
(/person-year)  
31 32 19 
Microbicide gel 55 [31-71] N Coitally 
3.69 [3-4.5] 
(/tube)** 
Manufacturer 
(Kessel33) 
SILCS diaphragm 55 [31-71] N Coitally 
5.19 [4-6] 
(/diaphragm) 
Manufacturer 
(Kessel33) 
Vaginal ring 55 [31-71] N Monthly 
6 [5-7] (/ring) Distributor 
(IPM34) 
Injectable ARV 
agent 
75 [55-90] N 
Three 
monthly 
6 [5-7] 
(/injection) 
Assumption 
from vaginal 
ring 
No condom 0 N Coital 
N/A 
(comparator) 
 
Multi-purpose    
Marginal 
direct cost of 
MPT  
 
Male condom 95 [66-94] Y Coital 
N/A 
(comparator) 
 
MPT oral PrEP 61 [40-75] Y Daily 
8.72 [6.17-
11.5] 
 
(/person-year) 
35 
MPT microbicide 
gel 
55 [31-71] Y Coitally 
9.14 [6.4-12] 
(/person-year) 
35 
SILCS diaphragm 
& microbicide 
gel 
55 [31-71]* Y Coitally 
-  
MPT vaginal ring 55 [31-71] Y Monthly 
9.14 [6.4-12] 
(/person-year) 
Assumed 
equal to 
highest cost 
product 
(injectable)35 
Injectable MPT 
agent 
75 [55-90] Y 
Three 
monthly 
9.14 [6.4-12] 
(/person-year) 
35 
*Due to co-use, the efficacy of the SILCS diaphragm was assumed the same as the 
microbicide gel 
**Assumptions on product use and other associated costs of provision listed fully in 
supplementary file 3 
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Rollout scenarios 
We modelled product uptake for five rollout scenarios that differed in product 
characteristics and availability. Table 2 shows the scenarios modelled, for all of which 
we use current practice as the base case for comparison. Scenario 1 is the most likely to 
occur first, as single-purpose oral PrEP is already available to FSW groups in South 
Africa36. Cautiously positive results from intravaginal ring trials5 indicate that a single-
purpose ring with HIV prevention may be introduced next, whilst a multi-purpose ring 
could be available in the medium term; we refer to this MPT ring plus PrEP scenario as 
scenario 311. Finally, we model the introduction of a varied suite of single then multi-
purpose products in scenarios 4 and 5 respectively. Although poor efficacy in clinical 
trials has seen the HIV prevention field move away from microbicide gels8, we include 
them here to inform the development of other topical ARV-based preventative methods, 
including vaginal tablets or films37. 
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Table 2: Product scenarios modelled 
   Product(s) HIV 
protection 
Pregnancy 
protection 
Reference-
scenario 
Current male condom usage. No ARV-based single- 
or multi-purpose prevention 
  
Scenario 1 Oral PrEP X   
Scenario 2 Oral PrEP X   
  Vaginal ring X   
Scenario 3 Oral PrEP X  
  MPT vaginal ring X X 
Scenario 4 Oral PrEP X   
  Intravaginal ring X   
  Injectable ARV agent X   
  Microbicide gel X  
  SILCS diaphragm & microbicide gel X X 
Scenario 5 MPT oral PrEP X X 
  MPT vaginal ring X X 
  Injectable MPT agent X X 
  MPT Microbicide gel X X 
  SILCS diaphragm & microbicide gel X X 
 
Estimating HIV protection 
To be conservative, and to focus on differences between populations and the relative 
preferences for different products, we do not model temporal reductions in the overall 
level of HIV transmission due to long- term product use. Instead, we model the yearly 
impact of introducing each product scenario among three female population groups in 
South Africa, and compare the total and incremental costs and benefits of each 
introduction scenario.  
We use formula (1) to estimate the impact of each product scenario on the average level 
of protection conferred to an individual22 38. This measure gives the average decrease in 
HIV transmission probability across a population for an average sex act, combining the 
protection provided from several products with different efficacies being used at 
different levels. For a single product x, we assume the average protection against HIV, px, 
from using product x is a function of its efficacy, Ex, and uptake (or use) Ux, 
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𝑝𝑥 = 𝐸𝑥𝑈𝑥 (1) 
We begin by denoting Px as the existing protection provided by male condoms with 
efficacy E0 and consistency of use U0,., before any new products are introduced Our DCE 
then gives projections of the degree to which condom users and non-condom users 
(defined by use at last sex act) uptake each new product in each scenario s, and for 
condom users the probability that the woman still uses the condom (ε) in addition to the 
new products. For scenario s involving a number m of new products (denoted by 
subscript i=1…m), each with efficacy 𝐸𝑖
𝑠 and differing uptake  𝑈𝑖𝑐
𝑠  amongst condom users 
(c=1) and non-condom users (c=0), respectively, the average protection provided 
provided to an individual in the population due to condoms and the introduction of m 
new products (not just amongst users of the product) is estimated as 𝑃𝑚
𝑠 : 
𝑃𝑚
𝑠 = 𝑈0 [𝐸0 − ∑ 𝑈𝑖,1
𝑠
𝑖=1..𝑚
(1 − 𝜀)𝐸0 + (1 − 𝜀) ∑ 𝐸𝑖
𝑠𝑈𝑖,1
𝑠
𝑖=1..𝑚
+ 𝜀 ∑ (1 − 𝐸0)𝐸𝑖
𝑠𝑈𝑖,1
𝑠
𝑖=1..𝑚
] + (1 − 𝑈0) ∑ 𝐸𝑖
𝑠𝑈𝑖,0
𝑠
𝑖=1..𝑚
 
(2) 
The uptake of each product amongst condom and non-condom users depends not only 
on the efficacy of the product for preventing HIV but also on whether they provide 
pregnancy protection. The prevention protection provided by different products is 
assumed to be additive. Users are assumed to use only one new ARV-based prevention 
product, except the diaphragm and gel which are necessarily used together for MPT 
protection. When condoms are used with a new product, the new product was assumed 
to proportionately decrease the remaining risk still existing after the 85% protection 
provided by the condom39. The uptake of each new product 𝑈𝑖,𝑐
𝑠   can be defined as uptake 
multiplied by adherence, and we vary the latter in a one-way sensitivity analysis and 
both in probabilistic sensitivity analysis.  
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For oral PrEP, we assumed an HIV efficacy of 61% (40-75% used in probabilistic 
sensitivity analysis) as found in a recent meta-analysis of the efficacy of oral PrEP 
amongst highly adherent women (>75% adherence)40. We then assume that the vaginal 
ring is introduced with a HIV efficacy of 55% (31-71% used in probabilistic sensitivity 
analysis), as found amongst older women in a recent trial41. Although some clinical trials 
of microbicide gels have shown a lack of efficacy, they have been shown to be efficacious 
in others and work continues to develop a gel which could also offer multi-purpose 
protection11. We assume that a microbicide gel would not be introduced if it was less 
effective than the next-least effective product, in this case the vaginal ring, and we use 
the same uncertainty bounds and allow each to vary in probabilistic simulations. A 
higher efficacy for HIV protection of 75% (55-90% used in probabilistic sensitivity 
analysis) was assumed for injectable ARVs because there should be fewer issues of 
adherence. 
Estimating DALYs averted through preventing HIV infection 
Our simple impact model estimates the number of infections averted through one year’s 
use of different product scenarios, where incremental protection, 𝑃𝑚
𝑠 ,is used to decrease 
HIV incidence. We estimate the total discounted lifetime treatment costs averted from 
these infections. We use World Bank estimates of the size of the general population in 
South Africa in 2017 among two female groups aged 16-24 and 25-4942 and apply HIV 
prevalence estimates from the South African HSRC National HIV Prevalence, Incidence 
and Behaviour Survey 201243 to estimate the HIV negative population in each group. For 
FSWs, we used national estimates of FSW population size and HIV prevalence in South 
Africa44 45. Standard DALY weights are used for HIV/AIDS with and without ART taken 
from the 2010 Global Burden of Disease study46, full details of the DALY calculations are 
listed in supplementary files S1 and S3. 
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We obtained group level incidence estimates from national surveys, as well as from 
recent HIV treatment and prevention trials in South Africa40 43 47 48 presented in Table 3. 
For each group, we model scenarios of low, central and high estimates of incidence. The 
level of protection provided by each scenario, 𝑃𝑚
𝑠 , is used to model a decrease in 
incidence: 
𝐼𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒𝑛𝑒𝑤 = 𝐼𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒𝑐𝑢𝑟𝑟𝑒𝑛𝑡 ∗ (1 − 𝑃𝑚
𝑠 ) (3) 
 
Table 3: Estimates of HIV incidence per 100 person years 
  Low Incidence Central 
Incidence 
High 
Incidence 
Reference 
 Females 16-24  1.62 2.54 5.00 41 48 49 
 Female 25-49 1.20 1.62 3.50 41 48 49 
 FSW* 3.50 5.00 8.00 8 
* No FSW incidence data found, instead high level female incidence figures were used 
Estimating unintended pregnancies averted 
We take the median projected unmet need for contraception among females in the 
general population as defined by the United Nations Population Division 50, and assume 
that FSWs who report using no method of contraception have unmet need. Informed by 
DCE estimates, in the initial comparison case we assume that 20% of women with unmet 
need will use products with contraceptive properties, and explore how variation in this 
parameter affects results in a sensitivity analysis. Following the family planning 
literature, DALYs are averted solely from the reduction in estimated maternal mortality 
from pregnancies averted through MPT use51 52.  
Estimating costs 
We estimate costs related to the delivery of a combination prevention package across all 
South African public clinics from a health system perspective. Included intervention 
costs are listed in Table 4, and details of their estimation given in supplementary file S3. 
Products have varying frequencies of collection and use which we model using realistic 
clinical use scenarios, informed by the South African national guidelines for PrEP rollout 
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among high risk groups36. Where MPT products do not yet exist, we used existing 
contraceptive product costs to account for costs of additional active compounds35. 
Lifetime averted costs were estimated by multiplying the number of HIV infections and 
unwanted pregnancies averted by the discounted lifetime cost of ART treatment (using 
estimates of life expectancy on ART 53), and delivery, or abortion costs respectively.  
Table 4: Included intervention costs  
Fixed costs 
 
National start-up costs 
Training of providers 
Mass media 
Variable costs 
(based on 
predictions of use)  
Facility distribution costs 
Staff time 
Product 
Screening tests 
Health system mark-up and                                  
      overheads 
Averted health costs 
Antiretroviral treatment 
Miscarriages and births from    
     unplanned pregnancies  
 
Sensitivity analyses 
We present results for each group and each scenario at high, medium, and low incidence 
estimates. In addition, we perform a series of one-way deterministic sensitivity analyses 
to explore how changes in qualitatively important characteristics affect estimates. 
Finally, a probabilistic sensitivity analysis (PSA) explored the sensitivity of our model to 
a range of parameter uncertainties, using a Monte Carlo simulation with 1000 draws. 
Point estimate and distributional assumptions for the variables included in the PSA are 
listed in supplementary file 1, and results presented in supplementary file 8.  
Assessment of cost-effectiveness 
We assessed the cost-effectiveness of different scenarios by computing the incremental 
cost-effectiveness ratio (ICER) for each intervention: the net costs of an intervention 
divided by the number of DALYs averted, and compare this to a willingness-to-pay 
(WTP) threshold. The South African government does not have a generally accepted 
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WTP threshold; in the absence of this we use the threshold estimates of Woods et al54 to 
represent the opportunity cost of health forgone from other potential interventions. We 
took a conservative stance and applied the lowest estimate, the lower-bound USD 
threshold of $1,175/DALY averted (range: $1,175-$4,714), which was lower than the 
purchasing-power adjusted range ($2,221-$8,909) and alternative thresholds such as 1x 
and 3x GDP/capita54 55. 
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Results  
Deterministic model analysis 
Results suggest that co-provision or co-formulation of contraceptive and HIV prevention 
products will be cost-effective among younger women and FSWs, but not among older 
women. Younger women show distinct preferences for multi-purpose over single-
purpose products as shown in Figure 2 which aggregates uptake among condom and 
non-condom users. Notably, we predict that just 8% of women aged 16-24 would use at 
least one of the full range of single-purpose HIV prevention products, however uptake 
increases by 27 percentage points if products were co-formulated as MPTs. The 
predicted uptake of single-purpose products is much greater among older women (26%) 
and FSWs (30%), but additional uptake from including pregnancy protection is 
relatively low at 7 and 6 percentage points respectively. Where all products are 
introduced, the decrease in HIV incidence attributable to additional uptake due to multi-
purpose protection was higher among younger women (reduction of 19%) than among 
other groups (8% for older women and FSWs).  
Of the 12.9 million women aged 15-49 in 2017, 10.1 million were estimated to be HIV 
negative43. Assuming central HIV incidence estimates, 201,552 new HIV infections are 
predicted to occur without intervention. Figure 3 illustrates DALYs averted for each 
product scenario among each population group. We focus here on cost-effectiveness, but 
present full impact results in supplementary file S6. Net intervention costs are presented 
in supplementary figure S7, where rollout among the 1.7-times larger population of 
women aged 25-49 leads to a four-fold increase in net intervention costs than among 
those aged 16-24.  
Figure 4 shows ICERs for each product scenario and population group. For all groups, 
oral PrEP plus a MPT intravaginal ring (Scenario 3) is the most cost-effective scenario 
modelled, with an ICER of $563/DALY averted among younger women and dominating 
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the comparator among FSWs. All scenarios modelled among women aged 16-24 and 
among FSWs are cost-effective when compared to the WTP threshold of $1,175, whilst 
the no rollout status quo scenario is cost-effective among women aged 25-49. Among all 
populations, scenarios where multi-purpose products are introduced are more cost-
effective than any combination of single-purpose products. 
These results show the cost-effectiveness of interventions relative to current levels of 
condom use, yet the increasing availability of oral PrEP in South Africa mean that a more 
meaningful comparator may be that of oral PrEP provision. Table 5 displays ICER 
estimates for introducing single- and multi-purpose products, with the comparator of 
oral PrEP and the range of single-purpose products that may be available. Again, results 
indicate that at under all incidence assumptions, introducing additional ARV-based 
prevention products will be cost-effective among women aged 16-24 and FSWs. Results 
differ among women aged 25-49, where introducing additional MPT products is 
estimated to be cost-effective (in most cases cost-saving), but adding a single-purpose 
ring to provision of single-purpose PrEP is not cost-effective except under assumptions 
of high incidence. 
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Table 5: ICER values of comparative scenarios 
  Women 16-24 Women 25-49 FSW 
Incidence 
assumption 
Low Central  High  Low Central  High  Low Central  High  
Single-purpose                   
Adding vaginal 
ring to PrEP 
(Scenario 2 
compared to 
Scenario 1) 
$1,691 $801 $30 $4,763 $3,282 $1,008 $792 $-66 $-398 
Multi-purpose                   
Adding MPT ring 
to PrEP (Scenario 
3 compared to 
Scenario 1) 
$727 $243 $-225 $-401 $-482 $-669 $-532 $-709 $-791 
Adding MPT range 
to single-purpose 
range (Scenario 5 
compared to 
Scenario 4) 
$1,214 $543 $-79 $88 $-114 $-503 $-1,810 $-1,502 $-1,334 
 
*Negative ICER values in this table indicate cost-saving interventions with a positive 
impact 
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Figure 2: Product uptake by group 
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Figure 3: DALYs averted by population, scenario, and incidence assumption 
 
 
Coloured bars represent DALYS averted at central incidence estimates, with upper and lower incidence assumptions indicated for each 
scenario. Populations presented separately due to scale differences in small FSW population. 
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Figure 4: Average cost per DALY averted by scenario and incidence assumption 
  
Nb. Negative ICERs among FSWs are cost-saving and DALY increasing interventions with a positive impact.  
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Figure 5: One-way sensitivity analysis on incidence assumptions 
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Figure 6: One-way sensitivity analyses of scenario 1 
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Sensitivity analyses 
Figure 5 shows one-way sensitivity analyses for incidence assumptions. Our base case 
model assumptions are represented by squares, whilst lines to the upper-left and lower-
right demonstrate ICER estimates at lower and upper incidence assumptions 
respectively. Points to the south-east of the dashed WTP line are interpreted as cost-
effective. In all but two scenarios modelled (both among FSWs), using an upper or lower 
incidence assumption means that the estimated ICER crosses the willingness-to-pay 
threshold. The incidence level at which the most cost-effective scenario became cost-
ineffective was 1.3, 1.6, and 1.1 infections per 100 person-years for women aged 16-24, 
25-49, and FSWs respectively. 
Further one-way sensitivity analyses explored the effect of parameter uncertainty on 
model outputs. Tornado plots for scenario 1 are presented in Figure 6 which became 
cost-ineffective among women aged 16-24 and FSWs when adherence was assumed to 
be 30%, or if ART coverage was increased to meet the 90% WHO target56. Including STI 
preventative attributes in addition to HIV and pregnancy does not markedly change cost-
effectiveness estimates. Tornado plots for the most cost-effective scenario (oral PrEP 
plus MPT ring) are included in supplementary file S6, and demonstrate cost-
effectiveness in females aged 16-24 and FSWs for all parameter variations.  
MPT cost-effectiveness was broadly robust to reductions in the assumed efficacy of 
products. Additional one-way sensitivity analyses (not shown in Figure 6 were carried 
out on assumptions of product efficacy. Reducing the effectiveness of all products to 50% 
meant that all three scenarios of solely single-purpose products would not be cost-
effective among women aged 16-49 (Scenario 1 had the highest ICER of $1,281), though 
all MPT scenarios and scenarios among FSWs would remain cost-effective. MPT 
scenarios among younger women were estimated not to be cost-effective at an efficacy 
of 45%.  
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Figure 7 presents cost-effectiveness acceptability curves for each scenario among each 
population, whilst simulation plots on the cost-effectiveness plane are included in 
supplementary file S7. For all groups, both scenarios including MPTs were most likely to 
be cost-effective. For older women, younger women, and FSWs respectively, the model 
predicts a 0.1%, 71%, and 99% probability that the most cost-effective scenario, 
scenario 3,will be cost-effective. The PSA also confirms the primacy of interventions 
among FSWs and women aged 16-24, as even the least cost-effective scenario for each 
group was 60% likely to be cost-effective at the $1,175 threshold.  
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Figure 7: Cost-effectiveness acceptability curves  
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Discussion 
This study is the first to estimate the cost-effectiveness of a range of candidate MPT 
products, and suggests that co-formulated or co-provided MPTs could be an impactful 
and efficient use of resources. Based on the stated preferences in the DCE, incorporating 
contraceptive characteristics into HIV prevention products would result in a meaningful 
increase in product use, reinforcing evidence of unmet demand for MPTs among many 
groups11 12. Results indicate that multi-purpose prevention products are likely to be cost-
effective among younger women (aged 16-24) and FSWs compared to current condom 
provision, with scenario 3, oral PrEP plus a MPT ring, and scenario 5, the full range of 
MPT products, estimated to be the most cost-effective. However, despite being cost-
effective, our uptake projections suggest that products are unlikely to achieve dramatic 
decreases in HIV incidence. Even if all MPT products were introduced, incidence among 
older women and FSWs is projected to reduce by just 8% (19% among younger women), 
far under the estimated 48% reduction from achieving UNAIDS’ 90-90-90 target57. 
Although MPTs offer a cost-effective option for tacking the HIV epidemic, a range of 
programmes will be required to reduce incidence substantively. 
The co-formulation or co-provision of products is likely to increase programme cost-
effectiveness for two reasons. First, the multi-purpose nature of the products makes 
them more attractive to potential users, increasing uptake and therefore economies of 
scale from product use. Second, the costs associated with unwanted pregnancies averted 
reduce the net costs of the intervention overall, and increase benefits accrued from 
averted maternal mortality.  Incorporating STI prevention does not markedly change 
cost-effectiveness estimates. 
These estimates of cost-effectiveness are broadly comparable to published studies, 
though there is considerable heterogeneity in these20. Although we base our 
counterfactual scenario on empirical data from trials and nationally representative 
population based studies, our simple incidence model predicts a higher number of 
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annual infections than more complex models, such as Thembisa and EPP/Spectrum 
models58 59. The reason for this is uncertain, although it is worth noting that the both 
models underestimate the 2012 HIV incidence in South Africa compared to empirical 
estimates by around 0.4 infections/100 person years among women aged 16-2960. 
Additionally, when incidence is varied in our sensitivity analysis, our results are 
consistent with other models. We note that the relatively low effectiveness figures 
observed in topical PrEP trials (e.g.5 61) may reduce the likelihood of governments 
investing in them, but incorporating additional benefits such as contraception into 
partially effective products may increase their chances of introduction. 
This study has several limitations. First, we used a simple static transmission model to 
estimate the short-term benefits of introducing different products. This model does not 
consider prevention benefits accruing into the future, including the dynamic effect of 
reductions in incidence on prevalence. However, this simplicity is also a strength 
because it gives transparent estimations of the individual benefits of using these 
products, resulting in estimates of impact and cost-effectiveness similar to what would 
be produced from a trial. Unfortunately, although dynamic transmission models can be 
more realistic in capturing the longer-term benefits of an intervention, their reliance on 
numerous assumptions, particularly around the future dynamics of infection, makes 
their projections uncertain. Indeed, a recent analysis of 12 models for South Africa 
showed that none were able to correctly predict the future dynamics of infection 
between 2006 and 201162. Importantly, our use of a static model results in conservative 
impact projections, as a dynamic model would predict increased numbers of secondary 
infections averted with product use. However, when new preventive methods are used 
by a small proportion of the population, as predicted here, total population protection 
has been shown similar to a static model of efficacy multiplied by use63, suggesting our 
model projections may be fairly accurate. 
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Second, the model does not incorporate differential adherence between products, 
although the one-way sensitivity analysis shows that adherence could be less than 50% 
and products still be cost-effective. Third, results are sensitive to incidence assumptions, 
and 8 of the 10 cost-effective scenarios become cost-ineffective if low HIV incidence 
assumptions are used. However, a PSA shows that MPT scenarios among FSWs and 
women aged 16-25 are 99% and 71% likely to be cost-effective at the conservative 
$1,175 threshold respectively. Fourth, we do not consider reductions in paediatric HIV 
incidence due to unintended pregnancies averted, making estimates conservative. Fifth, 
we consider one-year estimates of cost and benefit from each scenario. In reality, this 
may overestimate costs due to the potential for economies of scale in delivery over time. 
Estimates of benefit could also be overestimated, if uptake is graduated over time 
leading to the level assumed here, or if adherence was assumed to vary over time, 
reducing as a function of length of use for example. Sixth, we estimate the costs of multi-
purpose products to be additive of that to single-purpose products, which may 
underestimate the true cost of products, particularly if coformulated, in a real-world 
value-based pricing framework. This means that our cost estimates for MPTs may be too 
low, making MPTs seem more cost-effective than they may be in reality, however since 
the estimated costs of oral PrEP are substantively higher than those observed in real-
world demonstration projects (e.g. 64), the overall impact may be mitigated. Finally, 
although single-purpose contraceptives are available for all delivery mechanisms 
modelled (oral, injectable and topical products), there is variation in which mechanisms 
are being developed for co-formulation to provide multi-purpose prevention. The 
introduction of a range of five MPTs is unlikely to occur in reality.  
This paper is also the first to use a discrete choice experiment to predict product uptake 
within a cost-effectiveness analysis in HIV, which allows us to explicitly consider 
heterogeneity in end-user preferences between different groups. While DCE survey data 
were randomly sampled and reweighted to match the age structure of the female South 
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African population, these data are unlikely to be generalisable to the entire country or 
other countries. Furthermore, the FSW data were collected through respondent driven 
sampling (RDS) and, although reweighted, the highly variable nature of sex work in 
South Africa makes reliable statements about generalisation difficult45.  
Conclusion 
This study estimates the cost-effectiveness of five candidate MPTs, and finds that co-
formulation or co-provision of contraceptive and HIV prevention products would be an 
efficient and effective use of resources among younger female groups and FSWs at 
current levels of HIV incidence. Younger women in particular find MPTs more attractive 
than single-purpose technologies, suggesting that incorporating contraceptive 
properties in HIV prevention products – or vice-versa – could lead to substantive HIV 
and family planning benefits in this group. These results strengthen calls for more 
research and development in the co-formulation or co-provision of products to reduce 
unmet need in sexual and reproductive health services. 
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Supplementary file S1: List of model parameters: cost-effectiveness model 
Parameter Point estimate Lower Credible 
Interval/95%CI 
Upper Credible 
Interval/95%CI 
PSA 
Distribution 
(SE where 
included) Source(s) 
Cost inputs      
Product variable costs (per person 
year) 
    
 
Oral Prep $289 $269 $309 Uniform* See supplementary material S3 
Vaginal Ring $258 $243 $273 Uniform* See supplementary material S3 
Injectable $212 $192 $230 Uniform* See supplementary material S3 
Microbicide Gel $438 $349 $516 Uniform* See supplementary material S3 
SILCS Diaphragm and Microbicide Gel $217 $199 $235 Uniform* See supplementary material S3 
Product fixed costs      
Staff training across all facilities $34,696,831    Conservative assumptions 
using staff salary costs. 3 days, 
100 staff each training day 
from four facilities (25 per 
facility), 5 nurse facilitators 
Mass media (annual) $5,000,000    (1) 
Outreach cost $403,920    Assumption based on FSW 
sample size, one clinic with 12 
outreach staff per 1,500 FSWs 
Population sizes      
Females 15-24 4,810,897    (2) 
Female 25-49 8,156,317    (2) 
FSW 153,000 132,000 182,000 Uniform (3) 
HIV Prevalence      
Females 15-24 11% 10% 13% Normal 
(0.009) (4) 
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Female 25-49 29% 27% 32% Normal 
(0.014) (4) 
FSW 74% 59% 83% Normal 
(0.049) (4) 
HIV Incidence**      
Females 15-24 2.54 1.62 5.00 Uniform (5-7) 
Female 25-49 1.62 1.62 3.50 Uniform (5-7) 
FSW 5.00 2.54 8.00 Uniform (8) 
Contraception parameters      
Percentage of women married/in union 
(relationship) from data 
86% 82% 90% Beta 
(0.022) Primary data 
Percentage of women in relationship with 
unmet contraceptive need 
72% 66% 78% Beta 
(0.030) Primary data 
Percentage of FSWs with unmet 
contraceptive need 
16% 11% 21% Beta 
(0.026) Primary data 
Probability of getting pregnant using 
product (year) (perfect use) 
14% 18% 14%  
SILCS, winner NEJM (9, 10) 
Likelihood of becoming pregnant with no 
product (/year) 
40%    
(11) 
ART costs (year) 4,586.99    (12) 
Parameters for DALY calculations      
Discount rate 0.03 3% 7%   
Age weighting modulation factor 1    (13) 
Constant 0.1658    (13) 
parameter from the age weighting 
function 
0.04    (13) 
DALY Weight: pre-ART 0.051    (14) 
DALY Weight: symptomatic, not linked to 
care 
0.221    (14) 
DALY Weight: on ART 0.053    (14) 
DALY Weight: AIDS 0.547    (14) 
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DALY Weight: Infertility 0.006    (14) 
ART Access rate 0.72    (15) 
Product Efficacy      
Oral Prep 61% 40% 75% Uniform (16) 
Vaginal Ring 56% 31% 71% Uniform (6) 
Injectable  75% 55% 90% Uniform Assumption based on lower 
adherence requirement, large 
uncertainty bound modelled 
Microbicide Gel 85% 66% 94% Uniform Assumption that a microbicide gel 
would not be introduced if it was 
less effective than the next-least 
effective product (vaginal ring) 
SILCS Diaphragm and Microbicide Gel 56% 31% 71% Uniform Assumption that a microbicide gel 
would not be introduced if it was 
less effective than the next-least 
effective product (vaginal ring) 
* Separate PSA was carried out on cost-model inputs as described in supplementary file S3. A uniform distribution used here so as to not 
prescribe a functional form on the results of this PSA, and to allow greater uncertainty around these estimates into the final model  
** Uniform distribution used on incidence assumptions to avoid prescribing a specific functional form to these data, largely obtained from 
trials 
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Supplementary file S2: Information on DCE and the 
impact model 
DCE data were gathered in October to December 2015 in Ekurhuleni Metropolitan 
Municipality through a randomised household survey among 158 adult females and 204 
adolescent girls (aged 16-17), who self-reported as HIV negative, and data were 
reweighted by two age strata to the general population structure of South African 
women(18). A respondent driven sampling process collected data for 122 FSWs from 
the same geographical area, which was reweighted using RDSAT software(19, 20). 
Figure S2:1: Example DCE task presented to participants:  
 
DCE data are used to predict uptake through predicted probability analysis, as described 
in earlier work.(21) Briefly, coefficients from DCE nested logit utility functions are 
summed according to expected characteristics of potential prevention products as 
shown in table 1 such that: 
𝑃𝑛,𝑖 =
𝑒𝑉𝑛,𝑖
∑ 𝑒𝑉𝑛,𝑖𝐽𝑗=1
 
DCE analysis is based on the assumption that people make rational choices to maximise 
utility.(22) By analysing what respondents choose in ten hypothetical choice sets 
presented to them, we are able to compute the probability of a respondent making a 
252 
 
specific product choice depending on the characteristics of that product (based on real-
world attributes of products), and defining what other products are available and their 
characteristics.(21) This method of simulating from choice data has been termed 
predicted probability analysis (PPA), and has been applied in fields of health, 
environmental and transport economics.(23, 24) Although the DCE presented MPT 
options as co-formulations, these results could also inform the co-provision of 
contraceptive and HIV preventative products. 
We estimate uptake among condom users and non-condom users for each scenario and 
among each population, and use data from the primary survey to assume that condom 
use in partnership with new products is 60%. In the probabilistic sensitivity analysis, 
variation in DCE coefficients (and therefore uptake) is simulated through drawing from 
a normal distribution using the mean and standard error reported by the discrete choice 
model. All DCE coefficients are varied in this manner. 
Impact model 
Formula 1 firstly takes the original protection provided by condoms (𝑈0𝐸0), removes the 
loss in protection due to new product users stopping using condoms (𝑈0 ∑ 𝑈𝑖,1
𝑠
𝑖=1..𝑚 (1 −
𝜀)𝐸0), then adds the new product protection amongst those individuals that stop using 
condoms (𝑈0(1 − 𝜀) ∑ 𝐸𝑖
𝑠𝑈𝑖,1
𝑠
𝑖=1..𝑚 ), the new protection amongst new product users that 
carry on using condoms ( 𝑈0𝜀 ∑ (1 − 𝐸0)𝐸𝑖
𝑠𝑈𝑖,1
𝑠
𝑖=1..𝑚 ), and the added protection of 
individuals that did not use condoms before but now use the new products 
((1 − 𝑈0) ∑ 𝐸𝑖
𝑠𝑈𝑖,0
𝑠
𝑖=1..𝑚 ).   
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Supplementary file S3: The cost model 
Cost model methods 
This cost model estimates the costs associated with the roll-out of five new 
antiretroviral(ARV)-based HIV prevention products: oral pre-exposure prophylaxis 
(PrEP), a microbicide gel, a SILCS diaphragm used in concert with microbicide gel, an 
intravaginal ring (IVR), and an injectable ARV. The main cost model takes a health 
system (provider) perspective. It considers the direct medical costs of provision for each 
method, associated health system costs, and costs averted from HIV infection alongside 
unwanted or mistimed pregnancies.  
As per South African guidelines, we assume that when first prescribed a prevention 
product, users will be tested for HIV infection immediately and after one month, then 
returning for a test every third month. We assume that all users receive the services 
detailed in the guidelines.   
We carried out a probabilistic sensitivity analysis which explored the role of parameter 
uncertainty in the model. Inputs were obtained from published literature or computed 
from a primary survey carried out in Gauteng Province in late 2015 (survey protocol in 
appendix IX) and from the 2003 DHS dataset.(11, 25) Where data were unavailable 
through these sources, we contacted international experts and product-development 
sources for remaining parameters. 
 
The setting and distribution scenarios 
The model represented all South African public health clinics, a large network of 3,182 
facilities, as the South African PrEP guidelines indicate that provision will be fully 
integrated within primary healthcare clinics to mitigate stigmatisation when trying to 
obtain PrEP.(26) We model that the introduction of the new products is via public 
facilities, supported by a mass media campaign run annually: for six months prior to 
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rollout (at double intensity – and thus cost than that which would follow in later years. 
The model allows for differential demand on staff time by product, however do not 
include substantial variation across products in the base case in table 2. Different 
products have different frequencies of collection and use which we model using realistic 
clinical use scenarios informed by the South African national guidelines for PrEP rollout 
among high risk groups which requires persons using PrEP to obtain an HIV, and 
associated other medical, tests every three months.(26) As per these guidelines, we 
assume that when first prescribed a prevention product, users will be tested for HIV 
infection immediately and after one month, then returning for a test every third month. 
Finally, as per these guidelines, users will receive the tests detailed in table 3 before 
initiation, and during maintenance on products. We assume that all users receive the 
services detailed in the guidelines.  
Whilst some products have a well-defined regimen, the SILCS diaphragm and 
microbicide gel are used coitally and oral PrEP daily, the newer products (namely the 
IVR and injectable ARV) are still in development and regimens as yet unknown. We use 
expert opinion to parameterise use for these products, defining both as products which 
require monthly application via a health facility. In a sensitivity analysis, we reduce the 
health system contacts required for efficacious use of these products.  
Distribution Costs 
The main cost model takes a health system (provider) perspective and presents the 
incremental costs of each new prevention product (total costs less costs averted by the 
introduction of the products). Table S3:4 (at the end of this supplementary file) displays 
model parameters and sources. Included are fixed provider costs,  mass-media costs (at 
a country level) alongside with initial and refresher training (annually at a third of the 
initial intensity) at a provider level. (10) (10) (9) (7)(20)(18)(17) Provider training costs 
were based on personal communication with the female sex worker PrEP rollout in 
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South Africa and based on actual training provision for the rollout of oral PrEP, as per 
Table S3:1. Training was held over three days, with around 25 participants from a facility 
per day comprising of 20 nursing staff and 5 HIV counsellors. Variable costs vary with 
the number of users and include direct product and associated testing costs, and user 
counselling costs. In addition to this, following the literature (10, 27), overhead costs are 
accounted for through the use of a facility mark-up factor which captures direct health 
facility costs as twice labour costs, alongside a health system cost (half of the facility 
mark-up) which captures resources spent on upper management and logistics.  
It is anticipated that the initial introduction of products would incur large fixed costs 
relating to training and mass media, whilst later products would not need such a large 
volume of initial resources. So that the sequence of product introduction does not affect 
cost-effectiveness estimates, as presented in supplementary material S1, we assume a 
pool of common, fixed training ($34.7m) and mass media ($5m) costs before the 
introduction of any product. Because we assume that all products in a scenario are 
brought to market at the same time, fixed costs are divided equally across products 
introduced in each scenario. When estimating population level costs, the division of fixed 
costs is weighted proportionately to the number of users in each group, which is 
described fully in supplementary table S4. To estimate costs for MPTs that do not yet 
exist, we use cost estimates for presently available injectable and oral contraceptive 
products to estimate unit costs of compounds and associated health services.(28) These 
costs would be present if MPTs were either co-formulated or co-provided.  
The SILCS diaphragm is assumed to have a 1 year useable life (likely a conservative 
estimate (10)), whilst gel, oral PrEP and IVR supplies are refreshed after a three month 
period when a user reports to a facility for HIV and syndromic STI testing alongside a 
panel of other maintenance tests. This period is based on the South African PrEP 
guidelines (26), alongside the resource planning of the International Partnership for 
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Microbicides (IPM), the producer of a leading dapivirine IVR (personal communication). 
Injectable ARVs are assumed to require monthly engagement with the system to receive 
new injections. We assume no shipping taxes or customs excises, and take a provider 
perspective as, in the South African context, the public health system is most likely to 
finance the rollout of new prevention technologies.  
Oral PrEP is estimated to have an annual cost of $75 ($70-$130), with the unit price 
taken from costing studies and the Clinton Health Access Initiative ceiling price list 
(49)(43).The SILCS diaphragm is estimated to cost $5.19 per diaphragm, whilst gel use 
is estimated at 4ml per dose in an average of two sex acts per week.(29) Assuming 10% 
wastage for gels, users require seven 70ml tubes of gel per year at US$3.69 per tube, with 
an annual gel cost of US$25.83 (CONRAD, personal communication). Due to their 
continued development, unit costs for the injectable ARV are not available. One option, 
used in other studies have assumed similarities in costs to oral PrEP.(1, 30) We explore 
a range of injectable costs through a sensitivity analysis, but base our mean product cost 
on that of the vaginal ring, however note that the higher requirements for health system 
utilisation of an injectable regimen will likely make this product cost more per person 
per year. 
Cost parameters were taken from peer-reviewed sources where possible, with 
programmatic experts approached to inform assumptions around new products or 
unknown factors. All costs are presented in 2015 US Dollars (US$). Non-tradable goods 
(training and labour costs for example) were inflated using local currency inflation rates, 
whilst tradable goods (product costs) were inflated using the US$ inflation rate. 
Unwanted or mistimed pregnancies  
Where new HIV prevention products offer contraceptive properties in addition to HIV 
protection, secondary benefits will accrue. We calculate the additional impact of 
contraceptive properties among women who are not currently using modern 
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contraceptives through estimating the number of pregnancies averted by product use. 
The likelihood of getting pregnant without using contraception was estimated as 40% 
based on DHS data for South Africa.(11)  As in Lepine et al 2013 (10), we define the added 
benefit of new products as the difference between this figure and the annual likelihood 
of conception when using a new product multiplied by the number of women using each 
product. For all products, we parameterise contraceptive aspects of the model using the 
characteristics of the SILCS diaphragm. The annual probability of pregnancy while using 
the SILCS diaphragm with a contraceptive gel is 17.8% for typical use and 13.7% for 
perfect use per year.(31)  
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Table S3:1 Included costs 
Provision 1st year by month 
 Initiation Maintenance 
 0 1 4 7 10 
HIV Test x x x x x 
Creatinine clearance and chemistry panel x x x x x 
Urine pregnancy test x     
Syphilis test (RPR) x     
Syndromic STI screening x x x x x 
Address side effects  x x x x 
Adherence counselling  x x x x 
Product distribution x x x x x 
Behavioural sexual risk reduction 
counselling 
x x x x x 
*Injectables are assumed to be delivered monthly not quarterly, though the suite of testing is only assumed to be 
completed quarterly as per current PrEP guidelines 
Adapted from South Africa PrEP guidelines, May 2016 Final Draft 
Averted DALYs and costs 
The average age of infection was assumed to be 20 among women aged 16-24 and 30 
among women aged 25-49 and FSWs and varied in a one-way sensitivity analysis. After 
the first 3 years of asymptomatic HIV, those with no ART access live 5 years with 
symptomatic HIV followed by 2 years of AIDS ending in palliative care and death (32). 
We use estimates of life expectancy for those on ART and those uninfected from a South 
African cohort.(33) Loss-to-follow up is assumed to be zero, rendering this analysis on 
the conservative side, however the lower levels of use assumed in the sensitivity analysis 
could be interpreted as loss to follow up as the impact model used does not consider 
adherence over time. Standard DALY estimates are used for HIV/AIDS with and without 
ART taken from the 2010 Global Burden of Disease study.(14) Disease progression and 
costs averted are estimated separately for the proportion of HIV positive persons 
receiving ART (assumed to be 71% of HIV positive persons(12), though raised to 80% 
and 90% in a one-way sensitivity analysis), whilst lifetime treatment costs for HIV 
positive persons receiving ART are estimated by multiplying expected life expectancy on 
ART (33) by annual cost estimates of Meyer-Rath et al.(12) and discounting. For those 
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not accessing ART, we estimate average lifetime HIV/AIDS health care costs using 
inpatient cost data, varying this in a sensitivity analysis (34).  
As per DHS data, we assume that 92% of pregnant women access antenatal care and 
delivery (11) with visits using 30 minutes of nurse time over four prenatal visits.(35) 
Our delivery cost estimate is a weighted average of five possible delivery outcomes: 
healthy child delivery, low birth-weight child, neonatal death, stillbirth and miscarriage. 
We follow Lepine et al. (10) in estimating costs averted from the prevention of 
unintended pregnancies by separating unintended births, and mistimed births that 
occur early but would have occurred in the future. In the 2003 DHS survey, among 
women who did not want their last child (n = 1,434 representing 52% of total women), 
49% declare that the last child was unwanted and 51% declare that they would have 
liked to have this birth in the future(11). We follow Trussell (36) to assume that a 
mistimed birth would have occurred two years later, and incorporate a 10.5% abortion 
rate (37) by assuming that abortion amongst wanted pregnancies is zero, whilst the 
abortion rate among women with mistimed or unwanted births is estimated at 20.2% 
(10.5/0.52).  
Sensitivity analysis  
We adhere to the ISPOR guidelines for a robust sensitivity analysis, and only apply 
probabilistic distributions around appropriate parameters.(38) The primary outcome 
measure used in the sensitivity analysis is product cost per person per year. At this stage 
we do not take into account sensitivity due to fixed costs, such as staff training or media 
costs.  
From the literature and expert opinion, we derive a reasonable range of uncertainty 
around each parameter central estimate. Where more than one estimate was found in 
the literature, we specify upper and lower bounds according to the smallest and greatest 
values found and use a uniform distribution to sample random draws. Where 
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parameters are reported in the literature with estimates of statistical uncertainty, e.g. 
standard errors, these are recorded and an applicable distributional form assigned. 
Where there is no variation in reported parameters, we use expert opinion to set higher 
and lower bounds for parameters, and use a uniform distribution. We run a Monte Carlo 
simulation with 1,000 draws for each aggregated parameter of interest (e.g. cost per 
person per year). Results are reported with the mean and inter-quartile range for each 
measure. 
Separate PSAs were run on the cost and cost-effectiveness models. We incorporate 
variation in cost parameters in the cose-effectiveness model one-way sensitivity analysis 
by using the 25th and 75th percentile cost estimates, and sample a uniform distribution 
between these quartiles in the PSA to reflect the large degree of uncertainty in their 
estimation. 
Results 
The average variable cost per person per year by product is shown in table S3:2. First 
year costs were higher due to the more intensive initiation period. First year costs 
ranged from $281 for gel, adding the SILCs diaphragm only increased costs by $6. The 
highest estimated first year costs were for injectables ($625).  
Modelling estimates were sensitive to direct product costs and the number of visits 
required per year. The higher frequency of visit required for monthly injections 
increased costs for the injectable ARV substantively, and injectable costs are very 
sensitive to the frequency of dosage. The remaining four products have a very similar 
patterns of contact with the health system, and have similar cost estimates. Microbicide 
gel and SILCS diaphragm (with gel) costs were very sensitive to the number of sex acts 
per year, as gel use is coitally specific. Fixed costs were mostly driven by assumptions 
made around the mass media profile for each product which will be variable depending 
on available resources. There was limited data to base these assumptions on, and the 
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modelling literature has used a variety of assumptions around mass media strategies, 
synergies, and potential costs. Bottom up data are available for individual programmatic 
activities in Malawi and Zambia, however, these were not included in this model due to 
a) the context specific nature of the costs themselves, and b) the lack of evidence to 
predict total social marketing spend by population group. Instead, the standardised 
overhead cost applies to each population across each product. 
Table S3:2: Resource use per prevention product visit – first visit and maintenance visits 
 First two visits combined  
(month 0 and month 3) 
Maintenance visits 
  
Product Nurse time 
(hours) 
Counsellor 
time (hours) 
Nurse time 
(hours) 
Counsellor time 
(hours) 
Oral PrEP 0.5 0.5  0.5 
Microbicide 0.5 0.5  0.5 
SILCS 
diaphragm 
0.5 0.5  0.5 
Vaginal ring 0.5 0.5  0.5 
Injectable 0.5 0.5 0.25 0.5 
 
Comparison with other studies 
These cost profiles are generally 1.5-3 times greater than other estimates in the 
literature. Given that the model is parameterised using similar inputs to other studies, it 
is likely that this increase is driven by the incorporation of full chemistry panels and 
syndromic STI tests as per South African guidelines – most other models do not include 
these costs. 
Limitations 
As with any modelling exercise, this model is a simplification of reality. To make the 
model operational, we make a number of assumptions around product availability and 
rollout. Firstly, we assume that products become available across South Africa at the 
same time, as indicated by assumptions around training in each health facility and mass 
media costs. In reality there would likely be a smaller-scale pilot phase of rollout. 
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Depending on how roll-out occurred, it is unclear a priori how this would affect these 
estimates. Secondly, we assume that there are no economies of scale within product 
rollout, for example assuming that all training sessions are of the same size and are held 
by each provider individually. We also assume no synergies in rollout across products, 
for example the use of mass media to promote more than one PrEP delivery system, or 
the reduction in potential user reticence to use a new product in previous products have 
been marketed well. Both of these assumptions are likely to make our estimates 
conservative.  
Thirdly, we assume that guidelines around PrEP are adhered to perfectly, though we 
allow for treatment coverage to be less than 100%, as has been observed. This is likely 
to reduce effectiveness of products and thus reduce averted costs; the impact of 
imperfect adherence is also likely to be different across the products considered. We also 
assume that the published guidelines for oral PrEP among female sex workers in South 
Africa, so far the only available PrEP guidelines, are applicable for all populations and all 
products – this is the cause of the similarity in resource use estimates across products. 
In reality, there is likely to be some variation across products in these factors, however 
it is unclear before their introduction and guideline publication how, for example, three-
monthly HIV testing, might vary across products in reality.  
Cost model results 
Table S3:3 and Figure S3:1 detail the results of a probabilistic sensitivity analysis on the 
cost model, alongside the interquartile range of estimates. In this analysis, we only use 
the first-year cost, which results in a more conservative analysis given the anticipated 
reduction in costs in later years, particularly due to less intensive training. 
Figure S3:1: Average variable costs per product (probabilistic approach) 
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Table S3:3 Annual variable product cost per person per year, first year of introduction 
Product Point estimate Lower Credible 
Interval/95%CI 
Upper Credible 
Interval/95%CI 
Oral Prep $289 $269 $309 
Vaginal Ring $258 $243 $273 
Microbicide Gel $212 $192 $230 
Injectable $438 $349 $516 
SILCS Diaphragm 
and Microbicide 
Gel 
$217 $199 $235 
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Table S3:4 Cost model inputs 
 Central value 
(Costs US$ 
2015) 
Upper Bound 
(if available) 
Lower Bound 
(if available) 
Source PSA distribution (if applicable) 
Fixed costs      
Number of public 
sector facilities 
3182     
(39) 
 
Training cost per 
facility 
10904   
Calculation and (26) 
Uniform (+- 25%) 
Annual refresher 
cost per facility 
3635   
Calculation and (26) 
Uniform (+- 25%) 
Mass media (total 
budget) 
5000000 5,000,000 1,000,000 
(1) 
Uniform (+- 25%) 
      
Wage of staff 
providing 
products 
   
 
 
Nurse wage per 
hour 
19.11 24 8 
(40)  
Uniform (+- 25%) 
HIV counsellor wage 
per hour 
14.42   
(41) 
Uniform (+- 25%) 
Physician wage per 
hour 
75.09   
(15) 
Uniform (+- 25%) 
      
Consumables      
HIV test 6.19 6.75 4.67 (42, 43) Uniform (+- 25%) 
Chemistry panel inc. 
creatinine clearance 
33.03 40 30 
(42) 
Uniform (+- 25%) 
      
Averted costs - 
Pregnancy 
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Pregnancy outcome 
cost (healthy) 
75.6   
(44) 
Uniform (+- 50%) 
Pregnancy outcome 
cost (Low birth 
weight) 
1570.8   
(44) 
Uniform (+- 50%) 
Pregnancy outcome 
cost (Neonatal 
death) 
3724.6   
(44) 
Uniform (+- 50%) 
Pregnancy outcome 
cost (Stillbirth) 
75.6   
(44) 
Uniform (+- 50%) 
Pregnancy outcome 
cost (Miscarriage) 
73.1   
(44) 
Uniform (+- 50%) 
Spontaneously 
aborted pregnancy 
36.3   
(44) 
Uniform (+- 50%) 
      
Pregnancy costs      
Average number of 
days of work lost 
due to pregnancy 
3   
Assumption 
 
Number of prenatal 
visits per pregnancy  
4   
(11) 
 
Proportion of births 
that are really 
unwanted 
49%   
(11) 
 
Proportions of 
unwanted births 
that are mistimed 
51%   
(11) 
 
Years when 
mistimed births 
would occur 
2   
(45) 
 
Abortion rate 10.50%   (46)  
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Abortion rate 
among unintended 
pregnancies 
20.20%   
(11) 
 
Delivery rate among 
unintended 
pregnancies 
79.80%   
(11) 
 
Number of visits for 
abortion (pre-act) 
3   
(47) 
 
% of women 
receiving antenatal 
care 
92%   
(11) 
 
% of women where 
delivery was 
assisted by skilled 
health worker 
92%   
(11) 
 
Number of prenatal 
visits needed when 
pregnant 
4   
(11) 
 
      
      
Product-specific 
costs 
   
 
 
SILCS Diaphragm 
cost per year 
5.19 6 4 Kessel (Personal 
communication) {Kessel, 
2015 #1464} 
Uniform (bounds) 
Oral PrEP drug cost 
per year 
75 130 70  Assumed using ranges 
from primary studies: 
CHAI ceiling price 2015: 
$67.20/year (49) 
South African Investment 
case: $75.13(43); 
CHAI ceiling price 2010 
$75 cited in 
(50)Walenksy(42) (direct 
Uniform (bounds) 
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link no longer available). 
(1) 
Microbicide gel tube 
cost 
3.69 4.5 3 Kessel (Personal 
communication) {Kessel, 
2015 #1464}, Population 
council (personal 
communication) 
Uniform (bounds) 
Intravaginal ring 
cost 
6 7 5 Bodarky, (personal 
communication){Bodarky
, 2015 #1465} 
Uniform (bounds) 
Injectable cost per 
injection 
5 7 5 Assumption from cost of 
IPM IVR 
Uniform (bounds) 
Number of sex acts 
per year 
104 208 20 
(29) 
Uniform (bounds) 
Quantity of gel used 
per sex (in ml) 
4   Kessel (Personal 
communication) {Kessel, 
2015 #1464} 
Uniform (bounds) 
      
Clinic visits per 
year by product 
   
 
 
SILCS diaphragm, 
microbicide gel, oral 
PrEP, IVR 
4 4 3 
(26) 
 
Injectable ARV 12 12 4 (51)  
      
Discount rate 0.03   (52)  
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Supplementary file S4: Division of fixed costs across populations 
To estimate population-level cost-effectiveness, we account for the allocation of programme fixed costs across the three groups differently, 
depending on the type of cost. We allocate facility-level fixed costs for training across general population groups according to the proportion 
of general population females in each group. FSW training costs are calculated through multiplying the number of FSW-specific facilities 
operating in South Africa by estimated training costs per facility. Mass media costs are only allocated to general population groups, 
proportional to size. Finally, FSW peer-educator and outreach costs are estimated by assuming 12 peer-educators per site working one day 
per week. Table S3:1 displays these costs as allocated. 
Table S4:1 Summary of annual fixed costs by population group 
Assumptions Training Mass media Peer educator / outreach costs Total 
Women 15-24 $12,872,686.84 $1,855,023.45  $16,561,101.57 
Women 25-49 $21,824,143.70 $3,144,976.55  $28,077,422.00 
FSWs $1,112,217.70 $- $403,920.00 $1,574,444.67 
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Supplementary file S5: HIV infections averted 
Table S5:1 Total HIV infections averted by scenario 
Women 15-24 HIV 
infections 
  HIV Infections averted  
Scenario Low 
incidence 
Central 
Incidence 
High 
incidence 
Low 
incidence 
Central 
Incidence 
High 
incidence 
Counterfactual 69,052 108,266 213,123    
Scenario 1: Oral PrEP with HIV protection 
only 
65,020 101,945 200,680 4,031 6,321 12,443 
Scenario 2: Oral PrEP & vaginal ring with HIV 
protection only 
64,238 100,719 198,265 4,814 7,548 14,858 
Scenario 3: MPT ring plus oral PrEP 62,234 97,577 192,080 6,818 10,690 21,043 
Scenario 4: All five products with HIV 
protection only 
63,911 100,206 197,256 5,141 8,060 15,867 
Scenario 5: All five products with 
multipurpose protection 
51,946 81,446 160,327 17,106 26,820 52,796 
       
Women 25+   HIV 
infections 
  HIV Infections 
averted 
 
Scenario Low 
incidence 
Central 
Incidence 
High 
incidence 
Low 
incidence 
Central 
Incidence 
High 
incidence 
Counterfactual 69,100 93,285 201,543    
Scenario 1: Oral PrEP with HIV protection 
only 
58,675 79,212 171,137 10,425 14,074 30,406 
Scenario 2: Oral PrEP & vaginal ring with HIV 
protection only 
56,993 76,940 166,229 12,108 16,345 35,314 
Scenario 3: MPT ring plus oral PrEP 56,747 76,608 165,511 12,354 16,677 36,031 
Scenario 4: All five products with HIV 
protection only 
56,310 76,019 164,238 12,790 17,267 37,304 
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Scenario 5: All five products with 
multipurpose protection 
51,915 70,085 151,418 17,186 23,201 50,125 
        
FSW   HIV 
infections 
  HIV Infections 
averted 
 
Scenario Low 
incidence 
Central 
Incidence 
High 
incidence 
Low 
incidence 
Central 
Incidence 
High 
incidence 
Counterfactual 1,026 2,020 3,231    
Scenario 1: Oral PrEP with HIV protection 
only 
877 1,727 2,763 149 293 469 
Scenario 2: Oral PrEP & vaginal ring with HIV 
protection only 
737 1,451 2,321 289 569 910 
Scenario 3: MPT ring plus oral PrEP 739 1,455 2,329 287 564 903 
Scenario 4: All five products with HIV 
protection only 
747 1,471 2,353 279 549 878 
Scenario 5: All five products with 
multipurpose protection 
685 1,349 2,158 341 671 1,073 
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Supplementary file S6: One-way sensitivity analyses 
Scenario 2.1: Oral PrEP and MPT ring 
 
 
272 
 
 
 
 
 
273 
 
Supplementary file S7: Net intervention costs 
Figure S7:1: Net intervention costs by population 
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Supplementary file S8: Additional data from 
probabilistic sensitivity analysis 
Below are a series of cost-effectiveness plane plots showing the results of 1000 Monte 
Carlo simulations carried out for the probabilistic sensitivity analysis. All ICERs are 
plotted as coloured shapes. Results are plotted on the cost-effectiveness plane and, 
similarly to Figure 5, when compared to the dashed WTP threshold line, can be 
interpreted as cost-effective when they lie to the south east. These simulations were also 
used to generate the CEAC curves in the main analysis.  
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Conclusions from paper R2 
This paper provides estimates of the short-term impact of a range of candidate MPT 
products. The finding that MPTs may be cost-effective among younger female groups is 
important, and reinforces calls from further development of effective MPTs to meet the 
needs of this group.  
This paper also indicates that MPTs may be cost-effective if introduced among FSW 
groups. Yet, as described in the background section, this model follows the trend of the 
economic literature and makes assumptions around risk compensation that are not 
based on empirical data. The next paper, paper R3, uses a DCE to predict the behavioural 
response of FSWs as a result of PrEP to estimate the influence of economic factors on 
risk compensation under PrEP use.  
Further considerations arising from paper R2 
A limitation of the model in paper R2, which was not noted in the accepted version of the 
paper, is the assumption that unit costs do not vary with scale. In reality, there will likely 
be some intertemporal dynamic variation between the cost of products and demand: 
demand for products will depend, in part, on the price of products, whilst prices may be 
influenced by economies of scale in production. The former may not be such an issue in 
this case since products are assumed to be provided by the South African Department of 
Health at no cost to users, though high levels of demand might have a budget impact 
despite predictions of cost-effectiveness. However, high demand may substantively 
reduce product unit cost through economies of scale in production; a decrease in unit 
cost would increase the cost-effectiveness of products, making these results 
conservative. 
National guidelines on long-acting reversible contraception (LARC) in South Africa 
recommend that condoms are used alongside other contraceptive methods for “dual 
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protection purposes and enhanced protection from pregnancy”6. In the DCE, condom-
using participants who chose new products were asked whether they would use them 
alongside or in place of condoms, with 49% indicating engagement in co-use (implying 
51% condom substitution). If MPT users were to adhere to national guidelines, using 
condoms with hormonal MPT products, they would be more cost-effective than 
estimated here, since overall protection would be higher (increasing the final summation 
in equation (2)).  
In addition, the model only considers two health outcomes: HIV infection and 
unintended pregnancy. It therefore does not consider the direct impact of other STIs, 
alongside any indirect impact of increasing individual susceptibility to HIV acquisition. 
Not accounting for such negative externalities means that the cost-effectiveness 
estimates of this model are lower (more favourable) than if STIs were considered. The 
DALY disability weights for common sequela associated with the three STIs included in 
the Global Burden of Disease Study (chlamydia, syphilis, gonorrhoea)46 are lower than 
those associated with HIV infection, however without explicitly modelling these we are 
not able to comment on how cost-effectiveness estimates may change.  
Although this paper assesses cost-effectiveness, it does not consider the potential 
budgetary impact of introducing interventions. If MPTs are introduced to large 
populations – such as the general population groups modelled here – the overall impact 
on the health budget may make them unaffordable. Though beyond the scope of this 
paper, a rigorous, policy-focused budget analysis is required before recommending the 
introduction of MPT products. 
                                                             
6 Page 72, National Contraception Clinical Guidelines, Department of Health, Republic of South 
Africa. https://www.mm3admin.co.za/documents/docmanager/3c53e82b-24f2-49e1-b997-
5a35803be10a/00037761.pdf.  
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Finally, we conducted a threshold analysis presented in table 6 to explore the product 
unit costs above which we would estimate that products are not cost-effective. Results 
indicate that the SILCS diaphragm could sustain the largest price increase and remain 
cost-effective (ceteris paribus) with a four-fold price increase. Oral PrEP could sustain 
the smallest price increase (36%) when introduced in isolation. Results suggest a degree 
of flexibility in the unit cost of products which are yet to be introduced (i.e. all expect 
oral PrEP) before the model indicates that they will become cost-effective; this is 
important since cost assumptions for these products are highly uncertain when made 
prior to introduction and therefore robust programmatic costing.  
 
Table 6: Threshold analysis of scenarios among women aged 15-24, central incidence 
 
 PrEP** Ring SILCS Gel Injectable 
Base-case price  $    75.13   $      7.00   $        5.19   $      3.69   $        7.00  
      
Threshold price by scenario  S1 (PrEP)     
(holding other prices constant)  $    95.53      
 S2 (PrEP) S2 (ring)    
  $  102.24   $    15.84     
  S3 (PrEP)   S3 (ring)     
  $  100.58   $    15.47     
  S4 (PrEP)   S4 (ring)   S4 (SILCS)   S4 (gel)   S4 (inject)  
  $  215.65   $    20.70   $      22.26   $    11.85   $      12.76  
  S5 (PrEP)   S5 (ring)   S5 (SILCS)   S5 (gel)   S5 (inject)  
  $  288.24   $    18.25   $      24.13   $      8.86   $      15.80  
**Annual price, other prices reflect unit product cost 
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Chapter 8: Paper R3 – The effect of HIV 
prevention products on the supply of 
condomless commercial sex amongst female 
sex workers in South Africa 
Overview of paper R3 
Chapter 3 detailed how existing mathematical models have incorporated assumptions of 
risk compensation. This paper presents the results of a second DCE, carried out solely 
among FSWs, with the aim of estimating the impact of introducing an effective HIV 
prevention product on the choices of FSWs. The paper uses a repeated discrete choice 
experiment with a difference in framing to quantify substitution from condoms under 
PrEP, and explore changes in act pricing. Results are analysed using MNL and MMNL 
models, and preference heterogeneity is considered though the incorporation of random 
parameters and interaction terms incorporating participant characteristics.  
The paper is written in a different style from others in this thesis as it is currently under 
submission to Health Economics, which has different expectations of terminology, 
structure, and referencing style compared to public health or disease-specific journals. 
This paper meets thesis objective 3, to assess whether HIV prevention products will 
change FSW preferences for the supply of condomless commercial sex. It also 
contributes to objective 4, to explore if changing incentives in sex work could 
substantially impact the impact of HIV prevention products, by producing behavioural 
predictions which are incorporated into the mathematical model in paper R4 which 
immediately follows this paper. 
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commercial sex amongst female sex workers in South Africa 
Matthew Quaife*1,2, Peter Vickerman3, Shanthi Manian4, Robyn Eakle1,2, Maria A. 
Cabrera-Escobar2, Sinead Delany-Moretlwe2, Fern Terris-Prestholt1 
1 Department of Global Health and Development, London School of Hygiene and Tropical 
Medicine, London, UK 
2 Wits RHI, University of the Witwatersrand, Johannesburg, South Africa 
3 School of Social and Community Medicine, University of Bristol, Bristol, UK 
4 Washington State University, Pullman, WA, USA 
* Corresponding author 
Abstract 
Evidence suggests that economic factors play an important role in commercial sex work, 
in particular that condomless sex commands a price premium relative to condom 
protected sex. This paper explores whether the use of an HIV prevention product, 
described as 100% effective in preventing HIV, could change the price and quantity of 
condomless commercial sex supplied. We collected stated preference data from 122 HIV 
negative female sex workers (FSWs) in urban South Africa, using a repeated choice 
experiment to simulate the impact of using this product on prevention choices. Results 
suggest that the price premium for condomless sex would decrease by 73% with the use 
of this product. The price of an act does not significantly affect choices without 
protection, but strongly influences choices where full HIV protection is an option. The 
utility offered by condoms is reduced by around 15% under product use. Because some 
HIV prevention products do not protect against other STIs or pregnancy, the unintended 
consequences of introducing new HIV prevention products should be closely monitored, 
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whilst users should not face stigma or blame for reacting rationally to exogenous 
changes to market conditions. 
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Introduction 
Women engaged in commercial sex, or female sex workers (FSWs), face daily risks of 
HIV acquisition[1], not least in urban South Africa where HIV prevalence among FSWs is 
estimated to be as high as 72% in some cities[2]. FSWs face different choices and 
incentives from other high-risk populations, because, in addition to navigating the 
complexities of sexual and personal risk in non-commercial sexual relationships, 
economic and social inequalities mean that FSWs often face strong competition from 
FSW colleagues, client resistance to condom use, and threats and use of violence from 
clients and police[3-6]. A growing topic for economic research, analyses have sought to 
explain entry into and persistence of the industry[7-9], the intensive margin of 
risk/benefit trade-offs[10, 11], and vulnerabilities faced by FSWs from broader 
economic forces[12, 13]. 
Financial incentives in sex work may directly affect the HIV, STI, and pregnancy risk 
FSWs bear. For example, econometric work has estimated a price premium for 
condomless sex relative to protected sex, referred to in the literature as the condom 
differential. Anecdotal evidence of this differential (e.g. [6]) was first empirically 
estimated by Rao[10] who found that Indian FSWs who used condoms consistently faced 
income losses of up to 79% as compared to colleagues not using condoms, whilst further 
econometric evidence has estimated price premia in different contexts between 7% 
(Belgium and the Netherlands) tand 81% (Bangladesh)[10-12, 14-17]. In many 
circumstances, FSWs are highly dependent on sex work to support themselves and their 
families[18], and therefore may be at heightened risk when offered more money for 
unprotected sex. 
The HIV prevention landscape has evolved considerably in recent years, not least due to 
emerging evidence that antiretroviral (ARV) drugs can be used for HIV prevention. Pre-
exposure prophylaxis (PrEP) has been shown to offer a high degree of protection when 
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used by HIV-negative persons in different contexts and populations worldwide[19]. In 
2015 the World Health Organisation (WHO) recommended oral PrEP to be used in 
groups at high risk of HIV acquisition[20]. By implementing national guidelines for the 
provision of PrEP among FSWs in 2016, South Africa became one of the first countries 
worldwide to offer ARV-based prevention to any group[21]. In these early stages of PrEP 
implementation, and with impending new products in the development pipeline in mind, 
it is critical that we fully understand the impact that effective products might have on 
potential users’ behaviours, specifically to understand potential unintended 
consequences associated with sustained alternate prevention product use. Such risk 
compensation cannot be identified by standard comparisons in placebo-controlled 
trials[22]. 
We hypothesise that the introduction of a fully effective HIV prevention product will 
affect the supply of protected and condomless sex because an HIV negative user will bear 
less risk from engaging in condomless sex. Such a product does not exist, but this 
provides a useful hypothetical experiment to analyse the perspectives of FSWs. 
According to the theory of compensating differentials, this would result in both a) an 
increase in the quantity of condomless sex supplied, and b) a decrease in the price 
premium for condomless sex. To empirically test this, we interviewed 203 FSWs in 
Ekurhuleni Municipality, in the urban periphery of Johannesburg, South Africa. We used 
stated preference methods, a repeated discrete choice experiment (DCE) presented with 
and without framing of alternate HIV protection, to estimate the effect of hypothetical 
product use on FSW preferences for condom, price, and client characteristics. Stated 
preference methods are used frequently in health[23], transport[24, 25] and 
environmental economics[26], offering a flexible and theoretically robust approach to 
eliciting preferences towards products and situations that do not yet exist[27]. Although 
their hypothetical nature means that stated and revealed preferences may not be 
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perfectly concordant, empirical research in health has shown relatively small levels of 
hypothetical bias and reasonable external validity[28-30]. 
When asked to respond as if using a hypothetical, fully effective HIV prevention product, 
the utility provided to respondents by condom use was diminished by 15%. We find that 
when given the choice, the use of a 100% effective alternate HIV prevention product will 
reduce the price premium for condomless sex by 73%, and simulations indicate that the 
quantity of condomless sex supplied will more than double. The price of an act does not 
significantly affect choices without protection, but strongly influences choices under full 
HIV protection. 
This paper makes two contributions to the economic literature on sex work and HIV 
prevention, and provides new insights into a critical population in the country with the 
world’s largest HIV burden. First, to date a body of economic work exists which explores 
the nature and challenges of sex work, yet no research has looked at the potential impact 
of new prevention products on the incentives, risks and pressures that FSWs face. 
Secondly, despite a high estimated prevalence among a national population of 130,000 
FSWs[31], to date this is the only published piece of economic work among South African 
FSWs.   
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Theoretical model 
The following model is an extension of that devised by Gertler, Shah and Bertozzi[11], 
the first paper to formalise the FSW/client relationship in a partial equilibrium 
framework. First, we describe their model which considers the market where condoms 
are the only way of preventing HIV transmission, before extending it to consider the 
effect of a new prevention product.  
FSW and client utility payoffs 
Take a client's willingness to pay (utility) for sex to be V, whilst his maximum willingness 
to pay to not use a condom (disutility) is 𝛽. Then: 
𝑌𝑐𝑜𝑛𝑑𝑜𝑚
𝑐𝑙𝑖𝑒𝑛𝑡 = 𝑉 − 𝛽 − 𝑃𝑐  
Where 𝑌𝑐𝑜𝑛𝑑𝑜𝑚
𝑐𝑙𝑖𝑒𝑛𝑡  is a client's utility payoff from condom protected sex with a FSW, and 𝑃𝑐  
the price he pays her for protected sex. Considering his utility payoff from unprotected 
sex, the 𝛽 element is dropped and his payoff function becomes: 
𝑌𝑛𝑜𝑐𝑜𝑛𝑑𝑜𝑚
𝑐𝑙𝑖𝑒𝑛𝑡 = 𝑉 − 𝑃𝑛𝑐 
Where 𝑌𝑛𝑜𝑐𝑜𝑛𝑑𝑜𝑚
𝑐𝑙𝑖𝑒𝑛𝑡  is a client's utility payoff from unprotected sex with a FSW, and 𝑃𝑛𝑐 is 
the price he pays her for unprotected sex.  
The utility payoffs for FSWs are: 
𝑌𝑐𝑜𝑛𝑑𝑜𝑚
𝐹𝑆𝑊 = 𝑃𝑐  
And: 
𝑌𝑛𝑜𝑐𝑜𝑛𝑑𝑜𝑚
𝐹𝑆𝑊 = 𝑃𝑛𝑐 − 𝛾 − 𝑊 
Thus FSW utility payoffs depend on the amount a client pays. However, when she 
engages in unprotected sex, she suffers a disutility from exposing herself to risk (from 
any source), discomfort, or other negative attributes of unprotected sex. Furthermore, 
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the sex-worker can expect to receive W from the next-best use of her time. Note that this 
model implicitly assumes the opportunity cost of a client's next best use of time is zero.  
We assume that clients and FSWs have a choice whether to engage in any type of sex, 
though allow for differences in bargaining power between the two groups. The model 
suggests that a FSW will supply unprotected sex if both she and the client agree not to 
use a condom. For FSWs, this will occur when the marginal revenue she receives from 
unprotected sex (𝑃𝑛𝑐 − 𝑃𝑐) is greater than or equal to her disutility from not using a 
condom. For clients, this will occur when his marginal cost of not using a condom (𝑃𝑛𝑐 −
𝑃𝑐) is less than his disutility from condom use. Therefore, two conditions must hold for 
unprotected sex to occur: 
𝛽 > 𝛾 
And: 
𝑉 > (𝑊 + 𝛾) 
In other words, that the maximum a client is willing to pay not to use a condom is greater 
than the maximum a FSW is willing to accept to take the risk; and that the client's 
maximum willingness to pay for sex is greater than a FSW's costs associated in non-
condom sex.  
We consider the effect of PrEP on client and FSW payoffs. First, we assume that the FSW's 
disutility from supplying unprotected sex declines. We define a new parameter,𝜂, that 
represents this change, so that her payoff from non-condom use is now:  
𝑌𝑛𝑜𝑐𝑜𝑛𝑑𝑜𝑚
𝐹𝑆𝑊 = 𝑃𝑛𝑐 − (𝛾 − 𝜂) 
Similarly, we assume that male clients' utility from non-condom sex increases by the 
extent to which a client values HIV protection (which is now provided by PrEP). We 
represent the clients' utility gain from PrEP by 𝜉 so that his payoff from non-condom use 
is now: 
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𝑌𝑛𝑜𝑐𝑜𝑛𝑑𝑜𝑚
𝑐𝑙𝑖𝑒𝑛𝑡 = 𝑉 + 𝜉 + 𝑃𝑛𝑐 
Payoffs from condom use have not changed, so we retain the equilibrium price of 
unprotected sex from Gertler, Shah, and Bertozzi[11]: 
𝑃𝐶 = (1 − 𝛼)(𝑉 − 𝛽) + 𝛼𝑊 
To find the new equilibrium price for non-condom use with PrEP, we maximise: 
(𝑉 + 𝜉 − 𝑃𝑛𝑐)𝛼(𝑃𝑛𝑐 − 𝛾 − 𝑊)(1−𝛼)  where 𝛼  represents the client’s bargaining power, 
and (1- 𝛼 ) FSW bargaining power. We obtain: 
𝑃𝑛𝑐 = (1 − 𝛼)(𝑉 + 𝜉) + 𝛼(𝑊 + 𝛾) 
Then, by subtracting 𝑃𝑛𝑐 − 𝑃𝑐 , we obtain the price differential between protected and 
unprotected sex: 
𝑃𝑛𝑐 − 𝑃𝑐 = (1 − 𝛼)(𝛽 + 𝜉) + 𝛼(𝛾 − 𝜂) 
We can then compare the price premium for non-condom use with PrEP to that without 
PrEP: 
𝑃𝑟𝑒𝑚𝑃𝑟𝐸𝑃 − 𝑃𝑟𝑒𝑚𝑂𝑟𝑖𝑔 = (1 − 𝛼)𝜉 − 𝛼𝜂 
The impact of PrEP on the price premium for non-condom use therefore depends on the 
relative bargaining weights of the FSW and client, and the amount of utility the client and 
the sex worker each gain through the use of PrEP. The premium will decline if the 
following condition holds: 
1 − 𝛼
𝛼
<
𝜂
𝜉
  (1) 
And rise if the opposite inequality holds. 
The following pair of assumptions would generate a decline in the price premium under 
PrEP: 
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(i) The client’s bargaining power is greater than the FSW’s: 𝛼 > 1 − 𝛼 
(ii) The FSW gains more utility from PrEP than the client: 𝜂 > ξ 
Under these two assumptions, the left hand side of condition (1) is less than 1, whilst the 
right hand side is greater than 1, so the inequality is always satisfied. 
Empirical methods 
Study overview 
A respondent-driven sampling (RDS) method[32] was used to recruit 203 FSWs in 
Ekurhuleni Municipality, Gauteng Province. Peer educators were used to locate sex work 
hotspots and 12 were asked to act as seeds to start RDS chains in different areas (i.e. 
women working in brothels, hotels or on the street). Seeds were invited to complete the 
survey and received ZAR 50 (USD $3.50) compensation for their time before they were 
given four coupons containing study information to distribute to other FSWs. When each 
referred FSW attended for an interview, their peer recruiter received a small incentive 
in the form of a ZAR 20 (USD $1.40) voucher.  
The DCE was designed to elicit FSW preferences towards clients and sex act 
characteristics. To estimate the impact of a new, 100% effective prevention product on 
choices, the same ten DCE tasks were presented twice to HIV negative FSWs, firstly with 
no framing: “You have the choice between providing services to one of two clients. Which 
would you prefer?” prior to a comprehensive description of a range of potential products 
to respondents. Then, the choice tasks were presented again with a protected framing: 
“Now I would like you to choose between 10 more sets of clients, but this time I would like 
you to make your choices imagining you were using a product which prevented you from 
getting infected with HIV. This means that there would be no risk of getting HIV from any 
client, whether or not you use a condom. Which would you prefer?” 
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Because respondents answered the same choice tasks twice (with different frames), we 
were able to test whether different choice task framings had a causal impact on FSW 
choices. Interviewers were experienced in sexual history surveying, and were 
thoroughly trained and tested on their explanation of products and the DCE. In a 
separate DCE carried out in the same sample, preferences for product characteristics 
were consistent with prior expectations, demonstrating participant understanding of 
the protective benefits of products[33, 34]7.  
The study was reviewed and approved by the University of the Witwatersrand Human 
Research Ethics Committee (HREC) and the Research Ethics Committee at the London 
School of Hygiene and Tropical Medicine. All participation in the DCE, alongside 
supporting qualitative studies, was voluntary and subject to completion of written 
informed consent. The background survey asked several questions which led to a 
number of disclosures of distressing events, and a comprehensive distress protocol 
ensured that participants who disclosed these were referred to named persons at local 
clinics and NGOs. 
Questionnaire 
Selection of attributes and levels 
The development of the DCE tasks was primarily based on thematic analysis of four focus 
group discussions. These were carried out with 52 self-reported active FSW participants 
recruited through convenience sampling, with the assistance of FSW peer-educators 
through a local non-governmental organisation. Qualitative analysis (presented 
elsewhere[35]8) generated a long list of potential DCE attributes, supplemented by key 
themes emerging from a scoping literature review. Final attributes and pictorial 
representations of choice tasks were then chosen through discussions with FSWs, peer 
                                                             
7 Chapter 6 of this thesis 
8 Appendix X of this thesis 
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educators, the FSW community advisory board at the Wits RHI, and input from UK and 
South African experts in DCE methods. Table 1 presents the final list of attributes and 
their levels, alongside the hypothesised direction of impact for each (positive or negative 
impact on utility). For example, we expect the act price to have a positive coefficient and 
increase utility, whilst providing services to clients perceived to have an STI or HIV is 
likely to have a negative coefficient as it reduces utility. Figure 1 gives an example of a 
choice task as presented to respondents. The rest of the questionnaire captured data on 
a range of factors which may influence risk and pricing decisions such as socio-economic 
characteristics, commercial and non-commercial sexual history, and exposure to 
structural risk factors such as intimate partner violence; these are used to explore 
preference heterogeneity though interaction terms.  
Figure 1: Example choice task without protection framing 
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Table 1: Attributes and levels 
Attribute Levels Hypothesised 
coefficient 
sign  
   
Condom use Condom vs. no condom + 
Type of sex Vaginal sex vs. anal sex + 
Perceived client HIV 
risk 
 “You don't think this client has HIV” vs. “You think this 
client has HIV” 
- 
Perceived client STI 
risk 
“You think this client has an STI” vs. “You don't think 
this client has an STI” 
- 
Price for sex R100 (US $7.03), R200 (US $14.06), R400 (US $28.12), 
R800 (US $56.24) 
+  
Task frame No framing: “You have the choice between providing 
services to one of two clients. Which would you prefer?” 
Protection framing: “Now I would like you to choose 
between 10 more sets of clients, but this time I would like 
you to make your choices imagining you were using a 
product which prevented you from getting infected with 
HIV. This means that there would be no risk of getting HIV 
from any client, whether or not you use a condom. Which 
would you prefer?” 
 
 
Experimental design 
We apply best-practice DCE design methods and use a fractional factorial design to 
generate the experimental design used in piloting, with pilot data subsequently 
providing Bayesian priors for the final design[27]. A 10-task, D-efficient unlabelled 
design was generated using NGENE software [36] with four unconstrained binary 
attributes (condom, sex, HIV risk, STI risk) and one continuous linear attribute (price). 
Discussion continues in the literature on the best way to create efficient DCE designs, yet 
D-efficient designs are increasingly popular due to their computational efficiency and 
statistical performance[23, 37-39].  
Analysis 
Multinomial logit (MNL) estimation 
Random utility models are used extensively in choice modelling, with the majority of 
health applications based on the multinomial logit (MNL) model[23, 40]. The MNL is 
computationally simple to implement, however, requires stringent assumptions 
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including the absence of taste heterogeneity across respondents alongside restrictive 
patterns of substitution across alternatives. Nevertheless, the MNL is a useful model with 
which to explore choice patterns in the data before moving to more advanced estimation 
methods[27].  
Thus, the utility of respondent n for alternative i is given by a deterministic and 
measurable element 𝑉𝑛,𝑖 and a stochastic, unobserved element 𝜀𝑛,𝑖: 
𝑈𝑛,𝑖 = 𝑉𝑛,𝑖 + 𝜀𝑛,𝑖 (1) 
Assuming that 𝜀𝑛,𝑖 has a type I extreme value distribution with values independently and 
identically distributed, the probability of choosing alternative i from choice set j is given 
by: 
𝑃𝑛,𝑖 =
𝑒𝑉𝑛,𝑖
∑ 𝑒𝑉𝑛,𝑖𝐽𝑗=1
 
(2) 
The MNL model is estimated by defining 𝑉𝑛,𝑖 as a vector of explanatory variables from 
the DCE design 𝑋𝑛,𝑖
′ 𝛽𝑖  and maximising a log-likelihood function in relation to 𝛽. 
Mixed multinomial logit (MMNL) estimation 
As described by Hess et al. [41], we estimate a mixed multinomial logit (MMNL) where 
the parameter vector 𝛽 is assumed to be randomly distributed rather than fixed, such 
that 𝛽~𝑓(𝛽, Ω): 
𝑃𝑛,𝑖 = ∫ 𝑃𝑛,𝑖
 
𝛽
(𝛽, 𝑥𝑛,𝑖)𝑓(𝛽, Ω)𝑑𝛽 
(3) 
Where Ω is a parameter vector of the distribution of the elements contained in 𝛽.  
A restriction of the MMNL model is that the analyst needs to specify which parameters 
are randomly distributed across agents, as well as the way they are distributed (i.e. 
according to a normal, lognormal, or uniform distribution). The requirement of these 
assumptions is generally seen as a small cost for the ability of MMNL specifications to 
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allow for taste heterogeneity, where preferences are allowed to vary across individuals 
[27, 41].  
To test the effect of the DCE framing we define 𝛽𝑛,𝑖 to include  
𝛽𝑛,𝑖 = 𝛼𝑛 + 𝛿𝑛 ∗ 𝐻𝐼𝑉 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 𝑝𝑟𝑜𝑡𝑒𝑐𝑡𝑖𝑜𝑛_𝑓𝑟𝑎𝑚𝑒𝑛  (4) 
Where 𝛼𝑛  is a coefficient vector capturing preferences with no framing, 
𝐻𝐼𝑉 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 𝑝𝑟𝑜𝑡𝑒𝑐𝑡𝑖𝑜𝑛_𝑓𝑟𝑎𝑚𝑒  a binary variable equal to 1 when the HIV product 
protection framed DCE is being presented, and 𝛿𝑛  a coefficient vector capturing 
deviations between the two framings. We calculate robust t-ratios to test the divergence 
of 𝛿  elements from zero. All parameters are estimated as random and normally 
distributed in MMNL estimation to reflect uncertainty in the distribution of their 
variance, except act price which is estimated with a lognormal distribution. 1000 Halton 
draws are created to estimate the model. 
Willingness to accept condomless sex 
Analogous to willingness to pay estimates in the literature, we compute the relative 
importance of sex-act attributes in monetary terms. For example, assuming a utility 
function which is linear in parameters, the willingness to accept (WTA) condomless sex 
can be expressed as the monetary value: 
𝑤𝑘 =  
𝛽𝑘
𝛽𝑐
 
(5) 
Where 𝛽𝑘 is the parameter for condom use, and 𝛽𝑐 the price parameter. Because 𝛽𝑘 and 
𝛽𝑐 are estimated with uncertainty, we consider the extent to which 𝑤𝑘 is uncertain using 
the Delta method to estimate the standard error of 𝑤𝑘. Assuming that ?̂? is asymptotically 
distributed such that 𝛽?̂?
𝐷
→ 𝑁(𝛽, Ω𝛽), then, as shown in in Bliemer and Rose [42], the 
asymptotic standard error of 𝑤𝑘 is: 
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𝑠𝑒(𝑤𝑘 )̂ =  
1
𝛽𝑐
√𝑣𝑎𝑟(𝛽𝑘) − 2𝑤𝑘𝑐𝑜𝑣(𝛽𝑘 , 𝛽𝑐) + 𝑤𝑘
2𝑣𝑎𝑟(𝛽𝑐) 
(6) 
We use the Delta method to assess the significance of the ratio of condom use and price 
parameters (the condom differential) in the unframed DCE, the HIV product protection 
framed DCE, and to test whether the ratio 𝑧𝑘 is significantly different from zero: 
𝑧𝑘 =
𝛽𝑘
𝑝𝑟𝑒𝑝/𝛽𝑐
𝑝𝑟𝑒𝑝
𝛽𝑘
𝑛𝑜𝑝𝑟𝑒𝑝/𝛽𝑐
𝑛𝑜𝑝𝑟𝑒𝑝 
(7) 
Simulations of behaviour change 
We apply predicted probability analysis to simulate the impact of a hypothetical fully 
effective prevention product on the price and supply of protected and condomless sex. 
As elsewhere in the health literature[27, 43, 44], we predict the supply response to the 
product introduction by summing the model coefficients with imputed attribute levels. 
As best-practice in WTP studies from DCE data, we rescale results for simulation using 
revealed preference data. We take the absolute price premium as self-reported by FSWs, 
and reduce it by the factor 𝑧𝑘 to generate the new price of condomless sex. We hold all 
attributes except condom use and price constant across framings, and use MNL model 
outputs for transparency in simulations, simply substituting 𝑉𝑛,𝑖  into equation (2). 
Results 
Characteristics of respondents 
Table 2 displays the descriptive statistics from the sample. In total 203 FSWs were 
interviewed, of whom 81 (40%) self-reported as being HIV positive, all of whom 
reported currently receiving antiretroviral treatment. The remaining 122 HIV negative 
respondents completed both DCEs (thus acting as their own counterfactual), and we 
restrict analysis to this group. Each DCE had ten choice tasks, meaning that we had 20 
observations per respondent (10 without protection, and 10 with protection) resulting 
in 2,440 choice data points. The average age of HIV negative respondents (29.48) was 
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significantly (p>0.01) lower than HIV positive respondents (32.95) and they were 
significantly less likely to have children (p>0.01). In addition, HIV negative FSWs were 
more likely to make all their income from sex work (p>0.01), and to have earned more 
from sex work in the last week (p=0.05). The marriage rate was low at 2% for both HIV 
positive and negative respondents, though 65% reported being in a relationship. 
Reported rates of consistent condom use (“always”) with commercial partners are much 
higher than other FSW surveys in South Africa[2]. Interestingly, HIV positive FSWs 
report charging significantly more than HIV negative FSWs (p=0.04) for protected sex, 
whilst there is no significant difference for condomless acts. The price premium for 
unprotected sex among HIV negative FSWs is 1.6 times greater than that of HIV positive 
sex workers (ZAR 394 ($30) vs. ZAR 248 ($19)).  
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Table 2: Descriptive Statistics 
Variable 
Whole 
sample %/(SD) 
HIV 
Negative 
(n=122) %/(SD) 
HIV 
Positive 
(n=81) %/(SD) 
Difference 
between HIV 
positive and 
negative: t-
test p-value 
Age 30.87 (6.17) 29.48 (5.72) 32.95 (6.27) >0.01 
Secondary education 155 76% 96.38 79% 59.13 73% 0.44 
Married 4.06 2% 2.44 2% 1.62 2% 0.59 
In a relationship 
132 65% 55 63% 77 68% 
0.49 
Any children 
182 90% 104.92 86% 76.95 95% 
>0.01 
Always use condoms with clients 196 97% 119 98% 76.95 95% 0.35 
Experienced IPV in the last year 70 34% 41.48 34% 29.16 36% 0.75 
Used alcohol at last sex 32 16% 18 15% 14 17% 0.15 
Low household income 
(<R5000/month) 
125.86 62% 69.54 57% 55.89 69% 0.1 
Knows other FSWs engaging in 
condomless sex 
81.2 40% 45.14 37% 35.64 44% 0.28 
In debt 78 38% 42.7 35% 34.83 43% 0.26 
All income made from sex work 174 86% 108 89% 65.61 81% >0.01 
Amount charged to last client 
(ZAR) 103.57 (156.70) 114.75 (188.28) 86.73 (88.92) 0.21 
Money earnt from sex work in last 
week (ZAR) 
1606.45 (1392.34) 1762.54 (1548.29) 1371.36 (1084.49) 0.05 
Average price charged for 
protected sex 
83.06 (90.24) 72.38 (72.98) 99.14 (109.88) 0.04 
Average price charged for 
condomless sex 
411.16 (355.97) 466.52 (385.13) 347.5 (316.84) 0.28 
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DCE results 
Tables 3 and 4 show results from MNL and MMNL main effects estimation respectively. 
Both tables show results for the unframed (models 3A and 4A) and protection framed 
(models 3B and 4B) DCEs. These tables also show the interaction specification of 
equation 4 (models 3C and 4C), where interaction coefficients represent the difference 
in preference weights between framings, and where a statistically significant parameter 
indicates that choices under assumed 100% HIV protection differ from those under no 
protection.  
Results are broadly consistent across MNL and MMNL specifications, and coefficient 
signs are in line with the theoretical expectations in Table 1. The non-significant price 
parameters in the unframed models 3A and 4A suggest that FSWs do not choose clients 
based on price in current practice, but condom use, client characteristics and the type of 
sex are all important to decision making. However, the significant price parameter in 
models 3B and 4B suggest that price could strongly influence choices after the 
introduction of a fully effective prevention product. We test the hypothesis that price 
will become more important with use by examining the price*protection framing 
parameter in models 3C and 4C, which show significance at the 95% level and therefore 
suggests there is strong evidence for an increased influence of price on choices after the 
introduction of a fully effective product. Additionally, we find that the utility of protected 
sex is significantly reduced by product use. In the MNL model, we find evidence that the 
framing of tasks was broadly understood due to the significant reduction in disutility 
from a client suspected as being HIV positive. However, this is not observed in the MMNL 
specification suggesting heterogeneity in the effect of framing across respondents. In 
both models, providing anal sex causes significant disutility in current practice and the 
extent of this does not appear to change with product introduction.  
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The MMNL displays lower log-likelihood, AIC and BIC values than the MNL, however, 
these cannot be directly compared to assess model performance as the randomness 
introduced by the MMNL will inevitably affect these measures. However, the general 
consistency across MNL and MMNL specifications is reassuring. The differences that do 
occur are likely to be because of heterogeneity in preferences among the sample, which 
is not incorporated by the MNL.  
Results suggest that the price premium for unprotected sex will reduce by 73% under 
full HIV protection, as denoted by the significant condom use and price parameters when 
interacted with framing. When the significance of the change in the ratio of these two 
parameters is assessed by the delta method, the change in price premium due to 
protection is also statistically significant (p=0.046). 
There is no evidence that HIV protection affects preferences for anal sex, providing 
services to clients who are suspected of having HIV or an STI, or opting out of providing 
services to clients. The lack of statistically significant parameters in the unframed DCE 
WTA ratios, presented in Supplementary Appendix I, may be due to the lack of precision 
in the price estimate which, in fact, further highlights the relative importance of the price 
attribute under product use.  
Simulations 
Since the condomless sex price premium we observe from revealed preference data 
without a prevention product is ZAR 394 (ZAR 466 – ZAR 72), we predict that the 
premium will fall to ZAR 107. All else equal, this reduction in the condom differential will 
lead to an increase in condomless sex by a factor of 2.27 with alternate product use, 
compared to before introduction. If the premium were to remain constant at ZAR 394, 
the change in the utility provided by condoms and price indicates that the quantity of 
condomless sex would increase by a factor of 3.2.  
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Heterogeneity 
We explore observed heterogeneity in our data though specifying interaction effects 
with several respondent characteristics shown in Table 5. This is a MNL model, as the 
MMNL model did not successfully converge. The most important finding here is that the 
impact of the fully protective product does not vary among FSW subgroups (Model 6C), 
however these null findings may be due to the number of parameters estimated in this 
model relative to the sample size. Although the effect of the product is consistent across 
the sample, there is some heterogeneity in preferences for the DCE attributes. Married 
FSWs value act price significantly less than their unmarried peers across both framings, 
and there is indicative evidence that recent experience of IPV and knowing other FSWs 
who engage in condomless sex may increase the influence of price under product 
introduction.  
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Table 3: DCE Results – main effects MNL 
  Model 3A: No frame MNL 
Model 3B: Protection framed 
MNL Model 3C: Interacted MNL 
  Coeff.  SE Coeff.  SE Coeff.  SE 
Price 0.0004  0.0005 0.0012 *** 0.0004 0.0004  0.0005 
Condom use (base: no condom)          
 Condom 4.53 *** 0.24 3.69 *** 0.22 4.53 *** 0.24 
Type of sex (base: vaginal)          
 Anal -2.89 *** 0.18 -2.98 *** 0.17 -0.29 *** 0.18 
Perceived client HIV risk (base: no risk)          
 Think client has HIV -0.48 *** 0.14 -0.24 ** 0.13 0.48 *** 0.14 
Perceived client STI risk (base: no risk)          
 Think client has STI -0.83 *** 0.16 -0.64 *** 0.15 0.83 *** 0.16 
Opt-out (no services to either) 1.46 *** 0.17 1.00 *** 0.14 1.46 *** 0.00 
Interactions (protection framing x)          
 Price       0.0008 *** 0.0006 
 Condom use       -0.84 ** 0.33 
 Anal sex       -0.09  0.25 
 Client HIV       0.24 ** 0.20 
 Client STI       0.19  0.22 
 Opt-out       -0.46 ** 0.22 
Model diagnostics          
 Log likelihood -587.31   -701.79   
-
1289.10   
 AIC 1186.62   1415.58   2602.21   
 BIC 1216.60   1445.58   2670.51   
 N 122   122   244   
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Table 4: DCE Results - main effects MMNL 
  
Model 4A: No framing 
MMNL 
Model 4B: Protection 
framed MMNL 
Model 4C: Interacted 
MMNL 
  Coeff.  SE Coeff.  SE Coeff.  SE 
Price 0.0002  0.0009 0.003 ** 0.0009 0.0018 *** 0.0006 
Condom use (base: no condom)          
 Condom 7.46 *** 0.56 6.34 *** 0.45 6.09 *** 0.33 
Type of sex (base: vaginal)          
 Anal -1.54 *** 0.33 -1.29 *** 0.33 -1.66 ** 0.29 
Perceived client HIV risk (base: no risk)          
 Think client has HIV -0.89 *** 0.32 -0.97 *** 0.31 -0.69 ** 0.21 
Perceived client STI risk(base: no risk)          
 Think client has STI -2.33 *** 0.41 -1.44 *** 0.30 -1.05 *** 0.21 
Opt-out (no services to either) -1.58 ** 0.46 -1.67 *** 0.40 -0.92 ** 0.25 
Interactions (protection framing x)          
 Price       0.0019 ** 0.0007 
 Condom use       -0.86 ** 0.42 
 Anal sex       -0.10  0.35 
 Client HIV       0.32  0.25 
 Client STI       0.33  0.28 
 Opt-out       -0.11  0.30 
Distribution parameters  
(distribution of standard deviation)          
 Price  0.0008 *** 0.0003 -0.0005  0.0005 -0.0006 ** 0.0002 
 Condom 0.16  0.17 -0.13  0.12 0.12  0.07 
 Anal -4.00 *** 0.50 -4.85 *** 0.61 -2.08 *** 0.23 
 Think client has HIV 0.01  0.21 0.40 * 0.20 0.09  0.13 
 Think client has STI 1.08 *** 0.25 0.51 ** 0.21 0.00  0.12 
 Opt-out (no services to either) 3.11 *** 0.37 2.58 *** 0.25 2.34 *** 0.16 
 Protection framing x price       0.0019 ** 0.0007 
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 Protection framing x condom use       -0.86  0.42 
 Protection framing x anal sex       -0.10  0.35 
 Protection framing x client HIV       0.32  0.25 
 Protection framing x client STI       0.33  0.28 
 Protection framing x opt-out       -0.73 *** 0.15 
Model diagnostics          
 Log likelihood -456.76   -538.05   -1058.664   
 AIC 937.5   1100.1   2165.33   
 BIC 997.4   1160.1   2301.93   
 N 122   122   244   
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Table 5: Heterogeneity in preferences - interaction effects 
  
Model 6A: No framing 
MNL 
Model 6B: Protection 
framed MNL Model 6C: Interacted MNL 
  Coeff.  SE Coeff.  SE Coeff.  SE 
Price -0.0005  0.0007 -0.0011  0.0006 -0.0005  0.0007 
Condom use (base: no condom)          
 Condom 4.39 *** 0.29 3.80 *** 0.28 4.39  0.29 
Type of sex (base: vaginal)          
 Anal -2.92 *** 0.18 -3.05 *** 0.18 -2.92  0.18 
Perceived client HIV risk (base: no risk)          
 Think client has HIV -0.49 *** 0.14 -0.28 *** 0.14 -0.49  0.14 
Perceived client STI risk (base: no risk)          
 Think client has STI -0.87 *** 0.17 -0.75 *** 0.15 -0.87  0.17 
Opt-out (no services to either) 1.43 *** 0.17 0.92 *** 0.14 1.43 *** 0.17 
Frame interactions: Protection framing x          
 Price       -0.0006  0.0009 
 Condom use       -0.59 * 0.40 
 Anal sex       -0.13  0.25 
 Client HIV       0.21 ** 0.20 
 Client STI       0.12  0.23 
 Opt-out       -0.51  0.22 
Respondent characteristic interactions          
 Price x married -0.003 ** 0.005 -0.01 *** 0.004 -0.003 ** -0.67 
 Price x low income 0.000  0.001 0.001  0.001 -0.0002  -0.23 
 Price x experience of IPV in previous 12 months 0.001  0.001 0.002 ** 0.001 0.001  1.78 
 Price x know FSWs who engage in condomless sex 0.001  0.001 0.002 *** 0.001 0.001  1.78 
 Condom x married 1.404 * 1.246 0.87  1.07 1.40 * 1.13 
 Condom x low income 0.341  0.274 0.13  0.28 0.34  1.24 
 Condom x experience of IPV in previous 12 months -0.070  0.292 0.37  0.31 -0.07  -0.24 
 
Condom x know FSWs who engage in condomless 
sex 
-0.010  0.284 -0.55  0.29 -0.01  -0.03 
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Frame interactions: 
   Protection framing x          
 Price x married       -0.002  -0.35 
 Price x low income       0.001  1.21 
 Price x experience of IPV in previous 12 months       0.001  0.76 
 Price x know FSWs who engage in condomless sex       0.001  1.35 
 Condom x married       -0.53  -0.32 
 Condom x low income       -0.21  -0.54 
 Condom x experience of IPV in previous 12 months       0.44  1.04 
 
Condom x know FSWs who engage in condomless 
sex       -0.54  -1.34 
 Model diagnostics          
 Log likelihood -581.41   -671.39   -1252.79   
 AIC 1190.81   1370.78   2561.59   
 BIC 1260.70   1440.78   2720.95   
 N 122   122   244   
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Discussion 
This study is the first to consider quantitatively the impact of a hypothetical fully 
effective HIV prevention product on the economics of sex work. We use stated 
preference methods to estimate the effect of introducing an effective HIV prevention 
product on the supply of commercial sex. HIV negative FSW participants completed two 
identical DCEs at the beginning and end of a larger survey, where the first DCE was 
framed in the context of current practice (i.e. without alternative HIV prevention 
protection), and the later DCE framed as if a 100% effective HIV prevention product was 
readily available and accessible to FSWs. Consistent with prior expectations, we found 
that this alternate product use increased the influence of price on FSW choices whilst 
condoms were valued significantly less. Results strongly suggest that alternate product 
use could reduce the condom differential (price premium for condomless sex) and 
increase condomless commercial sex. There was some evidence of preference 
heterogeneity between married and unmarried FSWs, however, our results do not 
suggest that the response to alternate prevention product introduction will vary much 
across FSWs. We find that the price of acts does not play an important part in FSW 
decisions at present, but would be likely to significantly impact choices after the 
introduction of a fully effective product. This may have implications for future HIV 
prevention product introduction, although current products have average estimated 
efficacy which is much lower than condoms[19]. 
Our simulations of choice data indicate that the condom differential could reduce by up 
to 73% under use of a fully effective product. Moreover, the quantity of condomless sex 
provided by FSWs is predicted to more than double with use of a fully protective product. 
There are three key reasons why this is an important consideration in the HIV 
prevention response. It is possible that if condom use falls after introducing alternate 
products, but FSWs are able use these new products effectively, then the projected 
increase in condomless sex will not substantively affect the HIV epidemic. However, 
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higher levels of condomless sex could increase the transmission of STIs which are a 
burden in their own right, but also increase the risk of HIV transmission, thus dampening 
the overall health benefits of single-purpose products[45]. Theoretical modelling work 
has shown this may not be important [46], but more research is required.  
Some data from oral PrEP trials, largely conducted among MSM populations to-date, 
indicate that self-reported condom use has not changed among PrEP users[47-50]. Yet, 
self-reported condom use data could be substantially over-reported, as shown by a list-
randomisation study among FSWs in Senegal which estimated that condom use was 
overestimated by 20 percentage points[51]. In contrast, a number of MSM studies have 
detected increased STI rates among PrEP users than non-users, an objective indication 
of increased levels of condomless sex, though it is not generally clear how many detected 
STIS were pre-existing or newly acquired[52-55]. Mathematical modelling work 
suggests that, if present, condom substitution may substantively reduce the impact of 
partially effective products[56, 57]. Future work is required in this area. 
This study suggests that effective HIV prevention products could exacerbate the 
difficulties that FSWs face in negotiating condom use with commercial sexual partners, 
if clients are aware that FSWs are using highly effective products other than condoms. In 
this instance, where FSWs are economically vulnerable, or do not have sufficient 
negotiating power with clients to insist on condom use, alternate product use may 
increase the occurrence of condomless sex. We also show that FSWs who increase the 
supply of unprotected sex with PrEP use are simply reacting rationally to exogenous 
market changes imposed by HIV prevention programmes, and should not face blame or 
stigma as a result. Instead, any unintended consequences of alternate product 
introduction should be fully considered by programme implementers through collection 
of reliable data on act price and condom use, alongside data on coercion from clients to 
provide condomless sex.  
313 
 
This paper is the first to estimate the effect of new HIV prevention products on the 
supply of condomless commercial sex. These findings are important for HIV prevention 
programmes among FSWs as they suggest that condom use may fall after the 
introduction of new, highly effective HIV prevention products, in part due to the 
increased importance of act price.  
There are strong scientific, economic, and human rights arguments for implementing 
new HIV prevention products, such as oral PrEP and future alternatives, among FSWs as 
soon as possible [1], and rollout has begun in many countries including South Africa[21]. 
The findings of this study do not reduce the public health imperative to make effective 
HIV prevention products available to FSWs, rather we suggest three things: 1) any 
unintended consequences of new product implementation should be explicitly 
measured to assess how the incentive structure of sex work will change as a result of 
introduction; 2) FSWs who may struggle to adhere consistently to new products should 
be identified and supported in their adherence, particularly if they are also women who 
are less able to use condoms consistently; and 3) the impact of new HIV prevention 
product provision on client attitudes and demands for protected and condomless sex 
should be monitored, as clients (who already have a strong bargaining position) may 
place excessive pressure on FSWs perceived to be using alternate protection to provide 
condomless sex. More research is needed to investigate the extent to which substitution 
away from condoms occurs following the introduction of different PrEP modalities (i.e. 
a daily tablet, monthly vaginal ring, six-weekly injection), and to explore how rational 
economic responses to introduction will affect its impact and cost-effectiveness.  
This paper has several limitations. First, the DCE is a simplistic representation of choices 
in sex work. The description of product use, describing a perfectly effective product with 
no adherence requirements, does not reflect the imperfect effectiveness of a product 
such as oral PrEP, and we acknowledge that this may overstate that behavioural 
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response to HIV protection. In fact, the product profile does not represent the most 
optimistic scenario of protection from a long-acting injectable. However, this simplistic 
representation was a pragmatic decision to simplify the choice task itself after extensive 
piloting showed that participants found it difficult to understand frames describing 
imperfect effectiveness or additional protection from STIs. It is also unrealistic to assume 
that FSWs can reliably judge client STI or HIV status. Importantly, the uptake of oral PrEP 
in demonstration projects and through the health system has been lower than 
anticipated [58], perhaps because real experience of products provides greater 
opportunity to make decisions about multiple risks. 
Second, the choice task itself assumes that FSWs have a substantial degree of agency over 
their choice of clients which may not be accurate. However, qualitative research during 
the design of this study suggests that the large pool of potential clients in this particular 
setting makes this a reasonable assumption [35], whilst the RDS sample necessarily 
identified FSWs with some link to peer-educators who are likely to have higher self-
efficacy than FSWs not reached by clinical or peer networks. This assumption may not 
hold for other sex work contexts in South Africa, or beyond.  
Third, we use stated preference data on FSW choices because observational revealed 
preference data from PrEP trials (the newest HIV prevention option to be implemented) 
or programmes is not yet available. Reassuringly, however, evidence from health 
focused studies suggests that stated and revealed preferences may be closely correlated 
[29, 30], whilst even if available, revealed preference data may still be subject to 
reporting biases.  
Fourth, we do not consider the demand side of the commercial sex market, specifically 
the impact of alternate product use among FSWs on the preferences of clients. If clients 
know, or perceive FSWs to be using an alternate product such as PrEP, they could use 
the reduced risk of HIV acquisition in coercive arguments for unprotected sex. Finally, 
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the diverse nature of sex work within South Africa and across sub-Saharan Africa makes 
generalisability difficult to assess from this small sample of FSWs. 
Conclusion 
We explored how the introduction of effective HIV prevention products might influence 
the economics and supply of condomless commercial sex. By applying stated preference 
methods in the form of a repeated discrete choice experiment, we show that introducing 
an 100% effective HIV prevention product may double the number of condomless acts 
supplied, and considerably reduce (by 73%) the price premium for condomless sex 
through decreasing the value placed on condoms and increasing the utility obtained 
from act price. These findings have implications for the possible impact of new HIV 
prevention product rollout, among FSW groups, which is proceeding worldwide, 
especially in scenarios where women may find adherence to tablet based prevention 
difficult. In these settings, the reduced use of condoms may reduce the impact of an 
alternate HIV prevention product. Further research is needed on the revealed 
preferences of FSWs and clients to assess how new products such as PrEP and associated 
economic incentives related to condomless sex affect health choices in commercial sex 
to allow appropriate support interventions to be put in place. 
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Supplementary Appendix I: Willingness to accept ratios  
  WTA: No framing MNL 
WTA: PrEP framed 
MMNL 
  Coeff.  SE Coeff.  SE 
Price 1 - - 1 - - 
Condom use       
 Condom*PrEP framing 11721.8  10436.5 3184.3 *** 804.9 
Type of sex       
 Anal*PrEP framing -7529.0  6907.2 -2572.1 *** 709.4 
Perceived client HIV risk       
 Think client has HIV*PrEP framing -1240.4  1117.4 -207.3 ** 87.2 
Perceived client STI risk       
 Think client has STI*PrEP framing -2156.5  2150.7 -549.3 *** 174.1 
Opt-out (no services to either)       
 Opt-out*PrEP framing 3795.5  3135.1 860.6 *** 227.1 
 
  
320 
 
Conclusions from paper R3 
Paper R3 is the first to estimate the impact of new HIV prevention products on the supply 
of condomless commercial sex. It provides evidence that introducing effective HIV 
prevention products may cause a change in condom use and pricing behaviours among 
FSWs, potentially leading to an increase in the supply of condomless commercial sex. It 
is possible that introducing effective new products might exacerbate pressures on FSWs 
to provide condomless sex. Since oral PrEP, as currently provided in South Africa, does 
not protect against other STIs or unwanted pregnancy, increases in condomless sex may 
lead to increases in these. Furthermore, if HIV prevention products cannot be used 
effectively by FSWs, or if they stimulate a change in risky behaviours as a result of 
changing economics, such as leading to an increase in the provision of commercial acts, 
the impact of PrEP may be substantially reduced. 
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Chapter 9: Paper R4 – How could risk 
compensation change the impact of new HIV 
prevention products? Modelling stated 
preference evidence from female sex workers 
Overview of paper R4 
Paper R3 provides evidence that introducing effective HIV prevention products may lead 
to a decrease in the price premium for unprotected sex, and a potential increase in the 
supply of condomless sex. This paper, R4, uses simulations from this DCE to 
parameterise scenarios in a dynamic transmission model. In addition, it incorporates 
economic theory to describe how labour supply can be impacted by changing financial 
incentives for work. This paper meets objective 4 to explore if changing incentives in sex 
work could substantially impact the impact of HIV prevention products through risk 
compensation.  
This paper has been prepared for submission to Health Economics, and is awaiting co-
author comments ahead of submission.  
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Abstract  
Female sex workers (FSWs) face substantial health risks, not least through exposure to 
HIV and other sexually transmitted infections (STIs). Many groups face these, however 
FSW choices are complicated by the existence of financial incentives to provide riskier 
services to clients, such as unprotected sex, for an increased price. The development and 
early roll-out of efficacious pre-exposure prophylaxis (PrEP) for HIV prevention offers 
promise in enabling FSWs to protect themselves from HIV without relying on clients to 
use a condom. Yet a lower risk associated with providing unprotected sex, coupled with 
financial incentives to do so, may lead to risk compensation: a reduction in condom use, 
an increase in the amount of sex supplied, or both. This paper integrates economic 
theory into a dynamic transmission model to explore how risk compensation might 
change the impact of PrEP. Scenarios modelling changes in condom use and the quantity 
of unprotected sex supplied were parameterised by combining simulations from stated 
preference data with microeconomic theory. Competition between PrEP users and non-
users was also considered. Results indicate that the impact of PrEP could be highly 
sensitive to risk compensatory behaviours, including those driven by changes in the 
economics of sex work. In addition, the extent to which competition affects the 
behaviours of non-PrEP users is also important to results. We find that current 
transmission models, which do not commonly consider risk compensation, may 
overestimate the impact of HIV prevention products. Further research is needed to 
explore potential risk compensatory behaviours among FSWs and clients, and data is 
required to assess the impact of non-user behaviour. 
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Introduction 
Women engaged in commercial sex, or female sex workers (FSWs), face daily health 
risks, not least from sexually transmitted infections (STIs) including the human 
immunodeficiency virus (HIV)[1]. In some areas of sub-Saharan Africa, the HIV 
prevalence among FSWs is estimated to be at least 50%[2] and as a result FSWs and their 
clients are termed key populations in the HIV response[1]. Like other key populations 
enhanced HIV testing, treatment, and prevention programmes are frequently focused on 
FSW and client populations[1].  
FSWs face different choices and incentives from other key populations. In addition to 
navigating the complexities of non-commercial sexual relationships, the economic 
context of sex work means that FSWs can face strong price competition from other 
commercial sex providers, alongside client resistance to condom use, including threats 
and use of violence[3-6]. In many circumstances FSWs are financially dependent on sex 
work to support themselves and their families[7].  
A large body of economic research on sex work has shown that financial incentives are 
positively correlated with the HIV, STI, and pregnancy risk borne by FSWs. In all 
published econometric studies to-date, a compensating differential, or price premium, 
has been shown to exist for unprotected sex compared to protected sex. Anecdotal 
evidence of this differential (e.g. [6]) was first empirically estimated by Rao et al.[8] who 
found a price premium of 79% for unprotected sex among Indian FSWs, terming this the 
condom differential. Further econometric evidence has estimated a price premium 
between 7% (Belgium and the Netherlands) and 81% (Bangladesh)[8-14]. In addition, 
evidence has shown that the size of the price premium depends on workplace conditions, 
and the bargaining power of FSWs[15]. Similar patterns have been seen in data from 
male sex workers, although risks and market factors differ substantively from those 
facing FSWs[16].  
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Recent technological developments have led to the development of antiretroviral-based 
HIV prevention products, for use as pre-exposure prophylaxis (PrEP)[17]. When used 
effectively, PrEP products, which currently exist in oral tablet, topical gel and 
intravaginal ring form, have been shown to offer very high levels of HIV protection[18]. 
Yet PrEP effectiveness – a function of product efficacy and adherence – has been shown 
to vary across different population groups and in different contexts, whilst products to-
date only offer protection from HIV, and not STIs or pregnancy (ibid.). As such, condoms 
remain a critical part of the HIV prevention armoury, and PrEP users are encouraged to 
use condoms consistently alongside ARV-based products[19].  
In a standard consumer demand model, agents respond to technologies that reduce the 
risk of a utility-providing behaviour by increasing consumption of this behaviour. In 
other words, if PrEP reduces the risk associated with unprotected sex, then FSWs may 
increase the quantity of unprotected sex that they supply. This response, termed risk 
compensation, means that the anticipated impact of PrEP may be smaller than predicted 
[20]. In recent years, developments in the science of HIV prevention have been met with 
concerns that risk compensation may mitigate the impact of interventions on the 
epidemic (e.g. [21, 22]). If individuals overestimate the benefits of interventions, or if 
there are externalities associated with the behaviour, risk compensatory behaviours 
may even lead to interventions having a negative overall impact on welfare. This paper 
explores this hypothesis. 
This paper makes three contributions to the economic and epidemiological literatures 
on risk compensation in HIV prevention. Firstly, this is the first study to explicitly 
integrate economic behaviour into a HIV transmission model. Specifically, we set the 
amount of condom-protected and unprotected sex supplied to be dependent on 
economic considerations of act-price and the behavioural economic concept of income 
targeting[23], obtained from stated preference data. Secondly, we explicitly model 
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competition between prep-using and non-using FSWs to account for the externalities 
associated with risk compensation in a competitive market. We assume that demand for 
unprotected sex among clients is persistent, and the PrEP-using section of the market is 
willing to provide this at a lower price. Thus, to remain competitive, non-users must 
adjust their willingness to accept risk. Thirdly, this is the first study to explicitly model 
risk compensation among FSWs based on empirical (stated preference) data. 
There has been no published evidence to-date from FSW populations that condom use 
is markedly reduced under PrEP use (e.g. [24]). Yet condom use data are largely self-
reported and subject to acceptability biases [25, 26]. Studies among other groups of PrEP 
users have detected increased STI rates among PrEP users than non-users, an objective 
indication of increased levels of condomless sex [27-30].  
This study uses stated preference data to parameterise a mathematical dynamic 
transmission model of HIV infection among FSWs and clients. Mathematical models are 
widely used to estimate the potential impact and cost-effectiveness of HIV treatment and 
prevention interventions among FSWs, including PrEP (e.g. [31-35]). To-date, only a 
handful of models explicitly account for condom substitution or other forms of risk 
compensation. When modelled, the existence and magnitude of condom substitution due 
to PrEP has not been driven by data or a strong theoretical justification. Foss et al.[36] 
and Grant et al.[37] predict that condom substitution could only be tolerated among 
FSWs with lower levels of condom use, or if the effectiveness of PrEP was higher than 
currently estimated (>75%). Mitchell et al.[38] found that a 50% reduction in condom 
use by PrEP users would negate the beneficial impact of PrEP. Among MSM in the UK, 
Punyacharoensin et al.[39] estimated that PrEP effectiveness would be significantly 
reduced if the amount of condomless sex or number of sexual partners increased by 
50%. 
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In a previous study, we used a hypothetical discrete choice experiment (DCE) to show 
that PrEP is likely to substantively impact the economics of sex work[40]9. DCEs are 
commonly applied in health to elicit preferences for products or services before they are 
introduced[41], and have been shown to have reasonable predictive accuracy[42]10 . 
Specifically, we found that condoms became less influential and price became more 
influential under PrEP use. Behavioural simulations from the DCE suggest that the 
condom differential, the price of unprotected sex relative to that of protected sex, would 
fall by 73% from ZAR 411 to ZAR 172 whilst the amount of unprotected sex supplied 
could more than double, increasing by a factor of 2.3. 
Although interesting, these findings do not immediately tell us how the impact of PrEP 
could be affected by changes to the economics of sex work. Therefore, in this paper we 
combine these results with theory from classical and behavioural microeconomics to 
explore how the PrEP impact might be affected by changes in the economics of 
commercial sex. We parameterise a compartmental dynamic transmission model to 
represent a generic sub-Saharan African HIV epidemic among FSWs and their clients. To 
get an understanding of how the impact of PrEP use could be affected by economic 
effects, we take a stepwise approach including five scenarios, with each scenario 
incorporating additional complexity.  
Methods 
We parameterised a deterministic, compartmental dynamic model of HIV transmission 
among FSWs and male clients to match the characteristics of a generic, large sub-Saharan 
Africa HIV epidemic.  
In the following five scenarios, we introduce additional complexity from economic 
theory at each stage: 
                                                             
9 Chapter 11 of this thesis 
10 Chapter 5 of this thesis 
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Scenario 1 makes the same assumption as many mathematical models, of no condom 
substitution due to PrEP use.  
Scenario 2 uses simulations from the DCE to predict the degree of condom substitution 
that would occur amongst PrEP users, holding all other sexual behaviours and condom 
use in non-PrEP users constant.  
Scenario 3. Since the DCE predicts that PrEP users will accept a (73%) lower price to 
provide unprotected sex compared to non-users, this scenario uses a theory from 
microeconomics – the target income hypothesis – to hypothesise that FSWs on PrEP will 
increase their frequency of commercial sex to compensate for this reduction in income 
to ensure a the same income.  
Scenarios 4 and 5 take a whole-market perspective to acknowledge that the behaviour 
of PrEP non-users may be affected by that of PrEP users, depending on the extent of PrEP 
coverage, due to competition in supply to a limited client base. To our knowledge this is 
the first mathematical model of infectious disease to explicitly incorporate behavioural 
patterns from economic theory.  
Building economics into a transmission model 
This section demonstrates how we allow economic factors to influence the behaviours 
which are important to an infectious disease model. In the simplest economic model, 
income is defined as the price of a good multiplied by the quantity supplied. Here we 
assume that FSWs only provide commercial sex acts, which can be a) condom-protected 
(denoted by the subscript c), or b) condom-less or unprotected (denoted by the subscript 
nc). Thus: 
𝑀𝑗
𝑘 = 𝑄𝑐𝑗
𝑘 ∗ 𝑃𝑐𝑗
𝑘 + 𝑄𝑛𝑐𝑗
𝑘 ∗ 𝑃𝑛𝑐𝑗
𝑘  (1) 
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Where M represents the total income from sex work, 𝑄𝑛𝑐
𝑘  and 𝑄𝑐
𝑘  are the number of 
condomless and protected sex acts supplied, respectively, and 𝑃𝑛𝑐
𝑘  and 𝑃𝑐
𝑘 are the price 
paid for condomless and protected sex acts, respectively. We divide FSWs into categories 
𝑘 = {𝑝𝑟𝑒𝑝, 𝑛𝑜𝑝𝑟𝑒𝑝} for each scenario 𝑗 = (1,2,3,4,5), where j=1 refers to the baseline 
scenario where PrEP has not been introduced.  
As discussed, the economic literature has explored the dynamics of 𝑃𝑐
𝑘  and 𝑃𝑛𝑐
𝑘 , 
specifically the distance between prices (the condom differential) and changes 
associated with the health risks associated with each type of act. However, the important 
parameters for an HIV transmission model are not the price but the quantity and type of 
sex acts in the market. 
If we assume the level of condom use for PrEP users and non-users (k) is 𝜋𝑗
𝑘 for each 
scenario (of how PrEP use effects condom use (j=1,..,5)), then the number of protected 
and condomless sex acts can be defined as follows: 
𝑄𝑐𝑗
𝑘 = 𝑁𝑗
𝑘(𝜋𝑗
𝑘) (2) 
𝑄𝑛𝑐𝑗
𝑘 = 𝑁𝑗
𝑘(1 − 𝜋𝑗
𝑘) (3) 
 
Where 𝑁𝑗
𝑘  is the number of sex acts for PrEP users and non-users in each scenario. 
Substituting (2) and (3) into (1) and factorising: 
𝑀𝑗
𝑘 = 𝑁𝑗
𝑘(𝜋𝑗
𝑘 × 𝑃𝑐𝑗
𝑘 + (1 − 𝜋𝑗
𝑘) × 𝑃𝑛𝑐𝑗
𝑘 ) (4) 
 
The DCE results allow us to predict the relative change in the frequency of condomless 
sex compared to condom-protected sex for FSWs that start using PrEP, 𝜌𝑗
𝑝𝑟𝑒𝑝
 and 
𝜌𝑗
𝑛𝑜𝑝𝑟𝑒𝑝
. We use the parameter 𝜌𝑗
𝑘 to adjust how baseline condom use, 𝜋1
𝑘, is affected in 
each scenario. 
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𝜋𝑗
𝑘 = 1 − (1 − 𝜋1
𝑘)𝜌𝑗
𝑘 (5) 
 
Predicting risk compensation from stated preference data 
The DCE study [40]11 estimated that use of an effective HIV prevention product would 
reduce the amount of money a FSW would need to compensate for the disutility of 
providing unprotected sex to a client. We use predicted probability analysis to simulate 
the impact of a fully effective prevention product on the price and supply of protected 
and condomless sex. As elsewhere in the health literature [43-45], we predict the supply 
response to product introduction by summing the model coefficients with imputed 
attribute levels. As best-practice in predicting with stated preference data, we rescale 
results for simulation using revealed preference data. We hold the price of protected sex 
constant (ZAR 72, USD $5.41) take the absolute price premium as self-reported by FSWs 
(ZAR 394, USD $29.50), and reduce it by 73% to generate the new price of condomless 
sex (ZAR 106, $8). 
Description of transmission model 
The model structure is relatively simple, and divides HIV negative FSWs by PrEP status, 
and HIV positive clients and FSWs by acute, chronic, and AIDS state infections alongside 
engagement with antiretroviral treatment (ART). In addition to cessation of FSW or 
client status, individuals leave the population due to natural mortality from all 
compartments, or AIDS-related mortality from AIDS compartments. ART users are 
assumed to progress through the same acute-chronic-AIDS stages of HIV infection as 
non-users, but at a slower rate. ART dropout is modelled, with reinitiation assumed to 
be the same rate as ART-naive individuals. ART initiation is assumed to occur in chronic 
and AIDS stages, but not at acute infection. 
                                                             
11 Chapter 11 of this thesis 
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Individuals enter the model in the HIV negative or chronic compartments according to 
estimates of HIV prevalence in the general population. The infectivity of HIV positive 
persons is assumed higher in acute and AIDS stages relative to chronic infection. 
Infectivity is reduced for persons using ART.  
The transmission model 
Figure 1 shows the model structure, and the generalised model as a system of differential 
equations is shown below.  
Figure 1: Model structure 
 
Female sex workers 
𝑑𝑋1,𝑖
𝐹𝑆𝑊
𝑑𝑡
= (1 − 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒𝑖
𝐹𝑆𝑊)𝑇𝑖
𝐹𝑆𝑊(𝜁𝑖
𝐹𝑆𝑊 + µ) + 𝑋2,𝑖
𝐹𝑆𝑊𝜓𝑖 − 𝑋1,𝑖
𝐹𝑆𝑊𝜆𝑖
𝑛𝑜𝑝𝑟𝑒𝑝 − 𝑋1,𝑖
𝐹𝑆𝑊(𝜏𝑖
+ 𝜁𝑖
𝐹𝑆𝑊 + µ) 
𝑑𝑋2,𝑖
𝐹𝑆𝑊
𝑑𝑡
= 𝑋1,𝑖
𝐹𝑆𝑊𝜏𝑖 − 𝑋2,𝑖
𝐹𝑆𝑊𝜆𝑖
𝑝𝑟𝑒𝑝 − 𝑋2,𝑖
𝐹𝑆𝑊(𝜓𝑖 + 𝜁𝑖
𝐹𝑆𝑊 + µ) 
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𝑑𝑌11,𝑖
𝐹𝑆𝑊
𝑑𝑡
= 𝑋1,𝑖
𝐹𝑆𝑊𝜆𝑖
𝑛𝑜𝑝𝑟𝑒𝑝 + 𝑋2,𝑖
𝐹𝑆𝑊𝜆𝑖
𝑝𝑟𝑒𝑝 − 𝑌11,𝑖
𝐹𝑆𝑊(𝛾0,𝑖 + 𝜁𝑖
𝐹𝑆𝑊 + µ) 
𝑑𝑌21,𝑖
𝐹𝑆𝑊
𝑑𝑡
= 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒𝑖
𝐹𝑆𝑊𝑇𝑖
𝐹𝑆𝑊(𝜁𝑖
𝐹𝑆𝑊 + µ) + 𝑌11,𝑖
𝐹𝑆𝑊𝛾0,𝑖 + 𝑌22,𝑖
𝐹𝑆𝑊𝜔𝑖
− 𝑌21,𝑖
𝐹𝑆𝑊(𝛾1,𝑖 + 𝜎𝑖 + 𝜁𝑖
𝐹𝑆𝑊 + µ) 
𝑑𝑌31,𝑖
𝐹𝑆𝑊
𝑑𝑡
= 𝑌21,𝑖
𝐹𝑆𝑊𝛾1,𝑖 + 𝑌32,𝑖
𝐹𝑆𝑊𝜔𝑖 − 𝑌31,𝑖
𝐹𝑆𝑊(𝛾2,𝑖 + 𝜎𝑖 + 𝜁𝑖
𝐹𝑆𝑊 + µ) 
𝑑𝑌22,𝑖
𝐹𝑆𝑊
𝑑𝑡
= 𝑌21,𝑖
𝐹𝑆𝑊𝜎𝑖 − 𝑌22,𝑖
𝐹𝑆𝑊(𝜅𝛾1,𝑖 + 𝜔𝑖 + 𝜁𝑖
𝐹𝑆𝑊 + µ) 
𝑑𝑌32,𝑖
𝐹𝑆𝑊
𝑑𝑡
= 𝑌22,𝑖
𝐹𝑆𝑊𝜅𝛾1,𝑖 + 𝑌31,𝑖
𝐹𝑆𝑊𝜎𝑖 − 𝑌32,𝑖
𝐹𝑆𝑊(𝜅𝛾2,𝑖 + 𝜔𝑖 + 𝜁𝑖
𝐹𝑆𝑊 + µ) 
Clients 
𝑑𝑋1,𝑖
𝑐𝑙𝑖𝑒𝑛𝑡
𝑑𝑡
= (1 − 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒𝑖
𝑐𝑙𝑖𝑒𝑛𝑡)𝑇𝑖
𝑐𝑙𝑖𝑒𝑛𝑡(𝜁𝑖
𝑐𝑙𝑖𝑒𝑛𝑡 + µ) − 𝑋1,𝑖
𝑐𝑙𝑖𝑒𝑛𝑡𝜆𝑖
𝑛𝑜𝑝𝑟𝑒𝑝 − 𝑋1,𝑖
𝑐𝑙𝑖𝑒𝑛𝑡(𝜁𝑖
𝑐𝑙𝑖𝑒𝑛𝑡
+ µ) 
𝑑𝑌11,𝑖
𝑐𝑙𝑖𝑒𝑛𝑡
𝑑𝑡
= 𝑋1,𝑖
𝑐𝑙𝑖𝑒𝑛𝑡𝜆𝑖
𝑛𝑜𝑝𝑟𝑒𝑝 − 𝑌11,𝑖
𝑐𝑙𝑖𝑒𝑛𝑡(𝛾0,𝑖 + 𝜁𝑖
𝑐𝑙𝑖𝑒𝑛𝑡 + µ) 
𝑑𝑌21,𝑖
𝑐𝑙𝑖𝑒𝑛𝑡
𝑑𝑡
= 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒𝑖
𝐹𝑆𝑊𝑇𝑖
𝑐𝑙𝑖𝑒𝑛𝑡(𝜁𝑖
𝑐𝑙𝑖𝑒𝑛𝑡 + µ) + 𝑌11,𝑖
𝑐𝑙𝑖𝑒𝑛𝑡𝛾0,𝑖 + 𝑌22,𝑖
𝑐𝑙𝑖𝑒𝑛𝑡𝜔𝑖 − 𝑌21,𝑖
𝑐𝑙𝑖𝑒𝑛𝑡(𝜎𝑖
+ 𝛾1,𝑖 + 𝜁𝑖
𝑐𝑙𝑖𝑒𝑛𝑡 + µ) 
𝑑𝑌31,𝑖
𝑐𝑙𝑖𝑒𝑛𝑡
𝑑𝑡
= 𝑌21,𝑖
𝑐𝑙𝑖𝑒𝑛𝑡𝛾1,𝑖 + 𝑌32,𝑖
𝑐𝑙𝑖𝑒𝑛𝑡𝜔𝑖 − 𝑌31,𝑖
𝑐𝑙𝑖𝑒𝑛𝑡(𝛾2,𝑖 + 𝜎𝑖 + 𝜁𝑖
𝑐𝑙𝑖𝑒𝑛𝑡 + µ) 
𝑑𝑌22,𝑖
𝑐𝑙𝑖𝑒𝑛𝑡
𝑑𝑡
= 𝑌21,𝑖
𝑐𝑙𝑖𝑒𝑛𝑡𝜎𝑖 − 𝑌22,𝑖
𝑐𝑙𝑖𝑒𝑛𝑡(𝜅𝛾1,𝑖 + 𝜔𝑖 + 𝜁𝑖
𝑐𝑙𝑖𝑒𝑛𝑡 + µ) 
𝑑𝑌32,𝑖
𝑐𝑙𝑖𝑒𝑛𝑡
𝑑𝑡
= 𝑌22,𝑖
𝑐𝑙𝑖𝑒𝑛𝑡𝜅𝛾1,𝑖 + 𝑌31,𝑖
𝑐𝑙𝑖𝑒𝑛𝑡𝜎𝑖 − 𝑌32,𝑖
𝑐𝑙𝑖𝑒𝑛𝑡(𝜅𝛾2,𝑖 + 𝜔𝑖 + 𝜁𝑖
𝑐𝑙𝑖𝑒𝑛𝑡 + µ) 
We define 𝜃  as the overall effectiveness of PrEP incorporating those that use PrEP 
adherently or not, βmf the per act transmission probability from a HIV positive male to a 
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HIV negative female and vice versa forβfm, and 𝜀 the efficacy of condoms. The force of 
infection for FSWs using and not using PrEP in scenario j are presented below, where 
𝑇𝑐𝑙𝑖𝑒𝑛𝑡  and 𝑇𝐹𝑆𝑊  represent the total number of clients and FSWs, 𝜂𝑎𝑐𝑢𝑡𝑒 , and 𝜂𝐴𝐼𝐷𝑆 
represent heightened transmissibility of HIV positive persons in acute and AIDS stages 
respectively , and 𝜂𝐴𝑅𝑇 reduced transmissibility attributable to ART use: 
𝜆𝐹𝑆𝑊
𝑝𝑟𝑒𝑝 = βmf ∗ [𝑁𝐹𝑆𝑊,𝑗
𝑝𝑟𝑒𝑝
∗ (
𝜂𝑎𝑐𝑢𝑡𝑒𝑌11
𝑐𝑙𝑖𝑒𝑛𝑡 + 𝑌21
𝑐𝑙𝑖𝑒𝑛𝑡 + 𝜂𝐴𝐼𝐷𝑆𝑌31
𝑐𝑙𝑖𝑒𝑛𝑡 + 𝜂𝐴𝑅𝑇(𝑌22
𝑐𝑙𝑖𝑒𝑛𝑡 + 𝑌32
𝑐𝑙𝑖𝑒𝑛𝑡)
𝑇𝑐𝑙𝑖𝑒𝑛𝑡
)]
∗ [(1 − 𝜀𝜋𝑗
𝑝𝑟𝑒𝑝) ∗ (1 − 𝜃)] 
𝜆𝐹𝑆𝑊
𝑛𝑜𝑝𝑟𝑒𝑝 = βmf ∗ [𝑁𝐹𝑆𝑊,𝑗
𝑛𝑜𝑝𝑟𝑒𝑝
∗ (
𝜂𝑎𝑐𝑢𝑡𝑒𝑌11
𝑐𝑙𝑖𝑒𝑛𝑡 + 𝑌21
𝑐𝑙𝑖𝑒𝑛𝑡 + 𝜂𝐴𝐼𝐷𝑆𝑌31
𝑐𝑙𝑖𝑒𝑛𝑡 + 𝜂𝐴𝑅𝑇(𝑌22
𝑐𝑙𝑖𝑒𝑛𝑡 + 𝑌32
𝑐𝑙𝑖𝑒𝑛𝑡)
𝑇𝑐𝑙𝑖𝑒𝑛𝑡
)]
∗ (1 − 𝜀𝜋𝑗
𝑛𝑜𝑝𝑟𝑒𝑝)  
𝜆𝐶𝐿𝐼𝐸𝑁𝑇
𝑛𝑜𝑝𝑟𝑒𝑝 = βfm ∗ [𝑁𝐶𝐿𝐼𝐸𝑁𝑇,𝑗
𝑛𝑜𝑝𝑟𝑒𝑝
∗ (
𝜂𝑎𝑐𝑢𝑡𝑒𝑌11
𝐹𝑆𝑊 + 𝑌21
𝐹𝑆𝑊 + 𝜂𝐴𝐼𝐷𝑆𝑌31
𝐹𝑆𝑊 + 𝜂𝐴𝑅𝑇(𝑌22
𝐹𝑆𝑊 + 𝑌32
𝐹𝑆𝑊)
𝑇𝐹𝑆𝑊
)]
∗ (1 − 𝜀𝜋𝑗
𝑛𝑜𝑝𝑟𝑒𝑝)  
Model parameterisation  
The size of the FSW population was assumed to be 132,000 as estimated for South Africa 
in 2013[46] and the client population ten times this based on a population balance 
equation. FSWs cease sex work at a rate of 14% per year (𝜁𝐹𝑆𝑊)which assumes the 
average length of time in sex work as seven years, the third quartile of self-reported time 
in sex work in a 2015 cross-sectional survey of FSWs in South Africa[47]. We assume 
that clients cease sex work at a rate of 10% per year (𝜁𝑐𝑙𝑖𝑒𝑛𝑡), implying that individuals 
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are clients for, on average, ten years. The rate of entry to being a FSW or client was 
assumed equal to the exit rate of both before accounting for HIV-related death.  
Self-reported estimates of condom use can be higher than reality due to acceptability 
bias[26]. The DCE survey in South Africa asked a number of questions which aimed to 
estimate condom use, as described in supplementary Table S1. We use the middle value 
of these to parameterise condom use, the proportion of FSWs who reported charging 
any price for unprotected acts, at 78%. For the simplest PrEP scenario modelled, we 
assume this remains unchanged among both PrEP users and non-PrEP users i.e. there is 
no condom substitution. In later scenarios, we model the impact of condom substitution. 
Parameters for the baseline number of sex acts provided by FSWs per month (33) were 
also taken from the primary survey in South Africa[40]; this parameter was found to be 
within the interquartile range of other FSW surveys in South Africa[48].  
Biological parameters and the efficacy of condoms and ART in preventing HIV 
transmission were obtained from published literature. The multiplicative factors by 
which the probability of HIV transmission during the AIDS and acute HIV phases are 
increased compared to the chronic stage are taken from meta-analysis data[49]. The 
effectiveness of ART in reducing progression to the AIDS state and death is assumed to 
be 92%, taken from published studies[50, 51]. Details of model parameters are included 
in Table 1. 
 
 
 
336 
 
Table 1: Summary of model parameters 
Parameter Symbol Value Lower Upper Source 
FSW population size 𝑇𝐹𝑆𝑊  132000 131000 182000 [46] 
Client population size 𝑇𝑐𝑙𝑖𝑒𝑛𝑡   
PrEP uptake rate 𝜏 15% 5% 30% [47] 
PrEP dropout rate 𝛹 20%   Assumption as in [38] 
Condom efficacy 𝜀 80% 66% 94% [52] 
Treatment initiation rate 𝜎 0.3654 0.3132 0.4698 58% [47], 63% linking per year [53] 
ART failure rate 𝜔 0.04 0.01 0.07 [54] 
Multiplicative factor modelling the 
reduced progression to AIDS due to 
ART treatment 𝜒 0.3   Assumption as in [38] 
Natural death rate (FSWs and clients) 𝜇        0.02    1/ life expectancy of 62.4 [55] 
Exit rate from sex work 𝜁𝐹𝑆𝑊 0.1333333   Upper IQR [47]  
Exit rate from being a client 𝜁𝑐𝑙𝑖𝑒𝑛𝑡  0.098 0.091 0.105 Assumption as in [38] 
1/Duration of acute HIV stage 𝛾1 0.242 0.103 0.381 [56] 
1/Duration of chronic stage 1/𝛾2 10.05 9.28 10.81 [56] 
1/Duration of AIDS stage 1/𝜅 0.83 0.61 1.06 [56] 
Multiplicative transmission factor in 
the acute stage 𝜂𝑎𝑐𝑢𝑡𝑒  11.65 4.5 18.8 [49] 
Multiplicative transmission factor in 
the AIDS stage 𝜂𝐴𝐼𝐷𝑆 8.15 4.4 11.9 [49] 
Multiplicative transmission factor due 
to treatment 𝜂𝑡 0.08 0 0.16 [50, 51] 
Female to male per act transmission 
probability 𝛽𝑓𝑚 0.0004   [57] 
Male to female per act transmission 
probability 𝛽𝑚𝑓     [57] 
Baseline condom use 𝜋 78%   As described, taken from [47] 
Starting FSW Prevalence  18%   Assumption 
Starting client prevalence  9.9% 8.90% 11% South Africa [58] 
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Gen pop male prevalence  9.90% 8.90% 11% South Africa [58] 
Gen pop female prevalence  14.40% 13.30% 15.60% South Africa [58] 
      
PrEP adherence  50/75% 0.5 0.75 Assumption 
Monthly clients seen by FSW  33 27 45 [47] 
Price of protected act  83   [47] 
Price of unprotected act  811   [47] 
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Model calibration 
We do not fit the model to a particular epidemic, but use general HIV prevalence and 
treatment coverage assumptions based on published data, including that from South 
Africa. A baseline HIV prevalence of 18% is seeded into the epidemic in 2004, 13 years 
before the assumed introduction of PrEP, and is in line with empirical estimates of FSW 
prevalence in the general population in South Africa [34]. The transmission parameter 
for male to female transmission (βmf) was reduced from a starting value of 0.008, as 
estimated by the US Centers for Disease Control[57], to 0.006 to give results in a stable 
HIV prevalence of 19% in 2017 when PrEP interventions are introduced. The female to 
male transmission parameters ( β𝑓𝑚 ) was assumed to be 0.004 (ibid.). Treatment 
coverage is broadly matched to observed scale-up from zero coverage in 2004 to around 
70% coverage in 2017.  
Impact analyses 
To make estimates of absolute changes to PrEP effectiveness conservative, PrEP efficacy 
was assumed to be 71%, the highest estimated among female groups in a PrEP trial to-
date[59], and we assume high and low adherence scenarios of 75% and 50%. PrEP 
impact is quantified as the absolute change in HIV infections compared to a 
counterfactual scenario of no rollout. Table 2 shows how economic parameters vary 
across scenarios. 
Base case PrEP use, no condom substitution 
The scenario 1 is the current approach used in many PrEP impact models, and does not 
account for potential economic influences on behaviour. As per the authors’ previous 
work predicting demand for PrEP among this group of FSW respondents, we estimate 
PrEP uptake to be 15%[60]12.  
                                                             
12 Chapter 10 of this thesis 
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Condom substitution response among PrEP users 
The DCE [40]13 predicted that under PrEP use, the price premium for condomless sex 
will fall by 73% (from ZAR 411 to ZAR 172 per condomless sex act) and the quantity of 
condomless sex will increase 2.3-fold, i.e. 𝜌𝑗𝑘 = 2.3. Substituting this into equation (5) 
suggests that, among PrEP users, the consistency of condom use 𝜋1
𝑝𝑟𝑒𝑝
 decreases from 
78% to 50% of sex acts, i.e. non-condom protected sex acts in PrEP users increases from 
22% to 22%*2.3=50.6% 
In this scenario, we assume that PrEP use only affects the condom use of FSWs using 
PrEP, and hold the level of condom use for non-PrEP users constant (i.e. assuming that 
there is no competition between these FSWs). We also assume no change in the total 
number of sex acts provided, and that PrEP use has no effect on the price charged for sex 
with a condom. This means that FSWs using PrEP will bear an 18% income reduction of 
ZAR 920 (USD $71) per week, whereas FSWs not using PrEP will see no reduction in 
income. 
Constant income hypothesis: adjusting quantity supplied 
This scenario extends scenario 2 by incorporating evidence from behavioural 
microeconomics, the target income hypothesis. Economic research has shown that, in 
contrast to the predictions of classical model, when suppliers are faced with an 
exogenous shock to wages, they adjust the quantity supplied to keep income constant 
within a particular period of time. The target income hypothesis, popularised in the 
seminal study by Camerer et al. [23], demonstrated that taxi drivers in New York City 
make supply decisions with a reference-dependent income target, cease working when 
it is reached – working less hours when wages are higher. Similar results, indicative of a 
backward-bending supply curve, have been found in studies among Singaporean taxi 
drivers [61] baseball stadium vendors [62], and Swiss bicycle messengers [63]. 
                                                             
13 Chapter 11 of this thesis 
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Following from this literature, in scenario 3 we assume that FSWs also respond to price 
shocks through pursuing an income target. As in scenario 2, we assume that the price of 
condomless sex falls by 73% under PrEP use, and the price of sex with a condom remains 
constant at 𝑃𝑛𝑐1
𝑝𝑟𝑒𝑝
. However, we assume that PrEP users increase their overall frequency 
of commercial sex to ensure the same income. We therefore want to find the new 
frequency of sex 𝑁3
𝑝𝑟𝑒𝑝
 which gives the same income, which we obtain through 
rearranging equation (4): 
𝑁3
𝑝𝑟𝑒𝑝 =
𝑀0
𝑝𝑟𝑒𝑝
𝑃𝑐0𝜋3
𝑝𝑟𝑒𝑝 + (1 − 𝜋3
𝑝𝑟𝑒𝑝
)𝛼𝑗𝑃𝑛𝑐0
𝑝𝑟𝑒𝑝 
(6) 
Where the ratio of prices for condomless sex with and without PrEP 𝛼𝑗 = 2.3, obtained 
from the DCE. We assume that the consistency of condom use among PrEP users 𝜋3
𝑝𝑟𝑒𝑝
 
is 50% of acts, as in scenario 2, but set the weekly income as fixed to the same level as 
before the introduction of PrEP (𝑀0
𝑝𝑟𝑒𝑝
=ZAR 5120 or USD $400). As before, we assume 
that the FSWs using PrEP have no impact on the level of condom use of non-PrEP users 
and does not affect the price they can charge for condomless sex. We consider the impact 
of this scenario for different PrEP coverage levels amongst FSW.  
A competitive market: Non-PrEP users change the amount of sex supplied  
The previous scenarios assume that only PrEP users respond to changing market 
conditions caused by the introduction of PrEP. A more realistic assumption would be 
that the dynamics of the commercial sex market would shift to some extent for all FSWs, 
not just those using PrEP, due to working in a competitive market. For example, non-
PrEP users would also face pressures to charge lower prices for condomless sex and/or 
increase their supply of condomless sex.  
We model the potential impact of this competition in scenarios 4 and 5. Scenario 4 
assumes that non-PrEP users face pressure to reduce the price of condomless sex due to 
the reduction in price by PrEP users. However, we assume that this will be related to the 
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uptake of PrEP; when PrEP uptake is low, non-PrEP users will only see a small effect of 
competition, whereas if PrEP use is higher, then non-users are more likely to feel the 
effect of competition.  
We account for this by using a parameter to mediate the extent to which the behaviour 
of non-PrEP users tends to that of PrEP users. This factor 𝐻𝑗
𝑛𝑜𝑝𝑟𝑒𝑝 = 𝛺𝑗𝑈𝑗  describes the 
extent by which overall PrEP uptake 𝑈𝑗  affects the behaviour of non-PrEP users 
according to a competition coefficient, 𝛺𝑗 bounded[0,1], which determines the extent to 
which uptake impacts behaviour. For example, if PrEP uptake is 20% and 𝛺𝑗 set to 1, 
then the price of condomless sex among non-PrEP users would be 20% closer to what it 
is among PrEP users compared to before PrEP. If 𝛺𝑗 is reduced to 0.5, then the impact of 
competition would be halved. In the base case, 𝛺𝑗 is set to 0.5 with variation explored in 
a sensitivity analysis. 
In scenario 4 we assume that non-PrEP users will not start providing more condomless 
sex, and hold condom use constant (i.e. set 𝜌𝑗
𝑛𝑜𝑝𝑟𝑒𝑝 = 1, though maintain 𝜌𝑗
𝑝𝑟𝑒𝑝 = 2.26). 
Instead, we assume that non-PrEP users will increase their total number of commercial 
sex acts to maintain their current income, while assuming a lower price for unprotected 
sex.  
To calculate the new price of unprotected sex among non-PrEP users, we relate the price 
of condomless sex among non-PrEP users to that of PrEP users using price values 
obtained from DCE simulation and factor 𝐻𝑗 (here listed as calculated in scenario 1): 
𝑃𝑛𝑐4
𝑛𝑜𝑝𝑟𝑒𝑝 = 𝑃𝑛𝑐1
𝑛𝑜𝑝𝑟𝑒𝑝 − 𝐻𝑗(𝑃𝑛𝑐1
𝑛𝑜𝑝𝑟𝑒𝑝 − 𝑃𝑛𝑐1
𝑝𝑟𝑒𝑝) (7) 
This value is substituted into equation (6) to calculate the number of acts provided by 
non-PrEP users. 
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A competitive market: Non-PrEP users change the amount and type of sex supplied  
In extension to scenario 4, instead of competition only inducing an increase in the 
number of acts among non-PrEP users, we assume that non-PrEP users change both the 
number ( 𝑁𝑗𝑘
𝑛𝑜𝑝𝑟𝑒𝑝
) and the type ( 𝜋𝑗𝑘
𝑛𝑜𝑝𝑟𝑒𝑝) of sex acts supplied according to the 
behaviours of PrEP users, i.e. they also increase their rate of unprotected sex acts based 
on the same competition coefficient that we hypothesised would affect the price of 
unprotected sex. Extending (5) we see that: 
𝜋𝑗
𝑛𝑜𝑝𝑟𝑒𝑝 = 𝜋1
𝑛𝑜𝑝𝑟𝑒𝑝 − 𝐻(𝜋1
𝑛𝑜𝑝𝑟𝑒𝑝 − 𝜋𝑗
𝑝𝑟𝑒𝑝) (8) 
  
We then substitute 𝜋𝑗
𝑛𝑜𝑝𝑟𝑒𝑝
 from equation (8) into equation (6). 
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Table 2: Variation in economic parameters  
  Counterfactual 
Scenario 1 
Base case, no 
condom 
substitution 
Scenario 2 
Condom substitution 
among PrEP users 
Scenario 3  
Constant income 
hypothesis – PrEP 
users increase the 
quantity supplied 
Scenario 4 
Competition – Non-
PrEP users increase 
the amount of sex 
supplied 
Scenario 5 
Competition – Non-
PrEP users change 
the amount and 
type of sex supplied 
  
PrEP 
users 
non-PrEP 
users 
PrEP 
users 
non-PrEP 
users 
PrEP 
users 
non-PrEP 
users 
PrEP 
users 
non-PrEP 
users 
PrEP 
users 
non-PrEP 
users 
PrEP 
users 
non-PrEP 
users 
Condom use N/A 78% 78% 78% 50% 78% 50% 78% 50% 78%* 50% 50-78%* 
Number of commercial sex 
acts per month N/A 33 33 33 33 33 40 33 40 33 40 33-40* 
Price of unprotected act N/A 411 411 411 172 411 172 411 172 172-411* 172 172-411* 
Price of protected act N/A 83 83 83 83 83 83 83 83 83 83 83 
Monthly income from sex 
work (ZAR) 
N/A 5,120 5,120 5,120 4,199 5,120 5,120 5,120 5,120 5,120 5,120 5,120 
                       
*Dependent on H=Ω*PrEP coverage. Parameters in bold signify marginal changes in each scenario as compared to the previous. ZAR 5120 = USD $385.26, 
ZAR 4199 = USD $316.
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Results 
Baseline prevalence and incidence trends 
Without a PrEP intervention and as shown in Figure 2, the model predicted a stable HIV 
epidemic for the period modelled between 2004 and 2037 with HIV prevalence in FSW 
predicted to be between 22 and 25% after being seeded at 25% initially. Client 
prevalence was seeded at 30% and increased, at a decreasing rate, to around 60% 
towards the end of the modelled period.  
Figure 2 shows projection of HIV prevalence under the scenarios modelled, with the 
baseline (no intervention) projection shown by the black line. Because we only model a 
low coverage of PrEP in this scenario, the impact achieved is not large for any scenario.  
Scenario 1: Base case, no condom substitution  
Scenario 1 (red line in Figure 2), where condom use is assumed to remain constant under 
PrEP use, shows the greatest reduction in HIV prevalence of all of those modelled. For 
the low adherence (50%) scenario, we project a 3.7% reduction in total HIV infections 
over the 20 years following the introduction of PrEP, corresponding to a 0.4 percentage 
point decrease in overall HIV prevalence. Conversely, for the high adherence (75%) 
scenario, we predicted an 5.7% reduction in total infections and a 0.6 percentage point 
decrease in HIV prevalence.  
Scenario 2: Condom substitution among PrEP users 
Scenario 2 (blue line in Figure 2) assumes that PrEP users engage in risk compensation 
and so increase the proportion of unprotected sex acts after PrEP initiation. Under the 
assumption of low (50%) adherence, the model suggests that risk compensation due to 
PrEP would stimulate sufficient risk compensation to negate its impact, resulting in a 
0.1% increase in total HIV infections over the 20 years after the introduction of PrEP. 
For the high adherence scenario (75%), the reduction in impact is less, with the decrease 
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in HIV infections reducing to 5.7% over 20 years and HIV prevalence reducing by 0.3 
percentage points.  
Figure 2: Impact of low or high adherence PrEP use on HIV prevalence among 
FSWs for different scenarios of how PrEP use affects frequency of, and condom use 
in, commercial sex acts  
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Figure 3: Percentage decrease in HIV infections amongst FSWs and clients over 20 
years for low and high adherence of PrEP use and different scenarios of how PrEP 
use affects frequency of, and condom use in, commercial sex acts 
Scenario 3: Constant income hypothesis – PrEP users increase the quantity 
supplied 
Scenario 3 (green line in Figure 2) assumes that, in addition to decreasing condom use, 
PrEP users also increase the quantity of sex supplied to keep income constant, reacting 
to the reduction in price due to the reduction in compensating differential. Under 
assumptions of high PrEP adherence (75%), projections suggest that PrEP will still have 
a small positive impact by reducing the number of HIV infections by 1% and prevalence 
after 20 years by 0.1 percentage points. Under the assumption of low (50%) adherence, 
the model suggests that risk compensation due to PrEP would lead to a 2.1% increase in 
the number of infections and an increase in HIV prevalence of 0.25 percentage points. 
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Scenario 4: Competition – Non-PrEP users increase the amount of sex 
supplied 
Scenario 4 (yellow line in Figure 2) assumes that all FSWs operate in one competitive 
market, regardless of PrEP status, and that non-PrEP users increase the quantity of sex 
supplied. The responsiveness of the quantity of sex supplied by non-PrEP users is 
increased by the product of the competition coefficient 𝛺𝑗, set to 0.5 in the base case, and 
PrEP coverage. Condom use among non-PrEP users is set to be constant and the same as 
before PrEP introduction.  
Assuming that competition increases the total sexual activity among non-PrEP users has 
a substantial effect on the estimated impact of PrEP. Under assumptions of high 
adherence, PrEP introduction is estimated to lead to a 0.3% decrease in the total number 
of HIV infections over the 20-year time horizon. However, lower adherence assumptions 
project a more pessimistic scenario where PrEP introduction is projected to increase the 
total number of HIV infections by 2.8%. 
Scenario 5: Competition – Non-PrEP users change the amount and type of 
sex supplied  
Scenario 5 (purple line in Figure 2) extends scenario 4 to assume that alongside 
increasing the quantity of unprotected acts supplied, non-PrEP users also reduce 
condom use according to the factor 𝛺𝑗 and PrEP coverage. When adherence to PrEP is 
high (75%), increases in the quantity of acts and decreasing condom use results in a 
0.2% increase in HIV infections, a 0.4 percentage point increase in prevalence. However, 
when adherence to PrEP is low (50%), overall HIV prevalence is estimated to increase 
by 0.04 percentage points, a 3.2% increase in the number of infections. 
Sensitivity analysis 
In addition to presenting scenarios of high and low adherence to PrEP, we conduct 
further one-way sensitivity analyses to examine the sensitivity of model results to key 
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assumptions. An important assumption behind the finding that PrEP may have an 
adverse impact on HIV prevalence is the assumption made about how competition in the 
market between PrEP users and non-users results in non-users providing a greater 
quantity of commercial sex acts (scenario 4) and decreasing their condom use (scenario 
5) to ensure they maintain their existing earnings. In the main analyses, we assume that 
the competition coefficient, 𝛺𝑗, is 0.5, i.e. non-PrEP user behaviours will be affected half 
as much as PrEP users. For the low and high adherence scenarios, Figure 4 shows the 
effect of assuming different values for 𝛺𝑗 on the impact of PrEP, in terms of the relative 
number of infections averted resulting from PrEP introduction. We find that, even when 
the effect of competition is very low (e.g. 𝛺𝑗 = 0.01), introducing PrEP may have an 
adverse impact. 
Figure 4: Variation in adverse impact of PrEP according to competition coefficient 
 
Nb. The higher the number, the higher the number of HIV infections  
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Discussion 
These results suggest that the impact of PrEP in reducing HIV infections will be highly 
sensitive to risk compensatory behaviours, including those driven by changes in 
economic incentives in sex work. The externalities of risk compensation among PrEP 
users, which we assume to influence the behaviour of non-PrEP users through 
participation in a single competitive market, are estimated to be particularly important 
to the effectiveness of PrEP. In line with other modelling studies, PrEP impact is highly 
dependent on adherence assumptions. 
This study is not intended to be a precise representation of a particular HIV epidemic or 
of how economic incentives could affect the impact of PrEP. These results will not 
perfectly predict the impact of PrEP, nor behavioural responses to its introduction. 
However, results are striking in the magnitude and implications of their predictions; 
specifically, that the impact of PrEP may be negated by risk compensation among PrEP 
users, consistent with evidence from economic research. In addition, when externalities 
of risk compensation are considered such that behaviours of non-PrEP users are 
influenced by those of PrEP users, this study suggests that introducing PrEP may have a 
negative overall impact, resulting in an increase in HIV infection transmission. 
Importantly, this is most likely if PrEP is being used with low adherence such that it has 
low efficacy.  
To-date, no studies have considered the effect of PrEP – or other preventative 
interventions – on the economics of sex work. A broad range of data are collected during 
trials and demonstration projects of HIV prevention products, which offer the 
opportunity to gather revealed preference data on the extent of risk compensatory 
behaviours. However, these studies do not generally collect data from FSWs who are not 
using PrEP, and are often dependent on self-reported condom use which can be biased. 
The results of this analysis demonstrate that changes in the behaviours of non-PrEP 
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users may be important in maximising the impact of PrEP programmes. Further research 
is needed to assess the real-world impact of interventions on the economics of sex work 
and how that then effects the behaviour of all FSWs, including, but not limited to, the 
extent that financial incentives for risky behaviours are modified by interventions. 
We do not consider changes in the demand side of the market. All scenarios assume 
perfect competition with unlimited demand for condomless sex among clients, where 
changes in individual supply do not affect demand, whilst the market continues to clear 
by reductions in price. An alternative interpretation, which we do not address in this 
paper, would consider demand for unprotected sex finite and satiated before the 
introduction of PrEP. In this case, the PrEP would not lead to an increase in supply of 
unprotected sex, however may lead to an increase in the supply of protected sex as FSWs 
maintain a constant income. Since this analysis relies on the price of protected sex 
remaining constant, we are unable to explore this further. Conversely, if protected and 
unprotected sex are substitute goods, a reduction in price for unprotected sex may lead 
to a reduction in the price and quantity supplied of protected sex, meaning that we 
overestimate the extent to which PrEP’s impact is reduced. 
This paper makes a number of assumptions which may not hold in reality. Firstly, risk 
compensatory behaviours among FSWs are predicted through the analysis of stated 
preference DCE data and may suffer from hypothetical bias. Although systematic review 
evidence suggests that the predictive ability of DCEs is reasonable[42] 14 , they are 
thought to over-predict desired behaviour changes, and underestimate undesirable 
behaviour[64, 65]. Therefore, this analysis may overstate the responsiveness of FSWs to 
price changes, predicting greater risk compensation than might be observed in reality.  
Secondly, we impose a restrictive model of the market for commercial sex. Demand is 
assumed to be constant. Although PrEP use is likely to be unobserved by clients, FSW 
                                                             
14 Chapter 5 of this thesis 
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revelation of use could signal her HIV negative status alongside a willingness to protect 
her health. This signal that an act may be safer could increase a client’s willingness to 
pay for unprotected sex, increasing incentives in the provision of unprotected sex. Also, 
FSWs may also exhibit risk compensatory behaviour if they are HIV positive and on HIV 
treatment; one study in Senegal finds that condom use among persons using ART is 
lower than that among HIV negative or HIV positive persons not on treatment[26]. 
In addition, if client preferences are augmented by actual or perceived FSW PrEP use, 
the market may become segmented such that clients only purchase sex from PrEP users 
or non-users, and do not operate in a single market as modelled here. This would reduce 
the impact of externalities among non-PrEP users, and mean we underestimate the 
impact of PrEP in scenarios 4 and 5. However, the extent to which FSWs might want to, 
or could, reliably signal PrEP use to clients is unclear. 
Scenarios 3, 4 and 5 use the target income hypothesis to justify the assumption that 
FSWs set a weekly income target. This assumption is different to a classic dynamic model 
of labour supply which predicts that people will work less when wages fall, due to a 
lower opportunity cost of leisure time[66]. Although multiple studies have found 
evidence of this reference dependence in labour supply [23, 61, 62, 67] and research has 
repeatedly shown weak or insignificant evidence of this [68-70], there is some studies 
have demonstrated behaviours consistent with the classic model of labour supply[71]. 
We do not use economic theory when modelling changes to the extensive margin, or 
entry to and exit from, sex work. Instead we use standard assumptions of transmission 
modelling to retain a fairly consistent population size, minus HIV-related mortality. If 
wages fall after the introduction of PrEP, the benefits of a career in sex work in the form 
of financial earnings far greater than available in other areas of the economy, may be 
substantively reduced. In this instance, we would expect the number of new HIV negative 
entrants to sex work to reduce.  
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This model only considers changes to HIV transmission, and does not consider other STIs 
or unintended pregnancies. New HIV prevention products are generally single-purpose, 
and only prevent HIV transmission, yet condoms are multipurpose products which 
confer protection from unintended pregnancy and other STIs. Substitution from 
condoms to a single-purpose product may result in additional health losses from these, 
which are not accounted for here. In addition, DCE data have shown that other attributes 
of HIV prevention products may be more attractive to some FSWs than HIV prevention, 
including additional protection from unintended pregnancy or STIs. 
Conclusion 
This paper raises the question of how prevention interventions may affect the economics 
of sex work and so have other unforeseen effects. It shows how the impact of a new HIV 
prevention product, pre-exposure prophylaxis (PrEP), may be reduced by changing the 
supply-side economics of commercial sex. This study is the first to explicitly incorporate 
economic factors, which have elsewhere been demonstrated to affect the behaviours of 
FSWs and clients, into a dynamic HIV transmission model. Through using stated 
preference data and behavioural economic theory, we model the possible effect that risk 
compensation among FSWs may have on the impact of PrEP in reducing HIV infection. 
We find that existing models may substantially overestimate the impact of PrEP where 
they do not account for risk compensation among users, in terms of the quantity and 
type of sex acts they engage in. Results indicate that ensuring high (>75%) adherence to 
PrEP will be critical in achieving a substantive impact on HIV transmission.  
This study explores a number of hypotheses which merit further investigation, ideally 
with high-quality observational data collected among both PrEP users and non-users. In 
particular, results suggest that economic factors might mitigate the impact of PrEP 
interventions, yet act-level data on price or other dynamics are rarely collected in PrEP 
demonstration or implementation projects or their process evaluations. Few data are 
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also collected among FSW groups who are not engaged with clinical trials or 
demonstration projects, yet longitudinal data on economic factors will be essential to 
fully explore the impact of HIV prevention interventions. Further work is also needed to 
counter potential biases in the reporting of prevention interventions, including 
condoms. 
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Supplementary Table S1: Potential measures of condom use in primary survey 
carried out in South Africa in 2015 
Survey question 
Inferred 
condom use 
parameter 
Reporting that a condom is always used in commercial sex acts 96% 
Reporting condom use a last sex (commercial or otherwise) 91% 
Reporting an amount when asked on average how much she sells 
unprotected sex for 78% 
Reporting knowledge of other FSWs who provide unprotected 
sex 60% 
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Conclusions from paper R4 
This paper explores how a new HIV prevention product, referred to here as generic PrEP, 
could affect the economic environment of sex work and change the behaviours of FSWs. 
It found that risk compensation among FSWs, attributable to changes in the economics 
of sex work, may have a substantive negative impact on the population-level benefits of 
PrEP products.  
This paper has a number of limitations. Risk compensation is predicted from DCE data, 
which were shown in the systematic review of chapter 4 to be at risk of incorrectly 
predicting the sensitivity of individual choices to changes in the choice environment. 
Furthermore, it is not calibrated to a particular HIV epidemic in sub-Saharan Africa, 
although South African data is used from the primary fieldwork of this thesis. This, 
coupled with the fact that the model is a simple characterisation of the epidemic, may 
mean that some inferences may not be robust. 
However, although the empirical results of this paper may not be precise, the predicted 
effect of risk compensation on the impact of PrEP is indicative that more research is 
needed to investigate the potential adverse effects resulting from PrEP introduction and 
use. In particular, data is needed from FSWs who choose not to uptake PrEP products to 
explore if behavioural externalities, which we model based on theoretical expectations, 
may impact behaviour in reality.  
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Chapter 10: Discussion 
This thesis set out to assess the potential impact and cost-effectiveness of new HIV 
prevention products by eliciting the stated preferences of men, women, adolescent girls, 
and FSWs. This chapter provides a critical assessment of the major findings of the thesis, 
notes their strengths and limitations, and discusses their implications for research and 
policy. This chapter meets research objective 5, to identify key findings from this thesis 
and discusses the implications for the introduction of HIV prevention products 
Major findings 
This section summarises key results arising from this thesis, presented according to the 
objectives outlined in chapter 1. 
Objective 1: To quantify the determinants of demand for new HIV prevention 
technologies among adult men, women, and adolescent girls in the general 
population, and female sex workers 
The first objective was addressed in paper R1, where a DCE with 661 self-reported HIV-
negative respondents found that the largest determinant of product demand across all 
groups would be HIV efficacy. We also found strong preferences for MPTs, with 
pregnancy and STI characteristics important to the choices of all groups. However, less 
promising for the HIV response among AGYW groups, evidence from MNL and MMNL 
models respectively suggested that adolescents find the intravaginal ring and oral PrEP 
intrinsically less appealing products compared to other women.  
However, this paper also identified some promising areas for HIV prevention moving 
forward. All four groups displayed strong preferences for injectable PrEP products, 
while the minor side-effects included in the DCE were not important to respondents. 
Perhaps most importantly, latent class results suggest that products offering 
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multipurpose protection would be desirable to younger women and FSWs, who 
displayed weaker preferences for single-purpose HIV protection products.  
Objective 2: To estimate the impact and cost-effectiveness of new HIV prevention 
products among South African men, women, adolescent girls, and female sex 
workers 
The second objective was addressed in paper R2, where a cost-effectiveness analysis 
showed that a range of candidate multipurpose HIV prevention products would likely be 
cost-effective if introduced among younger women (aged 16-24) or FSWs but are 
unlikely to be cost-effective if introduced among older women (aged 25-49). Roll out 
scenarios that included one or more MPTs were predicted to be slightly more cost-
effective than scenarios of single-purpose products for two reasons. First, MPTs were 
predicted to be more attractive to potential users, leading to greater uptake and 
economies of scale from product use. For example, we predicted that product uptake 
among women under 25 would be 8% for a range of single-purpose products, but that 
uptake would increase by 27 percentage points to 35% for a full range of MPTs. Second, 
the costs associated with averting unintended pregnancies reduced the net costs of the 
intervention and led to greater benefit through averting maternal mortality.  
The impact model used in this paper is relatively simple; however, its results are broadly 
comparable to published studies estimating the cost-effectiveness of single-purpose 
PrEP[1]. In a series of one-way sensitivity analyses, we tested the sensitivity of this 
model to qualitatively important parameters and found the results sensitive to 
assumptions of HIV incidence, product adherence, and the coverage of ART. This paper 
strengthens the evidence for continued investment in MPTs to improve sexual and 
reproductive health. 
Objective 3: To assess whether HIV prevention products will change female sex 
worker preferences for the supply of condomless commercial sex  
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The third objective was addressed in paper R3, where a repeated DCE with two different 
framings found that PrEP could markedly change the supply side of the commercial sex 
market. We predict that PrEP use would lead to a substantial decrease in the condom 
differential, the price premium for unprotected sex, by 73% due to an increase in utility 
provided by the fee for an act and a parallel decrease in the utility provided by condoms. 
Notably, simulations from DCE data indicate that the quantity of condomless sex 
supplied could more than double, increasing by a factor of 2.3. There was no significant 
heterogeneity in the impact of PrEP on supply. However, there was some evidence of 
market segmentation, and this may have been due to the small sample of HIV-negative 
FSWs identified.  
Objective 4: To explore if changing incentives in sex work could substantially 
affect the impact of HIV prevention products through risk compensation 
The fourth objective was addressed in paper R4, which used the results of the FSW DCE 
to explore if changes in the economics of sex work due to the introduction of an effective 
HIV prevention product could substantially reduce their impact through risk 
compensation. This paper combined an epidemiological dynamic transmission model of 
HIV with microeconomic theory and found that 1) the impact of PrEP is likely to be highly 
dependent on adherence; and 2) the extent of competition among PrEP users and non-
users – particularly how much behaviour change among users is replicated among non-
users – could substantively affect the overall impact of PrEP. Although the model was 
not parameterised for a specific HIV epidemic, the substantive changes in estimates of 
PrEP impact attributable to risk compensation due to economic factors indicate that 
more research is needed in the area. 
Objective 5, to identify key findings from this thesis, and discuss the implications for the 
introduction of HIV prevention products, is met by this discussion Chapter. 
An additional methodological objective was: 
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Objective 6: To assess the reliability of discrete choice experiments to predict 
health-related choices 
A systematic review (chapter 4) sought to validate the application of DCEs in this thesis, 
specifically assessing their accuracy in predicting health-related behaviours. The review 
identified eight studies that met the inclusion criteria, where individual-level stated and 
revealed preference data were captured for health choices. A meta-analysis pooled the 
results of these studies using a bivariate mixed-effects model to account for the co-
dependency between measures of sensitivity and specificity.  
We found that DCEs have reasonable accuracy when used to predict behaviour with a 
sensitivity of 88% (95%CI: 81%, 92%) and a specificity of 34% (95%CI: 23%, 46%). This 
means that when a DCE suggests that somebody will behave in a certain way (for 
example, opting for a treatment or programme), this may be a more reliable statement 
than if it suggested that somebody will not behave in a certain way (for example, they 
will not use a treatment or programme). 
Although low compared to the accuracy of diagnostic tests, these figures indicate that 
DCEs can be useful tools when other forms of prediction are inaccurate or unavailable, 
such as in the early stages of product introduction. The low number of studies assessing 
the validity of DCEs means that we conclude that substantial additional work is required 
in the area, particularly to explore heterogeneity in results. 
Contribution to knowledge  
The contribution to knowledge of this thesis can be summarised in terms of those of 
empirical findings, and those of methods. 
Contribution of empirical findings 
This thesis contributes knowledge to inform the development and roll-out of ARV-based 
prevention in South Africa. A key finding of paper R1, that female groups find oral PrEP 
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or intravaginal ring products less appealing, is particularly important because emergent 
HIV prevention initiatives, such as the DREAMS programme in South Africa[2], are 
investing substantial resources to the scale-up distribution of these products among 
AGYW. Large-scale spending on products that potential users will not find attractive will 
likely lead to misallocation of scarce resources, a particular concern when donor 
spending on HIV is forecast to decrease in the short to medium term, exacerbating the 
opportunity cost of decisions[3].  
Taken together, papers R1 and R2 show the value of including end-user preferences in 
programme planning and modelling. Assuming the predictions of the DCE are valid as 
shown in chapter 4, at least for estimating relative uptake between groups, results show 
that heterogeneity in preferences across populations is likely to impact cost-
effectiveness estimates to some extent. Also, the sensitivity analysis of paper R2 showed 
that variation in predicted uptake is likely to have a relatively small effect on cost-
effectiveness when compared to other factors - particularly assumptions relating to 
incidence in different groups and scale-up of ART. 
Importantly, papers R1 and R2 strengthen the economic case for the scale-up of oral 
PrEP among South African AGYW populations, in addition to FSWs among whom it has 
recently been introduced[4]. Aside from increased economies of scale where fixed costs 
are divided among a greater number of users, the high HIV incidence among younger 
women means that we predict single-purpose oral PrEP and intravaginal rings to be 
cost-effective in this group, despite the ring having a very low demand among AGYW. 
However, the latent class model in paper R1 predicted that younger women were less 
likely to value HIV prevention in a product than older women. To achieve high PrEP 
coverage, and therefore cost-effectiveness, among this group, efforts should be made to 
motivate uptake and encourage adherence. Predictions of cost-effectiveness despite a 
comparative dislike of the ring and oral PrEP products suggest that, if these products 
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could be made more attractive to younger users, increases in uptake and use could 
improve their cost-effectiveness. 
In papers R3 and R4, our attention turned to the implications of introducing PrEP among 
the FSW population. Paper R3 details the results of a DCE, the first to be carried out 
among FSWs to-date, which indicates that PrEP could have a substantive impact on the 
economics of commercial sex, decreasing the price premium for condomless sex and 
potentially increasing the quantity of condomless sex supplied. This is also the first study 
to explore the impact of new HIV prevention products on the economic aspects of 
commercial sex work, filling the gap in the economic literature that does not consider 
how new prevention products will change incentives in commercial sex work.  
In line with the general approach of this thesis, paper R4 extends the use of DCEs beyond 
their current application where, in combination with key findings from microeconomics, 
results are used to better inform epidemiological models of PrEP impact. Until now, 
epidemiological transmission models have made zero, or arbitrary, changes to 
parameters simulating risk compensation under PrEP use (e.g. [5-7]). This study is the 
first to formalise a risk compensation framework based on widely-accepted and 
empirically evidenced economic theory, albeit not in commercial sex.  
In doing so, this study takes the economically significant findings from paper R3, 
extrapolates from the surrogate outcome of condom substitution to impact on the HIV 
epidemic, to suggest that condom substitution due to changing economic factors may 
have substantial epidemiological importance. We also find that ensuring high adherence 
to PrEP will be critical to maximising impact. Interestingly, paper R4 highlights how even 
small changes to the behaviour of non-PrEP users, as a plausible result of competition, 
may reduce or negate impact. Few data are currently captured among FSWs who are not 
participating in a PrEP trial or demonstration project. To validate (or refute) the stated 
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preference evidence in this thesis, a broader range of data must be collected from non-
users. 
Taken together, results from papers R2 and R4 highlight the importance of using high-
quality end-user data to maximise the impact and cost-effectiveness of interventions. 
Importantly, the sensitivity of the cost-effectiveness and dynamic transmission models, 
used in papers R2 and R4 respectively, to adherence parameters indicate that 
investments in interventions to enhance consistent product use are likely to be cost-
effective. Ideally, programmes supporting uptake and adherence would be designed 
using reliable end-user data, such as that obtained from DCEs. 
Contribution to methods 
An important methodological contribution of this thesis is to apply DCEs to inform 
uptake parameters in an economic evaluation. Paper R2 is one of the first published 
examples of DCE use for this purpose in any health context and the first in the HIV field. 
As found in the systematic review exploring the predictive ability of DCEs in chapter 4, 
DCEs are imperfect tools for prediction. Yet when compared to alternatives of expensive 
trials or obtaining expert opinion, we have argued throughout that they may be less 
biased and allow a greater understanding of the heterogeneity of uptake within and 
across different groups. Chapter 4 is the first systematic review to synthesise evidence 
of the predictive ability of DCEs in health and provides an evidence base for their further 
use in the absence of alternative predictive methods. 
An additional methodological contribution is the integration of a microeconomic model 
of behaviour within an infectious disease model. To date, models of interventions among 
FSW have used arbitrary changes in assumptions to assess the sensitivity of models to 
behavioural responses to interventions, such as condom substitution. Also, although 
many models carry out one-way, two-way, and probabilistic sensitivity analyses, none 
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were identified which co-dependently varied the rate of condom use and the number of 
commercial acts supplied, the key prediction from the empirical findings of paper R3.  
Finally, to my knowledge, these DCEs are the first to be carried out among a FSW 
population. When gathering data among FSWs, flexibility is required in many survey 
methods including sampling strategy, considerations of confidentiality, and 
arrangements for interviewer and participant safety. Yet, the successful implementation 
of both DCEs among the FSW sample shows that they can be useful tools to elicit the 
preferences of this group. 
Limitations of thesis approach 
The strengths and limitations of specific methodological and analytical approaches have 
been discussed in the preceding Chapters. Therefore this section focuses more on 
overarching themes.  
Modelling as a simplification of reality 
The modelling of complex phenomena, such as the spread of HIV in a population or the 
costs required to reach populations at risk, require necessary simplifications of reality. 
The models employed in this thesis were designed with the aim to identify and explore 
the impact of important factors thought to influence the HIV epidemic, for example 
estimating the differential impact of interventions in older and younger women. In 
addition, due to requiring assumptions around important parameters such as 
effectiveness or adherence, ex-ante impact and cost-effectiveness models may be less-
robust than ex-post evaluations which are able to incorporate more certain 
observational data. Sensitivity analyses are included in papers R2 and R4 in an effort to 
mitigate the impact of parameter or methodological uncertainty. Nevertheless, these 
cost and impact models are likely to have omitted important factors which may 
substantively influence results.  
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For example, assumptions around adherence to PrEP has been shown to be a critical 
factor in both observational and modelling studies, e.g. [1, 8, 9]. In this thesis, adherence 
is included in both models through linear reductions in the product efficacy parameter, 
yet this may not accurately reflect the complexity of adherence in reality. For example, 
an individual may use ARV-based prevention products adherently for short periods of 
time when they consider themselves to be at risk, and not at all at other times. In another 
scenario, a proportion of users might use PrEP perfectly adherently while others never 
use a product. Separate compartments would be required to model this, with an 
understanding of the interaction between other factors and the likelihood of high 
adherence. Data are not yet available for adherence patterns to ARV-based prevention 
(some research has been carried out on adherence to ART[10]), though we can expect 
the determinants of adherence to be heterogeneous across users.  
The FSW DCE and model in papers R3 and R4 aimed to predict risk compensation among 
FSWs, specifically the provision of more unprotected sex if they were to initiate effective 
HIV prevention. The behavioural response to PrEP initiation is also likely to be 
heterogeneous, and likely correlated with socio-economic circumstance or FSW 
bargaining power. The DCE did not detect any differential response to PrEP introduction 
by observable characteristics, yet the main interaction effect was only marginally 
significant, and it is likely that the DCE was underpowered to detect these differences. If 
some FSWs are highly responsive to the introduction of PrEP, and some are not, it will 
be important to understand which women need additional support in maintaining 
consistent condom use with commercial partners.  
Imperfect analytical and predictive ability of DCEs 
Chapter 4 presents the first systematic review of the predictive ability of DCEs in health, 
and although it shows that DCEs give reasonable predictions of real-world behaviours, 
the number of included studies was very small and estimated sensitivity and (in 
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particular) specificity values low. Yet the use of DCEs in this thesis was motivated by a 
desire to obtain objective, rapid, and relatively inexpensive data on the preferences of 
different populations towards HIV prevention products, and predictions are presented 
with this caveat in papers R2 and R4. These were the first DCEs to be carried out among 
FSW populations, while very few have been conducted among persons under the age of 
18. The consistency of results with prior expectations suggests that the internal validity 
of DCEs holds within these populations. However it would have been optimal if stated 
preference data could have been combined with revealed preference data obtained from 
PrEP trials or demonstration projects.  
On reflection, closer collaboration with ongoing PrEP projects based at Wits RHI could 
have provided this data. However, the delays in the early stages of this project meant 
that data collection in the TAPS demonstration project began before we had sufficiently 
strong collaborative links with the institution to suggest the collection of economic data. 
I hope to investigate this in postdoctoral work.  
We aimed to reduce hypothetical bias in both DCEs by engaging in extensive piloting and 
testing, and by including opt-out alternatives in the final design. This approach should 
have enhanced the process validity of the DCEs, while the direction of coefficients was 
broadly in line with a priori assumptions, further supporting the theoretical validity of 
findings.  
Nevertheless, erroneous predictions due to hypothetical bias may have important 
implications for using DCE predictions, particularly if they over-predict demand. Over-
prediction would bias the results of paper R2 towards being more cost-effective and 
therefore potentially problematic for the method. Although Lancsar and Swait[11] 
suggest that DCEs predict fairly well outside of the health field, they suggest that the 
inconsequentiality of choices in health DCEs may exacerbate hypothetical biases, or that 
the reduced form choices presented in DCE tasks omit key features of choices which may 
369 
 
be important to respondents. We are unable to assess this with the stated preference 
data collected for this thesis. 
Design decisions for both DCEs were taken with the aim of detecting statistically 
significant effects among attributes. This meant that potentially important attributes, or 
interactions between attributes (for example the risk and duration of side-effects), were 
considered but ultimately left out. On reflection, this may have been an excessively 
cautious approach given the use of efficient designs, our large sample sizes, and the 
number of significant parameters in the main effects models of both DCEs.  
Reliance on self-reported data 
Due to financial and human resource constraints, we were not able to collect biomarker 
data to objectively assess HIV or treatment status and we relied on participants 
accurately self-reporting their HIV status, sexual behaviour, and other sensitive 
information. Self-report is a quick and cost-effective means of collecting data. However, 
the validity and completeness of self-reported sexual behaviour data is unclear at best 
[12-15].  
Often self-report is often the only way to obtain individual-level data on important 
sexual behaviours. Based on best practice developed by the UK’s National Surveys of 
Sexual Attitudes and Lifestyles (NATSAL) [16, 17], we took steps to minimise reporting 
bias during data collection: 1) our fieldwork team comprised solely of interviewers with 
prior experience of collecting sexual behaviour data from general population groups; 2) 
extensive training was led by specialist researchers at the University of the 
Witwatersrand to enhance the capturing of data around intimate partner violence and 
condom negotiation; and 3) surveys were coded into tablet computers in an accessible 
manner to allow participants to answer directly on the tablets themselves, rather than 
have to reveal information orally to an interviewer.  
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Despite this, self-reported HIV prevalence was lower in the general population than in 
national representative surveys[18], and lower among FSWs than other RDS 
surveys[19]. Reported condom use at last sex was also higher among all four populations 
in this survey than others (ibid.). These data indicate that that acceptability biases may 
have led to the misreporting of HIV status and other sensitive behaviours. For the 
modelling work in this thesis, we attempt to mitigate this bias by taking the majority of 
parameters from representative studies (such as the South African Health Science and 
Research Council surveys[18]), which capture biomarker data in addition to self-
reported information.  
Time and resource constraints in fieldwork  
Fieldwork was initially planned to take place over 15 months from September 2014 to 
December 2015. However, staff movement and administrative delays in our 
collaborating institution meant that ethical approval for piloting work was not obtained 
until August 2015. Although a great deal of the survey implementation work was front-
loaded, including the design and programming of pilot tools and the recruitment and 
training of interviewers, the reduction in project time from 15 months to 5 months 
meant that some planned activities had to be dropped. For example, the products DCE 
was designed without primary FGD work to identify attributes and, instead, we used FGD 
data from a similar DCE carried out by the primary supervisor of this thesis in 2005. 
Nevertheless, we managed to protect the three-month window allocated to quantitative 
data collection, and ensure that the quality of interviews and sampling methods was not 
reduced by time constraints. 
Strengths of thesis approach 
Combination of economic and epidemiologic methods  
Perhaps the key strength of this thesis is the formal integration of economic methods 
into infectious disease models. This approach allows us to objectively consider 
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complexity in model parameters, specifically variation in prevention product uptake and 
condom substitution estimates, and offers a greater understanding of potentially 
important nuances in estimating the impact and cost-effectiveness of ARV-based HIV 
prevention products. 
The uptake predictions used in paper R2, derived from DCE results, suggest that uptake 
of an MPT product among AGYW would be three times that of a single-purpose product. 
Although previous research has identified unmet contraceptive need among this group 
[20], there has been limited work to estimate the incremental demand that an MPT could 
command. The integration of end-user DCE data into a cost-effectiveness model meant 
that we were able to explicitly model the cost-effectiveness of MPTs, accounting for the 
heterogeneity in demand for contraceptive characteristics that we observed across 
female populations.  
Paper R4 also uses the results of a DCE to inform a mathematical model and is the first 
to incorporate an explicit economic model of behaviour in the estimation of key 
parameters. Economic theory describes how people trade off risk and reward in labour 
markets, which is useful in modelling shocks to a market such as the introduction of 
PrEP. Yet, despite evidence that economic factors can strongly influence FSW and client 
behaviours, noted in the earlier systematic review, to-date mathematical models have 
not incorporated these factors when modelling HIV transmission in the market for 
commercial sex.  
South Africa as a research context 
South Africa was chosen as a study site for this research for a number of reasons, 
including strong institutional links between LSHTM and Wits RHI, and research capacity 
in the data collection team. Moreover, the high HIV prevalence in South Africa, alongside 
the proven political and social acceptability of ARV-based HIV prevention methods, 
means that the results of this thesis have the potential to contribute to discussions on 
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how to implement PrEP or develop MPTs for South African users. South Africa is also a 
comparatively wealthy country in sub-Saharan Africa, and is aiming to integrate heath 
technology assessment in its decision making in the medium term [21]. This may make 
the cost-per-DALY averted estimate in paper R2 more applicable here than in other 
contexts, where health decisions may be less likely to be explicitly made incorporating a 
transparent health economic framework. 
Due to its profile and status at the forefront of the epidemic, there has been a wealth of 
economic and infectious disease modelling work carried out in South Africa in recent 
years. Although this reduces the scope for novelty in this thesis, a large quantity of high-
quality health and economic indicator data are available (and have been used in this 
thesis) to aid in these research efforts. As such, in the models presented here, we have 
been less reliant on self-reported data to parameterise inputs than we would have been 
in other countries. Additionally, we were able to compare the results of these models to 
existing, accepted studies and assess the implications of the innovations in considering 
a) MPT products and b) changes in behaviour due to risk compensation. 
Finally, although residents of certain areas of Johannesburg have been inundated with 
requests to participate in HIV trials, surveys and programmes, by travelling 30km South-
East of the city centre for fieldwork we were able to reach a relatively research naïve 
population (except for the 2005 DCE by the supervisor of this thesis, which was also 
partly carried out in Vosloorus township). This meant that, although interviewers had to 
spend a large proportion of interview time introducing the new products and discussing 
how they work, the preference data we gathered are less likely to be influenced by 
previous participation in HIV prevention research.  
A new perspective on multipurpose prevention technologies (MPTs) 
Although research on candidate MPT products has previously identified an unmet need 
for effective, female-initiated products (e.g.[14, 22-25]), just one study has assessed the 
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potential cost-effectiveness of an MPT[26]. A strength of this thesis is the use of robust 
economic evaluation methods to assessing the cost-effectiveness of different MPT 
rollout strategies among a range of population groups. The results of the DCE and this 
study have been of particular interest to the MPT advocacy community, and the author 
has since presented a webinar for the Initiative for Multipurpose Technologies (IMPT). 
Data quality and generalisability to other settings 
The randomised sample of general population participants means that we can be 
relatively confident in generalising the findings of the DCE to other urban and peri-urban 
areas of South Africa. After applying sample weighting, our sampled showed reasonable 
similarity in background characteristics to other surveys of the South Africa population. 
That said, contextual factors may limit the extent to which findings can be generalised, 
as there is huge racial heterogeneity within and across administrative areas in South 
Africa. 
The RDS sample among FSWs used best-practice methods to obtain 203 interviews with 
the hard-to-reach population. Because of the low prevalence of sex work in the general 
population, RDS methods enabled a targeted, snowballing approach to be deployed to 
reach a sufficient sample size. Survey weights were then used to quantitatively adjust 
results to make results generalisable to the FSW population. As noted in the results 
papers, RDS methods do not entirely mitigate the sampling biases introduced by RDS, 
and a number of assumptions are required for data to be representative to all FSWs. Even 
then, the heterogeneous nature of sex work contexts in South Africa means that 
generalisability may not even be possible for sex work locations geographically close to 
data collection. Nevertheless, since the alternative approach would be to simply analyse 
data collected among a snowball sample, the RDS adjustment is preferable. 
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Implications for research 
This section considers the broad research implications of this work, alongside its 
generalisability to other settings. 
Implications for the further development of MPTs 
In April 2017, during the writing up stage of this thesis, the International Partnership for 
Microbicides (IPM) initiated a phase 1, randomised trial of the pharmacokinetic and 
safety characteristics of a multipurpose HIV and contraceptive 
Dapirivine/Levonorgestrel vaginal ring (MTN-030/IPM 041)[27]. Although this is a 
promising step towards the development of an effective MPT option in LMICs15, the 
results in paper R1 suggest that it would be optimistic to assume that a ring-based MPT 
will be an attractive option for younger women, yet potentially cost-effective as 
demonstrated in paper R2. 
Instead, results from this thesis suggest that future research should focus on the 
development of alternative MPT modalities, particularly injectable products. Also, more 
research is needed on the short- and medium-term opportunities that co-provision of 
individually produced and regulated products could have. Although MPTs were 
described in the products DCE as co-formulations, there is no evidence suggesting that 
co-provision would be less impactful. 
Alternatively, while this thesis shows what can be done with relatively little hypothetical 
choice data, this is no substitute for a well-powered, observational study of revealed 
preference product uptake. It is essential that the uptake of single- and multi-purpose 
products be monitored throughout phase III trials and early implementation studies to 
ensure that they have the potential to meet end-user expectations. 
                                                             
15  IPM owns the exclusive licence for Dapirivine from Janssen Sciences Ireland UC, an 
arrangement that aims to ensure that women in low-resource settings have affordable access to 
effective, topical HIV prevention  
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Finally, rigorous assessment of the cost-effectiveness of candidate MPT products is 
needed to ensure that resources are efficiently allocated as MPT products become 
available. It is likely that the pharmacokinetic and regulatory barriers to MPT 
introduction will result in a high unit cost, which may or may not be fully passed on to 
purchasing governments or individuals. In the short to medium term, co-provision of 
HIV preventative and contraceptive products may be one option to capture the potential 
benefits of MPTs.  
Health systems in high HIV burden countries are likely to have notably limited resources, 
and purchasing MPTs, or single-purpose prevention products, is likely to require 
disinvestment from current health spending. As South Africa moves towards 
implementing formal HTA processes, the quality of the economic evidence for MPT 
introduction will face increased scrutiny, and it is important that economic evaluations 
meet as many of best-practice criteria as possible, for example, those in the Bill and 
Melinda Gates Foundation Reference Case [28]. 
The case to consider unintended consequences of introducing ARV-
based prevention among FSWs 
The optimism in research and advocacy groups for ARV-based prevention interventions 
to reduce HIV incidence among FSW groups is not unfounded, and PrEP trials and 
demonstration projects among FSW have shown encouraging acceptability and 
adherence results[29]. Yet this work demonstrates that maximising the impact and cost-
effectiveness of interventions may be more nuanced than currently considered in the 
epidemiological literature. Drawing from a large body of economic research into sex 
work, until now not considered by impact models, paper R4 shows that a relatively 
simple model predicts that the impact of PrEP could be substantially, or entirely, 
mitigated by economic influences in sex work.  
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For such unintended consequences to be measured and fully considered, data needs to 
be captured by PrEP implementation programmes on potential areas of risk 
compensation, including changes in the quantity, type, and price of sex supplied to 
different cadres of clients. Where possible, innovative techniques should be used to 
minimise desirability biases in responses, for example, list randomisation methods [30, 
31]. 
Paper R4 also demonstrated the importance of measuring the impact of interventions 
among non-recipients, particularly when risks emerge from competitive market 
equilibria such as in sex work. Although difficult to do, capturing data from non-users 
has three benefits: 1) exploring why some users do not uptake products; 2) enabling the 
use of more robust impact evaluation methods (e.g. difference-in-differences 
approaches) in estimating intervention impact, and 3) monitoring potential externalities 
from behaviour change among PrEP users.  
Implications for policy 
Not all products will be attractive to end-users 
Although this thesis shows that there is likely to be demand for effective HIV prevention 
products, not all population groups display the same preferences, and contraceptive 
properties are likely more desirable among some groups than others. As shown by the 
comparative failure of microbicide trials, largely due to poor adherence[9], it is critical 
to understand which products will be most effective in different contexts. When more 
than one ARV-based prevention modality is available, as is likely in the near-term due to 
successful trials of the intravaginal ring[32, 33], careful consideration is needed to 1) 
ensure that the right products are made available to different population groups, 2) that 
products are not withheld from potential users due to their demographic or risk profile, 
and 3) that effective adherence support is provided to users to encourage consistent and 
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effective product use. Condoms remain an important tool in HIV prevention 
programming 
Although condom substitution was shown in paper R4 to potentially mitigate the 
beneficial impact of PrEP among FSWs, paper R2 found that MPTs were largely cost-
effective under assumptions of 51% condom substitution; although this model does not 
consider the direct or indirect impacts of other STIs. If condom substitution is minimised 
among product users, the impact cost-effectiveness of new single- and multi-purpose 
technologies will be improved. 
South Africa guidelines for PrEP and LARC use explicitly recommend the continued use 
of condoms alongside other preventative technologies; however the results of this thesis 
suggest that this recommendation must continue to be highlighted in guidelines and 
clinical practice. As with existing imperfect prevention methods, such as VMMC, 
consistent and continued information provision is required to ensure that product users 
understand the extent to which they are (and are not) protected from HIV and 
unintended pregnancy, and explicitly that they are not protected from many STIs when 
using non-barrier methods.  
The need for innovative programming for HIV prevention among FSW 
and AGYW groups 
This thesis has demonstrated that making effective HIV prevention products available to 
FSWs may not be sufficient to reduce HIV incidence and indicates that more innovative 
programming may be needed.  
Among FSWs, papers R3 and R4 show that financial incentives could reduce the impact 
of products through risk compensation, as FSWs increase their supply of unprotected 
commercial sex to keep income constant. One option to reduce the financial pressures 
on FSWs to reduce the supply of unprotected sex is to enhance risk-coping mechanisms 
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in the form of conditional cash transfers (CCTs) or increased access to credit, savings, 
and insurance products.  
One CCT has been carried out among FSWs, the RESPECT II pilot study in Tanzania, with 
financial incentives given to FSWs conditional on remaining without an STI, yet final 
results have not been published[34]. Research among male sex workers in Mexico found 
a strong rationale for a CCT to reduce sexual risk taking [35], based on similar risks 
associated with the availability of higher wages for unprotected sex. CCTs have been 
carried out among AGYW groups to reduce risks attributable to transactional sex, 
however they have shown mixed evidence of effectiveness in reducing HIV prevalence 
[36, 37].  
Formal risk-coping mechanisms are not available to many FSWs or AGYW, and there is 
no evidence examining the impact of providing these on sexual activity. Providing better 
risk coping mechanisms could affect the intensive and extensive margins of sex work 
[38]. In the general population, an association has been found between HIV prevalence 
and negative income shocks due to drought across 19 African countries, which the 
authors attribute to increasing quantities and risk in transactional sex[39]. Improved 
access to instruments for coping with financial risks in the general population, including 
among AGYW, could reduce dependence on transactional sex, and reduce HIV incidence.  
The need for investment in uptake and adherence support 
The importance of adherence to ART has led to a large number of studies evaluating the 
effectiveness of adherence-enhancing interventions[10], showing efficacy and – where 
assessed – cost-effectiveness. PrEP programmes have the opportunity to use the lessons 
learnt in treatment adherence interventions to design optimal support systems to 
maximise adherence to PrEP. Given the importance of adherence assumptions in papers 
R2 and R4 of this thesis, we would anticipate that interventions to support adherence to 
PrEP have a high probability of being cost-effective.  
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Encouraging uptake does not require the complexity of maintaining adherence over 
time, but some uptake-enhancing interventions – for example, financial incentives 
conditional on product uptake – may be considered to coerce product initiation and be 
ethically unacceptable. Instead, policymakers should focus on making products and the 
health services from which they are delivered as attractive as possible to potential users.   
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Conclusion 
New ARV-based HIV prevention products offer promise in tackling the HIV epidemic, 
particularly in high-burden, generalised epidemics such as South Africa. This thesis set 
out to explore the preferences of end-users for new products and to estimate their 
impact and cost-effectiveness among different groups, accounting for risk-
compensatory behaviours. It finds that products offering effective multipurpose 
protection would be attractive and cost-effective among younger female groups. A 
simple model also predicted the cost-effectiveness of products among FSWs. However, 
risk compensation due to changes in economic factors could substantially affect product 
impact. This thesis has shown the value of combining economic and epidemiological 
modelling methods to explore preventative behaviours in HIV. Further work is needed 
to accurately assess the external validity of these methods. 
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Appendix I: Published correspondence: The 
promise of multipurpose pregnancy, STI, and 
HIV prevention 
The following paper, the promise of multipurpose pregnancy, STI, and HIV prevention, is a 
piece of correspondence published in The Lancet Infectious Diseases, which provides 
background on the arguments for MPT development, and the rationale for their 
integration with existing HIV and reproductive health programming. This paper is 
presented as published, and Appendix II gives evidence of Elsevier’s permission for this. 
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include published version of The promise of 
multipurpose pregnancy, STI, and HIV 
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Appendix V: NGENE output for 10- and 15-task DCEs 
15-task DCE: 
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Informed Consent Form and Information Sheet: Focus 
Group Discussions 
 
Hello, my name is ….. I am working for Progressus Research and Development on a 
project for the Wits Reproductive Health and HIV Institute and the London School of 
Hygiene and Tropical Medicine. I would like to invite you to participate in a research 
study on women, men and adolescent girls from Ekurhuleni. 
 
Why are we conducting this study? 
Many people in South Africa are infected with HIV every day. Often it is because 
people find it difficult to persuade their partners to use condoms. At the moment, the 
male and female condoms are the only widely available methods of preventing HIV. 
Researchers are currently developing new methods that people can use to prevent HIV 
such as daily tablets, topical gels, long-acting injectable anti-retrovirals, diaphragms 
to be used with or without gels and intra-vaginal rings. 
 
What is this study about? 
This study aims to understand the reason that people may decide to the use these newer 
methods for HIV prevention, if they are found to be effective. We are interested in 
what people think about these new methods and what features are important to increase 
uptake and ensure continued use. We are also interested in how couples choose 
prevention methods together. This study will provide us with important information 
necessary to develop new prevention methods for men and women to use against HIV.  
 
REMEMBER: WE ARE NOT PROVIDING ANY PRODUCTS FOR THIS STUDY 
Who can take part? 
You can take part if you: 
 Are willing to participate in a focus group discussion 
 Are between the age of 18 and 45  
 Have had sexual intercourse at least once in the past 6 months 
What do you have to do if you agree to take part? 
You have been asked to participate in focus group discussions. The focus group 
discussion will take approximately two hours of your time.  
All focus group discussions will be recorded on audio tape. This is to ensure that 
the information we collect is accurately recorded. Later we will write down the 
information and store this on a computer. All digital recorders will be kept in a 
locked cabinet. No one except program staff will be able to listen to the digital 
recorder or view the material. After the research has been completed all audio 
tape recordings will be destroyed. 
This information will be used by us to gain more insights into how to ask people 
what features of the new prevention methods are most important and how they 
would choose between them. By participating you are helping us decide on how 
to do research on new prevention technologies.  
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Will the information from these focus group discussions be confidential? 
As researchers we will ensure that you will not be identified by name on any 
documentation. No one will have access to any recordings and all digitally 
recorded voice files will be destroyed at the end of the study. We cannot, 
however, guarantee that other participants in the focus group discussion 
maintain your confidentiality but will encourage confidentiality through a 
discussion of this issue with all participants before the FGD starts. We will 
attempt to ensure that all participants maintain one another’s confidentiality by 
requesting that you, or any of the participants, do not discuss the content of what 
any of the participants said during the focus group discussion with any people 
outside. This is to ensure your opinion and other people’s opinions and 
experiences are kept confidential. But you should carefully consider the 
information that you choose to share with the group as we cannot guarantee that 
other participants will maintain confidentiality 
Will the study benefit you? 
There is no immediate benefit to you by participating in this part of the study. 
However, you will be offered a phone airtime voucher to the value of R50.00 as a 
token of appreciation.  
What are the risks? 
The focus group discussions may discuss some personal issues. You will also be 
asked to discuss your experiences in a group setting but you may chose not to tell 
what you consider private information in the company of others. Although all 
participants are requested to not discuss what has been said during these 
discussions with anyone else, we cannot guarantee full confidentiality. 
What happens if you change your mind about taking part? 
You can choose not to answer any of the questions that you do not want to 
answer. You can withdraw from the focus group discussion at any time without 
giving a reason. Not answering specific questions or withdrawal from the 
discussion will not negatively affect you.  
What happens if I have any problems during the individual interview?  
If you have a problem resulting from your participation in this focus group 
discussion, please contact the investigators: Maria Cabrera or Robyn Eakle or 
Prof Sinead Delany-Moretlwe at Wits RHI in South Africa on Tel: 011 358 5100, 
or Fern Terris-Prestholt in London; on Tel: +44207927 2271.  
Who has approved this study? 
This study was reviewed and approved by the University of the Witwatersrand 
Human Research Ethics Committee (Medical). For more information or if you 
have any concerns or complaints please contact Prof P Cleaton-Jones, the HREC 
(Medical) Chairperson, (Tel 011 717 2302 or email: peter.cleaton-
jones@wits.ac.za or contact the secretariat: Ms Z Ndlovu, (Tel 717 1252 or email: 
Zanele.ndlovu@wits.ac.za) OR Ms A Keshav (Tel 011 717 2700 or email: 
anisa.keshav@wits.ac.za) 
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The participant must complete the following questions herself/with a staff member 
who did not administer the consent 
Have you had an opportunity to read the consent form/have it 
read to you?  
YES NO 
Have you had an opportunity to ask questions and discuss this 
study? 
YES NO 
Have you received satisfactory answers to all of your questions? YES NO 
Have you received enough information about the study? YES NO 
Do you understand the benefits of the study? YES NO 
Do you understand the risks of the study? YES NO 
Which study staff member have you spoken to about the study? 
PLEASE PRINT HIS/HER NAME: ______________________________ 
  
Do you understand that you are free to withdraw from the 
interview at any time without having to give a reason for 
withdrawing? 
YES NO 
Do you agree to take part in this study? YES NO 
If the participant answers NO to any of the above questions then she may not be 
enrolled in the study. 
Printed name of Investigator  
 
Date 
 
Time Signature of participant   
 
   
Consent for audio recording of interviews  
Do you agree to the interview being audio recorded?  YES NO 
Printed name of Investigator  
 
Date 
 
Time Signature of participant 
 
 
 
Do you agree that some of your responses be quoted in a manner 
in which you cannot be identified?  
YES NO 
Printed name of Investigator  
 
Date 
 
Time Signature of participant 
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Appendix VII: Focus group discussion guide 
 
Interviewer  Date 
 
Venue 
 
INSTRUCTIONS FOR THE MODERATOR – How to use this FGD Guide  
 
1. There are 3 levels of questions:  
 
 Numerical research questions/topic areas highlighted in grey: the questions/areas that we as researchers want to get answers to. These don’t need 
to be read aloud.  
 Discussion questions: the questions that you as the Interviewer will ask respondents in order to get answers to the research questions. These 
questions will be underlined and in bold.  
 Probes: they are indicated with a bullet. The interviewer should ensure that key topics listed in the probes have been addressed/discussed during 
the interview. So, depending on what has already been discussed you may ask these probes or not.  
 
2. Instructions/suggestions to interviewer are in italics and brackets [ ].  
 
3. The discussion guide is divided into three columns.  
 
 The left-hand column contains the research questions, discussion questions and probes. The discussion questions are suggestions for getting the 
discussion going. It is not required to read them verbatim, but they are written to ensure some consistency across discussion. You may adapt the 
question, depending on how the discussion develops, and you as the Interviewer will have to ensure that at the end the research questions have 
been answered.  
 
 The right-hand column is for summarising the themes brought up by the women in the discussions. These should be summaries of the general 
issues raised in connection with the research question. These summaries should be more than just yes/no, but not longer than a few sentences of 
bullet points. They do not need to be detailed, as we have the details on the tape.  
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INTRODUCTION  
 
Welcome the participants and thank them for coming. Hand each participant a sociodemographic information sheet. 
 
Explain the general purpose of the discussion:  
“We are holding a few discussions with up to 10 women at a time to talk about your experiences of negotiating with clients and other partners. We 
would like to find out your experiences when convincing men to use condoms, as well as how you agree an amount of money men give you for sex.” 
 
Introduce the team and the different roles of the members.  
 
Outline general ground rules such as the importance of everyone speaking up, talking one at a time, and being prepared for the moderator to interrupt to 
assure that all the topics can be covered.  
 
Address the issue of confidentiality: Inform the group that information discussed is going to be analysed as a whole and that the participants' names will not 
be used in any analysis of the discussion.  
 
Explain the presence and purpose of audio recording equipment.  
 
Before starting the discussion, the Interviewer explains to the group (please state verbatim):  
 
We will begin the tape recorder now. [Interviewer: start the tape recorder.]  
As you know from your informed consent, this focus group discussion will be tape recorded today. Please verbally indicate that you are 
aware that we are tape recording this session and that it is okay with you. [Interviewer: be sure to get a verbal okay from the group.] 
Have the group members introduce themselves. They should create a nickname for the discussion. Have them write it down on a sheet of paper that they 
will keep on their laps and refer to throughout the discussion.  
 
Ask for any questions.  
Ask “ice-breaker”: Go round the group and ask each participant to introduce themselves by their nickname and ask them to share the 
strangest or funniest thing that happened to them in the last week.   
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 Today we are going to talk about different types of sexual partners. First, let’s talk about clients. By clients I mean men who give 
you money in return for sex.  
 
You may have clients you see just once or a few times, but you do not know them well. We will call these occasional clients. You may 
have clients you see more regularly, who you know and recognise well. We will call these regular clients. 
 
Can you explain back to me your understanding of what these different types of clients are? It might help to think about what type 
of client you last had sex with? 
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 Research Question, Focus Group Questions and 
Probes 
Summary/Notes 
1. What types of client characteristics do sex-workers 
prefer?  
 
What makes a good client? 
 
 Could you describe your ideal client? 
 
 Do you prefer clients who you see regularly, 
or those you see occasionally? Why? 
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2. What characteristics make it more or less likely that sex 
workers will insist on using a condom? 
 
What kind of clients do you think women should always 
use condoms with? 
 
 What are these clients like? 
 
 What sort of protection would you use? Male condoms? 
Female condoms? 
 
 Does it make a difference if they are an occasional 
client? What about a regular client? 
 
 What about clients who look like they might have an 
infection? 
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3. What are sex worker’s perceptions on their negotiation power 
for protection? 
 
How do you get your clients to use condoms?  
 
 Is it always possible to persuade clients to use a 
condom? 
 
 Is this different for regular or occasional clients? 
 
 What issues might people have trying to make clients 
use condoms? 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reminder:   
Client: a man who gives you money in return for sex 
 
Occasional Clients: clients you see just once or a few times, but 
you do not know them well. 
 
Regular Clients: clients you see more regularly, who you know 
and recognise well 
 
422 
 
5. What makes it more or less likely that sex workers will insist on 
using a condom? 
 
When do you think women might not use a condom? 
 
 What makes it more or less likely that women will use a 
condom? 
 
 Do you think the chance to earn more money influences 
women’s decisions to use condoms? 
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6. How do sex-workers negotiate price with clients? 
 
How do you agree on the amount of money a client gives 
you for sex? 
 
 Are there standard rates you charge for services, or 
does it depend on the situation? 
 
 What sorts of things make you reduce or increase the 
amount? 
 
 Do you suggest an amount, or do you wait for the client 
to offer an amount? 
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7.  Does disclosure of FSW HIV status affect condom use and price 
with clients?  
 
What do you think about disclosing your HIV status to 
clients? Does it affect whether you use a condom?  
 
 Would you disclose your status to a client? Why? 
 
 Have you done it before? What happened? 
 
 Would it affect the amount of money a client gives you? 
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Now let’s talk about sexual partners who do not give you money in return for sex.  
 
One type is a main partner, like a husband, boyfriend, or someone you might call an emotional partner that you see regularly whom you do not see 
as a client and who does not give you money or gifts in exchange for sex.  
 
Another type is a casual partner, someone you might see from time to time but whom you do not consider to be someone you are in a serious 
relationship with and who is also not a client.  
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7.    How do FSWs perceive risk from clients and regular partners?  
 
Do you think sex workers are more likely to get HIV from 
their paying clients or from their main partners, like a 
boyfriend or husband? Why?  
 
 Are romantic/main partners more or less likely to use 
condoms?  
 
 Are clients more or less likely to use condoms?  
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8. What are FSW perceptions on their negotiation power for 
protection? 
 
How easy do you think it is to persuade partners who do 
not pay you for sex to use a condom?  
 
 Is it always possible to persuade partners who do not 
pay you for sex to use a condom? 
 
 Is this different for main or casual partners? 
 
 What issues might people have trying to make partners 
use condoms? 
 
 
 
 
 
 
 
 
 
 
Reminder:   
Main partner: a husband, boyfriend, or someone you might call an 
emotional partner that you see regularly whom you do not see as 
a client and who does not necessarily give you money or gifts in 
exchange for sex 
 
Casual partner: someone you might see from time to time but 
whom you do not consider to be in a serious relationship with. 
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9.  Does disclosure of FSW HIV status affect condom use with 
romantic/main partners?  
 
What do you think about disclosing your HIV status to 
romantic/main partners? Does it affect whether you use a 
condom? 
 
 Would you disclose your status to a partner? Why? 
 
 Have you done it before? What happened? 
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FGD No. 
Date: 
Study site: 
Name of the facilitator: 
Number of participants: 
 
Nick Name: ____________________    Date of birth (dd/mm/yyyy): 
__________________ 
 
Place of birth: ________________   Current place of residence:  _______________ 
 
Highest level of grade completed at school? (Please tick on the line)  
    
         No schooling                              Primary              Grade 8-10             
Grade 10-12   Higher      
 
Marital Status (Please tick on one of the lines)  
 
        Single Married                 Divorced/Separated           
Widowed   
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Appendix VIII: Product information sheets
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Appendix IX: Preferences for ARV based HIV 
prevention methods among adult men and 
women, adolescent girls and female sex 
workers in Gauteng Province, South Africa: A 
protocol for a discrete choice experiment 
Overview of paper 
The products DCE was developed by using qualitative work led by the supervisor of this 
thesis in 2005[1], brief literature reviews (led by a colleague before I joined the project), 
and extensive piloting and pretesting. A 3-round, iterative set of pre-pilot interviews 
assessed respondent understand of the choice tasks, and informed minor changes before 
a larger pilot refined outstanding issues before final implementation.  
The gold standard in DCE development involves an inductive qualitative process where 
attributes and levels are identified through qualitative interviews and/or focus group 
discussions[2]. I was unable to carry out primary qualitative data collection for this DCE 
due to budget and time constraints due to the end-date of a grant, however, to account 
for this the DCE outline and design was presented multiple times to a range of HIV and 
DCE experts in the UK and South Africa, and weight given to participant comments in 
piloting, however it is a limitation of this study that primary qualitative work was not 
conducted. 
Reference list 
1. MacPhail, C., et al., Managing men: women's dilemmas about overt and covert use 
of barrier methods for HIV prevention. Culture, Health & Sexuality, 2009. 11(5): 
p. 485-497. 
2. Hensher, D., J. Rose, and W. Greene, Applied Choice Analysis: Second Edition. 2015, 
Cambridge: Cambridge University Press. 
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Appendix X: FGD Poster as presented at HIV R4P 
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